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Clinical effectiveness and patient perspectives of different
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Background: Tourette syndrome (TS) is a neurodevelopmental condition characterised by chronic motor
and vocal tics affecting up to 1% of school-age children and young people and is associated with
significant distress and psychosocial impairment.
Objective: To conduct a systematic review of the benefits and risks of pharmacological, behavioural and
physical interventions for tics in children and young people with TS (part 1) and to explore the experience
of treatment and services from the perspective of young people with TS and their parents (part 2).
Data Sources: For the systematic reviews (parts 1 and 2), mainstream bibliographic databases, the
Cochrane Library, education, social care and grey literature databases were searched using subject
headings and text words for tic* and Tourette* from database inception to January 2013.
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Review/research methods: For part 1, randomised controlled trials and controlled before-and-after studies
of pharmacological, behavioural or physical interventions in children or young people (aged < 18 years) with
TS or chronic tic disorder were included. Mixed studies and studies in adults were considered as supporting
evidence. Risk of bias associated with each study was evaluated using the Cochrane tool. When there was
sufficient data, random-effects meta-analysis was used to synthesize the evidence and the quality of evidence
for each outcome was assessed using the Grading of Recommendations Assessment, Development and
Evaluation approach. For part 2, qualitative studies and survey literature conducted in populations of children/
young people with TS or their carers or in health professionals with experience of treating TS were included in
the qualitative review. Results were synthesized narratively. In addition, a national parent/carer survey was
conducted via the Tourettes Action website. Participants included parents of children and young people with
TS aged under 18 years. Participants (young people with TS aged 10–17 years) for the in-depth interviews
were recruited via a national survey and specialist Tourettes clinics in the UK.
Results: For part 1, 70 studies were included in the quantitative systematic review. The evidence
suggested that for treating tics in children and young people with TS, antipsychotic drugs [standardised
mean difference (SMD) –0.74, 95% confidence interval (CI) –1.08 to –0.41; n= 75] and noradrenergic
agents [clonidine (Dixarit®, Boehringer Ingelheim) and guanfacine: SMD –0.72, 95% CI –1.03 to –0.40;
n= 164] are effective in the short term. There was little difference among antipsychotics in terms of
benefits, but adverse effect profiles do differ. Habit reversal training (HRT)/comprehensive behavioural
intervention for tics (CBIT) was also shown to be effective (SMD –0.64, 95% CI –0.99 to –0.29; n= 133).
For part 2, 295 parents/carers of children and young people with TS contributed useable survey data.
Forty young people with TS participated in in-depth interviews. Four studies were in the qualitative review.
Key themes were difficulties in accessing specialist care and behavioural interventions, delay in diagnosis,
importance of anxiety and emotional symptoms, lack of provision of information to schools and
inadequate information regarding medication and adverse effects.
Limitations: The number and quality of clinical trials is low and this downgrades the strength of the
evidence and conclusions.
Conclusions: Antipsychotics, noradrenergic agents and HRT/CBIT are effective in reducing tics in children
and young people with TS. The balance of benefits and harms favours the most commonly used
medications: risperidone (Risperdal®, Janssen), clonidine and aripiprazole (Abilify®, Otsuka). Larger and
better-conducted trials addressing important clinical uncertainties are required. Further research is needed
into widening access to behavioural interventions through use of technology including mobile applications
(‘apps’) and video consultation.
Study registration: This study is registered as PROSPERO CRD42012002059.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
PR The interval between the beginning of the P wave and the beginning of the QRS complex of
the electrocardiogram.
QRS The QRS complex is a series of three deflections (Q, R and S waves) in an electrocardiogram that
represent electrical activity generated by ventricular depolarisation prior to contraction of the ventricles.
QT The interval between the start of the Q wave and the end of the T wave in the electrocardiogram.
QTC QT corrected for heart rate.
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disorder
AEI Australian Education Index
AIMS Abnormal Involuntary Movement
Scale
ASD autism spectrum disorder
ASSIA Applied Social Sciences Index
and Abstracts
BCI Biosis Citation Index
BP blood pressure
BREI British Education Index
C-GAS Children’s Global Assessment Scale
CAMHS child and adolescent mental
health services
CBCL Child Behaviour Checklist
CBIT comprehensive behavioural
intervention for tics
CDI Child Depression Inventory
CDI-S Child Depression Inventory –
short version
CDSR Cochrane Database of
Systematic Reviews
CENTRAL Cochrane Central Register of
Controlled Trials
CGB caregiver burden
CGI Clinical Global Impressions
CGI-I Clinical Global Impressions –
Improvement
CGI-Tic/
Neuro-S
Clinical Global Impressions –
severity of tics and other
neurological symptoms
CGI-TS Clinical Global Impressions –
Tic Severity
CI confidence interval
CINAHL Cumulative Index to Nursing and
Allied Health Literature
CTD chronic tic disorder
DARE Database of Abstracts of Reviews
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TA Tourettes Action
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Plain English summary
Tourette syndrome (TS) is a common condition affecting up to 1% of children and young people and ischaracterised by motor and vocal tics. TS frequently occurs together with attention deficit hyperactivity
disorder, autism spectrum disorder and obsessive–compulsive disorder. The main treatments for tics are
medication and behavioural interventions. The study has two main components: part 1 – to identify from a
systematic review of the published research literature of controlled trials which treatments for tics are most
effective and part 2 – to understand from the perspective of young people with TS and their parents how
they experienced treatment and care for TS, including which interventions they found helpful or harmful
and what outcomes they valued most. Part 2 involved a national online survey of 358 parents/carers
(295 contributing usable data) and in-depth interviews with 40 young people with TS. In the part 1, study
a ntipsychotics and noradrenergic agents [clonidine (Dixarit®, Boehringer Ingelheim)] were found to be
effective for treating tics in children and young people with TS. However, antipsychotics can cause
troublesome adverse effects (sedation, weight gain and neurological symptoms) and aripiprazole (Abilify®,
Otsuka) may be better tolerated than other antipsychotics. Habit reversal therapy was also found to be
effective for treating tics. Overall, the number and quality of clinical trials is low and this downgrades
the strength of the evidence and conclusions. Larger and better-conducted trials addressing important
clinical uncertainties are required. The key themes identified in part 2 were difficulties in access to specialist
care, delay in diagnosis, limited access to behavioural interventions (only 25% of young people had a
behavioural intervention), the importance of anxiety and emotional symptoms in TS, lack of provision of
information to schools and inadequate information regarding medication and adverse effects.
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Scientific summary
Background
Tourette syndrome (TS) is a neurodevelopmental condition characterised by chronic motor and vocal tics
affecting up to 1% of school-age children and young people and is associated with significant distress and
psychosocial impairment. The main treatments are pharmacological and behavioural interventions;
however, little is known about their benefits and risks, how they are experienced by children and young
people, and what treatment outcomes are most valued.
Objectives
To conduct a systematic review and meta-analysis of the benefits and risks of pharmacological, behavioural
and physical interventions for tics in children and young people with TS (part 1), and to conduct a
Qualitative study of Experiences of Services and Treatment to explore the experience of treatment and to
understand which outcomes are most valued from the perspective of young people with TS and their
parents (part 2).
Methods
Data sources
For the systematic reviews (parts 1 and 2), mainstream bibliographic databases (EMBASE, MEDLINE,
PREMEDLINE In-Process & Other Non-Indexed Citations and PsycINFO), the Cochrane Library [Cochrane
Central Register of Controlled Trials (CENTRAL) – Database of randomised controlled trials (RCTs) and
other controlled trials], Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of
Reviews of Effectiveness (DARE) and Health Technology Assessments (HTA), education (e.g. British
Education Index), social care (e.g. Applied Social Sciences Index and Abstracts) and grey literature
(e.g. Health Management Information Consortium) databases were searched using subject headings and
text words for tic and tourette from database inception (or 1995 for part 2) to January 2013.
For part 2, additional data were collected from two sources (1) an online national survey hosted via the
Tourettes Action website (www.tourettes-action.org.uk/) of the experiences of care and treatment of
parents of children and young people with TS (aged 17 years or younger), and (2) in-depth qualitative
interviews with young people with TS (aged 11–17 years) to explore their experiences of care
and treatment.
Study selection
For part 1, results were screened for RCTs and controlled before-and-after studies of pharmacological,
behavioural or physical interventions in children or young people (aged < 18 years) with TS or chronic tic
disorder. Studies in adults or mixed populations were considered as supporting evidence.
For part 2, results were screened for qualitative systematic reviews, qualitative studies and survey literature
of access to and experience of care for young people with TS. Results for the quantitative searches (part 1)
were also screened for any relevant studies.
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Data extraction and synthesis
For part 1, the critical outcome for the review was tic severity/frequency. Data were abstracted by one
reviewer and checked by a second. The Cochrane risk of bias tool was used for the risk of bias assessment
and the Grading of Recommendations Assessment, Development and Evaluation approach for assessing
the overall quality of the evidence.
For part 2, results are presented under theme headings, to group information from different studies on
similar outcomes or themes. Related participant quotations are presented to illustrate the themes but no
exploration or synthesis of the original quotes from the primary study was performed.
Results
For part 1, of 6345 citations screened, 70 studies were included in the quantitative systematic review. The
main review findings suggest:
l There is clear evidence that antipsychotics [standardised mean difference (SMD) –0.74, 95% confidence
interval (CI) –1.08 to –0.41; n= 75] and noradrenergic agents [clonidine (Dixarit®, Boehringer Ingelheim)
and guanfacine] (SMD –0.72, 95% CI –1.03 to –0.40; n= 164) produce improvements in tics that may be
clinically meaningful in children and young people with TS. The quality of the evidence was generally low.
l The available evidence suggests that there are unlikely to be important clinical differences in tic
reduction among antipsychotics and between antipsychotics and noradrenergic agents. There is no
clear evidence that the clinical effectiveness of antipsychotics or noradrenergic agents is moderated by
either tic severity or comorbidity.
l There is evidence that, in the short term, neither stimulants and atomoxetine (Strattera®, Lilly) (used to
treat comorbid TS and attention deficit hyperactivity disorder) nor fluoxetine (Prozac®, Lilly) (used
to treat comorbid TS and obsessive–compulsive disorder) significantly exacerbate or worsen tics, but
atomoxetine may reduce tics. The quality of the evidence was generally very low.
l Topiramate (Topamax®, Janssen), pergolide, metoclopramide (Maxolon®, AMCo) and desipramine are
other agents with evidence that suggests they may be effective in reducing tics. However, the known
adverse effect profiles of these drugs, balanced against relatively weak poor-quality evidence of
benefits, means that these agents are unlikely to be considered clinically useful for treating tics.
l A number of other agents were reviewed and were found not to be clinical effective for treating tics:
levetiracetam (Keppra®, UCB Pharma), selegiline (Eldepryl®, Orion; Zelapar®, TEVA UK), pramipexole
(Mirapexin®, Boehringer Ingelheim), mecamylamine (Inversine®, Targacept Inc.), ondansetron (Zofran®,
GSK), baclofen (Lioresal®, Novartis), omega-3 fatty acids and transdermal nicotine patches. The quality
of the evidence was generally low.
l There is clear evidence that habit reversal training (HRT)/comprehensive behavioural intervention for tics
(CBIT) produces improvements in tics that may be clinically meaningful (SMD –0.64, 95% CI –0.99 to
–0.29; n= 133). There is no evidence that the effects of HRT/CBIT are moderated by tic severity.
The quality of the evidence was moderate to low.
l There is some preliminary evidence that delivering HRT/CBIT remotely via video consultation
(telemedicine) may be as effective as face-to-face therapy. The quality of the evidence was low.
l There are no RCTs of negative (massed) practice or exposure and response prevention (ERP) compared
with control interventions. However, head-to-head comparisons suggest that HRT is a more effective
intervention than negative practice, while HRT and ERP may be equally effective interventions for tics.
The quality of evidence for interventions other than HRT/CBIT is low and so conclusions drawn from
this evidence should be treated with caution.
l There is no conclusive evidence that relaxation therapy in isolation is an effective treatment for tics.
Anger control training may be a useful intervention for young people with tics and comorbid disruptive
behaviour and behaviour problems may be improved by parent training, although there is no
conclusive evidence that parent training is an effective treatment for tics. The quality of the evidence
was generally very low.
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l There is no robust evidence to suggest that the physical interventions reviewed [deep brain stimulation
(DBS), repetitive transcranial magnetic stimulation, intravenous (i.v.) immunoglobulin, botulinum toxin
and acupuncture] are sufficiently effective and safe to be considered as treatments for tics in children
and young people with TS.
l There is no conclusive evidence that i.v. immunoglobulin or penicillin are effective treatments for tics in
children and young people identified with Paediatric Autoimmune Neuropsychiatric Disorders
Associated with Streptococcal infection (PANDAS). The quality of the evidence was low.
l There is a high degree of uncertainty with respect to the benefits and harms of plasma exchange in the
treatment of tics in children and young people identified with PANDAS. The quality of the evidence
was generally very low.
For part 2, four studies were included in the qualitative systematic review. For the online survey,
358 parents from across the UK consented to complete the online survey and useful data were analysed
from 295 respondents. The majority of respondents were mothers (92.2%) and the mean age of their
child with TS was 12.4 years [standard deviation (SD) 3.0] and 79.3% of the children were male. The
mean age of onset of tics was 5.9 years (SD 2.8) and mean age at diagnosis of TS was 9.1 years (SD 2.7).
For the in-depth interviews, 40 young people with TS, median age 13.0 (range 10–17 years) were
interviewed; 31 (77.5%) were male. Main research findings and themes:
l The online national survey found that just over half of young people with TS had received medication
for tics. The most commonly used drugs were risperidone (Risperdal®, Janssen), clonidine and
aripiprazole (Abilify®, Otsuka).
l Young people and parents reported that medication could be helpful in reducing tics but frequently
expressed concerns about adverse effects and lack of provision of relevant information explaining the
rationale for using medication for tics and possible adverse effects.
l Of the medications surveyed, parents of young people with TS perceived aripiprazole as being most
helpful with least troublesome adverse effects.
l The online national survey found that about one-quarter of young people with TS had received a
behavioural intervention (broadly conforming to HRT/CBIT) for tics. Behavioural interventions were
almost always delivered together with medication.
l Young people with TS and parents reported that behavioural interventions (HRT/CBIT) could be helpful
in reducing tics and adverse effects were rarely reported. Young people reported that they valued the
opportunity to learn behavioural techniques that helped them control tics and build on strategies
that they had developed themselves. However, some young people found these approaches difficult to
use and were not always helpful.
l Young people with TS and their parents frequently reported concerns about lack of knowledge of TS
and its treatment among health professionals both in primary care (general practitioners) and
secondary care [child and adolescent mental health services (CAMHS) and paediatrics].
l Delays in recognition and referral for diagnosis were common with the average delay of 3 years from
onset of tics to diagnosis of TS.
l Young people with TS and their parents placed great emphasis on the provision of information about
TS and its management. Often this information was not provided by health services or was viewed as
inadequate. An important finding was the lack of information provided by health services to schools on
TS and its management. In only one-quarter of children and young people with TS surveyed had health
professionals contacted and provided information to the school.
l Young people with TS and their parents highlighted the importance of recognising and managing
anxiety symptoms associated with TS.
l Young people with TS and their parents regarded reducing the frequency and intensity of tics and
increasing control over tics as the most important outcomes of treatment.
l Reducing anxiety and stress associated with tics was viewed by young people in particular as important.
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Limitations
The number and quality of clinical trials is low and this downgrades the strength of the evidence and
conclusions. In the qualitative study, lack of information on dosing and comparison with a control
intervention means that findings relating to the experience of treatment cannot be interpreted as evidence
of effectiveness or lack of harm.
Conclusions
The findings of this systematic review and evidence synthesis show that there are effective pharmacological
(e.g. antipsychotics and noradrenergic agents) and behavioural interventions (e.g. HRT/CBIT) available for
the treatment of tics in children and young people with TS. However, the number and quality of clinical
trials is low and this downgrades the strength of the evidence and conclusions. Larger and better-conducted
trials addressing important clinical uncertainties are required. Key themes from the qualitative study were
difficulties in access to specialist care, delay in diagnosis, importance of anxiety and emotional symptoms in
TS, lack of provision of information to schools and inadequate information regarding medication and
adverse effects. Of the medications surveyed, parents of young people with TS perceived aripiprazole as
being most helpful with least troublesome adverse effects. Only one-quarter of young people in the
national online survey, and less than one-fifth of young people interviewed, reported having received an
evidence-based behavioural intervention (HRT/CBIT) for tics. The perspective of young people with TS and
their parents on their experience of treatment and care have received little research attention. Therefore,
these findings should lay the foundations for future research and contribute to the development of
patient-centred treatment guidelines.
Implications for health care
Access to behavioural interventions is currently limited and delay in diagnosis of TS was on average 3 years
from symptom onset. Knowledge of TS and its management among health professionals is often inadequate
and information provision to schools is generally poor. Those working in primary care should be aware of the
prevalence and clinical features of children and young people presenting with tics and suspected TS. There
appears to be a lack of clear care pathways and inadequate care may result from a lack of integration in
the commissioning and provision of physical and mental health services. Care pathways for children with
suspected TS need to be established to accelerate access to expert assessment and diagnosis. It is important
that health commissioners recognise that local CAMHS should provide assessment and treatment of TS and
also offer referral and support for patients who need to access specialist centres. Information packages for
schools should be developed and evaluated. The relevance of associated anxiety and emotional symptoms is
often overlooked and requires greater attention from both clinical practice and research. This is a complex
issue as anxiety can be both a cause and consequence of tics and is also related to premonitory urges.
Recommendations for research
Further research is needed to inform the development of clinical guidelines for children and young people
with TS, in particular to answer questions about the order in which interventions should be given, how
interventions should be combined and how their clinical effectiveness and cost-effectiveness is affected by
comorbidity and tic severity. Aripiprazole was perceived by parents of young people with TS as the most
helpful medication with a relatively favourable adverse effect profile. However, lack of information on
dosing and comparison with a control intervention means that this cannot be interpreted as evidence of
effectiveness or lack of harm. Currently, there are no placebo-controlled studies available for aripiprazole in
the treatment of tics, although trials may be ongoing. Therefore, evidence from controlled trials is needed
for aripiprazole before firm conclusions regarding its efficacy and safety can be drawn.
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Health services research is required to identify barriers to care and unmet needs for services for young
people with TS and to develop targeted interventions to improve referral practice and reduce the delay
between onset of tics and diagnosis. Poor access to behavioural interventions is an important issue and
research is needed to test whether or not technological innovations (e.g. mobile digital and video
technology) can be used to widen access, reduce the cost and face-to-face duration of therapy while
maintaining the effectiveness of the intervention.
Finally, tic reduction is a relevant primary outcome for both clinical practice and research trials and current
measures such as the Yale Global Tic Severity Scale should continue to be used. Secondary outcomes
should include reduction in associated anxiety, stress and improved self-esteem.
Key research questions and priorities
1. Is the combination of a behavioural intervention together with medication management more clinically
effective and cost-effective in the short term than either behavioural intervention alone or medication
management alone for the treatment of moderate and severe tics in children and young people
with TS?
2. What is the feasibility, acceptability, clinical effectiveness and cost-effectiveness of a behavioural
intervention for tics that is delivered remotely (e.g. via telemedicine/videoconference or Skype™
(Microsoft Corporation, Redmond, WA, USA) compared with traditional face-to-face delivery
of therapy?
3. What is the feasibility, acceptability, clinical effectiveness and cost-effectiveness of a behavioural
intervention (HRT/CBIT) and self-monitoring mobile application (‘app’) for tics compared with traditional
face-to-face delivery of therapy?
Study registration
The study is registered as PROSPERO CRD42012002059.
Funding
The National Institute for Health Research HTA programme.
DOI: 10.3310/hta19XXX HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. X
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Hollis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
UNCORRECTED PROOF DATE: 12/09/2015 FILE: 10-142-01-2P.pdf
xli
Chapter 1 Introduction
Clinical features
Tourette syndrome (TS) is a childhood-onset neurodevelopmental disorder characterised by multiple motor
tics and one or more vocal/phonic tics, lasting longer than a year.1,2 The Diagnostic and Statistical Manual
of Mental Disorders-Fifth Edition criteria1 for TS are very similar to those in International Classification of
Diseases, Tenth Edition.2
The mean age at onset of TS is 7 years, with the onset of motor tics usually preceding vocal tics. Tics can
be simple (e.g. blinking, eye rolling, nose twitching, head nodding, mouth pouting) or complex (e.g.
touching, squatting, jumping, hopping). The onset of simple tics usually precedes more complex tics.
Tics usually begin in the head and face, and blinking is often the first and most common tic. Simple vocal
tics include sniffing, throat clearing, gulping, snorting and coughing. Complex vocal tics include barking,
the making of animal noises and uttering strings of words. Other complex tic phenomena include echolalia
(copying what other people say), echopraxia (copying what other people do) and palilalia (repeating the
last word or part of sentence said by the individual).3,4 Self-injurious behaviours5 and non-obscene socially
inappropriate behaviours6 occur in one-third of TS patients. Tics typically increase in severity until mid-teens
and then decline (but usually do not disappear) in late adolescence and early adult life. Tics follow a
fluctuating (waxing and waning) course and may be exacerbated by stress, tiredness or boredom and
improved by focused mental and physical activity. Tics are commonly preceded by an uncomfortable
premonitory sensation or ‘urge’, either localised (around the area of the tic) or generalised (covering a
wide area of the body), often described as an uncomfortable physical sensation and/or build up of tension,
with the performance of the tic resulting in relief from the urge. Although involuntary, older children and
young people may be able to briefly suppress or postpone a tic at the expense of increased feelings of
tension and an urge to complete the tic and/or increased anxiety.7,8
Coprolalia (inappropriate and involuntary swearing, which is often disguised by the patient) is uncommon,
occurring in only 10–15% of patients, often starting at around 15 years of age. Many clinicians, and the
wider public, are still under the misapprehension that coprolalia must be present in order to make the
diagnosis, thereby leading to under-diagnosis. Instead of uttering a complete swear word, many people
say only parts of the word (e.g. ‘Fu’, ‘Shi’, ‘Cu’), and disguise it (e.g. by coughing, saying something or
covering their mouths).9
Epidemiology and prevalence
Tourette syndrome occurs worldwide and in different cultures. Boys and men are more commonly
affected, with the male-to-female ratio between three and four to one. Clinical characteristics are similar
irrespective of the country of origin. It is often reported that within families, the affected males have
predominant tic symptoms, whereas the females have obsessive–compulsive behaviours (OCBs).10,11
Tourette syndrome was once considered to be very uncommon, but the worldwide prevalence in children
and young people is now estimated to be around 1%. Good-quality epidemiological studies (involving
direct assessment of the subjects) show remarkably consistent findings and suggest a prevalence of
between 0.4% and 3.8% for young people between the ages of 5 and 18 years (studies undertaken in
the UK, Europe, USA, South America, the Middle East, Oceana, Asia, North Africa).10–12 The prevalence of
TS is higher in those with learning difficulties, emotional and behavioural disorders or autism spectrum
disorder (ASD).10–12
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Comorbidities and coexisting psychopathologies
Robertson9 suggested a differentiation between comorbid disorders and coexisting psychopathology. This
was based on emerging clinical, epidemiological and aetiological data suggesting that some disorders have
more in common with TS than others, particularly from a genetic perspective. Thus, Robertson9 suggested
that OCB and obsessive–compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD) and
ASD are comorbid with TS. It is important to distinguish OCB (also known as ‘compulsive tics’ that are
common in TS), such as ‘evening-up behaviours’, compulsive touching and counting rituals, from
symptoms more typical of OCD such as checking, washing and cleaning rituals. In TS, the performance of
OCBs results in a relief from a premonitory ‘urge’ (similar to other tics), while in OCD performance of
rituals results in temporary relief from anxiety linked to specific fears (e.g. contamination). For this reason,
OCB associated with a premoniraty urge are regarded as a complex tic rather than a symptom of a
separate disorder (OCD). Some refer to mild OCB as obsessive–compulsive symptoms (OCSs).13
Prevalence of the comorbid disorders differ in clinical and community TS populations. In clinical TS samples,
ADHD is present in about 60% of patients,7 while OCD occurs in just under 40%7,13 and OCBs/OCSs may
occur in up to 90% of patients.13 The prevalence of ASD in clinic patients with TS has not been widely
studied, but in one large international multicentre study encompassing 7288 TS patients, the point
prevalence of ASD was 4.6% (much higher than in the general population).14
In community studies, around 90% of TS individuals have other comorbid diagnoses15–17 and in one
community study, 36% of the individuals had three or more diagnoses.15,16 In TS individuals, ADHD is the
most common comorbid diagnosis occurring in 17.8% to 68%, then OCD in 10.9% to 20.5%, and
“disruptive behaviours” in 10.9% to 16%.18 TS occurs in between 6% and 11% of youngsters with ASD
in community studies.7,9
The common neurodevelopmental comorbidities (ADHD, OCB/OCD and ASD) not only occur much more
than by chance,19 but the research data also suggest that they share a common genetic aetiology.19,20 In
contrast, while depression and depressive symptomatology are common in TS, the two disorders are not
genetically related.21 Thus, the coexistent psychopathologies (e.g. depression, social anxiety, substance
misuse) may well be a consequence of having TS, rather than being an integral part of TS.
Thus, both in clinical populations as well as in the community, approximately only 10% of people with TS
have solely tics or, another way of putting it is that 90% of individuals with TS, be they in the clinic or in
the community, have other comorbid diagnoses or psychopathology.
Early research suggested that individuals with TS were at increased risk for depression, anxiety and hostility.22
Thereafter, in several controlled studies in adults with TS, the patients were shown to have more depressive,
anxious, obsessional symptomatology and hostility symptoms than age-matched and sex-matched
healthy control subjects, and the subjects with TS were also shown to have significantly more personality
disorders.21,23–26 In further controlled studies, young people with TS have been shown to have more
depressive and obsessional symptomatology than control subjects.27,28
Robertson and Orth29 reviewed the literature of depressive symptoms and illness in people with TS in
detail, showing that, in 16 uncontrolled studies in specialist centres that examined mood changes among
5409 TS patients, depressive symptomatology, dysthymia, mood swings and/or major depressive disorder
(MDD) or depressive illness were found in between 13% and 76% of the patients . The main diagnosis
was that of MDD. In addition, 13 controlled investigations found both young people and adults with TS
(n= 741) to be significantly more depressed than age-matched and sex-matched healthy control subjects.29
Since 2000, some research groups have separated TS individuals on the basis of clinical symptoms into
subgroups, specifically separating those with and without ADHD, demonstrating significant differences. Thus,
they have examined cohorts of children including children with TS only, and are comparing them with other
groups such as TS plus ADHD, ADHD only and unaffected healthy controls.27,30,31 These studies generally
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indicated that youngsters (aged 7–18 years) with TS only did not differ from unaffected controls on many
ratings, including aggression, delinquency or conduct difficulties. In contrast, children with TS plus ADHD
scored significantly above the unaffected controls and, similarly to those with ADHD only, on the indices of
disruptive behaviours. Studies further showed that youngsters with TS plus ADHD showed more internalising
behaviour problems and poorer social adaptation than children with TS only or controls. Of importance is
that youngsters with TS only were not significantly different from unaffected controls on most measures of
externalising behaviours and social adaptation, but did have more internalising symptoms. Similarly, in an adult
TS population, those patients with TS only were not disadvantaged, whereas those with TS plus ADHD
showed signs of social difficulties including drug and alcohol abuse and more aggression and more instances
of breaking the law.32 In summary, those individuals with TS only appear to be no different from healthy
control subjects (apart from having more internalising problems) and have significantly fewer externalising
problems and social adjustment difficulties than those with TS plus ADHD. This clearly has major management
and prognostic implications.
After an initial publication on the reduced quality of life (QoL) in adult patients with TS,33 there have been
over a dozen or so studies investigating QoL in young people with TS (review and references)7 and, more
recently, a study by Cavanna et al.34 The conclusions that can be drawn from these are that patients with
TS have a reduced QoL when compared with healthy controls, but have a better QoL than patients
with epilepsy or other psychiatric illnesses. The reduced QoL is generally associated with unemployment,
underachievement, increased tic severity, the presence of OCB, ADHD, anxiety and depression.7 It has also
been shown that the OCD and ADHD have differential effects on the QoL.35
The psychosocial aspects and adaptive functioning of people with TS have been addressed by both
Robertson36 and Sukhodolsky et al.37 There are numerous triggers which increase the tics and patients’
distress. In addition, patients with TS suffer as a consequence of their tics and associated comorbid
conditions and coexistent psychopathologies. Sukhodolsky et al.37 cited cases from their TS clinic (Yale
Child Study Centre, CT, USA) and also reviewed studies not included/mentioned above as their brief was
different. In essence, in their clinic, youngsters (aged 7–18 years) with TS had been teased because of their
tics. In one controlled study, TS youngsters were rated by their peers as more withdrawn and less likeable
than their peers. The severity of tics was not related with ratings of popularity, but was associated with
ADHD. In a second controlled study,38 peer victimisation was compared between youngsters with chronic
tic disorder (CTD) and type 1 diabetes mellitus and matched healthy controls: the youngsters with tics were
classified as reporting clinically significant greater peer victimisation (27%) compared with 9% of both
youngsters with diabetes mellitus and healthy controls.37
Lee et al.39 showed that more ‘stress’ (e.g. parental burden, psychopathology) was reported in the parents
of youngsters with TS, with one of the main stressors being child care difficulties. In addition, a correlation
was found between parenting stress and child sex, age, school situation, disease severity, parent age and
family income. Disease severity and family income were the variables with the greatest predictive power for
parenting stress, accounting for 42% of the variance.39 Cooper et al.40 compared ‘caregiver burden’ (CGB)
in parents of youngsters with TS with the parents of youngsters with asthma using standardised assessment
schedules including the Child and Adolescent Impact Assessment. The TS parents were significantly more
psychiatrically disturbed and had greater CGB than the parents of children with asthma.40 Overall, studies
have shown considerable parenting stress, CGB and psychopathology in the parents of youngsters with TS.
In summary, QoL in patients with TS is reduced, with children and young people with TS rated as less
likeable by their peers and also suffering significant ‘peer-victimisation’; the adverse effects on parents of a
child with TS are substantial.
The relationships between the comorbidities and psychopathology and psychosocial aspects and TS are
complex and have been discussed fully elsewhere,7,9,36,41 and are summarised as follows: (1) OCB/OCD is
generally accepted as an integral part of and genetically related to TS; (2) ADHD is common in TS and now
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recognised to be genetically related in some cases (a subgroup); and (3) ASD is common, sharing some
genetic/neurodevelopmental underpinnings with TS.
In summary, the comorbidities of TS change with age as do some of the psychopathologies (e.g.
depression worsens with age). This highlights the importance to address the TS phenotype and why the
separation of the other disorders in TS is crucial. This also clearly has treatment implications.
The Tourette syndrome phenotype
Recent studies42–44 using quantitative methods, such as principal component factor analysis, hierarchical
cluster analysis and latent class analysis have suggested that TS should no longer be considered a the
unitary condition described in the International Classification of Diseases and Diagnostic and Statistical
Manual of Mental Disorders classification systems. All studies also show that one type is ‘pure TS’, in other
words, there is heterogeneity of symptomatic presentation within the diagnostic umbrella of TS. Both
clinical and community studies have shown that as many as 90% of individuals with TS have comorbid
conditions and/or coexistent psychopathology and this clearly has management and treatment choices and
ramifications: treatment in TS should be symptom targeted in the patient, taking a holistic approach
including the family.7,9,45,46
Lifespan prognosis
It was initially thought that TS was lifelong with continuing severity, but then Erenberg et al.47 first indicated
that TS symptoms reduced with age. Leckman et al.48 subsequently highlighted the natural course of the
disorder, suggesting that the prognosis was better than previously thought, with the onset of TS at 5.6 years,
the worst severity being at 10 years and the majority of symptoms disappearing/reducing in half of the
patients by the age of 18 years. Coffey et al.49 assessed youngsters (aged 6–17 years) with TS having a mean
age of onset of 5.1 years. At baseline, 88% of subjects met threshold criteria for at least mild symptoms,
but only 30% met criteria for impairment. At a 2-year follow-up, 82% of the subjects met criteria for tic
persistence (no significant difference from baseline), but only 14% met criteria for TS-associated impairment,
which was significant. Bloch et al.50 more recently studied 46 TS children at follow-up after 7.6 years and
reported 85% had a reduction in tics during adolescence, only increased tic severity in childhood was
associated with increased tic severity at follow-up. The average age at worst tic severity was 10.6 years;
however, worst ever OCD symptoms occurred approximately 2 years later than worst tic severity, and
increased childhood intelligence quotient (IQ) was associated with increased OCD severity at follow-up.
Thus, although the prognosis of TS is better than originally thought with regards to tic symptomatology,
the course of associated psychopathology, such as OCD, may show greater persistence later on in the
individual’s life. Finally, a follow-up study, using a rigorous design, reviewed TS patients’ (aged 8–14 years)
assessments.51 Patients (n= 56) were filmed for 5 minutes originally between 1978 and 1991 according to a
strict protocol. Thirty-six of these patients aged > 20 years were contacted again and 31 were included into
the follow-up video study. A blinded video-rater assessed the 62 tapes and rated five tic domains; the two
videotapes were compared for each tic domain as well as a composite tic disability score. Results showed
that 90% of the adults still had tics and many adults who had suggested that they were tic free were
incorrect, as no fewer than 50% had objective evidence (on video) of tics. The mean tic disability score
reduced significantly with age. All tic domains improved with age and there were significant improvements
(p= 0.008) for motor tics. The improvements in tic disability were not related to medication, as only 13% of
adults received medication for tics, compared with 81% of children. The authors concluded that although
tics improve with time, most adults have persistent, but mild, tics.51 Finally, in a recent study examining the
effects of psychosocial stress predicting future symptoms in children with TS and/or OCD, advancing
chronological age was robustly associated with reductions in tic severity.52
The presence of comorbidities in a person with TS is associated with a worse prognosis. Rizzo et al.53
investigated 100 TS patients who were assessed at onset and at then again at follow-up 10 years later to
evaluate the severity of the tics, the presence of comorbidities and coexistent psychopathologies. In brief,
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they demonstrated that the comorbid conditions altered with increasing age. Unsurprisingly, they also
suggested that the ‘Pure TS’ phenotype (38% at the original assessment) had the best long-term outcome.
In contrast, those patients who presented at their original assessments with comorbidities (TS plus OCD, TS
plus ADHD, TS plus ADHD plus OCD) had a poorer prognosis.
What is also important to understand is that in a person with TS who also has multiple comorbidities, the
ASD typically begins first, then the ADHD, then the motor tics, then the vocal/phonic tics and then
the OCB (which is usually present by the time of diagnosis), while the OCD usually develops later. The
depression, anxiety, substance misuse and other coexistent psychopathologies usually emerge later and
may well be a consequence as much of the comorbid disorders as of TS itself.
In summary, following onset of TS, tic symptomatology may get worse until early teens with subsequent
improvement and although some tic symptoms usually remain into adult life, they usually do not impair
the individual. Those with ‘TS-only’ (‘pure-tics’) have the best prognosis. The comorbidities (ASD, ADHD,
OCD) and associated psychopathologies (e.g. depression) change with age and their impact many may
well increase during adolescence.
Aetiological theories
The main aetiological candidates for TS include genetic influences, infections and perinatal difficulties.
Originally, the aetiology of TS was considered to be psychological54,55 but, in the 1980s and 1990s, large
pedigrees with multiple affected family members were documented with tics or obsessive–compulsive
symptomatology, suggesting a familial pattern and possible genetic origin. Subsequent investigations
employing complex segregation analysis indicated that TS was inherited, consistent with a single major gene
and autosomal dominant transmission, but with incomplete penetrance. However, much of the genome was
subsequently excluded.7,9 The Tourette Syndrome Association International Consortium for Genetics56 using
sib-pair analysis, undertook one of the first genome scans in TS, as well as the first Genome Wide
Association Study (GWAS).57 The genetic susceptibility in TS has been recently reviewed by Fernandez and
State.20 There are five essential findings/conclusions: (1) that the GWAS identified the COL27A1 gene as a
possible contributing gene in a multiethnic cohort,58 but the finding requires replication, (2) some rare
variant studies have identified a mutation to the SLITRK1 gene,59 but subsequent studies have been
conflicting,60 (3) linkage analysis of an individual outlier TS family identified a deleterious mutation in the
HDC gene suggesting that histaminergic neurotransmission may be involved in the pathophysiology of TS,61
(4) pathway analysis of rare copy number variants has proven useful,20 and (5) there seems to be a significant
overlap of genes mapping within rare copy number variants in TS and those identified in ASD.19,20
Neuroimmunological theories possibly operating via the process of molecular mimicry have become of
interest in the aetiology of TS. Swedo et al.62 described a group of 50 children with OCD and tic disorders,
designated as Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infection
(PANDAS). The diagnostic criteria included presence of OCD and/or a tic disorder, pre-pubertal symptom
onset (usually acute, dramatic), association with group A beta-haemolytic streptococcal (GABHS) infections,
episodic course of symptom severity and association with neurological abnormalities. The relapsing,
remitting course was associated with significant psychopathology including emotional liability, separation
anxiety, night-time fears, bedtime rituals, cognitive deficits, oppositional behaviours and hyperactivity.
Other centres have found laboratory evidence of GABHS infections in some patients with TS, and/or
documenting that some TS patients have increased antibasal ganglia antibodies in cohort studies63 and
controlled studies.63–69 As most researchers have findings that supported a role of GABHS and basal
ganglia autoimmunity in a subgroup of TS patients, it was suggested that further research was needed to
clarify the phenomenology associated with antibasal ganglia antibodies.70 The majority of studies have
indicated a role of GABHS infections in TS, but there is a dissenting view predominantly from one
laboratory.71 Clearly, streptococcus does not cause TS, but it may well be that individuals inherit a
susceptibility to TS and to the way they react to some infections, including GABHS infections. The above
theory has now expanded into broadly two theories: (1) a lowered immunity and (2) autoimmunity.9
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Murphy72 reviewed the literature on the role of infections in the aetiopathogenesis of tic disorders
including TS and notes that many infectious agents have been suggested including not only GABHS but
also mycoplasma pneumoniae, other respiratory infections and, indeed, the common cold, have been
linked to the exacerbation of both OCD and tic symptomatology. Lyme disease, a complex multisystemic
illness, is the most common vector-borne disease in the USA and is caused by bacterial spirochete
Borrelia.73 Lyme disease has been reported as presenting as TS;74 in the UK,75 it is spread to humans by
infected ticks and named after the city of Lyme in Connecticut. If the tick bites an infected animal, the tick
becomes infected and can pass the disease to humans; most bites occur in late spring and early summer
and it is estimated that there are 3000 new cases in UK per year.76 Thus, there are more than one
infectious agent thought to be involved in the aetiopathology of TS, none of which cause TS, but may
trigger tics in an already vulnerable individual via mechanisms of lowered immunity or autoimmunity.
Leckman77 outlined the potential role of pre-natal and perinatal events in the pathogenesis of TS. The first
study in the area was a controlled study78 embracing a large sample size and the use of obstetric hospital
records, which demonstrated that the mothers of children with tics were 1.5 times as likely to have
experienced a complication during pregnancy than the mothers of children who did not have tics.
Two studies showed that among monozygotic twins discordant for TS, the twins with TS always had lower
birthweights than their unaffected twins. Leckman’s own group demonstrated that the severity of
maternal life stress during pregnancy, severe nausea and/or vomiting during the first trimester are risk
factors for developing tic disorders. A second controlled study79 demonstrated that TS patients have had
more pre-natal and perinatal difficulties than a control group. Several groups have now shown that
maternal smoking of cigarettes during pregnancy can produce more severe TS in the child.80 More recently,
both smoking and psychosocial stressors during pregnancy have been implicated in altering the TS
phenotype.52 In addition to the factors mentioned above, other perinatal risk factors for TS in the child
include older paternal age, more and earlier prenatal care visits, delivery complications, premature low
birthweight children as well as those with low Apgar scores at 5 minutes after birth.77,81 Maternal smoking
during pregnancy and low birthweight are risk factors for the presence of comorbid ADHD.81 Older
paternal age, maternal use of caffeine, cigarettes or alcohol during pregnancy and forceps delivery are risk
factors for the presence of comorbid OCD.81 These perinatal factors appear to also non-specifically increase
the risk of a range of neurodevelopmental disorders including TS, ADHD and ASD.
In summary, the aetiopathology of TS is more complex than previously recognised, with genetic risk
potentially interacting with some infections and pre-natal and perinatal difficulties to affect the
susceptibility to tics and phenotype of TS.
Cognitive functioning in Tourette syndrome
The neuropsychological assessment and functioning in TS has been recently reviewed by Murphy and
Eddy.82 The results of neuropsychological studies are, on the whole, inconsistent; more difficulties are
demonstrated in child rather than adult populations; those with ‘Pure TS’ (tics only) show no evidence of
global impairment of intellectual function and any difficulties (especially in adults) are mild and likely to
consist of subtle decrements in attention or inhibitory processing; and patients with TS seem likely to have
changes in social cognition. In addition, those with TS plus OCD may have a higher IQ, while those with
TS plus ADHD have a lower IQ and many of the neuropsychological difficulties are associated with the
presence of ADHD.82 This ‘ADHD effect’ is also seen with more behavioural difficulties in both youngsters
(aged 7–18 years)30 and adults32 and those with lower QoL, all of which have been mentioned above.7,9,36
On the other hand, there may be some cognitive advantages in having TS. There has been some evidence
that children with ‘pure TS’ (tics only) may have some enhanced aspects of executive function, possibly as
a compensatory mechanism resulting from habitual tic suppression.83 In addition, Jackson et al.84 employed
a manual switching task that created high levels of interhemispheric conflict in a study with those with
‘Pure TS’ and control subjects, and results indicated that the TS subjects showed faster reaction times
than controls.
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Neurobiology and neuroimaging
There have been many studies and reviews and these give evidence that those with TS may have the
following abnormalities: (1) basal ganglia and corticostriatal thalamic circuitry dysfunction, (2) a reduction
in caudate nucleus volume, with a negative correlation between caudate nucleus volume in childhood and
tic severity in later in life, (3) thinning of the sensory–motor cortices in both children and adults with TS,
with a negative correlation between thickness and orofacial tic severity, (4) adults with TS show cortical
thinning and reduced grey matter in pre-frontal areas (suggesting a failure in neural compensation to
control the tics into adulthood, (5) the supplementary motor area may be involved in the premonitory
urges/premonitory symptoms as shown by functional magnetic resonance imaging, (6) white matter
measurements have shown larger volumes and reduced fractional anisotropy in the corpus callosum in TS,
(7) putative cognitive control networks in TS are functionally immature and anomalous, and (8) changes in
the volume of the dorsolateral pre-frontal cortex. Apart from the suggestions given above, quite how the
changes affect brain function are unclear.85,86
Treatment interventions
The evidence for the clinical effectiveness of different interventions for the treatment of tics in children and
young people with TS is the focus of this report and the results will be presented in detail in Chapters 3–6.
Young people’s experiences and views on these interventions are presented in Chapter 7. In brief, the
main types of interventions used are:
l psychoeducation – the provision of accurate information about the diagnosis, course and treatment of
TS provided to children and young people, their parents, teachers and other health-care professionals
l behavioural interventions (see Chapter 4), which can be divided into:
¢ specific interventions for tics such as habit reversal training (HRT) and exposure and response
prevention (ERP)
¢ other general behavioural/psychological interventions such as relaxation training, anger
management training, individual and group counselling and psychotherapy and family therapy
l medication and dietary interventions (see Chapter 3) – examples of medications commonly used for tics
include noradrenergic agents [e.g. clonidine (Dixarit®, Boehringer Ingelheim)] and antipsychotics
[e.g. risperidone (Risperdal®, Janssen), aripiprazole (Abilify®, Otsuka)]
l physical treatments (see Chapter 5) – these are used rarely in children and young people except in
exceptional circumstances. Examples include electrical and magnetic brain stimulation [repetitive
transcranial magnetic stimulation (rTMS) and deep brain stimulation (DBS)], botulinum toxin,
immunotherapy for PANDAS and acupuncture.
The guiding principle of the treatment and management of tics in children and young people with TS is to
prevent, reverse or normalise the adverse effects of tics on self-esteem, physical health (e.g. pain, self-injury),
learning (loss of concentration and distraction due to tics and their suppression, time off school), lifestyle
(avoidance of normal physical and social activities) and relationships (victimisation and bullying, family stress
and burden) rather than to eliminate tics, per se. Although tic reduction can contribute significantly to these
outcomes, other supportive interventions including provision of information and psychosocial support to
young people, families and schools that builds resilience, self-esteem and effective coping strategies are
equally important.
Although psychoeducation should be offered in all cases following a diagnosis of TS, the decision to offer
more targeted behavioural interventions and medication will be determined by various factors such as the
severity and impairment associated with tics, the availability of trained (HRT/ERP) behavioural therapists and
the treatment preferences and motivation of young people and their families. If comorbidities are present,
relative impact of these different conditions on the child’s functioning will determine which condition
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(or group of symptoms) is given priority for treatment. Medication management of the common
comorbidity of TS and ADHD is further complicated by the belief that psychostimulants used to treat
ADHD can actually worsen or exacerbate tics.
Organisation of services and referral pathways for Tourette
syndrome in the UK
In the UK, children and young people with TS currently receive services of varying type and quality,
although there are few, if any, systematic data on current service provision. At present, there are four
‘tiers’ of health service provision from primary care to quaternary national services and children with tics
are seen in all settings. There are several factors that might contribute to the variability and inconsistency
of care received, including the nature of the condition itself, which sits at the interface between neurology/
paediatric and mental health services. The impression from service users and clinicians is that if children
and young people with TS access specialist (secondary) services, these may be either in paediatric or child
and adolescent mental health services (CAMHS). Currently in the UK, the commissioning and delivery of
paediatric services (primarily focused on physical health and development) and CAMHS are separate. These
services often provided in separate locations and with different funding streams. This is not ideal for the
child with TS, who may have need for input of skills from both mental health as well as paediatric services,
depending on the reported difficulties and findings following an assessment.
Tourette syndrome is defined in terms of the tic disorder (see Clinical features), but many children with
chronic motor and vocal tics may not come to the attention of services at all and, indeed, may not have
any functional impairment. If tics are worrying, intrusive or disruptive, children with tics are seen initially by
their general practitioner (GP) and may be subsequently referred to their community paediatrician, general
paediatrician or local CAMHS. In some cases, the children may be referred on to a paediatric neurology
services. Treatments that are then initiated by first-line clinicians (paediatrics or CAMHS) are variable,
depending on their knowledge of tic disorders and the resources available to them. Access to behavioural
therapy (e.g. HRT and/or ERP) outside specialist centres is very patchy and currently in the UK many
children will not be offered these interventions if they are treated by local community paediatric services or
local CAMHS. Consensus opinion in the management of tic disorders suggests that education for child,
family and school should be the initial intervention, as this may be sufficient to allay fears and enable
accommodation to the condition, if there is no functional impairment from the tics themselves. However,
in practice, it appears that authoritative psychoeducation is patchy in its provision and the primary
intervention from paediatricians is often a trial of medication for tics. Choice of first-line agent is also
highly variable.
The initial assessment of a child with TS is a crucial part of the management and treatment. The range of
needs that are identified at assessment should define the next steps in treatment and their prioritisation is a
second reason why care pathways and treatments are so variable. For example, both clinical experience and
several research studies34,35,87,88 show that the emotional and behavioural problems which often accompany
TS (psychiatric comorbidities) are more likely to contribute to impaired QoL than the tics themselves.
So, for many children, the identification and treatment of mental health needs such as ADHD and OCD, or
behavioural problems such as oppositional defiant disorder are the priority for treatment. An additional
comorbidity that is over-represented in children and young people with tics is ASD. If the initial assessment is
carried out by a clinician without an adequate knowledge of screening for mental health problems, these
comorbidities may be missed and the most important target for treatment may be bypassed.
Similarly, a substantial minority of children and young people with TS have either a specific or a global
intellectual disability.89 If this is not considered at the initial assessment it may be missed and often
contributes significantly to a child’s impairment or distress if they have unidentified and unmet special
educational needs. For this reason, a clinical or educational psychologist is likely to have an important role
in the assessment of some children and young people with TS.
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In summary, current service provision, referral pathways and treatments in the UK can be variable
depending on both the configuration of services in the local catchment area of the child and availability of
specific interventions (e.g. behavioural interventions). A possible depiction of current service provision and
referral pathways is given in Figure 1.
There are a wide range of services and treatments that might need to be deployed for children and young
people with TS and one of the key aspects of successful management is to identify their individual needs
and then attempt to find the appropriate intervention, which might be in a range of settings.
Assessment should include a careful history incorporating an account of the emergence and nature of tics
and their impact, a medical and developmental history, a mental health assessment incorporating family
and psychosocial history, and an account of school functioning. A full general physical examination and
neurological assessment looking for unusual features and comorbid movements such as tremor, dystonia
and chorea and associated dyskinesia should be performed. Cerebellar function examination and gait
examination can be useful. Depending on findings, treatments offered currently in the UK may include:
l for tics
¢ psychoeducation
¢ behavioural interventions (HRT or ERP)
¢ school liaison
¢ medication treatment (e.g. noradrenergic agents, antipsychotics)
¢ physical treatments (e.g. rTMS, DBS)
l for mental health problems, for example
¢ medication and psychosocial management for ADHD [National Institute for Health and Care
Excellence (NICE) guidelines]
¢ cognitive–behavioural therapy +/– medication for OCD (NICE guidelines)
¢ parent training and other interventions for oppositional defiant disorder/conduct disorder
¢ behavioural intervention and medication for challenging behaviour associated with learning
disability/ASD
¢ treatments for depression, other anxiety disorders, etc.
Tics are mild and 
cause no problems
Tics and learning
problems
Tics and emotional
and/or behavioural
problems
Tics cause worry,
distress to child,
family and others
Child with possible TS/tics
No referral needed
Referred to GP
Educational 
psychologist or 
other educational
services
Community paediatrics Community child mental health
Paediatric neurology Specialist TS clinics
FIGURE 1 Current service provision and referral pathways in the UK for TS.
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l for developmental/learning problems
¢ psychometric/cognitive assessment
¢ school liaison
¢ special educational needs provision
¢ assessment and management of social communication difficulties, that is ASD.
Overall aims and objectives of report
The overarching aims of the project are as follows.
l To identify the most clinically effective interventions and treatment strategies for children and young
people with TS. The primary objective is to answer the question: what interventions work for whom
and when? Key clinical questions include the order in which drug and behavioural/psychological
treatments should be offered and how they should be combined based on both clinical severity
and comorbidity.
l To elicit the views of young people with TS and their parents on their experiences of treatment and
what outcomes they value most.
l To produce recommendations for primary research that will fill gaps in the evidence and address key
issues raised by this project.
The project presents an evidence synthesis from diverse sources that include:
l A systematic review and meta-analysis (when applicable) of the clinical effectiveness of treatments for
tics in children and young people.
l A qualitative research study [Qualitative study of Experiences of Services and Treatment (QuEST)].
QuEST incorporates both a national survey of parents of children with TS and well as in-depth
interviews with young people focusing on their experiences of treatment and identifying which
outcomes matter most to them.
l An expert project advisory group – the Tourette Expert Group (TEG). The TEG included experts in
clinical practice, research and experience of care [service users/carers nominated by Tourettes Action
(TA)]. The TEG defined the key review questions (see Chapter 2, Review questions) and synthesised
diverse sources of evidence including the systematic review, review of grey literature, service user/carer
survey and qualitative interviews with young people. The TEG also reviewed and agreed the
recommendations for future primary research (see Chapter 3, Recommendations for further research).
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Chapter 2 Part 1: systematic review of
interventions for tics in children and adolescents with
Tourette syndrome
Methods
The review was conducted according to the review protocol (see www.nets.nihr.ac.uk/) (PROSPERO
registration number: CRD42012002059).
Review questions
Pharmacological interventions
1. For children and young people (< 18 years old) who have a clinical diagnosis of TS (including Tourette
disorder and chronic motor tic disorder, or chronic vocal tic disorder), what are the benefits and
potential harms associated with medication [including antipsychotic drugs, clonidine, tetrabenazine,
fluoxetine (Prozac®, Lilly), clonazepam] and dietary interventions (including zinc, omega-3 fatty acids,
caffeine) used for the treatment of tics, when compared with placebo or another intervention?
2. Is the clinical effectiveness of the treatment of tics with medication or diet moderated by the presence
of a comorbid disorder (e.g. ADHD, OCD, ASD or learning disability), age or tic severity?
i. In those with a comorbid disorder, is the treatment of comorbidities (e.g. psychostimulants used for
ADHD) associated with improvements or worsening of tic-related outcomes?
3. What are the views of patients and carers regarding the choice of medication and dietary interventions
available (including benefits and adverse effects) and what outcomes are considered most important
and meaningful?
Behavioural interventions
1. For children and young people (< 18 years old) who have a clinical diagnosis of TS (including Tourette
disorder and chronic motor tic disorder, or chronic vocal tic disorder), what are the benefits and
potential harms associated with psychological/behavioural and psychosocial interventions, when
compared with treatment as usual, a control group or another intervention?
2. Is the clinical effectiveness of the treatment of tics with psychological/behavioural and psychosocial
interventions moderated by the presence of a comorbid disorder (e.g. ADHD, OCD, ASD or learning
disability), age, awareness of premonitory urges or tic severity?
3. Is combination treatment (medication plus therapy behavioural intervention) more effective than either
treatment alone?
i. What is the most effective order of treatment (e.g. a behavioural intervention first followed by
medication, or medication first, followed by a behavioural intervention as an adjunct)?
4. What are the views of patients and carers regarding the choice of psychological/behavioural and
psychosocial interventions available and what outcomes are considered most important and meaningful?
5. What evidence is there that combining a behavioural intervention with medication increases
engagement and adherence with treatment?
DOI: 10.3310/hta19XXX HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. X
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Hollis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
UNCORRECTED PROOF DATE: 12/09/2015 FILE: 10-142-01-2P.pdf
11
Physical interventions
1. For children and young people (< 18 years of age) who have a clinical diagnosis of TS (including
Tourette disorder and chronic motor tic disorder, or chronic vocal tic disorder), what are the benefits
and potential harms associated with physical interventions (including neurotherapeutic interventions,
such as DBS, rTMS and other physical interventions such as acupuncture and botulinum toxin injection),
when compared with treatment as usual, a control group, or another intervention?
2. Is the clinical effectiveness of the treatment of tics with physical interventions moderated by the
presence of a comorbid disorder (e.g. ADHD, OCD, ASD or learning disability), age or tic severity?
3. What are the views of patients and carers regarding the choice of physical interventions available and
what outcomes are considered most important and meaningful?
Study selection
Search strategies
Searches for English-language and foreign-language studies were conducted in the following databases.
Major bibliographic: EMBASE, MEDLINE, PREMEDLINE In-Process & Other Non-Indexed Citations and
PsycINFO), The Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL) – database of
randomised controlled trials (RCTs) and other controlled trials, Cochrane Database of Systematic Reviews
(CDSR), Database of Abstracts of Reviews of Effectiveness (DARE) and Health Technology Assessment
(HTA). Education databases: Australian Education Index (AEI), British Education Index (BREI) and Education
Resources in Curriculum (ERIC). Social care databases: Applied Social Sciences Index and Abstracts (ASSIA),
International Bibliography of Social Science (IBSS), Social Sciences Citation Index (SSCI), Social Services
Abstracts (SSA), Sociological Abstracts and Web of Science. Grey literature databases: Health Management
Information Consortium (HMIC), PsycBOOKS and PsycEXTRA; and additional sources: Allied and
Complementary Medicine Database, Biosis Citation Index (BCI), Cumulative Index to Nursing and Allied
Health Literature (CINAHL). Search terms comprised subject headings and text words for tic* and tourette*
to identify populations with TS or with chronic phonic or motor tics (all referred to as TS in this review).
Searches were limited to systematic reviews, RCTs and observational studies. For standard mainstream
bibliographic databases, search terms for the population were combined with filters for each of the study
designs under review. For searches generated in The Cochrane Library (CENTRAL, CDSR, DARE, HTA) and
HMIC, search terms for the population were used without the appendage of a filter. Searches for RCTs
and observational studies were generated from the inception of the databases to January 2013. Searches
for systematic reviews were limited to research published from 1995 to January 2013. No language
restrictions were applied at the searching stage. The search strategy is provided in Appendix 1.
Screening
Citations obtained from the searches were screened for inclusion using a two-stage process. Titles and
abstracts were first screened to obtain potentially relevant studies. On further inspection of these studies,
hard copies of potentially relevant studies were obtained. The review inclusion/exclusion criteria as
specified in the protocol were applied in hard-copy screening to obtain the final list of included studies.
Inclusion/exclusion criteria
Participants
Studies of children and young people (< 18 years of age) with TS or CTD were included in the review.
Studies in children were the basis for the review but mixed studies in adults and children, and adult
studies, were considered to provide data in areas for which child studies were lacking or to corroborate
findings in child studies.
INTERVENTIONS FOR TICS IN CHILDREN AND ADOLESCENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
UNCORRECTED PROOF DATE: 12/09/2015 FILE: 10-142-01-2P.pdf
12
Intervention
Included interventions were:
l Any medication with marketing authorisation for any use in North America, Europe or Australasia or
any dietary intervention.
l Psychological/behavioural and psychosocial interventions including HRT/comprehensive behavioural
intervention for tics (CBIT), ERP, counselling and supportive psychotherapy (SP), family intervention
(including family therapy), psychoeducation, relaxation training, and self-hypnosis.
l Physical interventions including neurotherapeutic interventions, such as transcranial rTMS, DBS and
other physical interventions, such as acupuncture and botulinum toxin injection (botulinum toxin
type A; Botox®, Allergan).
Control
Studies with any control group were eligible for the review including treatment as usual, a waiting list
control or another active intervention.
Outcomes
The critical outcome for the review was tic severity/frequency. The important, but non-critical, outcomes
were QoL, educational attainment, psychological well-being and impact on peer relationships.
Study design
For the review questions concerning the clinical effectiveness and safety of treatments or moderators of
treatment effect, the only eligible study designs were RCTs or controlled before-and-after studies. For
review questions about patient views and barriers to treatment, any study design was eligible for inclusion.
Data abstraction
Data were abstracted by one reviewer for the outcomes specified and grouped under the headings of tics,
impairment (personal and social), psychological well-being, overall clinical outcome, and safety (no studies
reported controlled findings for QoL or educational attainment). When reported in studies, results for
follow-up were extracted for all outcomes.
For some outcomes (e.g. tics), studies often reported numerous scales making the interpretation of
findings difficult. For these outcomes, to avoid repetition and numerous statistical testing, this review limits
reporting to one scale. Priority was given to the Yale Global Tic Severity Scale (YGTSS) because this was the
most commonly reported scale in the included studies and is commonly used in clinical practice. For other
outcomes, when sparse data were reported in studies, results for all scales were included in the review.
Quality assessment
The Cochrane risk of bias tool was used to assess the quality of intervention studies.90 This tool assesses
the risk of bias owing to methods of randomisation and allocation of the randomisation (selection bas),
blinding of participants and providers to intervention allocation (performance bias), blinding of outcome
assessors (detection bias), rates of dropout from the study and methods used to deal with missing data in
the analysis (attrition bias) and the selective reporting of outcome data (selective reporting bias). For the
purposes of this review, two additional aspects of study design were also considered: the suitability of the
control group and, for crossover trials, the adequacy of the washout period between treatments.
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Overall risk of bias for each study was based on an overall assessment of whether or not any biases in that
study were likely to have had a significant impact on the findings, rather than a simple summation of the
quality ratings. Any source of bias considered to be a particular risk for the overall findings was alone
considered sufficient to determine that a study had a high overall risk of bias. Conversely, a study with a
high number of potential sources of bias, if not considered likely to have had a serious potential impact on
overall findings, may be classed as having a lower overall risk of bias.
The quality of evidence for each outcome was assessed using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach.91 Within this approach, RCTs start as
high-quality evidence, whereas observational studies start as low-quality evidence. For each outcome,
quality may be reduced depending on five factors: risk of bias, inconsistency, indirectness, imprecision and
publication bias. Studies may be down-graded by one or two levels for each of these elements depending
on the seriousness of the problem. For the purposes of this review, each factor was evaluated using criteria
provided in Table 1.
As child studies form the most applicable evidence for the review, when they were available, they formed
the primary evidence base and GRADE was applied. Mixed and adult studies were used as supporting
evidence. If child studies were not available, GRADE was applied to mixed or adult studies but these were
down-graded for lower applicability.
TABLE 1 Factors that decrease quality of evidence
Factor Description Criteria
Risk of bias Limitations in the study design and
implementation
Serious risks across most studies (that reported a
particular outcome). The evaluation of risk of bias was
made using the Cochrane risk of bias tool
Inconsistency Unexplained variation between study results Important heterogeneity (I2-value was statistically
significant and greater than 50%)
Indirectness How closely the outcome measures,
interventions and participants match those
of interest
For interventions in which child studies were not
available and adult or mixed populations were used,
these were considered as less applicable
Imprecision Results are imprecise when studies include
relatively few patients and few events and
thus have wide CIs around the estimate of
the effect
If either of the following two situations were met:
(1) the optimal information size (for dichotomous
outcomes, OIS= 300 events; for continuous outcomes,
OIS= 400 participants) was not achieved, (2) the
95% CI around the pooled or best estimate of effect
included both no effect and appreciable benefit or
appreciable harm
Publication bias Systematic underestimate or an
overestimate of the underlying beneficial or
harmful effect owing to the selective
publication of studies
In no cases could the presence of publication bias be
assessed (all meta-analyses contained small numbers of
studies); therefore, for this review this was criteria not
applied
CI, confidence interval; OIS, optimal information size.
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Data analysis
For parallel trials, continuous outcomes were analysed as change from baseline in the intervention
compared with the control group (i.e. change in intervention group mean score minus change in control
group mean score). This information was directly reported by some parallel trails. For other trials, results
were only presented as baseline and post treatment means and standard deviations (SDs) without an
estimate of the precision of change scores. In some cases, p-values for the net effect were reported and, in
these cases, p-values were used to calculate the standardised mean difference (SMD) and corresponding
standard error.
When only baseline and post treatment means and SDs were reported, in order to estimate the precision of
within-group changes, a correlation coefficient of 0.6 was assumed. This was selected after investigation
of studies in which baseline, post treatment and change scores were all reported with precision measurements
so that the correlation coefficient for outcomes could be determined. A range in correlation scores was
obtained (median 0.60, range 0.30–0.89) and 0.6 was selected for the primary analysis. For crossover studies,
outcomes were analysed as a comparison between post-treatment measures.
For continuous data, the SMD was used to judge the magnitude of effect, defined as small (–0.20),
medium (–0.50) and large (–0.80). For dichotomous data, risk ratios (RRs) were calculated and the
magnitude defined as small (< 2), medium (2–4) and large (> 4).
When possible, sensitivity analyses were used to test the robustness of findings for each intervention using
the meta-analysis with the largest number of studies (sensitivity analyses for all interventions were not
performed owing to the paucity of data). In the first set of sensitivity analyses, lower-quality studies and all
crossover studies were removed. In the second set of sensitivity analyses, for calculating the precision of
change scores, a correlation coefficient of 0.3 was used (rather than 0.6).
Data analysis was performed using the Cochrane Collaboration Review Manager software (RevMan version 5.2;
The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) using a random effects
model to pool results. Effect estimates were used to examine the magnitude of the effect and 95% confidence
intervals (CIs) to examine precision of the estimate.
Tourette expert group
Tourette expert group membership consisted of professionals in psychiatry, paediatrics, neurology, clinical
psychology, academic experts in psychiatry and psychology, and service user and carer representatives
nominated by TA. The majority of TEG members were co-applicants on the HTA grant that funded this
review. The review process was supported by staff from the National Collaborating Centre for Mental
Health (NCCMH), who undertook the clinical literature searches, reviewed and presented the evidence to
the Guideline Development Group, managed the process, and contributed to drafting the HTA report.
Four TEG meetings were held between June 2012 and May 2013. At each meeting, all TEG members
declared any potential conflicts of interest. During each day-long TEG meeting, in a plenary session, review
questions and clinical evidence were reviewed and assessed, and research recommendations formulated.
Service users were invited to attend expert group meetings. One service user attended an expert group
meeting. A dedicated time – ‘service user concerns’ – was allocated to giving the opportunity for the
service user to express their thoughts on the progress and direction of the review.
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Pharmacological interventions
Introduction
Although TS is now recognised as a biological disorder,9 no pharmacological treatment has yet been
developed specifically to target tics. Instead, existing medications used as primary treatments for other
conditions have been used [e.g. in the 1960s haloperidol (Haldol®, Janssen; an antipsychotic) used for
schizophrenia was found to also have an effect on reducing tics when tested on people with TS].92
The beneficial antitic effects of haloperidol, a potent dopaminergic D2 receptor antagonist, suggested that
dopaminergic system imbalances may be implicated in tics and TS. However, it is likely that noradrenergic,
glutamatergic, [gamma-aminobutyric acid (GABA)]-ergic, serotonergic and cholinergic systems also play a
role in tics and TS.93
A broad range of medications, with different pharmacological targets and primary indications for other
conditions, have been used to treat TS. These medications include antipsychotics (dopamine antagonists),
noradrenergic agents, anticonvulsant drugs, monoamine oxidase inhibitors, 5-HT3 receptor antagonists
(antiemetic and gastroprokinetic agents), dopamine receptor agonists (used to treat Parkinsonism), GABAB
receptor agonists (skeletal muscle relaxants), tricyclic antidepressants (TCAs), selective serotonin reuptake
inhibitors (SSRIs) and nicotinic acetylcholine receptor antagonists. Stimulant medication [methylphenidate
(Ritalin®, Novartis Pharmaceuticals UK) and dexamphetamine] has also been used in the treatment
of tics in association with ADHD.
In a recent prescribing survey among European expert clinicians,94 the most commonly used medications
for tics were, in descending order, risperidone, clonidine, aripiprazole (Abilify®, Otsuka), pimozide (Orap®,
Janssen), sulpiride (Dolmatil®, Sanofi-Aventis), tiapride (not available in the UK) and haloperidol. In the
pharmacological treatment of tics in children and young people, newer antipsychotics (e.g. risperidone and
aripiprazole) and noradrenergic agents (e.g. clonidine) have increasingly been favoured over the older
antipsychotic drugs (e.g. pimozide, sulpiride and haloperidol).
There have been a number of reviews and clinical guidelines of pharmacological treatment for TS94–96 but
no systematic review and quantitative meta-analyses of pharmacological treatments for tics have been
conducted to date.
Antipsychotic drugs
Pharmacology and prescribing
Antipsychotic drugs are sometimes divided into ‘first’- and ‘second’-generation antipsychotics, although this
really equates to older and newer antipsychotics. Both the older and newer antipsychotic drugs block
dopamine receptors (act as dopamine antagonists), with the risk of inducing extrapyramidal symptoms (EPSs)
and adverse effects (e.g. dystonia, Parkinsonism and tardive dyskinesia). Other potential adverse effects of
antipsychotics may include sedation, increased appetite, weight gain (with glucose and lipid dysregulation),
hyperprolactinaemia, reduced seizure threshold and cardiac conduction changes (e.g. QT prolongation).
Pimozide has been associated with sudden cardiac death (QT prolongation). Therefore, some antipsychotics
require routine electrocardiogram (ECG) monitoring.
Risperidone (non-proprietary; Risperdal®, Janssen) is a second-generation antipsychotic licensed in the UK
for a range of conditions, including the treatment of schizophrenia, manic episodes in bipolar disorder and
persistent aggression in conduct disorder. It is the best studied antipsychotic drug for the treatment of TS97
and was the most common medication used for treatment of children with TS among clinical members of
the European Society for the Study of Tourette Syndrome in a survey published in 2011.94
Aripiprazole (Abilify®, Otsuka) is a second-generation antipsychotic licensed in the UK for the treatment of
schizophrenia and the prevention and treatment of manic episodes in bipolar disorder. It is described as a
partial dopamine agonist.
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Olanzapine (non-proprietary; Zyprexia®, Lilly) is a second-generation antipsychotic licensed in the UK for
the treatment of schizophrenia, the treatment of moderate-to-severe manic episodes and prevention of
recurrence of manic episodes in patients with bipolar disorder.
Ziprasidone (Geodon/Zeldox®, Pfizer) is a second-generation antipsychotic approved by the US Food and
Drug Administration (FDA) for the treatment of schizophrenia and acute manic or mixed episodes associated
with bipolar disorder (with or without psychotic features), but is not currently licensed in the UK.
Haloperidol (non-proprietary; Dozic®, Rosemont; Haldol®, Janssen; Serenace®, TEVA UK) is a first-generation
antipsychotic licensed in the UK for a range of conditions, most commonly used in the treatment of
schizophrenia and psychosis. It is the only drug to have been granted a marketing authorisation (product
license) for TS in most European countries.97
Pimozide (Orap®, Janssen) is a first-generation antipsychotic licensed in the UK for the treatment and
prevention of relapse in chronic schizophrenia and other psychoses.
Sulpiride (non-proprietary; Domatil®, Sanofi-Aventis; Sulpor®, Rosemont) is a first-generation antipsychotic
licensed in the UK for the treatment of acute and chronic schizophrenia.
Included studies
Six studies presented data for the efficacy of antipsychotic medications compared with placebo [Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram, see Appendix 2]:
l haloperidol versus placebo: one child98 and one mixed99 study
l pimozide versus placebo: one child (same study as for haloperidol vs. placebo)98 and two
mixed99,100 studies
l risperidone versus placebo: one child101 and one mixed102 study
l ziprasidone versus placebo: one child study.103
Nine studies (head-to-head comparisons) compared the efficacy of one antipsychotic against another:
l pimozide versus risperidone: one child104 and one mixed105 study
l haloperidol versus pimozide: one child98 and two mixed99,106 studies
l aripiprazole versus tiapride: one child study107
l aripiprazole versus haloperidol: one child study108
l aripiprazole versus pimozide: one child study109
l olanzapine versus haloperidol: one child study.110
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. Four studies compared haloperidol with pimozide
and/or placebo. One crossover trial in 22 children compared haloperidol (mean dose of 3.5mg/day) and
pimozide (mean dose of 3.4 mg/day) with placebo for 6 weeks each.98 A mixed parallel trial (crossover study
but end of first-phase results used) in 57 participants compared the use of maximum dose of 10mg/day
haloperidol, maximum dose of 20mg/day pimozide and placebo for 6 weeks.99 In another mixed study,
20 participants underwent a crossover trial of maximum dose of 20mg/day (10mg/day for children aged
≤ 10 years) pimozide compared with placebo for 6 weeks each.100 In another mixed crossover study, nine
participants underwent treatment with maximum dose of 12mg/day haloperidol and pimozide in a
randomised order for 12 days each.106
Two studies compared risperidone with placebo. One parallel trial in 26 children101 (a mixed study but the
child data were presented separately) compared maximum dose of 3–4mg/day risperidone with placebo
for 8 weeks. A mixed parallel trial of 46 subjects compared the use of maximum dose of 6mg/day
risperidone with placebo for 8 weeks.102
DOI: 10.3310/hta19XXX HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. X
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Hollis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
UNCORRECTED PROOF DATE: 12/09/2015 FILE: 10-142-01-2P.pdf
17
One parallel trial in 28 children compared the use of maximum dose of 20mg/day ziprasidone103 with
placebo for 8 weeks.
Two studies compared pimozide with risperidone. One study was a crossover trial in which 19 children
underwent treatment with maximum dose of 4mg/day risperidone and pimozide in a randomised order
for 4 weeks each.104 The other study was a mixed parallel trial in which 50 adults and children were
randomised to either maximum dose of 6mg/day risperidone or pimozide for 8 weeks.105
One parallel study (quasi-randomised) in 200 children compared maximum dose of 15–25mg/day
aripiprazole with maximum dose of 300–500mg/day tiapride for 12 weeks.107
One parallel study (non-randomised) in 48 children compared maximum dose of 20mg/day aripiprazole
with maximum dose of 4.5mg/day haloperidol for 8 weeks.108
One controlled before-and-after study in 50 children investigated the comparative cardiovascular safety of
a mean dose of 4.4 mg (SD 1.5mg) twice a day of pimozide with a mean dose of 5.3mg (SD 2.4mg)
twice a day of aripiprazole for 24 months.109
One parallel RCT in 60 children compared maximum dose of 10mg/day olanzapine with maximum dose of
12mg/day haloperidol for 4 weeks.110
In all studies, the use of other psychotropic drugs was prohibited and previous medications were stopped
(with a washout period) before the start of the study.
Risk of bias
The crossover study of haloperidol, pimozide and placebo in children98 did not have clear methods for
randomisation or sequence generation but participants, providers and outcome assessors were blind to
treatment assignment. There was a 2-week washout period between treatments. The rate of dropout
was relatively low and the last observation carried forward was used in the analysis. Overall, the study was
considered to be at unclear risk of bias owing to possible cross-treatment contamination.
The mixed crossover study of haloperidol, pimozide and placebo99 had unclear methods of randomisation
and the presence of allocation concealment and outcome assessor blinding was unclear. First-phase data
were presented for this study and, for these results (used in this review), the risk of bias from cross-treatment
contamination is avoided. Analysis was of available case data but dropout from the study was reasonably
low (16%) and there may have been low risk of attrition bias. Overall, the study was considered to be at
unclear risk of bias owing to unclear provider and outcome assessor blinding.
The mixed crossover study comparing pimozide with placebo100 had unclear methods of randomisation and
the presence of allocation concealment and outcome assessor blinding was unclear. There was a 2-week
washout period between treatment periods. Attrition from the study was reasonably low (17%). Overall, the
study was considered to be at unclear risk of bias owing to unclear blinding of participants, providers and
outcome assessors and unclear cross-treatment contamination.
The mixed study of haloperidol compared with pimozide,106 had unclear methods for randomisation and
allocation concealment but there appears to have been blinding of participants, providers and outcome
assessors. The between-intervention washout period was 6 days. The number of participants randomised
in the study is not reported (only completers were analysed) and the risk of attrition bias is unclear. Overall,
owing to the short between-treatment washout period and the unclear risk of attrition bias, the study was
considered to be at unclear risk of bias.
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The parallel trial of risperidone compared with placebo in children101 had unclear methods of
randomisation and allocation concealment but participants, providers and outcome assessors were blind to
treatment allocation. The rate of dropout was low and last observation forward was used in the analysis.
Overall, the study was considered to be at low risk of bias.
The parallel study of ziprasidone compared with placebo in children103 had unclear methods of
randomisation and allocation concealment. It is unclear whether or not participants, providers and
outcome assessors were blind to treatment allocation. Dropout from the study was reasonably low and
data from all participants with one post-baseline measurement were carried forward in the analysis.
Overall, this study was considered to be at unclear risk of bias owing to unclear blinding of providers and
outcome assessors.
The mixed parallel study of risperidone compared with placebo102 had unclear methods for randomisation
and allocation concealment. It is stated that the drug was administered under double-blind conditions
but there is no description of participant, provider or outcome assessor blinding. Analysis was by last
observation carried forward for all participants with at least one post-baseline measurement and the risk of
attrition bias may have been low. Overall, the study was considered to have unclear risk of bias owing to
unclear patient, provider and outcome assessor blinding.
In the child crossover study of risperidone compared with pimozide,104 the method of randomisation,
allocation concealment and blinding of outcome assessors was unclear. There was a 2-week washout
period between interventions and it was unclear whether or not this was sufficient to avoid cross-treatment
contamination. There was a relatively high rate of dropout and analysis was of available case data. Overall,
the study was considered to be at high risk of bias owing to unclear risk of outcome assessor blinding,
possible cross-intervention contamination and attrition bias.
In the mixed parallel study of risperidone compared with pimozide,105 a computer-generated code was
used for randomisation but the presence of allocation concealment and blinding of participants, providers
and outcome assessors was unclear. There was a low rate of dropout and intention to treat analysis was
used. The study was considered to be at unclear risk of bias owing to unclear blinding of participants,
providers and outcome assessors.
In the parallel trial of aripiprazole compared with tiapride in children,107 quasi-randomisation was used with
participants assigned according to the order that the presented in clinic (odds aripiprazole, evens tiapride)
although baseline tic severity was similar. The presence of allocation concealment or blinding or
participants, providers or outcome assessors was unclear. The rate of dropout was low (2%) and although
intention-to-treat analysis was not used, the risk of attrition bias was low. The study was considered to be
at unclear risk of bias owing to unclear blinding of participants, providers and outcome assessors.
In the parallel study of aripiprazole compared with haloperidol in children,108 there was no randomisation
and participants could choose which drug they received. There was no blinding of participants, providers
and outcome assessors. The rate of dropout was moderate and different for aripiprazole (35%) and
tiapride (16%). Analysis was of available cases and there was unclear risk of attrition bias. The study was
considered to be at high risk of bias owing to lack of randomisation or blinding of participants, providers
and outcome assessors and unclear risk of attrition bias.
In the parallel safety study of pimozide compared with aripiprazole in children,109 participants do not
appear to have been randomised but the method of allocation is unclear. There was no blinding of
participants, providers and outcome assessors and attrition from the study is not reported. Outcomes were
objective (cardiovascular safety profiles) and the lack of blinding may not have been an important source
of bias. However, owing to the lack of randomisation and baseline dissimilarity (baseline age 9 years vs.
13 years for pimozide and aripiprazole, respectively) the study was considered to be at unclear risk of bias.
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In the study of olanzapine compared with haloperidol in children,110 participants were randomised
according to their hospital admission number and a computer-generated randomisation code. There
appears to have been allocation concealment and blinding of participants, providers and outcome
assessors. The rate of attrition was apparently low (10%) but participants were also excluded from the
study for poor compliance and serious adverse effects, but the numbers of these participants is not
reported. The study was considered to be at unclear risk of bias owing to the possibility of attrition bias.
Clinical evidence for antipsychotic drugs
Child and mixed-study findings for each drug compared with placebo are presented and head-to-head
comparisons (risperidone vs. pimozide and haloperidol vs. pimozide) are then presented. Findings for
all antipsychotic drugs compared with placebo are then presented combined.
Haloperidol compared with placebo
Two studies, one crossover trial in children and one parallel trial in a mixed population of adults and
children, investigated treatment with haloperidol compared with placebo.
Tics The child crossover study98 measured post-treatment tic severity with the TS global scale and the
mixed parallel study99 used the Shapiro Tourette Syndrome Severity Scale (TSSS). Results from each study
suggested a benefit for haloperidol compared with placebo on tic scores for children (SMD –0.50, 95% CI
–0.89 to –0.10; n= 22) and the mixed group (SMD –0.84, 95% CI –1.51 to –0.17; n= 37) (Figure 2).
For motor tics alone, post-treatment motor tic scores from the child study suggested a benefit for
haloperidol compared with placebo (SMD –0.63, 95% CI –1.04 to –0.22; n= 22) but the effect was
inconclusive in the mixed study (SMD –0.38, 95% CI –1.03 to 0.27; n= 37) (Figure 3).
For vocal tics, the effects post treatment were inconclusive (Figure 4).
Impairment For haloperidol, one study (n= 22) in children measured global outcome with the TS global
scale (contains components of tic frequency/severity and impairment),98 but the results were inconclusive
(Figure 5).
Impairment was also assessed with the Children’s Global Assessment Scale (C-GAS). Post treatment, the
results favoured haloperidol compared with placebo (SMD –0.49, 95% CI –0.88 to –0.09; n= 22) (C-GAS
higher scores show favourable effect, for consistency with other outcomes, scores reversed here) (Figure 6).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome The child and mixed study assessed overall clinical outcome with the
clinician-reported Clinical Global Impressions (CGI) Scale. In the child study, post-treatment CGI-Severity
score suggested a benefit for haloperidol compared with placebo (SMD –1.23, 95% CI –1.73 to –0.74;
n= 22) (Figure 7).
In the mixed study, CGI scores suggest a benefit for haloperidol compared with placebo for clinician (SMD
–0.80, 95% CI –1.47 to –0.13; n= 37) and patient rated scores (–0.87, 95% CI –1.55 to –0.19; n= 37)
(Figure 8).
Long-term outcome No relevant randomised trials reported long-term outcomes.
Safety In the child study,89 it is reported that general adverse effects did not differ between treatment
groups (p= 0.94). For EPSs, because a carryover effect was detected in the whole study analysis,
investigators analysed just the first-phase data for this outcome. There was no conclusive difference in
Extrapyramidal Symptom Rating Scale (ESRS) score for haloperidol compared with placebo (SMD 0.51,
95% CI –0.06 to 1.07; n= 11) (Figure 9).
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Study or subgroup SMD SE Weight
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SMD
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Subtotal (95% CI)
–0.496 –0.50 (–0.89 to –0.10)
–0.50 (–0.89 to –0.10)
0.202 100.0%
100.0%
–0.84 –0.84 (–1.51 to –0.17)
–0.84 (–1.51 to –0.17)
0.344 100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 2.46 (p = 0.01)
Mixed
Shapiro 198999
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.44 (p = 0.01)
–2 –1 0 1 2
Favours haloperidol Favours placebo
Test for subgroup differences: χ2 = 0.74, df = 1 (p = 0.39), I2 = 0%
FIGURE 2 Standardised post-treatment total tic scores for haloperidol compared with placebo in the child and mixed studies. df, degrees of freedom; IV, independent variable;
SE, standard error.
Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
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Subtotal (95% CI)
–0.626 –0.63 (–1.04 to –0.22)
–0.63 (–1.04 to –0.22)
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–0.38 –0.38 (–1.03 to –0.27)
–0.38 (–1.03 to –0.27)
0.332 100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 3.00 (p = 0.003)
Mixed
Shapiro 198999
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.14 (p = 0.25)
–2 –1 0 1 2
Favours haloperidol Favours placebo
Test for subgroup differences: χ2 = 0.39, df = 1 (p = 0.53), I2 = 0%
FIGURE 3 Standardised motor tic scores for haloperidol compared with placebo in the child and mixed studies. df, degrees of freedom; IV, independent variable;
SE, standard error.
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Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Children
Sallee 199798
Subtotal (95% CI)
–0.243 –0.24 (–0.62 to 0.14)
–0.24 (–0.62 to 0.14)
0.193 100.0%
100.0%
–0.55 –0.55 (–1.21 to 0.11)
–0.55 (–1.21 to 0.11)
0.337 100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 1.26 (p = 0.21)
Mixed
Shapiro 198999
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.63 (p = 0.10)
Test for subgroup differences: χ2 = 0.62, df = 1 (p = 0.43), I2 = 0%
–2 –1 0 1 2
Favours haloperidol Favours placebo
FIGURE 4 Standardised post-treatment vocal tic score for haloperidol compared with placebo in the child and mixed studies. df, degrees of freedom; IV, independent variable;
SE, standard error.
Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
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Children
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Subtotal (95% CI)
–0.367 –0.37 (–0.75 to 0.02)
–0.37 (–0.75 to 0.02)
0.197 100.0%
100.0%
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Test for overall effect: z = 1.86 (p = 0.06)
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FIGURE 5 Standardised post-treatment TS global score for haloperidol compared with placebo in the child study. IV, independent variable; SE, standard error.
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Study or subgroup SMD SE Weight
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IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Total (95% CI)
–0.488 –0.49 (–0.88 to –0.09)0.202 100.0%
Heterogeneity: not applicable
Test for overall effect: z = 2.42 (p = 0.02) –2 –1 0 1 2
Favours haloperidol Favours placebo
Sallee 199798
100.0% –0.49 (–0.88 to –0.09)
FIGURE 6 Standardised post-treatment C-GAS score for haloperidol compared with placebo in the child study. IV, independent variable; SE, standard error.
Study or subgroup SMD SE Weight
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IV, random, 95% Cl 
Total (95% CI)
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Heterogeneity: not applicable
Test for overall effect: z = 4.87 (p < 0.00001) –2 –1 0 1 2
Favours haloperidol Favours placebo
Sallee 199798
100.0% –1.23 (–1.73 to –0.74)
FIGURE 7 Standardised post-treatment CGI-Severity score for haloperidol compared with placebo in the child study. IV, independent variable; SE, standard error.
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FIGURE 9 Standardised post-treatment ESRS score for haloperidol compared with placebo in first phase of the child study. IV, independent variable; SE, standard error.
Study or subgroup
Post-treatment
haloperidol
Post-treatment
placebo
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Clinician rated
Shapiro 198999
Subtotal (95% CI)
–0.80 (–1.47 to –0.13)
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Unclear risk –0.87 (–1.55 to –0.19)
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Heterogeneity: not applicable
Test for overall effect: z = 2.33 (p = 0.02)
Patient rated
Shapiro 198999
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.52 (p = 0.01)
–2 –1 0 1 2
Favours haloperidol Favours placebo
FIGURE 8 Standardised post-treatment CGI score for haloperidol compared with placebo in the mixed study. IV, independent variable; ROB, risk of bias.
IN
T
E
R
V
E
N
T
IO
N
S
F
O
R
T
IC
S
IN
C
H
ILD
R
E
N
A
N
D
A
D
O
LE
S
C
E
N
T
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
2
4
Abnormal involuntary movements, assessed by the Abnormal Involuntary Movement Scale (AIMS), were
similar for haloperidol compared with placebo (SMD 0.11, 95% CI –0.27 to 0.48; n= 22) (Figure 10).
There was no evidence of electrocardiovascular effects for haloperidol in this study and it was
indistinguishable from placebo in its effects on heart rate, rhythm and waveform.
In the mixed study,99 based on the CGI score, there was evidence of increased adverse effects for
haloperidol compared with placebo when rated by physicians (SMD 0.78, 95% CI 0.11 to 1.45; n= 37)
and participants (SMD 0.75, 95% CI 0.08 to 1.42; n= 37) (Figure 11). In this study, for moderate or
marked adverse effects, it is reported that there was no significant difference between haloperidol and
placebo except for akinesia, and there were significantly more events in the haloperidol compared with the
placebo group [haloperidol: 50% (9/18), placebo: 11% (2/19); p= 0.011].
Moderators of effectiveness In the mixed study,99 investigators examined a large number of potentially
moderating factors on outcomes of the CGI and Shapiro TSSS (52 factors examined, e.g. age, sex and
history of tics). The only significant correlation was a negative correlation between age and CGI score
[r= –0.56; p= 0.003, favoured younger age (age range of participants in the study was 8–65 years and
was entered into the analysis as a continuous independent variable. The negative correlation of CGI score
with age suggests that older participants in this age range (8–65 years) showed the least improvement
with haloperidol)].
Pimozide compared with placebo
Tics
One child and two mixed studies measured intervention effects on tic scores for pimozide compared with
placebo (Figure 12). The child study98 used the TS global scale tic score and the mixed studies used the
Shapiro TSSS.99,100 In the child study, results from the post-treatment TS global scale tic score suggested a
benefit for pimozide compared with placebo (SMD –0.81, 95% CI –1.24 to –0.38; n= 22), but was
inconclusive when results from the two mixed studies were pooled (SMD –0.75, 95% CI –1.95 to 0.46;
n= 59). There was heterogeneity between the two mixed studies (I2= 85).
The studies presented data separately for motor (Figure 13) and vocal (Figure 14) tic components. The
results for post-treatment motor tic score suggested a benefit for pimozide compared with placebo in
children (SMD –0.75, 95% CI –1.17 to –0.32; n= 22) and the mixed group (SMD –0.94, 95% CI –1.76 to
–0.12; n= 59). There was heterogeneity between the two mixed studies (I2= 67%).
The post-treatment vocal tic score suggested benefit for pimozide compared with placebo in children
(SMD –0.66, 95% CI –1.07 to –0.25; n= 22), but the results were inconclusive when the two mixed
studies were pooled (SMD –0.63, 95% CI –1.54 to 0.28; n= 59). There was heterogeneity between mixed
studies (I2= 75%).
Impairment One child study reported post-treatment results for global TS severity (contains tic and
impairment components).98 The results suggested a benefit for pimozide compared with placebo (SMD
–0.65, 95% CI –1.06 to –0.23; n= 22) (Figure 15).
Impairment was also assessed with the C-GAS and post-treatment results suggested a benefit for pimozide
compared with placebo (SMD –0.64, 95% CI –1.05 to –0.23; n= 22) (C-GAS higher scores show
favourable effect, for consistency with other outcomes, scores reversed here) (Figure 16).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome In the child study,98 post-treatment CGI-Severity score was measured. The
results suggested a benefit for pimozide compared with placebo (SMD –1.23, 95% CI –1.73 to –0.74;
n= 22) (Figure 17).
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Heterogeneity: not applicable
Test for overall effect: z = 0.57 (p = 0.57) –2 –1 0 1 2Favours haloperidol Favours placebo
Sallee 199798
100.0% 0.11 (–0.27 to 0.48)
FIGURE 10 Standardised post-treatment AIMS score for haloperidol compared with placebo in the child study. IV, independent variable; SE, standard error.
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Post-treatment
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FIGURE 11 Standardised CGI adverse effects score assessed by physicians and patients in the mixed study for haloperidol compared with placebo. IV, independent variable;
ROB, risk of bias.
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Mixed
Shapiro 198999
Shapiro 1984100
Subtotal (95% CI)
–2 –1 0 1 2
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Heterogeneity: τ2 =  0.64; χ2 = 6.67, df = 1 ( p = 0.010); I2 = 85%
Test for overall effect: z = 1.21 ( p = 0.22)
FIGURE 12 Standardised post-treatment total tic scores for pimozide compared with placebo in the child and mixed studies. df, degrees of freedom; ROB, risk of bias;
SE, standard error.
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Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Children
Sallee 199798
Subtotal (95% CI)
–0.746 –0.75 (–1.17 to –0.32)
–0.75 (–1.17 to –0.32)
0.216 Unclear risk
Unclear risk
Unclear risk
100.0%
100.0%
–1.37
–0.53
–1.37 (–2.06 to –0.68)
–0.53 (–1.17 to 0.11)
–0.94 (–1.76 to –0.12)
0.352
0.329
48.9%
51.1%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 3.45 ( p = 0.0006)
Mixed
Shapiro 1984100
Shapiro 198999
Subtotal (95% CI)
–2 –1 0 1 2
Favours pimozide Favours placeboTest for subgroup differences: χ2 = 0.17, df = 1 ( p = 0.68), I 2 = 0%
Heterogeneity: τ2 = 0.24; χ2 = 3.04, df = 1 ( p = 0.08); I 2 = 67%
Test for overall effect: z = 2.24 ( p = 0.03)
FIGURE 13 Standardised post-treatment motor tic scores for pimozide compared with placebo in the child and mixed studies. df, degrees of freedom; IV, independent
variable; ROB, risk of bias; SE, standard error.
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Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Children
Sallee 199798
Subtotal (95% CI)
–0.657 –0.66 (–1.07 to –0.25)
–0.66 (–1.07 to –0.25)
0.21 Unclear risk
Unclear risk
Unclear risk
100.0%
100.0%
–0.17
–1.098
–0.17 (–0.80 to 0.46)
–1.10 (–1.76 to –0.43)
–0.63 (–1.54 to 0.28)
0.321
0.339
50.7%
49.3%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 3.13 ( p = 0.002)
Mixed
Shapiro 198999
Shapiro 1984100
Subtotal (95% CI)
–2 –1 0 1 2
Favours pimozide Favours placeboTest for subgroup differences: χ2= 0.00, df = 1 ( p = 0.95), I 2 = 0%
Heterogeneity: τ2 = 0.32; χ2 = 3.95, df = 1 ( p = 0.05); I2 = 75%
Test for overall effect: z = 1.35 ( p = 0.18)
FIGURE 14 Standardised post-treatment vocal tic score for pimozide compared with placebo in the child and mixed studies. df, degrees of freedom; IV, independent variable;
ROB, risk of bias; SE, standard error.
Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Children
Sallee 199798
Subtotal (95% CI)
–0.646 –0.65 (–1.06 to –0.23)
–0.65 (–1.06 to –0.23)
0.21 100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 3.08 (p = 0.002)
–2 –1 0 1 2
Favours pimozide Favours placebo
FIGURE 15 Standardised post-treatment TS global score for pimozide compared with placebo in children. IV, independent variable; SE, standard error.
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Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Total (95% CI)
–0.641 –0.64 (–1.05 to –0.23)0.209 100.0%
Heterogeneity: not applicable
Test for overall effect: z = 3.07 (p = 0.002) –2 –1 0 1 2
Favours pimozide Favours placebo
Sallee 199798
100.0% –0.64 (–1.05 to –0.23)
FIGURE 16 Standardised post-treatment C-GAS score for pimozide compared with placebo in the child study. IV, independent variable; SE, standard error.
Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Total (95% CI)
–1.233 –1.23 (–1.73 to –0.74)0.253 100.0%
Heterogeneity: not applicable
Test for overall effect: z = 4.87 (p < 0.00001) –2 –1 0 1 2
Favours pimozide Favours placebo
Sallee 199798
100.0% –1.23 (–1.73 to –0.74)
FIGURE 17 Standardised post-treatment CGI-Severity score for children following treatment with pimozide compared with placebo in the child study. IV, independent variable;
SE, standard error.
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In one of the mixed studies,99 CGI score was assessed by clinicians and participants (unclear which type of
CGI score this is, higher score appears to indicate better efficacy, axis have been reversed for clarity).
Treatment with pimozide resulted in better CGI scores when assessed by clinicians (SMD –0.70, 95% CI
–1.35 to –0.05; n= 39) and participants (SMD –0.68, 95% CI –1.33 to –0.04; n= 39) (Figure 18).
Long-term outcome No relevant randomised trials reported long-term outcomes.
Safety In the child study,98 it is reported that general adverse effects did not differ between treatment
groups (p= 0.94). For EPSs, because a carryover effect was detected in the whole study analysis,
investigators analysed just the first-phase data for this outcome and ESRS scores were similar for pimozide
compared with placebo (SMD 0.20, 95% CI –0.33 to 0.73; n= 11) (Figure 19).
In this study, abnormal involuntary movements, assessed by the AIMS, were similar for pimozide compared
with placebo (SMD 0.22, 95% CI –0.16 to 0.60; n= 22) (Figure 20). There was no evidence of
electrocardiovascular effects for pimozide and it was indistinguishable from placebo in its effects on heart
rate, rhythm and waveform.
In the mixed study,99 for adverse effects rated on the CGI scale, there was no conclusive difference in
adverse effect scores for pimozide compared with placebo when rated by physicians (SMD 0.44, 95% CI
–0.19 to 1.08; n= 39) or participants (SMD 0.31, 95% CI –0.32 to 0.95; n= 39) (Figure 21). In this study,
for moderate or marked adverse effects, it is reported that there was no significant difference in event
rates for pimozide compared with placebo.
In the safety study comparing pimozide with aripiprazole,109 there was no conclusive difference in heart
rate for pimozide compared with aripiprazole [mean difference (MD) 4.90, 95% CI –1.16 to 10.96;
n= 50], but there were greater reductions from baseline in systolic (MD –20.00, 95% CI –26.56 to –13.44;
n= 50) and diastolic (MD –13.70, 95% CI –17.39 to –10.01; n= 50) blood pressure (BP) and greater
increases in ECG-QT (MD 25.50, 95% CI 12.69 to 38.31; n= 50) and ECG-QTc (MD 19.10, 95% CI 10.07
to 28.31; n= 50) compared with aripiprazole.
Moderators of effectiveness In the mixed study,99 investigators examined a large number of potentially
moderating factors on outcomes of the CGI and Shapiro TSSS (52 factors examined, e.g. age, sex and
history of tics). The only significant correlation was a negative correlation between age and CGI score
(r= –0.39; p= 0.04, favoured younger age).
Risperidone compared with placebo
One child101 and one mixed102 parallel trial compared the efficacy of risperidone with placebo.
Tics
Results from the YGTSS total tic score suggested a benefit for risperidone compared with placebo in
children (SMD –1.10, 95% CI –1.94 to –0.26; n= 26) and in the mixed study in terms of Shapiro TSSS tic
(SMD –0.62, 95% CI –1.21 to –0.03; n= 46) (Figure 22).
Impairment No relevant studies reported this outcome.
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome In both studies, the CGI scale was used to assess overall clinical change. In the
child study, findings were dichotomised as the proportion of children who were much or very much
improved compared with those who were not and, in the mixed study, findings were reported as the
reduction in CGI-Severity score. A greater proportion of children were much or very much improved
following treatment with risperidone compared with placebo (RR 0.27, 95% CI 0.10 to 0.73; n= 26)
(Figure 23).
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Study or subgroup
Pimozide Placebo
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Clinician rated
Shapiro 198999
Subtotal (95% CI)
–0.70 (–1.35 to –0.05)
–0.70 (–1.35 to –0.05)
–3.2 –1.91.5 2.120
20
19
19
–3.2 –1.91.6 2.120
20
19
19
100.0%
100.0%
Unclear risk
Unclear risk –0.68 (–1.33 to –0.04)
–0.68 (–1.33 to –0.04)
100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 2.12 (p = 0.03)
Patient rated
Shapiro 198999
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.07 (p = 0.04)
–2 –1 0 1 2
Favours pimozide Favours placebo
FIGURE 18 Standardised CGI-Severity score for patients undergoing treatment with pimozide compared with placebo in the mixed study. IV, independent variable; ROB, risk of
bias; SE, standard error.
Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Total (95% CI)
0.2 0.20 (–0.33 to 0.73)0.272 100.0%
Heterogeneity: not applicable
Test for overall effect: z = 0.74 (p = 0.46) –2 –1 0 1 2
Favours pimozide Favours placebo
Sallee 199798
100.0% 0.20 (–0.33 to 0.73)
FIGURE 19 Standardised post-treatment ESRS score for pimozide compared with placebo in first phase of the child study. IV, independent variable; SE, standard error.
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Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Total (95% CI)
0.217 0.22 (–0.16 to 0.60)0.193 100.0%
Heterogeneity: not applicable
Test for overall effect: z = 1.12 (p = 0.26) –2 –1 0 1 2
Favours pimozide Favours placebo
Sallee 199798
100.0% 0.22 (–0.16 to 0.60)
FIGURE 20 Standardised post-treatment AIMS score for pimozide compared with placebo in the child study. IV, independent variable; SE, standard error.
Study or subgroup
Post-treatment
pimozide
Post-treatment
placebo
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Clinician rated
Shapiro 198999
Subtotal (95% CI)
0.44 (–0.19 to 1.08)
0.44 (–0.19 to 1.08)
1.3 0.81 1.220
20
19
19
1.3 0.91.3 1.220
20
19
19
100.0%
100.0%
Unclear risk
Unclear risk 0.31 (–0.32 to 0.95)
0.31 (–0.32 to 0.95)
100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 1.37 (p = 0.17)
Patient rated
Shapiro 198999
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.97 (p = 0.33)
–2 –1 0 1 2
Favours pimozide Favours placebo
FIGURE 21 Standardised CGI adverse effects scale for pimozide compared with placebo assessed by physicians and patients in the mixed study. IV, independent variable;
ROB, risk of bias; SE, standard error.
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Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Children
Scahill 2003101
Subtotal (95% CI)
–1.1 –1.10 (–1.94 to –0.26)
–1.10 (–1.94 to –0.26)
0.429 100.0%
100.0%
–0.62 –0.62 (–1.21 to –0.03)
–0.62 (–1.21 to –0.03)
0.3 100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 2.56 ( p = 0.01)
Mixed
Dion 2002102
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.07 ( p = 0.04)
–2 –1 0 1 2
Favours risperidone Favours placebo
Test for subgroup differences: χ2 = 0.84, df = 1 ( p = 0.36), I 2 = 0%
FIGURE 22 Standardised change in total tic scores for risperidone compared with placebo in the child and mixed study. df, degrees of freedom; IV, independent variable;
SE, standard error.
Study or subgroup
Risperidone
Events Total Events Total Weight Overall ROB
Placebo RR (non-event)
M–H, random, 95% Cl
RR (non-event)
M–H, random, 95% Cl
Total (95% CI)
0.27 (0.10 to 0.73)9 112 14
9 1
100.0% Low risk
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.60 (p = 0.009) 0.02 0.1 1 10 50
Favours risperidone Favours placebo
Scahill 2003101
100.0%12 14 0.27 (0.10 to 0.73)
FIGURE 23 Proportion of children CGI much or very much improved for risperidone compared with placebo in children (RR of not being much or very much improved).
M–H, Mantel–Haenszel; ROB, risk of bias.
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In the mixed study, the CGI-Severity score following treatment suggested a benefit for risperidone
compared with placebo (SMD –0.66, 95% CI –1.26 to –0.07; n= 46) (Figure 24).
Long-term outcome No relevant studies reported long-term outcomes.
Safety Both studies recorded adverse effects [for child study, adverse effects reported for the whole study
population (n= 34) and not the separate paediatric sample]. Common adverse effects reported in both
studies are shown in Figure 25 and adverse effects reported in only one or other of the studies, and with
an event rate of > 5, are shown in Figure 26.
For both studies combined, there were higher rates of fatigue (RR 3.72, 95% CI 1.57 to 8.85; n= 80),
somnolence/sedation (RR 5.38, 95% CI 1.24 to 23.30; n= 80) and increased appetite/weight gain (RR
7.68, 95% CI 1.46 to 40.43; n= 80) but similar rates of headache (RR 0.40, 95% CI 0.15 to 1.04; n= 80)
and abnormal vision (RR 1.14, 95% CI 0.07 to 17.91; n= 80) for risperidone compared with placebo.
For outcomes reported in only one of the studies with > 5 events (all from the mixed study), there was no
conclusive difference in rates of dizziness (RR 1.50, 95% CI 0.64 to 3.53; n= 46), depression (RR 6.00,
95% CI 0.78 to 45.99; n= 46), increased saliva (RR 2.00, 95% CI 0.57 to 7.05; n= 46), tremor (RR 3.00,
95% CI 0.67 to 13.34; n= 46), dry mouth (RR 2.50, 95% CI 0.54 to 11.60; n= 46) or hypertonia
(RR 1.33, 95% CI 0.34 to 5.30; n= 46).
In the study with the child subgroup,101 for the whole mixed study population there was an increase in
weight of 2.8 kg in the risperidone group compared with no change in the placebo group (p= 0.0001).
The study reported that a similar increase was observed in the paediatric sample alone. In this study, no
EPSs were reported and there were no abnormalities or clinically significant changes in laboratory values,
cardiovascular indices or vital signs. Two children taking risperidone had acute social phobia and treatment
was reduced in one child and discontinued in the other.
In the mixed study,102 the ESRS was used (Figure 27). The parkinsonism examination total score of the ESRS
suggested a harm for risperidone compared with placebo (SMD 1.01, 95% CI 0.39 to 1.63; n= 46) but
results from the dystonia subscale (SMD 0.00, 95% CI –0.58 to 0.58; n= 46) and the dyskinetic
movements subscale (SMD –0.09, 95% CI –0.67 to 0.49; n= 46) were inconclusive.
Ziprasidone compared with placebo
One small parallel trial in children compared the efficacy of ziprasidone with placebo.98
Tics
Tics were assessed with the YGTSS. The results suggested a benefit for ziprasidone when compared with
placebo (SMD –1.10, 95% CI –1.93 to –0.27; n= 27) (Figure 28).
Impairment No results for impairment were reported separately but impairment was measured as part of
the YGTSS global scale. There was a greater reduction from baseline in YGTSS global score for ziprasidone
compared with placebo (SMD –1.02, 95% CI –1.84 to –0.20; n= 27) (Figure 29).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Overall clinical outcome was assessed using the CGI-Severity scale, but the
results were not conclusive (SMD –0.71, 95% CI –1.50 to 0.09; n= 27) (Figure 30).
Long-term outcome No relevant studies reported long-term outcomes.
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Study or subgroup
Change risperidone
Mean MeanSD SDTotal Total Weight Overall ROB
Change placebo SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl
Total (95% CI)
–0.66 (–1.26 to –0.07)
–0.66 (–1.26 to –0.07)
–1 –0.35231.04 0.88 100.0% Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 2.18 (p = 0.03) –1–2 0 1 2
Favours risperidone Favours placebo
Dion 2002102
100.0%23
23
23
FIGURE 24 Standardised change in CGI-Severity score for risperidone compared with placebo in the mixed study. IV, independent variable; ROB, risk of bias.
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Study or subgroup Events EventsTotal Total
Risperidone Placebo RR
M–H, random, 95% ClWeight Overall ROB
Low risk
Unclear risk
RR
M–H, random, 95% Cl 
Fatigue
Scahill 2003101
Dion 2002102
Subtotal (95% CI)
6.75 (0.91 to 50.23)
3.25 (1.24 to 8.49)
3.72 (1.57 to 8.85)
6
13
1
4
16
23
39
18
23
41
18.6%
81.4%
100.0%
Total events 19 5
0.002 0.1 1 10 500
Favours risperidone Favours placebo
Heterogeneity: τ2 = 0.00; χ2 = 0.43, df = 1 (p = 0.51); I2 = 0%
Test for overall effect: z = 2.98 (p = 0.003)
Low risk
Unclear risk
Somnolence/sedation
Scahill 2003101
Dion 2002102
Subtotal (95% CI)
3.38 (0.39 to 29.28)
8.00 (1.09 to 58.93)
5.38 (1.24 to 23.30)
3
8
1
1
16
23
39
18
23
41
46.1%
53.9%
100.0%
Total events 11 2
Heterogeneity: τ2 = 0.00; χ2 = 0.34, df = 1 (p = 0.56); I2 = 0%
Test for overall effect: z = 2.25 (p = 0.02)
Low risk
Unclear risk
Headache
Scahill 2003101
Dion 2002102
Subtotal (95% CI)
0.16 (0.01 to 2.87)
0.44 (0.16 to 1.24)
0.40 (0.15 to 1.04)
0
4
3
9
16
23
39
18
23
41
11.2%
88.8%
100.0%
Total events 4 12
Heterogeneity: τ2 = 0.00; χ2 = 0.45, df = 1 (p = 0.50); I2 = 0%
Test for overall effect: z = 1.88 (p = 0.06)
FIGURE 25 Adverse events reported in the child and mixed studies of risperidone compared with placebo. df, degrees of freedom; M–H, Mantel–Haenszel; ROB, risk
of bias. (continued )
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Study or subgroup Events EventsTotal Total
Risperidone Placebo RR
M–H, random, 95% ClWeight Overall ROB
RR
M–H, random, 95% Cl 
0.002 0.1 1 10 500
Favours risperidone Favours placebo
Low risk
Unclear risk
Abnormal/blurred vision
Scahill 2003101
Dion 2002102
Subtotal (95% CI)
5.59 (0.29 to 108.38)
0.33 (0.04 to 2.97)
1.14 (0.07 to 17.91)
2
1
0
3
16
23
39
18
23
41
43.5%
56.5%
100.0%
Total events 3 3
Heterogeneity: τ2 = 2.26; χ2 = 2.28, df = 1 (p = 0.13); I2 = 56%
Test for overall effect: z = 0.09 (p = 0.93)
Low risk
Unclear risk
Insomnia
Scahill 2003101
Dion 2002102
Subtotal (95% CI)
1.13 (0.08 to 16.55)
2.50 (0.54 to 11.60)
2.05 (0.54 to 7.79)
1
5
1
2
16
23
39
18
23
41
24.6%
75.4%
100.0%
Total events 6 3
Heterogeneity: τ2 = 0.00; χ2  = 0.26, df = 1 (p = 0.61); I2 = 0%
Test for overall effect: z = 1.06 (p = 0.29)
Low risk
Unclear risk
Increased appetite/weight
Scahill 2003101
Dion 2002102
Subtotal (95% CI)
16.76 (1.03 to 272.11)
5.00 (0.63 to 39.54)
7.68 (1.46 to 40.43)
7
5
0
1
16
23
39
18
23
41
35.5%
64.5%
100.0%
Total events 12 1
Heterogeneity: τ2= 0.00; χ2 =  0.49, df = 1 (p = 0.48); I2 = 0%
Test for overall effect: z = 2.41 (p = 0.02)
FIGURE 25 Adverse events reported in the child and mixed studies of risperidone compared with placebo. df, degrees of freedom; M–H, Mantel–Haenszel; ROB, risk of bias.
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Study or subgroup Events EventsTotal Total
Risperidone Placebo RR
Weight Overall ROB
Unclear risk
Unclear risk
Unclear risk
M–H, random, 95% Cl
RR
M–H, random, 95% Cl 
Dizziness
Dion 2002102
Subtotal (95% CI)
Total events
Heterogeneity: not applicable 
Test for overall effect: z = 0.93 (p = 0.35)
1.50 (0.64 to 3.53)
1.50 (0.64 to 3.53)
9
9
6
6
23
23
23
23
100.0%
100.0%
0.01 0.1 1 10 100
Favours risperidone Favours placebo
Depression
Dion 2002102
Subtotal (95% CI)
Total events
Heterogeneity: not applicable 
Test for overall effect: z = 1.72 (p = 0.08)
6
6
1
1
23
23
23
23
100.0%
100.0%
Increased saliva
Dion 2002102
Subtotal (95% CI)
Total events
Heterogeneity: not applicable 
Test for overall effect: z = 1.08 (p = 0.28)
6
6
3
3
23
23
23
23
100.0%
100.0%
Unclear risk
Tremor
Dion 2002102
Subtotal (95% CI)
Total events
Heterogeneity: not applicable 
Test for overall effect: z = 1.44 (p = 0.15)
6
6
2
2
23
23
23
23
100.0%
100.0%
Unclear risk
Dry mouth
Dion 2002102
Subtotal (95% CI)
Total events
Heterogeneity: not applicable 
Test for overall effect: z = 1.17 (p = 0.24)
5
5
2
2
23
23
23
23
100.0%
100.0%
Unclear risk
Hypertonia
Dion 2002102
Subtotal (95% CI)
Total events
Heterogeneity: not applicable 
Test for overall effect: z = 0.41 (p = 0.68)
4
4
3
3
23
23
23
23
100.0%
100.0%
6.00 (0.78 to 45.99)
6.00 (0.78 to 45.99)
2.00 (0.57 to 7.05)
2.00 (0.57 to 7.05)
3.00 (0.67 to 13.34)
3.00 (0.67 to 13.34)
2.50 (0.54 to 11.60)
2.50 (0.54 to 11.60)
1.33 (0.34 to 5.30)
1.33 (0.34 to 5.30)
FIGURE 26 Adverse events with more than five events reported in only the mixed study of risperidone compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
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Study or subgroup
Change risperidone Change placebo
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Parkinsonism total score
Dion 2002102
Subtotal (95% CI)
1.01 (0.39 to 1.63)
1.01 (0.39 to 1.63)
3.17 –0.394.13 2.6323
23
23
23
100.0%
100.0%
Unclear risk
0.00 (–0.58 to 0.58)
0.00 (–0.58 to 0.58)
–0.09 (–0.67 to 0.49)
–0.09 (–0.67 to 0.49)
Heterogeneity: not applicable
Test for overall effect: z = 3.21 (p = 0.001)
Dystonia
Dion 2002102
Subtotal (95% CI)
00 0.19 0.0123
23
23
23
100.0%
100.0%
Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 0.00 (p = 1.00)
Dyskinetic movements total score
Dion 2002102
Subtotal (95% CI)
0.310.17 0.65 2.0223
23
23
23
100.0%
100.0%
Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 0.31 (p = 0.76)
–2 –1 0 1 2
Favours risperidone Favours placebo
FIGURE 27 Standardised ESRS scores for risperidone compared with placebo in the mixed study. IV, independent variable; ROB, risk of bias.
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Study or subgroup
Change ziprasidone Change placebo
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Sallee 2000103
–1.10 (–1.93 to –0.27)
–1.10 (–1.93 to –0.27)–8.6
Total (95% CI)
6.7 16 –1.7
16
11
11
5
100.0%
Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 2.60 (p = 0.009) –2 –1 0 1 2
Favours ziprasidone Favours placebo
100.0%
FIGURE 28 Standardised post-treatment YGTSS total tic score for ziprasidone compared with placebo. IV, independent variable; ROB, risk of bias.
Study or subgroup
Change ziprasidone Change placebo
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Sallee 2000103
–0.71 (–1.50 to 0.09)
–0.71 (–1.50 to 0.09)–1.4
Total (95% CI)
1 16 –0.7
16
11
11
0.9
100.0%
Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 1.74 (p = 0.08) –2 –1 0 1 2
Favours ziprasidone Favours placebo
100.0%
FIGURE 30 Standardised change in CGI-Severity score for ziprasidone compared with placebo. IV, independent variable; ROB, risk of bias.
Study or subgroup
Change ziprasidone Change placebo
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Sallee 2000103
–1.02 (–1.84 to –0.20)
–1.02 (–1.84 to –0.20)–18.3
Total (95% CI)
9.9 16 –7.6
16
11
11
10.6
100.0%
Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 2.43 (p = 0.02)
–2 –1 0 1 2
Favours ziprasidone Favours placebo
100.0%
FIGURE 29 Standardised post-treatment YGTSS global score for ziprasidone compared with placebo. IV, independent variable; ROB, risk of bias.
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Safety There were a greater number of participants experiencing treatment-emergent adverse effects for
ziprasidone compared with placebo (RR 1.68, 95% CI 1.05 to 2.70; n= 28) (Figure 31).
Most events were considered mild or moderate. One case of somnolence and one of akathisia were
experienced in the ziprasidone group at maximum drug dosage (dosage was reduced but treatment did
not have to be discontinued). The most common adverse effect was mild sedation (11 out of 16 in
ziprasidone group compared with 5 out of 12 in the placebo group had increase in sedation score at some
point, χ2= 1.44; p= 0.21).
The increase in body weight was similar for the ziprasidone (+ 0.7± 1.5 kg) and placebo (+ 0.8± 2.3 kg)
group (MD –0.1, 95% CI –1.59 to 1.39; n= 28) (Figure 32) and it was reported that there were no
discernible patterns in abnormalities detected on laboratory tests and there were no between-group
differences in vital signs, pulse rate, standing or sitting BP or ECG parameters.
Risperidone compared with pimozide
One child crossover study104 and one mixed parallel study105 compared the efficacy of risperidone
with pimozide.
Tics
In the child study,104 tic outcome was assessed with the YGTSS, whereas in the mixed study105 tic outcome
was assessed with the Shapiro TSSS. Results were not conclusive (Figure 33).
Within the mixed study, a subgroup analysis was conducted of participants aged < 18 years or ≥ 18 years.
It was reported that, although efficacy tended to be better for both drugs in the younger age group, there
was no significant difference for pimozide compared with risperidone for participants within either
age group.
Impairment In the child study,104 impairment was measured with the YGTSS impairment scale. In the
mixed study,105 impairment was measured with the Global Assessment of Functioning scale, which assesses
changes in social and occupational functioning. Results from both the child study (n= 13) and the mixed
study (n= 50) were not conclusive, although there was some evidence of a difference in the effect
between the child and the mixed study (I2= 72% for the subgroup difference) (Figure 34).
Psychological well-being In the mixed study (n= 50),105 anxiety was assessed using the Hamilton Rating
Scale for Anxiety, but the results were inconclusive (Figure 35).
Overall clinical outcome In the child study,104 overall clinical outcome was assessed with the Clinical
Global Impressions – Improvement (CGI-I) scale and, in the mixed study105 outcome was assessed as the
change from baseline on the CGI-Severity scale. In both the child study (n= 13) and the mixed study
(n= 50) the results were inconclusive (Figure 36).
Long-term outcome No relevant studies reported long-term outcomes.
Safety In both studies, participants’ weight was measured before and after treatment. In both studies,
there was a trend suggesting increased weight gain for risperidone compared with pimozide. The overall
difference in weight gain for risperidone compared with pimozide was 0.77 kg (95% CI –0.18 to 1.73;
n= 80) (Figure 37).
In the mixed study,105 participants were subgrouped by age and it is reported that weight gain during
risperidone administration was greater for participants aged ≤ 18 years compared with > 18 years but, for
pimozide, it was similar for participants aged ≤ 18 years and > 18 years (no data reported).
In both studies, the ESRS was used to assess any abnormal involuntary movements. There were similar
post-treatment ESRS scores for risperidone compared with pimozide in the child study (SMD –0.05,
95% CI –0.77 to 0.66; n= 30) (Figure 38) and in the mixed study there was no change in the risperidone
group and a reduction of 0.1 in the pimozide group (no precision reported).
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Study or subgroup
Ziprasidone
Events EventsTotal Total
Placebo RR
Weight M–H, random, 95% CI
RR
M–H, random, 95% CI
Sallee 2000103 1.68 (1.05 to 2.70)
1.68 (1.05 to 2.70)Total (95% CI)
16 7 12 100%
716
16
16 12 100%
Overall ROB
Unclear risk
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.16 (p = 0.03) 0.50.20.1 1 2 5 10
Favours ziprasidone Favours placebo
FIGURE 31 Number of patients experiencing adverse events for ziprasidone compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup
Ziprasidone
Mean MeanTotal TotalSD SD
Placebo
Weight
MD
IV, random, 95% CI
MD
IV, random, 95% CIOverall ROB
Unclear riskSallee 2000103 –0.10 (–1.59 to 1.39)
–0.10 (–1.59 to 1.39)Total (95% CI)
0.7 0.8 2.3 100%1.5 16 12
16 12 100%
Heterogeneity: not applicable
Test for overall effect: z = 0.13 (p = 0.90) –2–4 0 2 4
Favours ziprasidone Favours placebo
FIGURE 32 Change in body weight for ziprasidone compared with placebo. IV, independent variable; ROB, risk of bias.
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Study or subgroup WeightSESMD Overall ROB
High risk
Unclear risk
Gilbert 2004104
Subtotal (95% CI)
–0.54 (–1.32 to 0.24)
–0.54 (–1.32 to 0.24)
–0.04 (–0.59 to 0.51)
–0.04 (–0.59 to 0.51)
Children
Mixed
Heterogeneity: not applicable
Test for overall effect: z = 1.35 (p = 0.18)
–1–2 0 1 2
Favours risperidone Favours pimozide
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl
–0.54 0.4 100.0%
100.0%
Bruggeman 2001105
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.14 (p = 0.89)
–0.04 0.28 100.0%
100.0%
Test for subgroup differences: χ2= 1.05, df = 1 (p = 0.31), I2= 4.6%
FIGURE 33 Standardised tic scores for treatment with risperidone compared with pimozide in the child and mixed studies. df, degrees of freedom; IV, independent variable;
ROB, risk of bias; SE, standard error.
Study or subgroup WeightSESMD Overall ROB
High risk
Unclear risk
Gilbert 2004104
Subtotal (95% CI)
–0.77 (–1.57 to 0.02)
–0.77 (–1.57 to 0.02)
0.17 (–0.39 to 0.73)
0.17 (–0.39 to 0.73)
Children
Mixed
Heterogeneity: not applicable
Test for overall effect: z = 1.90 (p = 0.06)
SMD
IV, random, 95% Cl
–0.774 0.407 100.0%
100.0%
Bruggeman 2001105
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.59 (p = 0.55)
0.17 0.286 100.0%
100.0%
Test for subgroup differences: χ2 = 3.60, df = 1 (p = 0.06), I2 = 72.2%
SMD
IV, random, 95% Cl
–1–2 0 1 2
Favours risperidone Favours pimozide
FIGURE 34 Standardised impairment scores for treatment with pimozide compared with risperidone in the child and mixed studies. df, degrees of freedom; IV, independent
variable; ROB, risk of bias; SE, standard error.
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Study or subgroup WeightSESMD
Bruggeman 2001105 –0.22 (–0.78 to 0.34)
–0.22 (–0.78 to 0.34)
Heterogeneity: not applicable
Test for overall effect: z = 0.77 (p = 0.44) –1–2 0 1 2
Favours risperidone Favours pimozide
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl
–0.22 0.284 100.0%
100.0%Total (95% CI)
FIGURE 35 Standardised change from baseline Hamilton Rating Scale for Anxiety total score for risperidone compared with pimozide in the mixed study. IV, independent
variable; SE, standard error.
Study or subgroup WeightSESMD Overall ROB
High risk
Unclear risk
Gilbert 2004104
Subtotal (95% CI)
–0.63 (–1.42 to 0.16)
–0.63 (–1.42 to 0.16)
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Children
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Heterogeneity: not applicable
Test for overall effect: z = 1.57 (p = 0.12)
–1–2 0 1 2
Favours risperidone Favours pimozide
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IV, random, 95% Cl
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IV, random, 95% Cl
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100.0%
Bruggeman 2001105
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.32 (p = 0.75)
0.09 0.283 100.0%
100.0%
Test for subgroup differences: χ2 = 2.16, df = 1 (p = 0.14), I2 = 53.6%
FIGURE 36 Standardised CGI scores for treatment with risperidone compared with pimozide in the child and mixed studies. df, degrees of freedom; IV, independent variable;
ROB, risk of bias; SE, standard error.
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Study or subgroup WeightSEMD Overall ROB
High risk
Unclear risk
Gilbert 2004104
Subtotal (95% CI)
0.70 (–0.40 to 1.80)
0.70 (–0.40 to 1.80)
1.00 (–0.92 to 2.92)
1.00 (–0.92 to 2.92)
0.77 (–0.18 to 1.73)
Children
Mixed
Heterogeneity: not applicable
Test for overall effect: z = 1.25 (p = 0.21)
–2–4 0 2 4
Favours risperidone Favours pimozide
 MD
IV, random, 95% Cl
MD
IV, random, 95% Cl
0.7 0.56 75.4%
75.4%
Bruggeman 2001105
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.02 (p = 0.31)
1 0.98 24.6%
24.6%
Total (95% CI) 100.0%
Heterogeneity: τ2 = 0.00; χ2 = 0.07, df = 1 (p = 0.79); I2 = 0%
Test for overall effect: z = 1.59 (p = 0.11)
Test for subgroup differences: χ2 = 0.07, df = 1 (p = 0.79), I2 = 0%
FIGURE 37 Weight gain (kg) following treatment with risperidone compared with pimozide in the child and mixed studies. df, degrees of freedom; IV, independent variable;
ROB, risk of bias; SE, standard error.
Study or subgroup Weight Overall ROB
High risk
SESMD
Gilbert 2004104 –0.05 (–0.77 to 0.66)
–0.05 (–0.77 to 0.66)
Heterogeneity: not applicable
Test for overall effect: z = 0.14 (p = 0.89) –1–2 0 1 2
Favours risperidone Favours pimozide
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl
–0.051 0.365 100.0%
100.0%Total (95% CI)
FIGURE 38 Standardised post-treatment ESRS score for risperidone compared with pimozide in the child study. IV, independent variable; ROB, risk of bias; SE, standard error.
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In the child study,104 the Side Effects Checklist was used and there were similar post-treatment scores for
risperidone compared with pimozide (SMD –0.12, 95% CI –0.84 to 0.59; n= 30) (Figure 39).
In the mixed study,105 adverse effect event rates were reported separately. There was a lower incidence of
insomnia (RR 0.13, 95% CI 0.02 to 0.99; n= 50) but no conclusive difference in EPS-like adverse effects
(RR 0.46, 95% CI 0.16 to 1.34; n= 50), or injuries (RR 0.15, 95% CI 0.02 to 1.19; n= 50) for risperidone
compared with pimozide (Figure 40).
In both studies, cardiovascular measures were made and, for both studies, it was reported that there were
no significant differences in any ECG parameters (including QTC) for pimozide compared with risperidone.
Haloperidol compared with pimozide
One child crossover trial98 and two mixed trials (one parallel99 and one crossover106) evaluated treatment
with haloperidol compared with pimozide.
Tics
In the child study,98 tic outcome was assessed with the TS global scale. In one mixed study, they were
assessed with the Shapiro TSSS99 and in the other as tic count per 5 minutes.106 Results from both the child
study (n= 22) and the mixed studies (n= 47) were inconclusive. There was no evidence of heterogeneity
between the mixed studies (I2= 0%) (Figure 41).
The child study98 and one of the mixed studies99 reported results for separate measures of motor and vocal
tics, but results were inconclusive (Figure 42).
For vocal tics, results from post treatment were inconclusive for the child study (n= 22) and the mixed
study (n= 38) (Figure 43).
Impairment Only the child study assessed impairment and used the C-GAS. Post-treatment C-GAS score
was similar for haloperidol compared with pimozide (SMD 0.14, 95% CI –0.24 to 0.52; n= 22) (Figure 44).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome The child98 and one of the mixed99 studies assessed overall clinical outcomes
with the CGI scale. In the child study, post-treatment CGI-Severity score was similar for haloperidol and
pimozide (SMD 0.00, 95% CI –0.37 to 0.37; n= 22) (Figure 45).
In the mixed study, the results were inconclusive for physician-rated CGI (SMD –0.13, –0.77 to 0.51;
n= 38) and participant-rated CGI (SMD –0.19, 95% CI –0.83 to 0.44; n= 38) (Figure 46).
Long-term outcome No relevant studies reported long-term outcomes.
Safety In the child study,98 it was reported that general adverse effects did not differ between treatment
groups (p= 0.94). For EPS, because a carryover effect was detected in the whole study analysis, investigators
analysed just the first-phase data for this outcome, but the results were inconclusive (Figure 47).
For this study,98 post-treatment abnormal involuntary movements, assessed by the AIMS, were similar for
haloperidol and pimozide (SMD –0.09, 95% CI –0.47 to 0.28; n= 22) (Figure 48).
The number of children experiencing treatment-limiting adverse effects was greater for haloperidol
compared with pimozide but not conclusively different (RR 3.00, 95% CI 0.94 to 9.62; n= 22) (Figure 49).
It is reported that at least three haloperidol-treated participants developed treatment-emergent depression
or anxiety and two participants experienced academic failure attributed to the effects of haloperidol. It is
reported that most of the adverse effects caused by haloperidol were attributable to EPSs and included
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Study or subgroup Weight Overall ROB
High risk
SESMD
Gilbert 2004104 –0.12 (–0.84 to 0.59)
–0.12 (–0.84 to 0.59)
Heterogeneity: not applicable
Test for overall effect: z = 0.33 (p = 0.74) –1–2 0 1 2
Favours risperidone Favours pimozide
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl
–0.122 0.365 100.0%
100.0%Total (95% CI)
FIGURE 39 Standardised post-treatment Side Effects Checklist score for risperidone compared with pimozide in the child study. IV, independent variable; ROB, risk of bias;
SE, standard error.
Study or subgroup Events EventsTotal Total
Risperidone Pimozide
Weight Overall ROB
Unclear risk
RR
M–H, random, 95% Cl
RR
M–H, random, 95% Cl
EPS adverse events
Bruggeman 2001105
Subtotal (95% CI)
0.46 (0.16 to 1.34)
0.46 (0.16 to 1.34)
4 826
26
24
24
100.0%
100.0%
Total events 4 8
0.01 0.1 1 10 100
Favours risperidone Favours pimozide
Heterogeneity: not applicable
Test for overall effect: z = 1.42 (p = 0.15)
Unclear risk
Insomnia
Bruggeman 2001105
Subtotal (95% CI)
0.13 (0.02 to 0.99)
0.13 (0.02 to 0.99)
1 726
26
24
24
100.0%
100.0%
Total events 1 7
Heterogeneity: not applicable
Test for overall effect: z = 1.97 (p = 0.05)
Unclear risk
Injuries
Bruggeman 2001105 
Subtotal (95% CI)
0.15 (0.02 to 1.19)
0.15 (0.02 to 1.19)
1 626
26
24
24
100.0%
100.0%
Total events 1 6
Heterogeneity: not applicable
Test for overall effect: z = 1.80 (p = 0.07)
FIGURE 40 Proportion of patients with EPS-like symptoms, insomnia and injuries for risperidone compared with pimozide in the mixed study. M–H, Mantel–Haenszel;
ROB, risk of bias.
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Heterogeneity: not applicable
Test for overall effect: z = 0.43 (p = 0.67)
–2 –1 0 1 2
Favours haloperidol Favours pimozideTest for subgroup differences: χ2 = 0.07, df = 1 (p = 0.79), I2 = 0%
FIGURE 42 Standardised post-treatment motor tic scores for haloperidol compared with pimozide in the child and mixed studies. df, degrees of freedom; IV, independent
variable; SE, standard error.
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Heterogeneity: τ2 = 0.00; χ2 = 0.22, df = 1 (p = 0.64); I2 = 0%
Test for overall effect: z = 1.71 (p = 0.09)
FIGURE 41 Standardised tic scores for haloperidol compared with pimozide in the child and mixed studies. df, degrees of freedom; IV, independent variable;
SE, standard error.
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
X
X
X
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
X
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
H
o
llis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
4
9
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–2 –1 0 1 2
Favours haloperidol Favours pimozideTest for subgroup differences: χ2 = 3.69, df = 1 (p = 0.05), I2 = 72.9%
FIGURE 43 Standardised post-treatment vocal tic scores for haloperidol compared with pimozide in the child and mixed studies. df, degrees of freedom; IV, independent
variable; SE, standard error.
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Sallee 199798
100.0% 0.14 (–0.24 to 0.52)
FIGURE 44 Standardised post-treatment C-GAS score for haloperidol compared with placebo in the child study. IV, independent variable; SE, standard error.
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Favours haloperidol Favours pimozide
Sallee 199798
100.0% 0.00 (–0.37 to 0.37)
FIGURE 45 Standardised post-treatment CGI-Severity score for haloperidol compared with pimozide in children. IV, independent variable; SE, standard error.
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Heterogeneity: not applicable
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Shapiro 198999
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Heterogeneity: not applicable
Test for overall effect: z = 0.60 (p = 0.55)
–2 –1 0 1 2
Favours haloperidol Favours pimozide
FIGURE 46 Standardised post-treatment CGI score for haloperidol compared with pimozide in mixed parallel study. IV, independent variable; ROB, risk of bias.
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FIGURE 47 Standardised post-treatment ESRS score for haloperidol compared with pimozide in the child study. IV, independent variable; SE, standard error.
Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Total (95% CI)
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Heterogeneity: not applicable
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Sallee 199798
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FIGURE 48 Standardised post-treatment AIMS score for haloperidol compared with pimozide in the child study. IV, independent variable; SE, standard error.
Study or subgroup
Haloperidol
Events EventsTotal Total
Pimozide RR
Weight M–H, fixed, 95% CI
RR
M–H, fixed, 95% CI
Sallee 199798 3.00 (0.94 to 9.62)
3.00 (0.94 to 9.62)Total (95% CI)
9 3 22 100%
39
22
22 22 100%
Overall ROB
Unclear risk
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.85 (p = 0.06) 0.10.01 1 10 100
Favours haloperidol Favours pimozide
FIGURE 49 Proportion of children with treatment-limiting side effects for haloperidol compared with pimozide in the child study. M–H, Mantel–Haenszel; ROB, risk of bias.
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akathisia (n= 2) and akinesia (n= 2). Two pimozide-treated participants experienced weight gain and one
had treatment-emergent anxiety. It was reported that there was no evidence of electrocardiovascular
effects for haloperidol or pimozide and both were indistinguishable from placebo in their effects on heart
rate, rhythm and waveform.
In one of the mixed studies,106 it was reported that both haloperidol and pimozide caused adverse effects
including anticholinergic (dry mouth, blurred vision) and extrapyramidal (dystonic) reactions that were
equally frequent, intense and short-lived for both drugs. The most common event (accounting for more
than two-thirds of adverse effects) was lethargy or tiredness, but a very small sample size makes any
comparison between groups difficult to interpret (Figure 50).
In the other mixed study,99 for adverse effects rated on the CGI scale, there was no conclusive difference in
event rates for haloperidol compared with pimozide when rated by physicians (SMD 0.43, 95% CI –0.22
to 1.07; n= 38) or participants (SMD 0.44, 95% CI –0.21 to 1.08; n= 38) (Figure 51). In this study, it is
reported that, for moderate or marked adverse effects, there were no significant differences for
haloperidol compared with pimozide.
Aripiprazole compared with other antipsychotic drugs
One controlled before-and-after study compared aripiprazole to tiapride,107 one compared aripiprazole to
haloperidol,108 and one compared aripiprazole to pimozide (safety study).109
Tics
The study of aripiprazole compared with tiapride measured changes in tic severity/impairment with the
YGTSS global tic scale and the study of aripiprazole compared with haloperidol measured changes in tics
with the YGTSS total tic score. There was a similar reduction from baseline in global score for aripiprazole
compared with tiapride (SMD –0.07, 95% CI –0.35 to 0.21; n= 195) and no conclusive difference in
reduction from baseline tic score for aripiprazole when it was compared with haloperidol (SMD 0.53,
95% CI –0.07 to 1.13; n= 48). However, there was some evidence of a difference between studies
(I2= 68% for the subgroup difference), therefore, the two studies were not pooled (Figure 52).
For motor tic score alone, there was a similar reduction from baseline for aripiprazole compared with tiapride
(SMD –0.19, 95% CI –0.47 to 0.09; n= 195) and no conclusive difference compared with haloperidol (SMD
0.51, 95% CI –0.09 to 1.11; n= 48). However, there was some evidence of a difference between studies
(I2= 77% for the subgroup difference), therefore, the two studies were not pooled (Figure 53).
For vocal tic score, there was a similar reduction from baseline for aripiprazole compared with tiapride
(SMD 0.02, 95% CI –0.26 to 0.30; n= 48) or haloperidol (SMD 0.03, 95% CI –0.56 to 0.63; n= 195).
Overall, the change in vocal tic score was similar for aripiprazole compared with another antipsychotic drug
(SMD 0.02, 95% CI –0.23 to 0.28; n= 243) (Figure 54).
Impairment The study comparing aripiprazole with tiapride,107 measured impairment using the YGTSS
impairment scale. There was little difference in change from baseline impairment score for aripiprazole
compared with tiapride (SMD –0.04, 95% CI –0.32 to 0.24; n= 195) (Figure 55).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome The study comparing aripiprazole with tiapride assessed the proportion of
participants improved or markedly improved on the YGTSS and the study comparing aripiprazole with
haloperidol assessed the proportion of participants much or very much improved on the CGI-I scale. There
were similar proportions of participants much or very much improved for aripiprazole compared with
tiapride (RR 1.01, 95% CI 0.80 to 1.27; n= 195) and compared with haloperidol (RR 1.21, 95% CI 0.76 to
1.91; n= 48). Overall, there were similar proportions of children much or very much improved for
aripiprazole compared with other antipsychotic drugs (RR 1.05, 95% CI 0.85 to 1.29; n= 243) (Figure 56).
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Study or subgroup
Haloperidol
Events EventsTotal Total
Pimozide RR
Weight M–H, fixed, 95% CI
RR
M–H, fixed, 95% CI
Ross 1978106 1.73 (0.97 to 3.08)
1.73 (0.97 to 3.08)Total (95% CI)
9 5 9 100%
59
9
9 9 100%
Overall ROB
Unclear risk
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.85 (p = 0.06) 0.2 0.50.1 1 2 5 10
Favours haloperidol Favours pimozide
FIGURE 50 Proportion of patients experiencing tiredness on more than one study day for haloperidol compared with pimozide in the mixed study. M–H, Mantel–Haenszel;
ROB, risk of bias.
Study or subgroup
Post-treatment
haloperidol
Post-treatment
pimozide
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Physician
Shapiro 198999
Subtotal (95% CI)
0.43 (–0.22 to 1.07)
0.43 (–0.22 to 1.07)
1.8 1.31.3 118
18
20
20
1.9 1.31.4 1.318
18
20
20
100.0%
100.0%
Unclear risk
Unclear risk 0.44 (–0.21 to 1.08)
0.44 (–0.21 to 1.08)
100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 1.29 (p = 0.20)
Patient
Shapiro 198999
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.32 (p = 0.19)
–2 –1 0 1 2
Favours haloperidol Favours pimozide
FIGURE 51 Standardised CGI adverse effects scale for haloperidol compared with pimozide assessed by physicians and patients in the mixed study. ROB, risk of bias.
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Study or subgroup
Change aripiprazole Change antipsychotic
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Aripiprazole vs. tiapride
Liu 2011107
Subtotal (95% CI)
–0.07 (–0.35 to 0.21)
–0.07 (–0.35 to 0.21)
–29.38 –28.414.36 13.0398
98
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–14.4 –17.55.23 6.6231
31
17
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100.0%
100.0%
Unclear risk
High risk 0.53 (–0.07 to 1.13)
0.53 (–0.07 to 1.13)
100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 0.50 (p = 0.62)
Aripiprazole vs. haloperidol
Yoo 2011108
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.73 (p = 0.08)
–2 –1 0 1 2
Favours aripiprazole Favours antipsychoticTest for subgroup differences: χ2 = 3.15, df = 1 (p = 0.08), I2 = 68.3%
FIGURE 52 Standardised change in global/tic score for aripiprazole compared with other antipsychotics. df, degrees of freedom; ROB, risk of bias; IV, instrumental variable.
Study or subgroup
Aripiprazole Antipsychotic
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Aripiprazole vs. tiapride
Liu 2011107
Subtotal (95% CI)
–0.19 (–0.47 to 0.09)
–0.19 (–0.47 to 0.09)
–8.24 –7.633.39 2.8998
98
97
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–9.5 –124.41 5.4431
31
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100.0%
100.0%
Unclear risk
High risk 0.51 (–0.09 to 1.11)
0.51 (–0.09 to 1.11)
100.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 1.34 (p = 0.18)
Aripiprazole vs. haloperidol
Yoo 2011108
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.67 (p = 0.09)
–2 –1 0 1 2
Favours aripiprazole Favours antipsychoticTest for subgroup differences: χ2 = 4.34, df = 1 (p = 0.04), I2 = 77.0%
FIGURE 53 Standardised change in motor tic score for aripiprazole compared with other antipsychotics. df, degrees of freedom; IV, independent variable; ROB, risk of bias.
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Study or subgroup
Aripiprazole Antipsychotic
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Aripiprazole vs. tiapride
Liu 2011107
Subtotal (95% CI)
0.02 (–0.26 to 0.30)
0.02 (–0.26 to 0.30)
–7.8 –7.874.07 3.3498
98
97
97
–4.5 –4.75.39 6.6731
31
17
17
81.6%
81.6%
Unclear risk
High risk 0.03 (–0.56 to 0.63)
0.03 (–0.56 to 0.63)
0.02 (–0.23 to 0.28)
18.4%
18.4%
Heterogeneity: not applicable
Test for overall effect: z = 0.13 (p = 0.90)
Aripiprazole vs. haloperidol
Yoo 2011108
Subtotal (95% CI)
Total (95% CI) 129 114 100.0%
Heterogeneity: not applicable
Test for overall effect: z = 0.11 (p = 0.91)
–2 –1 0 1 2
Favours aripiprazole Favours antipsychotic
Heterogeneity: τ2 = 0.00; χ2 =0.00, df=1 (p = 0.96); I2 = 0%
Test for overall effect: z = 0.17 (p = 0.87)
Test for subgroup differences: χ2 = 0.00, df = 1 (p = 0.96), I2 = 0%
FIGURE 54 Standardised change in vocal tic score for aripiprazole compared with other antipsychotics. df, degrees of freedom; IV, independent variable; ROB, risk of bias.
Study or subgroup
Aripiprazole Tiapride
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Total (95% CI)
–0.04 (–0.32 to 0.24)
–0.04 (–0.32 to 0.24)
–13.26 –12.899.09 8.6198
98 97
97 100.0%
100.0%
Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 0.29 (p = 0.77) –2 –1 0 1 2
Favours aripiprazole Favours tiapride
Liu 2011107
FIGURE 55 Standardised change in impairment score for aripiprazole compared with tiapride. IV, independent variable; ROB, risk of bias.
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Study or subgroup
Aripiprazole Other antipsychotic
Events EventsTotal Total Weight Overall ROB
RR
M–H, random, 95% Cl 
RR
M–H, random, 95% Cl
Aripiprazole vs. tiapride
Liu 2011107
Subtotal (95% CI)
1.01 (0.80 to 1.27)
1.01 (0.80 to 1.27)
1.21 (0.76 to 1.91)
1.21 (0.76 to 1.91)
1.05 (0.85 to 1.29)
58 5798
98
97
97
22 1031
31
17
17
79.2%
79.2%
Unclear risk
High risk20.8%
20.8%
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.06 (p = 0.95)
58 57
22 10
80 67
Aripiprazole vs. haloperidol
Yoo 2011108
Subtotal (95% CI)
Total (95% CI) 129 114 100.0%
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.80 (p = 0.42)
Total events
0.50.2 1 2 5
Favours aripiprazole Favours antipsychotic
Heterogeneity: τ2 = 0.00; χ2 =0.48, df=1 (p = 0.49); I2 = 0%
Test for overall effect: z = 0.42 (p = 0.67)
Test for subgroup differences: χ2 = 0.47, df = 1 (p = 0.49), I2 = 0%
FIGURE 56 Proportion of patients much or very much improved for aripiprazole compared with another antipsychotic. df, degrees of freedom; M–H, Mantel–Haenszel;
ROB, risk of bias.
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Long-term outcome No relevant studies reported long-term outcomes.
Safety Adverse effects were measured in both studies and are shown in Figure 57 (for events occurring in
at least two participants). There were no conclusive findings (all CIs included no effect).
In the safety study comparing pimozide with aripiprazole,109 pimozide produced greater reductions from
baseline in systolic BP (MD –20.00, 95% CI –26.56 to –13.44; n= 50) and diastolic BP (MD –13.70,
95% CI –17.39 to –10.01; n= 50), greater increases in ECG-QT (MD 25.50, 95% CI 12.69 to 38.31;
n= 50) and ECG-QTc (MD 19.10, 95% CI 10.07 to 28.31; n= 50) compared with aripiprazole. There was
no conclusive difference in heart rate for pimozide compared with aripiprazole (MD 4.90, 95% CI –1.16 to
10.96; n= 50).
Olanzapine versus haloperidol
In one study,110 olanzapine was compared with haloperidol.
Tics
Changes in tics were assessed with the YGTSS scale and there was no conclusive difference in reduction in total
tic score for olanzapine compared with haloperidol (SMD –0.37, 95% CI –0.91 to 0.17; n= 54) (Figure 58).
Impairment No findings for changes in impairment were reported by this study.
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Overall clinical outcome was assessed with the CGI-Severity scale. The results
suggested a benefit for olanzapine compared with haloperidol (SMD –1.39, 95% CI –1.99 to –0.79;
n= 54) (Figure 59).
Long-term outcome No relevant studies reported long-term outcomes.
Safety This study measured adverse effects with the Subjective Treatment Emergent Symptom Scale
(STESS). Lower adverse effect scores were reported for olanzapine compared with haloperidol (SMD –0.57,
95% CI –1.12 to –0.03) (Figure 60).
All antipsychotic drugs
Tics
As reported above, all studies of antipsychotic drugs measured changes in tic severity. In studies of children
compared with placebo, all antipsychotic medications showed greater reductions in tic score as measured
by the YGTSS total tic scale101,103 or the TS global tic subscale.98 Overall, the SMD was –0.74 (95% CI
–1.08 to –0.41; n= 75) (Figure 61), with no evidence of between drug differences (I2= 0% for test of
subgroup differences).
When mixed studies were included, the SMD was –0.75 (95% CI –1.01 to –0.49; n= 197) (Figure 62).
Across all studies there was little evidence of between study variance (I2= 12%) or between drug
differences (I2= 0% for subgroup differences).
For motor score in the child and mixed studies, the SMD was –0.74 (95% CI –1.07 to –0.42; n= 99)
(Figure 63). There was little evidence of a between drug difference (I2 for subgroup differences= 3.4%).
For vocal tics, the SMD for child and mixed studies combined was –0.56 (95% CI –0.89 to –0.23; n= 99)
(Figure 64). There was little evidence of a between drug difference (I2 for subgroup differences= 0%).
INTERVENTIONS FOR TICS IN CHILDREN AND ADOLESCENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Study or subgroup
Aripiprazole Other antipsychotic
Events EventsTotal Total Weight Overall ROB
RR
M–H, random, 95% Cl 
RR
M–H, random, 95% Cl
Hypersomnia
Liu 2011107
Yoo 2011108
Subtotal (95% CI)
0.99 (0.30 to 3.31)
0.71 (0.49 to 1.02)
0.73 (0.51 to 1.04)
0.66 (0.11 to 3.86)
1.23 (0.45 to 3.42)
1.06 (0.44 to 2.55)
0.47 (0.19 to 1.17)
0.47 (0.19 to 1.17)
5
18
5
14
98
31
129
97
17
114
8.6%
91.4%
100.0%
Unclear risk
High risk
23 19
EPSs
Yoo 2011108
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.62 (p = 0.11)
Total events
0.10.02 1 10 50
Favours aripiprazole Favours antipsychotic
Heterogeneity: τ2 = 0.00; χ2 = 0.37, df=1 (p = 0.54); I2  = 0%
Test for overall effect: z = 1.77 (p = 0.08)
Nausea/vomiting
Liu 2011107
Yoo 2011108
Subtotal (95% CI)
2
9
3
4
98
31
129
31
31
17
17
100.0%
100.0%
97
17
114
24.9%
75.1%
100.0%
Unclear risk
High risk
High risk
11 7
6 7
6 7
Total events
Heterogeneity: τ2 = 0.00; χ2 =0.37, df=1 (p = 0.54); I2 = 0%
Test for overall effect: z = 0.12 (p = 0.90)
FIGURE 57 Proportion of children experiencing different adverse events for aripiprazole compared with another antipsychotic. df, degrees of freedom; M–H, Mantel–Haenszel;
ROB, risk of bias. (continued )
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Study or subgroup
Aripiprazole Other antipsychotic
Events EventsTotal Total Weight Overall ROB
RR
M–H, random, 95% Cl 
RR
M–H, random, 95% Cl
0.99 (0.14 to 6.89)
0.27 (0.11 to 0.67)
0.39 (0.13 to 1.21)
1.32 (0.30 to 5.74)
1.32 (0.30 to 5.74)
0.66 (0.11 to 3.86)
0.66 (0.11 to 3.86)
0.99 (0.25 to 3.85)
0.99 (0.25 to 3.85)
0.10.02 1 10 50
Favours aripiprazole Favours antipsychotic
Dizziness
Liu 2011107
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.37 (p = 0.71)
98
98
97
97
100.0%
100.0%
Unclear risk4 3
4 3
Fatigue
Liu 2011107
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.46 (p = 0.64)
98
98
97
97
100.0%
100.0%
Unclear risk2 3
2 3
Poor appetite
Liu 2011107
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.01 (p = 0.99)
98
98
97
97
100.0%
100.0%
Unclear risk4
4
4
4
Headache
Liu 2011107
Yoo 2011108
Subtotal (95% CI)
2
5
2
10
98
31
129
97
17
114
27.2%
72.8%
100.0%
Unclear risk
High risk
7 12Total events
Heterogeneity: τ2 = 0.25; χ2 =1.42, df=1 (p = 0.23); I2 = 30%
Test for overall effect: z = 1.64 (p = 0.10)
FIGURE 57 Proportion of children experiencing different adverse events for aripiprazole compared with another antipsychotic. df, degrees of freedom; M–H, Mantel–Haenszel;
ROB, risk of bias.
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Study or subgroup
Change olanzapine Change haloperidol
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Ji 2005110
–0.37 (–0.91 to 0.17)
–0.37 (–0.91 to 0.17)–23.64
Total (95% CI)
6.95 25 –20.89
25
29
29
7.73
100.0%
Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 1.33 (p = 0.18)
–2 –1 0 1 2
Favours olanzapine Favours haloperidol
100.0%
FIGURE 58 Standardised total tic score for olanzapine compared with haloperidol. IV, independent variable; ROB, risk of bias.
Study or subgroup
Change olanzapine Change haloperidol
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Ji 2005110
–1.39 (–1.99 to –0.79)
–1.39 (–1.99 to –0.79)–3.16
Total (95% CI)
0.46 25 –2.39
25
29
29
0.61
100.0%
Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 4.54 (p < 0.00001)
–2 –1 0 1 2
Favours olanzapine Favours haloperidol
100.0%
FIGURE 59 Standardised change in CGI-Severity score for olanzapine compared with haloperidol. IV, independent variable; ROB, risk of bias.
Study or subgroup
Olanzapine Haloperidol
Mean SD Total Mean SD Total Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Ji 2005110
–0.57 (–1.12 to –0.03)
–0.57 (–1.12 to –0.03)1.7
Total (95% CI)
2.56 25 3.98
25
29
29
4.79
100.0%
Unclear risk
Heterogeneity: not applicable
Test for overall effect: z = 2.05 (p = 0.04) –2 –1 0 1 2
Favours olanzapine Favours haloperidol
100.0%
FIGURE 60 Standardised STESS side effects score for olanzapine compared with haloperidol. IV, independent variable; ROB, risk of bias.
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Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Haloperidol
Sallee 199798
Subtotal (95% CI)
–0.496 –0.50 (–1.06 to 0.06)
–0.50 (–1.06 to 0.06)
0.286 Unclear risk36.0%
36.0%
100.0%
Heterogeneity: not applicable
Test for overall effect: z = 1.73 (p = 0.08)
Pimozide
Sallee 199798
Subtotal (95% CI)
–0.812 –0.81 (–1.42 to –0.20)
–0.81 (–1.42 to –0.20)
0.311 Unclear risk
Unclear risk
30.5%
30.5%
Heterogeneity: not applicable
Test for overall effect: z = 2.61 (p = 0.009)
Risperidone
Scahill 2003101
Subtotal (95% CI)
–1.18 –1.18 (–2.02 to –0.34)
–1.18 (–2.02 to –0.34)
0.43 Low risk15.9%
15.9%
Heterogeneity: not applicable
Test for overall effect: z = 2.74 (p = 0.006)
Ziprasidone
Sallee 2000103
Subtotal (95% CI)
–0.74 –0.74 (–1.54 to 0.06)
–0.74 (–1.54 to 0.06)
–0.74 (–1.08 to –0.41)
0.41 17.5%
17.5%
Heterogeneity: not applicable
Test for overall effect: z = 1.80 (p = 0.07)
Total (95% CI)
–2 –1 0 1 2
Favours antipsychotics Favours placebo
Heterogeneity: τ2 = 0.00; χ2 = 1.83, df = 3 (p = 0.61); I2 = 0%
Test for overall effect: z = 4.33 (p < 0.0001)
Test for subgroup differences: χ2 = 1.83, df = 3 (p = 0.61), I2 = 0%
FIGURE 61 Standardised post-treatment tic score for antipsychotics compared with placebo in studies of children. df, degrees of freedom; IV, independent variable;
ROB, risk of bias.
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2
Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Haloperidol
Shapiro 198999
Sallee 199798
Subtotal (95% CI)
–0.96
–0.496
–0.96 (–1.80 to –0.12)
–0.50 (–1.06 to 0.06)
–0.64 (–1.10 to –0.17)
0.431
0.286
Unclear risk
Unclear risk
8.8%
18.0%
26.8%
100.0%
Unclear risk
Ziprasidone
Sallee 2000103
Subtotal (95% CI)
–0.74 –0.74 (–1.54 to 0.06)
–0.74 (–1.54 to 0.06)
–0.75 (–1.01 to –0.49)
0.41 9.6%
9.6%
Heterogeneity: not applicable
Test for overall effect: z = 1.80 (p = 0.07)
Total (95% CI)
–2 –1 0 1 2
Favours antipsychotics Favours placebo
Heterogeneity: τ2 = 0.02; χ2 = 7.97, df = 7 (p = 0.34); I2 = 12%
Test for overall effect: z = 5.63 (p < 0.00001)
Test for subgroup differences: χ2 = 0.22, df = 3 (p = 0.97), I2 = 0%
Heterogeneity: τ2 = 0.00; χ2 = 0.80, df = 1 (p = 0.37); I2 = 0%
Test for overall effect: z = 2.68 (p = 0.007)
Risperidone
Scahill 2003101
Dion 2002102
Subtotal (95% CI)
–1.18
–0.54
–1.18 (–2.02 to –0.34)
–0.54 (–1.13 to 0.05)
–0.79 (–1.40 to –0.18)
0.43
0.301
Low risk
Unclear risk
8.8%
16.5%
25.3%
Heterogeneity: τ2 = 0.07; χ2 = 1.49, df = 1 (p = 0.22); I2 = 33%
Test for overall effect: z = 2.53 (p = 0.01)
Pimozide
Shapiro 1984100
Shapiro 198999
Sallee 199798
Subtotal (95% CI)
–0.37
–0.14
–0.812
–1.37 (–2.06 to –0.68)
–0.14 (–0.93 to 0.65)
–0.81 (–1.42 to –0.20)
–0.80 (–1.45 to –0.14)
0.352
0.401
0.311
Unclear risk
Unclear risk
Unclear risk
12.6%
10.0%
15.6%
38.3%
Heterogeneity: τ2 = 0.21; χ2 = 5.32, df = 2 (p = 0.07); I2 = 62%
Test for overall effect: z = 2.40 (p = 0.02)
FIGURE 62 Standardised post-treatment total tic score for antipsychotics compared with placebo in the child and mixed studies. df, degrees of freedom; IV, independent
variable; ROB, risk of bias; SE, standard error.
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Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Haloperidol
Sallee 199798
Shapiro 198999
Subtotal (95% CI)
–0.626
–0.36
–0.63 (–1.20 to –0.05)
–0.36 (–1.17 to 0.45)
–0.54 (–1.01 to –0.07)
0.295
0.411
Unclear risk
Unclear risk
26.3%
14.7%
40.9%
100.0% –0.74 (–1.07 to –0.42)Total (95% CI)
–2 –1 0 1 2
Favours antipsychotics Favours placebo
Heterogeneity: τ2 = 0.02; χ2 = 4.55, df = 4 (p = 0.34); I2 = 12%
Test for overall effect: z = 4.50 (p < 0.00001)
Test for subgroup differences: χ2 = 1.04, df = 1 (p = 0.31), I2 = 3.4%
Heterogeneity: τ2 = 0.00; χ2 = 0.28, df = 1 (p = 0.60); I2 = 0%
Test for overall effect: z = 2.23 (p = 0.03)
Pimozide
Sallee 199798
Shapiro 198999
Shapiro 1984100
Subtotal (95% CI)
–0.746
–0.5
–1.37
–0.75 (–1.34 to –0.15)
–0.50 (–1.30 to 0.30)
–1.37 (–2.06 to –0.68)
–0.89 (–1.37 to –0.40)
0.305
0.408
0.352
Unclear risk
Unclear risk
Unclear risk
24.8%
14.9%
19.4%
59.1%
Heterogeneity: τ2 = 0.06; χ2 = 3.00, df = 2 (p = 0.22); I2 = 33%
Test for overall effect: z = 3.57 (p = 0.0004)
FIGURE 63 Standardised post-treatment motor tic score for antipsychotics compared with placebo in the child and mixed studies. df, degrees of freedom; IV, independent
variable; ROB, risk of bias; SE, standard error.
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Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Haloperidol
Shapiro 198999
Sallee 199798
Subtotal (95% CI)
–0.67
–0.243
–0.67 (–1.49 to 0.15)
–0.24 (–0.78 to 0.29)
–0.37 (–0.82 to 0.08)
0.418
0.274
Unclear risk
Unclear risk
13.9%
27.4%
41.2%
100.0% –0.56 (–0.89 to –0.23)Total (95% CI)
–2 –1 0 1 2
Favours antipsychotics Favours placebo
Heterogeneity: τ2 = 0.03; χ2 = 4.97, df = 4 (p = 0.29); I2 = 19%
Test for overall effect: z = 3.35 (p = 0.0008)
Test for subgroup differences: χ2 = 0.81, df = 1 (p = 0.37), I2 = 0%
Heterogeneity: τ2 = 0.00; χ2 = 0.73, df = 1 (p = 0.39); I2 = 0%
Test for overall effect: z = 1.62 (p = 0.11)
Pimozide
Shapiro 198999
Sallee 199798
Shapiro 1984100
Subtotal (95% CI)
–0.17
–0.657
–1.098
–0.17 (–0.96 to 0.62)
–0.66 (–1.24 to –0.07)
–1.10 (–1.76 to –0.43)
–0.68 (–1.16 to –0.19)
0.403
0.297
0.339
Unclear risk
Unclear risk
Unclear risk
14.8%
24.3%
19.7%
58.8%
Heterogeneity: τ2 = 0.07; χ2 = 3.13, df = 2 (p = 0.21); I2 = 36%
Test for overall effect: z = 2.73 (p = 0.006)
FIGURE 64 Standardised post-treatment vocal tic score for antipsychotics compared with placebo in the child and mixed studies. df, degrees of freedom; IV, independent
variable; ROB, risk of bias; SE, standard error.
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Impairment Two studies in children presented changes in global measures of TS severity (tic and
impairment scores) measured with the YGTSS global scale103 or the TS global scale98 (Figure 65). No studies
in mixed populations presented findings for intervention effects on global TS measures. Overall, the SMD
was –0.51 (95% CI –0.86 to –0.15; n= 49), with no evidence of a between drug difference (I2 for
subgroup differences= 0%).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Overall clinical outcome was assessed with the CGI-Severity scale in two child
studies.98,103 Overall, there was a lower Clinical Global Impressions – Tic Severity (CGI-TS) score for
antipsychotic drugs compared with placebo (SMD –1.01 95% CI –1.49 to –0.53; n= 49) (Figure 66), with
little evidence of a between drug difference (I2 for subgroup differences= 23%).
Long-term outcome No relevant studies reported long-term outcomes.
Safety See separate safety sections for each drug compared with placebo or another drug above.
Clinical evidence summary for antipsychotic drugs
Haloperidol
In one crossover study with 22 children,98 there was low-quality evidence (see Appendix 4, Table 14) of a
medium-sized effect in favour of haloperidol when compared with placebo in terms of tics measured at
the end of 6 weeks of treatment. This was generally supported by evidence from global impairment and
overall clinical outcome. The study was at risk of bias from cross-treatment contamination but the results
were consistent with a parallel study in a mixed population of adults and children.99 Both studies provided
evidence of adverse effects with higher rates of EPSs98 and adverse effects based on CGI.99
Pimozide
In one study with 22 children98 (which also included a haloperidol arm), there was low-quality evidence
(see Appendix 4, Table 15) of medium-to-large effects in favour of pimozide in terms of tics, impairment
and overall clinical outcome at the end of 6 weeks of treatment. The study was at risk of bias from
cross-treatment contamination but results were consistent with the overall effect in two mixed studies
(one parallel, one crossover) of adults and children.99,100 The studies were inconclusive as to the presence of
adverse effects but pimozide tended to be associated with higher rates of EPSs,98 abnormal involuntary
movements98 and CGI-rated adverse effects.99 In the safety study comparing pimozide with aripiprazole109
(graded as low-quality evidence), pimozide had greater increases in QT and QTc than aripiprazole.
Pimozide is currently not regularly prescribed in the UK owing to concerns about its affect on increasing
the QT interval111,112 and the potentially fatal interaction with other drugs and the current evidence on its
safety may support caution over its use.
In the child study,98 when directly compared with haloperidol, there was low-quality evidence (see
Appendix 4, Table 19) that pimozide had similar effects on tics, impairment and overall clinical outcome,
but two mixed studies99,106 tended to favour haloperidol in terms of tics. For comparisons of adverse
effects, findings were inconclusive but tended to favour pimozide for EPSs,98 treatment-limiting adverse
effects,98 CGI-rated adverse effects99 and tiredness.106
Risperidone
In one study with 26 children,101 there was low-quality evidence (see Appendix 4, Table 16) of a large effect in
favour of risperidone in terms of tics and overall clinical outcome after 8 weeks of treatment, and these results
were supported by a mixed study in adults and children.102 When both studies were combined, there was
evidence of increased rates of fatigue, sedation and appetite/weight gain for those treated with risperidone.
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Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Haloperidol
Sallee 199798
Subtotal (95% CI)
–0.367 –0.37 (–0.91 to 0.18)
–0.37 (–0.91 to 0.18)
0.279 Unclear risk42.1%
42.1%
100.0% –0.51 (–0.86 to –0.15)Total (95% CI)
–2 –1 0 1 2
Favours antipsychotics Favours placebo
Heterogeneity: τ2 = 0.00; χ2 = 0.48, df = 2 (p = 0.79); I2 = 0%
Test for overall effect: z = 2.81 (p = 0.005)
Test for subgroup differences: χ2 = 0.48, df = 2 (p = 0.79), I2 = 0%
Heterogeneity: not applicable
Test for overall effect: z = 1.32 (p = 0.19)
Heterogeneity: not applicable
Test for overall effect: z = 2.18 (p = 0.03)
Pimozide
Sallee 199798
Subtotal (95% CI)
–0.646 –0.65 (–1.23 to –0.07)
–0.65 (–1.23 to –0.07)
0.296 Unclear risk37.4%
37.4%
Heterogeneity: not applicable
Test for overall effect: z = 1.38 (p = 0.17)
Ziprasidone
Sallee 2000103
Subtotal (95% CI)
–0.55 –0.55 (–1.33 to 0.23)
–0.55 (–1.33 to 0.23)
0.4 Unclear risk20.5%
20.5%
FIGURE 65 Standardised post-treatment global TS score for antipsychotics compared with placebo in child studies. df, degrees of freedom; IV, independent variable; ROB, risk
of bias; SE, standard error.
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Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Haloperidol
Sallee 199798
Subtotal (95% CI)
–1.233 –1.23 (–1.93 to –0.53)
–1.23 (–1.93 to –0.53)
–1.23 (–1.93 to –0.53)
–1.23 (–1.93 to –0.53)
0.358 Unclear risk35.2%
35.2%
100.0% –1.01 (–1.49 to –0.53)Total (95% CI)
–2 –1 0 1 2
Favours antipsychotics Favours placebo
Heterogeneity: τ2 = 0.04; χ2 = 2.60, df = 2 (p = 0.27); I2= 23%
Test for overall effect: z = 4.12 (p < 0.0001)
Test for subgroup differences: χ2 = 2.60, df = 2 (p = 0.27), I2 = 23.0%
Heterogeneity: not applicable
Test for overall effect: z = 3.44 (p = 0.0006)
Heterogeneity: not applicable
Test for overall effect: z = 3.44 (p = 0.0006)
Pimozide
Sallee 199798
Subtotal (95% CI)
–1.233 0.358 Unclear risk35.2%
35.2%
Heterogeneity: not applicable
Test for overall effect: z = 1.17 (p = 0.24)
Ziprasidone
Sallee 2000103
Subtotal (95% CI)
–0.47 –0.47 (–1.25 to 0.31)
–0.47 (–1.25 to 0.31)
0.4 Unclear risk29.6%
29.6%
FIGURE 66 Standardised post-treatment CGI-Severity score for antipsychotics compared with placebo in child studies. df, degrees of freedom; IV, independent variable;
ROB, risk of bias; SE, standard error.
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From one study with 13 children,104 there was very low-quality evidence (see Appendix 4, Table 18) that was
inconclusive with regards to the relative effect of risperidone compared with pimozide, but the direction of
the effect favoured risperidone for tics, impairment and overall clinical outcome. These findings were not
supported by a mixed study of adults and children105 that showed no difference in effects on tics, impairment
or overall clinical outcome. Comparisons of adverse effects were inconclusive, but there tended to be greater
weight gain,104,105 but less insomnia105 and physical injuries105 for risperidone compared with pimozide.
Ziprasidone
There was low-quality evidence (see Appendix 4, Table 17) from one study with 27 children103 of a large
effect in favour of ziprasidone in terms of tics, global tic/impairment and overall clinical outcome after
8 weeks of treatment (there were no supporting mixed or adult studies). There were higher rates of
adverse effects in the ziprasidone group, with sedation being the most common.
Aripiprazole
From one study with 195 children that compared aripiprazole with tiapride107 and one study in 48 children that
compared aripiprazole with haloperidol,108 there was very low-quality evidence (see Appendix 4, Table 20)
suggesting that aripiprazole was similar to other antipsychotic drugs in its effect on tics, impairment and overall
clinical outcome. Regarding adverse effects, data indicate that aripiprazole produced fewer QT and BP problems
than pimozide. In addition, although there was a tendency for there to be lower rates of hypersomnia, EPSs
and headaches in the aripiprazole group than other antipsychotic drugs, the results were inconclusive.
Olanzapine
From one study with 60 children,110 there was low-quality evidence (see Appendix 4, Table 21) that
olanzapine produced similar efficacy as haloperidol for tics, greater efficacy for overall clinical outcome and
lower rates of adverse effects.
All antipsychotic drugs
Given no apparent differences between antipsychotic drugs with regard to efficacy (I2 for subgroup
differences= 0%), three studies in children (n= 75) were combined providing low-quality evidence (see
Appendix 4, Table 22) of medium-to-large effects in terms of tics, impairment and overall clinical outcome.
There were three mixed studies99,100,102 that, when added to the meta-analysis with the child studies,
showed a similar overall effect size for tics.
Conclusion
Antipsychotic drugs are effective in the short term in reducing tics and tic-related impairments in children
and young people with TS. There are few clear differences between antipsychotics in effectiveness. The
side effect profile differs between antipsychotics, with weight gain, sedation, EPSs and cardiac risks being
particular concerns.
Noradrenergic agents
Pharmacology and prescribing
Noradrenergic agents are classified as either presynaptic alpha-2 adrenergic agonists (e.g. clonidine,
guanfacine) or noradrenergic reuptake inhibitors [e.g. atomoxetine (Strattera®, Lilly)]. Clonidine and
guanfacine were developed for use in higher doses as a treatment of hypertension and migraine, while
atomoxetine was developed as a treatment for ADHD. Clonidine and guanfacine may also be used as a
second-line treatment in ADHD.
The most common adverse effects of clonidine and guanfacine are sedation, bradycardia and postural
hypotension. Atomoxetine may produce tachycardia, hypertension, nausea, reduced appetite and fatigue.
More rarely, atomoxetine has also been associated with increased suicidal ideation, QTc prolongation and
hepatic disturbance.
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Clonidine (Non-proprietary; Dixarit® and Catapres®, Boehringer Ingelheim) is an alpha-2-adrenergic agonist
that inhibits noradrenergic activity and is licensed in the UK for the treatment of essential and
secondary hypertension.
Guanfacine (Intuniv®, Shire) is a selective alpha-2-adrenergic agonist with a similar mode of action and
clinical effects to clonidine. As with clonidine, guanfacine was developed originally for the treatment of
hypertension, but is now also used in the USA for the treatment of ADHD (US FDA approval) and tics.
Unlike clonidine, guanfacine does not have marketing authorisation for any treatment indication in the UK
and most European countries.
Atomoxetine is a highly selective, non-stimulant, noradrenergic reuptake inhibitor, which selectively inhibits
the presynaptic noradrenaline transporter. It is licensed in the UK for the treatment of ADHD.
Included studies
Nine studies in children and two mixed studies compared the efficacy of a noradrenergic agent with
placebo (PRISMA diagram, Appendix 2):
l clonidine versus placebo: three child113–115 and one mixed116 study
l clonidine patch versus placebo: two child117,118 and one mixed119 study
l guanfacine versus placebo: two child studies120,121
l atomoxetine versus placebo: one child study122 (subgroup analysis123).
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. One parallel trial in 136 children compared
maximum dose of 0.6mg/day clonidine, 60mg/day methylphenidate and a combination of clonidine and
methylphenidate with placebo for 16 weeks.113 For one mixed crossover trial, data for a subset of
24 children were obtained from authors.114 This study compared the use of 0.0075–0.015mg/kg/day
clonidine with placebo for 12 weeks each. One crossover trial in 37 children compared maximum dose of
0.2 mg/day clonidine (and maximum dose of 100mg/day desipramine) with placebo for 6 weeks each.115
One parallel trial in a mixed population of 47 adults and children compared maximum dose of 0.5mg/day
clonidine with placebo for 12 weeks.116
Two child117,118 studies and one mixed119 study compared the use of clonidine patches with placebo
patches. Both child studies were parallels trial of children given 1–2mg/day clonidine patches (depending
on body weight) over 4 weeks and one was in 437 children117 and the other in 76 children.118 The mixed
study was a crossover trial of 10 adults/children using maximum dose of 0.4mg/day clonidine patches
for 2 months.
Two parallel trials in children compared treatment with guanfacine and placebo. One compared the use of
maximum dose of 4mg/day guanfacine with placebo for 8 weeks in 34 children.120 The other compared
maximum dose of 2mg/day guanfacine with placebo for 4 weeks in 24 children.121
One parallel trial compared maximum dose of 1.5mg/kg/day atomoxetine with placebo for 18 weeks in
148 children with ADHD and comorbid tic disorder.122 In a subsequent publication,123 the subgroup of
117 children with TS (CTD patients excluded) were analysed.
Risk of bias
In one child study of clonidine compared with placebo,113 randomisation was computer generated and
there is assurance of allocation concealment and blinding of participants, providers and outcome assessors.
Dropout was relatively low (14%) and analysis was by intention to treat. Overall, this study was considered
to be a low risk of bias.
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In another child study of clonidine compared with placebo [mixed study but individual patient data (IPD)
for children obtained],114 the method of randomisation and the presence of allocation concealment was
unclear but there appears to have been blinding of participants and providers and outcome assessors. The
presence of dropout from the study was unclear. The study was a crossover with 1-week washouts
between treatments and this may have introduced bias from cross-treatment contamination. Overall, this
study was considered to be at unclear risk of bias owing to possible cross-treatment contamination.
In another child study of clonidine compared with placebo,115 the method of randomisation and the presence
of allocation concealment were unclear but there appears to have been blinding of participants, providers and
outcome assessors. The study was a crossover with 1-week washouts between treatments and this may have
introduced bias from cross-treatment contamination. The rate of dropout appears to have been low. Data
were only reported for outcomes where findings were statistically significant and these outcomes were
considered to be at risk from selective outcome reporting bias. Overall, this study was considered to be at
high risk of bias owing to possible cross-treatment contamination and selective outcome reporting bias.
In a mixed study of clonidine compared with placebo,116 the method of randomisation and the presence of
allocation concealment was unclear but there appears to have been blinding of participants, providers and
outcome assessors. Attrition was higher in the placebo compared with the intervention group (17% vs.
4%). This may tend to have led to more conservative estimates of efficacy but the risk of attrition bias was
not considered to be high. Overall, this study was considered to be at low risk of bias.
For one child study of clonidine patch compared with placebo,117 randomisation was by layering
segmenting randomisation of 800 random numbers but the presence of allocation concealment was
unclear. There appears to have been blinding of participants and providers but blinding of outcome
assessors was unclear. The rate of dropout was relatively low (13%) and the analysis was by intention to
treat with last observation carried forward. The risk of selective outcome reporting bias was unclear (CGI
score measured but results not reported). Overall, this study was considered to be at unclear risk of bias
owing to unclear outcome assessment blinding.
For the other child study of clonidine patch compared with placebo,118 randomisation was by random number
table and stratified by weight. The presence of allocation concealment and blinding of participants, providers
and outcome assessors was unclear. Only participants completing the study were reported by the paper
(stated in the exclusion criteria that participants unwilling/unable to take medication or be followed up were
excluded) and the risk of attrition bias is unclear. Overall, this study was considered at high risk of bias owing
to unclear blinding of participants, providers and outcome assessors and unclear risk of attrition bias.
In the mixed study of clonidine patch compared with placebo,119 the presence of randomisation, allocation
concealment and patient, provider and outcome assessor blinding is unclear. Analysis was of available
cases but the rate of dropout was low. There was a 2-week washout period between treatments and this
may have introduced bias from cross-treatment contamination. Overall, this study was considered to be
at high risk of bias owing to possible cross-treatment contamination and unclear randomisation and
blinding of participants, providers and outcome assessors.
For one child study of guanfacine compared with placebo,120 the method of randomisation and the
presence of allocation concealment was unclear but participants, providers and outcome assessors were
blinded to treatment allocation. The rate of dropout from the study was unclear. Overall, this study was
considered to be at low risk of bias.
For the other child study of guanfacine compared with placebo,121 the method of randomisation and the
presence of allocation concealment was unclear but there appears to have been blinding of participants,
providers and outcome assessors. The presence of dropout from the study was not reported. Overall,
this study was considered to be at low risk of bias.
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For the child study of atomoxetine compared with placebo,122 a computerised interactive voice response
system was used for randomisation. All clinical trial materials were blinded when provided to the
investigative site but there was no specific statement about blinding of outcome assessors. There was a
high rate of dropout (30%) but an intention-to-treat analysis was used with last observation carried
forward. Overall, this study was considered to have a low risk of bias.
Clinical evidence for noradrenergic agents
Clonidine compared with placebo
Two studies in children113,115 and two mixed studies114,116 in adults and children compared the efficacy of
clonidine with placebo. For one of the mixed studies,114 IPD for children and adolescents in the study
(24 children and adolescents from a total of 30 participants) were obtained. The other mixed study116 had
participants with a mean age of 15.6 years (SD 10.4 years, range 7–48 years); it was assumed that the majority
of participants were children and study data are combined with the other child studies in the meta-analysis.
Tics The majority of studies reported motor and vocal tic scores separately (and not total tic scores). Three
studies presented findings for motor tics and used the Tourette’s Syndrome Global Scale (TSGS) motor tic
score,116 the YGTSS motor tic score113 and an assessment of motor tic severity (body areas and motor tic
frequency also assessed).114 Motor tic score favoured clonidine compared with placebo (SMD –0.55, 95% CI
–0.90 to –0.20; n= 130) (Figure 67). There was little heterogeneity between studies (I2= 14%; p= 0.31).
For vocal tics, studies made assessments using the TSGS vocal tic scale,116 the YGTSS vocal tic scale113 and
an assessment of vocal tic severity (vocal tic frequency also assessed)114 and favoured clonidine but there
was no conclusive difference compared with placebo (SMD –0.30, 95% CI –0.62 to 0.01; n= 130)
(Figure 68). There was no heterogeneity between studies (I2= 0%).
In the other study,115 it is reported that there was no significant effect on tic suppression for the Shapiro
TSSS, the Hopkins tic scale or a visual analogue scale.
Impairment Tic-related impairment was measured in two studies. In one, it was assessed as part of the
TSGS with a measure of school and occupational function116 and, in the other, with the YGTSS impairment
scale.113 Impairment score favoured clonidine compared with placebo (SMD –0.54, 95% CI –0.93 to –0.16;
n= 106) (Figure 69) and there was no heterogeneity between studies (I2= 0%).
Both of these studies also measured changes in global TS scales (impairment and tic scores) and used the
TSGS total score116 and the YGTSS global score.113 Global TS favoured clonidine compared with placebo
(SMD –0.71, 95% CI –1.10 to –0.31; n= 106) (Figure 70) and there was no heterogeneity between
studies (I2= 0%).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Two studies assessed overall clinical outcome and used the CGI scale. In one
study,113 CGI outcome was graded by parents, teachers and investigators. A higher proportion of
participants improved on the CGI for clonidine than placebo when rated by parents (RR 2.51, 95% CI 1.38
to 4.55; n= 66), teachers (RR 1.88, 95% CI 1.10 to 3.23; n= 66) and investigators (RR 2.41, 95% CI 1.32
to 4.39; n= 66) (Figure 71).
In the other study,116 reduction in CGI-TS severity score was greater for clonidine than placebo (SMD –1.04,
95% CI –1.71 to –0.38; n= 40) (Figure 72).
Long-term outcome No relevant studies reported long-term outcomes.
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Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Kurlan 2002113
Leckman 1991116
Goetz 1987114
–0.516
–0.95
–0.28
–0.52 (–1.01 to –0.03)
–0.95 (–1.60 to –0.30)
–0.28 (–0.85 to 0.29)
0.25
0.334
0.291
Low risk
Low risk
Unclear risk
42.0%
25.5%
32.5%
100.0% –0.55 (–0.90 to –0.20)Total (95% CI)
–2 –1 0 1 2
Favours clonidine Favours placebo
Heterogeneity: τ2 = 0.01; χ2 = 2.31, df = 2 (p = 0.31); I2 = 14%
Test for overall effect: z = 3.08 (p = 0.002)
FIGURE 67 Standardised motor tic scores for clonidine compared with placebo in predominantly child studies. df, degrees of freedom; IV, independent variable; ROB, risk of
bias; SE, standard error.
Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Kurlan 2002113
Leckman 1991116
Goetz 1987114
–0.54667
–0.09
–0.16
–0.55 (–1.04 to –0.06)
–0.09 (–0.72 to 0.54)
–0.16 (–0.72 to 0.40)
0.25085
0.319
0.288
Low risk
Low risk
Unclear risk
42.1%
26.0%
31.9%
100.0% –0.30 (–0.62 to 0.01)Total (95% CI)
–2 –1 0 1 2
Favours clonidine Favours placebo
Heterogeneity: τ2 = 0.00; χ2 = 1.64, df = 2 (p = 0.44); I2 = 0%
Test for overall effect: z = 1.87 (p = 0.06)
FIGURE 68 Standardised vocal tic scores for clonidine compared with placebo in predominantly child studies. df, degrees of freedom; IV, independent variable; ROB, risk of
bias; SE, standard error.
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Study or subgroup SMD SE Weight
SMD
IV, fixed, 95% Cl
SMD
IV, fixed, 95% Cl 
Kurlan 2002113
Leckman 1991116
–0.76
–0.62
–0.76 (–1.26 to –0.26)
–0.62 (–1.26 to 0.02)
0.255
0.324
61.8%
38.2%
100.0% –0.71 (–1.10 to –0.31)Total (95% CI)
–2 –1 0 1 2
Favours clonidine Favours placebo
Heterogeneity: χ2 = 0.12, df = 1 (p = 0.73); I2= 0%
Test for overall effect: z = 3.53 (p = 0.0004)
FIGURE 70 Standardised change in global TS score for clonidine compared with placebo in predominantly child studies. df, degrees of freedom; IV, independent variable;
SE, standard error.
Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
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–0.32
–0.69 (–1.18 to –0.19)
–0.32 (–0.95 to 0.31)
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0.319
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Low risk
61.4%
38.6%
100.0% –0.54 (–0.93 to –0.16)Total (95% CI)
–2 –1 0 1 2
Favours clonidine Favours placebo
Heterogeneity: τ2 = 0.00; χ2 = 0.81, df = 1 (p = 0.37); I2 = 0%
Test for overall effect: z = 2.75 (p = 0.006)
FIGURE 69 Standardised impairment scores for clonidine compared with placebo in predominantly child studies. df, degrees of freedom; IV, independent variable; ROB, risk of
bias; SE, standard error.
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Study or subgroup Events EventsTotal Total Weight Overall ROB
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M–H, random, 95% Cl 
RR
M–H, random, 95% Cl
Kurlan 2002113
Subtotal (95% CI)
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100.0%
100.0%
9
9 2.51 (1.38 to 4.55)
2.51 (1.38 to 4.55)
0.1 0.2 0.5 1 2 5 10
Favours clonidineFavours placebo
Parent rated
Total events
Heterogeneity: not applicable
Test for overall effect: z = 3.03 (p = 0.002)
Low riskKurlan 2002113
Subtotal (95% CI)
22
22
34
34
32
32
100.0%
100.0%
11
11 1.88 (1.10 to 3.23)
1.88 (1.10 to 3.23)
Teacher rated
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.30 (p = 0.02)
Low riskKurlan 2002113
Subtotal (95% CI)
23
23
34
34
32
32
100.0%
100.0%
9
9 2.41 (1.32 to 4.39)
2.41 (1.32 to 4.39)
Investigator rated
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.86 (p = 0.004)
FIGURE 71 Proportion of children improving on the CGI scale as rated by parents, teachers and investigators for clonidine compared with placebo. M–H, Mantel–Haenszel;
ROB, risk of bias.
Study or subgroup Mean MeanSD SDTotal Total Weight Overall ROB
Change clonidine Change placebo SMD
IV, random, 95% Cl 
SMD
IV, random, 95% Cl
Leckman 1991116 –0.7 –0.10.5 0.62621
21 19
19 –1.04 (–1.71 to –0.38)
–1.04 (–1.71 to –0.38)
Low risk100.0%
–2 –1 0 1 2
Favours clonidine Favours placebo
100.0%Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 3.07 (p = 0.002)
FIGURE 72 Standardised change in CGI-TS score for clonidine compared with placebo. IV, independent variable; ROB, risk of bias.
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Safety In one study,114 it is reported that common adverse effects of clonidine were sedation (57%), dry
mouth (37%) and restlessness (27%) and that these effects were not experienced to the same degree in
the placebo group. In another study,115 a significantly higher proportion of children experienced adverse
effects with clonidine than placebo (RR 1.87, 95% CI 1.24 to 2.81; n= 34) (Figure 73).
In another study,116 more participants in the clonidine compared with the placebo group experienced
sedation/fatigue (RR 2.46, 95% CI 1.34 to 4.50; n= 40) but results were inconclusive for rates of dry
mouth (RR 2.17, 95% CI 0.94 to 5.02; n= 40), faintness and/or dizziness (RR 2.04, 95% CI 0.75 to 5.54;
n= 40) and irritability (RR 6.33, 95% CI 0.86 to 46.86; n= 40) (Figure 74).
Rates of sedation were also reported by another study,113 in which a greater proportion of participants
experienced moderate or severe sedation for clonidine compared with placebo (RR 5.65, 95% CI 1.37 to
23.29; n= 40) (Figure 75).
Moderators of clinical effectiveness In one study,116 investigators conducted subgroup analysis and
found no difference in treatment effectiveness for participants with and without ADHD and OCD, or those
aged < 18 years or ≥ 18 years and it is reported that an analysis of variance showed no effect of baseline
tic severity on treatment effect.
Guanfacine compared with placebo
Two parallel trials in children compared the efficacy of guanfacine with placebo.120,121
Tics
Both studies used the YGTSS to assess changes in tics. Overall, reduction in YGTSS total tic score was
greater for guanfacine compared with placebo (SMD –0.73, 95% CI –1.26 to –0.20; n= 58) (Figure 76).
One of the studies presented findings for motor and vocal tics separately.121 There was no conclusive
difference in change from baseline tic scores for guanfacine compared with placebo for motor (SMD –0.64,
95% CI –1.46 to 0.18; n= 24) or vocal (SMD –0.70, 95% CI –1.53 to 0.12; n= 24) tics (Figures 77 and 78).
Impairment One of the studies121 assessed changes in TS-related impairment with the YGTSS impairment
scale. There was no conclusive difference in change from baseline impairment score for guanfacine
compared with placebo (SMD 0.27, 95% CI –0.53 to 1.08; n= 24) (Figure 79) or for overall YGTSS global
score (SMD –0.29, 95% CI –1.10 to 0.51; n= 24) (Figure 80).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Overall clinical change was assessed by one study,120 but this was an assessment
of changes in symptoms of ADHD (and not TS-related symptoms) and is, therefore, outside of the scope for
this review.
Long-term outcome No relevant studies reported long-term outcomes.
Safety In one study121 it is reported that adverse effects for guanfacine were headache, flu-like symptoms
and fatigue (n= 1), fatigue/sleepiness (n= 1) and bad dreams (n= 1) (rates for placebo not reported).
In the other study,120 it is reported that no serious adverse effects were observed and no participant
showed a clinically meaningful change in cardiac conduction. The adverse effects reported included mild
sedation (n= 6), sleep awakening (n= 3), dry mouth (n= 4), constipation (n= 2) and loss of appetite
(n= 2), but rates of these events were not significantly more frequent than in the placebo group. It is
reported that there were no significant changes in weight from baseline in either group and no difference
between groups in weight change. It is reported that there were no significant differences in changes
in BP and pulse for guanfacine compared with placebo.
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Study or subgroup Events EventsTotal Total Weight Overall ROB
Low risk
Clonidine Placebo RR
M–H, random, 95% Cl 
RR
M–H, random, 95% Cl
Leckman 1991116
Subtotal (95% CI)
19
19
21
21
19
19
100.0%
100.0%
7
7 2.46 (1.34 to 4.50)
2.46 (1.34 to 4.50)
0.01 0.1 1 10 100
Favours clonidine Favours placebo
Sedation and/or fatigue
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.91 (p = 0.004)
Low riskLeckman 1991116
Subtotal (95% CI)
12
12
21
21
19
19
100.0%
100.0%
5
5 2.17 (0.94 to 5.02)
2.17 (0.94 to 5.02)
Dry mouth
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.81 (p = 0.07)
Low riskLeckman 1991116
Subtotal (95% CI)
9
9
21
21
19
19
100.0%
100.0%
4
4 2.04 (0.75 to 5.54)
2.04 (0.75 to 5.54)
Faintness and/or dizziness
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.39 (p = 0.16)
Low riskLeckman 1991116
Subtotal (95% CI)
7
7
21
21
19
19
100.0%
100.0%
1
1 6.33 (0.86 to 46.86)
6.33 (0.86 to 46.86)
Irritability
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.81 (p = 0.07)
FIGURE 74 Proportion of patients experiencing side effects for clonidine compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
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Study or subgroup Events EventsTotal Total Weight Overall ROB
Clonidine Placebo RR
M–H, random, 95% Cl 
RR
M–H, random, 95% Cl
Kurlan 2002113 12
12
34
34 32
2
2
32 5.65 (1.37 to 23.29)
5.65 (1.37 to 23.29)
Low risk100.0%
0.01 0.1 1 10 100
Favours clonidine Favours placebo
100.0%Total (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.39 (p = 0.02)
FIGURE 75 Proportion of participants experiencing moderate-to-severe sedation for clonidine compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Scahill 2001120
Cummings 2002121
–0.699
–0.778
–0.70 (–1.39 to –0.01)
–0.78 (–1.61 to 0.05)
–0.73 (–1.26 to –0.20)
0.353
0.423
Low risk
Low risk
58.9%
41.1%
–2 –1 0 1 2
Favours guanfacine Favours placebo
100.0%Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.02, df = 1 (p = 0.89); I2 = 0%
Test for overall effect: z = 2.70 (p = 0.007)
FIGURE 76 Standardised change in YGTSS total tic score for guanfacine compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of bias;
SE, standard error.
Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Cummings 2002121 –0.642 –0.64 (–1.46 to 0.18)
–0.64 (–1.46 to 0.18)
0.419 Low risk100.0%
100.0%Total (95% CI)
–2 –1 0 1 2
Favours guanfacine Favours placebo
Heterogeneity: not applicable
Test for overall effect: z = 1.53 (p = 0.13)
FIGURE 77 Standardised change in YGTSS motor tic scale for guanfacine compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
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Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Cummings 2002121 –0.701 –0.70 (–1.53 to 0.12)
–0.70 (–1.53 to 0.12)
0.421 Low risk100.0%
100.0%Total (95% CI)
–2 –1 0 1 2
Favours guanfacine Favours placebo
Heterogeneity: not applicable
Test for overall effect: z = 1.67 (p = 0.10)
FIGURE 78 Standardised change in YGTSS vocal tic scale for guanfacine compared with placebo in the child study. IV, independent variable; ROB, risk of bias;
SE, standard error.
Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Cummings 2002121 0.273 0.27 (–0.53 to 1.08)
0.27 (–0.53 to 1.08)
0.41 Low risk100.0%
100.0%Total (95% CI)
–2 –1 0 1 2
Favours guanfacine Favours placebo
Heterogeneity: not applicable
Test for overall effect: z = 0.67 (p = 0.51)
FIGURE 79 Standardised change in YGTSS impairment scale for guanfacine compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
Study or subgroup SMD SE Weight Overall ROB
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Cummings 2002121 –0.293 –0.29 (–1.10 to 0.51)0.41 Low risk100.0%
100.0% –0.29 (–1.10 to 0.51)Total (95% CI)
–2 –1 0 1 2
Favours guanfacine Favours placebo
Heterogeneity: not applicable
Test for overall effect: z = 0.71 (p = 0.47)
FIGURE 80 Standardised change in YGTSS global scale for guanfacine compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
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Clonidine patch compared with placebo
Two studies in children117,118 and one mixed study119 compared the efficacy of clonidine patches with
placebo patches. In one of the child studies,118 results were reported as percentage decreases and these
data could therefore not be combined with the other studies in the meta-analysis.
Tics
Tics were assessed in the child study117 using the YGTSS and, in the mixed study,119 using the TSGS
(Figure 81). In the child study, change from baseline tic score was similar for clonidine patch compared
with placebo (SMD –0.10, 95% –0.32 to 0.12; n= 437) and, in the mixed study, there was no conclusive
difference in post-treatment tic score for clonidine patch compared with placebo (SMD –0.36, 95% CI
–0.97 to 0.24; n= 9).
In the mixed study, motor and vocal tic elements were assessed separately using the Tourette Syndrome
Symptom List (TSSL). Post-treatment score was lower for clonidine patch than placebo for complex motor
score (SMD –1.17, 95% CI –1.93 to –0.41; n= 9), but there was no conclusive difference for simple motor
(SMD –0.52, 95% CI –1.14 to 0.11; n= 9), simple phonic (SMD –0.62, 95% CI –1.25 to 0.02; n= 9),
complex phonic (SMD –0.54, 95% CI –1.17 to 0.08; n= 9) and behavioural scores (SMD –0.28, 95% CI
–0.88 to 0.31; n= 9) (Figure 82).
In the other child study,118 motor and vocal tics were assessed with the YGTSS scale. There were greater
reductions for clonidine patch than placebo for motor [47.0% (SD 3.7%) vs. 12.1% (SD 11.4%)] and vocal
[22.7% (SD 4.4%) vs. 2.8% (SD 6.3%)] tic score.
Impairment In one child study,118 impairment was assessed with the YGTSS impairment scale. There was
a greater reduction in impairment score for clonidine patch than placebo [53.8% (SD 2.2%) vs. 12.0%
(SD 5.9%)].
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome In the second child study,118 overall clinical change was assessed with the
CGI-Severity scale. There was a greater reduction in CGI-Severity score for clonidine patch than placebo
[40.2% (SD 2.4) vs. 17.0% (SD 4.1)].
Long-term outcome Patient reports for long-term follow-up for the clonidine group are given by the
mixed study. It is reported that, after an average of 13 months, six participants (three children and
three adults) said that clonidine continued to be effective in controlling their tics.
Safety In one study of children,117 it is reported that adverse effects occurred in eight children in the
clonidine patch group (rashes n= 3, abnormal ECG n= 2, somnolence n= 1, light headedness n= 1,
insomnia n= 1) and eight children in the placebo patch group (rashes n= 6, nausea n= 1, dry mouth,
somnolence, light headedness and dizziness n= 1). In the mixed study, it is reported that adverse effects
experienced were heartburn (clonidine n= 1, placebo n= 4), dose-dependent drowsiness (clonidine n= 7),
dry mouth (clonidine n= 5, placebo n= 3) and erythema/dry skin (clonidine n= 4, placebo n= 2). In the
other child study,118 the results for clonidine patch compared with placebo patch were inconclusive for
itchy skin (RR 0.78, 95% CI 0.16 to 3.66; n= 76), dry mouth (RR 1.55, 95% CI 0.19 to 12.43; n= 76) and
dizziness (RR 1.24, 95% CI 0.15 to 10.41; n= 76) (Figure 83).
Atomoxetine compared with placebo
One parallel trial in children with TS and CTD compared the use of atomoxetine with placebo.122 This study
has since be published as a subgroup analysis of only children with TS (excluding those with CTD).123
Results are presented below for the whole sample and the TS subsample.
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Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Children
Du 2008117
Subtotal (95% CI)
–0.1 –0.10 (–0.32 to 0.12)
–0.10 (–0.32 to 0.12)
0.11 100.0%
100.0%
–0.363 –0.36 (–0.97 to –0.24)
–0.36 (–0.97 to –0.24)
0.308 100.0%
100.0%
Overall ROB
Unclear risk
High risk
Heterogeneity: not applicable
Test for overall effect: z = 0.91 (p = 0.36)
Mixed
Gancher 1990119
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.18 (p = 0.24)
–2 –1 0 1 2
Favours clonidine patch Favours placebo
Test for subgroup differences: χ2 = 0.65, df = 1 (p = 0.42), I2 = 0%
FIGURE 81 Standardised tic scores for clonidine patch compared with placebo for child and mixed studies. df, degrees of freedom; IV, independent variable; ROB, risk of bias;
SE, standard error.
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Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
Simple motor
Gancher 1990119
Subtotal (95% CI) 
–0.515 –0.52 (–1.14 to 0.11)
–0.52 (–1.14 to 0.11)
0.317 100.0%
100.0%
Overall ROB
High risk
Heterogeneity: not applicable
Test for overall effect: z = 1.62 (p = 0 .10)
–2 –1 0 1 2
Favours clonidine patch Favours placebo
–0.283 –0.28 (–0.88 to 0.31)
–0.28 (–0.88 to 0.31)
0.304 100.0%
100.0%
High risk
Behavioural
Gancher 1990119
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.93 (p = 0.35)
–0.616 –0.62 (–1.25 to 0.02)
–0.62 (–1.25 to 0.02)
0.325 100.0%
100.0%
High risk
Simple phonic
Gancher 1990119
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.90 (p = 0.06)
–1.17 –1.17 (–1.93 to –0.41)
–1.17 (–1.93 to –0.41)
0.387 100.0%
100.0%
High risk
Complex motor
Gancher 1990119
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 3.02 (p = 0.003)
–0.541 –0.54 (–1.17 to 0.08)
 –0.54 (–1.17 to 0.08)
0.319 100.0%
100.0%
High risk
Complex phonic
Gancher 1990119
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.70 (p = 0.09)
FIGURE 82 Standardised post-treatment TSSL scores for clonidine patch compared with placebo in the mixed study. IV, independent variable; ROB, risk of bias;
SE, standard error.
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Study or subgroup
Clonidine patch
Events Total Total
Placebo patch
Events
RR
M–H, random, 95% Cl Overall ROBWeight
Itchy skin
Zhong 2007118
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.32 (p = 0.75)
58
58
5
5 0.78 (0.16 to 3.66)
0.78 (0.16 to 3.66)
2
2
100.0%
100.0%
18
18
Unclear risk
Dry mouth
Zhong 2007118
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect:  z = 0.41 (p = 0.68)
58
58
5
5 1.55 (0.19 to 12.43)
1.55 (0.19 to 12.43)
1
1
100.0%
100.0%
18
18
Unclear risk
Dizziness
Zhong 2007118
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect:  z = 0.20 (p = 0.84)
58
58
4
4 1.24 (0.15 to 10.41)
1.24 (0.15 to 10.41)
1
1
100.0%
100.0%
18
18
Unclear risk
0.01 0.1 1 10 100
Favours clonidine patch Favours placebo patch
RR
M–H, random, 95% Cl
FIGURE 83 Proportion of patients with adverse events for clonidine patch compared with placebo patch. M–H, Mantel–Haenszel; ROB, risk of bias.
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Tics
Tic severity was measured using the YGTSS total tic scale (Figure 84). For children with TS or CTD, there
was no conclusive reduction in YGTSS total tic score (SMD –0.32, 95% CI –0.65 to 0.01; n= 145) but for
the subgroup of children with TS, YGTSS total tic score was reduced (SMD –0.40, 95% CI –0.77 to –0.03;
n= 116) for atomoxetine compared with placebo.
For the whole study sample, a greater proportion of children taking atomoxetine than placebo experienced
a ≥ 25% reduction in YGTSS total tic score (RR 0.76, 95% CI 0.57 to 1.00; n= 145) (Figure 85) (RR is the
RR of not having a 25% or more reduction).
When motor and vocal tic scores were considered separately (Figures 86 and 87) for the whole TS/CTD
population there was no conclusive difference for atomoxetine compared with placebo for motor tic score
(SMD –0.30, 95% CI –0.62 to 0.03; n= 145) and vocal tic score (SMD –0.22, 95% CI –0.54 to 0.11;
n= 145). For the subgroup with TS, the reduction was greater for atomoxetine compared with placebo for
motor tic score (SMD –0.41, 95% CI –0.78 to –0.04; n= 116) but, for vocal tic score there was no
conclusive difference (SMD –0.25, 95% CI –0.62 to 0.12; n= 116).
Impairment No findings for TS-related impairment were reported by these studies.
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Overall clinical outcome was measured using the Clinical Global Impressions –
severity of tics and other neurological symptoms (CGI-Tic/Neuro-S) scale, assessing TS and neurological
symptoms. The CGI-Tic/Neuro-S score suggested a benefit for atomoxetine compared with placebo
for children with TS or CTD (SMD –0.54, 95% CI –0.87 to –0.21; n= 145) and with TS alone (SMD –0.63,
95% CI –1.00 to –0.25; n= 116) (Figure 88).
Long-term outcome No relevant studies reported long-term outcomes.
Safety The number of children experiencing different adverse effects for atomoxetine compared with
placebo is reported for the whole trial population.122 A greater number of children experienced decreased
appetite (RR 5.68, 95% CI 1.32 to 24.52; n= 148) and nausea (RR 11.37, 95% CI 1.52 to 85.22; n= 148),
but there were no conclusive differences in rates of vomiting (RR 1.89, 95% CI 0.75 to 4.78; n= 148), fatigue
(RR 2.84, 95% CI 0.80 to 10.08; n= 148), cough (RR 0.42, 95% CI 0.14 to 1.31; n= 148), pharyngitis
(RR 0.32, 95% CI 0.09 to 1.12; n= 148), diarrhoea (RR 0.36, 95% CI 0.10 to 1.29; n= 148), headaches
(RR 1.08, 95% CI 0.57 to 2.05; n= 148) or upper abdominal pain (RR 0.74, 95% CI 0.29 to 1.87;
n= 148) (Figure 89).
Meta-analysis of noradrenergic agents
Studies in children (or predominantly children) comparing treatment with noradrenergic drugs (clonidine
and guanfacine) compared with placebo were combined. The child study of transdermal clonidine was not
included as the method of drug administration was different and likely to introduce clinical heterogeneity
into the meta-analysis. The studies of atomoxetine were not included in the meta-analysis as this agent
was considered by the TEG to be substantially different in its mode of action to clonidine and guanfacine.
Tics
Four studies presented data for tic score or global score and, in order to combine information across studies,
these scales have been combined.113,116,120,121 Studies used the YGTSS global score,116 the TS global score113 or
the YGTSS total tic score.120,121 Overall, the standardised tic/global score was –0.72 (95% CI –1.03 to –0.40;
n= 164) (Figure 90), with no evidence of between-drug differences (I2 for subgroup differences= 0%).
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Study or subgroup Mean SD Total Mean
Change atomoxetine Change placebo SMD
IV, random, 95% Cl Overall ROBSD Total Weight
SMD
IV, random, 95% Cl
TS and CTD
Allen 2005122
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.90 (p = 0.06)
6.9–5.5 –0.32 (–0.65 to 0.01)
–0.32 (–0.65 to 0.01)
74
74
–3 71
71
100.0%
100.0%
8.7 Low risk
TS only
Spencer 2008123
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.12 (p = 0.03)
7.1–5.1 –0.40 (–0.77 to –0.03)
–0.40 (–0.77 to –0.03)
60
60
–2 56
56
100.0%
100.0%
8.4 Low risk
–2 –1 0 1 2
Favours atomoxetine Favours placebo
FIGURE 84 Standardised change in YGTSS total tic score for children with TS or CTD or with TS alone following treatment with atomoxetine compared with placebo.
IV, independent variable; ROB, risk of bias.
Study or subgroup Events Total Events Total
Atomoxetine Placebo RR (non-event)
M–H, random, 95% Cl Overall ROBWeight
RR (non-event)
M–H, random, 95% CI
Allen 2005122
Total (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.95 (p = 0.05)
74
74
71
71
37
37 24
0.76 (0.57 to 1.00)
0.76 (0.57 to 1.00)
100.0%
100.0%
24 Low risk
0.2 0.5 1 2 5
Favours atomoxetine Favours placebo
FIGURE 85 Proportion of children with TS or CTD showing a 25% or more reduction in YGTSS total tic score for atomoxetine compared with placebo (RR of not having a 25%
or more reduction). M–H, Mantel–Haenszel; ROB, risk of bias.
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Study or subgroup Mean SD Total Mean
Atomoxetine Placebo SMD
IV, random, 95% Cl Overall ROBSD Total Weight
SMD
IV, random, 95% Cl
TS and CTD
Allen 2005122
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.77 (p = 0.08)
4.3–3.1 –0.30 (–0.62 to 0.03)
–0.30 (–0.62 to 0.03)
74
74
–1.7 71
71
100.0%
100.0%
5.1 Low risk
TS only
Spencer 2008123
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.19 (p = 0.03)
4.2–2.7 –0.41 (–0.78 to –0.04)
–0.41 (–0.78 to –0.04)
60
60
–0.9 56
56
100.0%
100.0%
4.5 Low risk
–2 –1 0 1 2
Favours atomoxetine Favours placebo
FIGURE 86 Standardised change in YGTSS motor tic score for children with TS or CTD or with TS alone for atomoxetine compared with placebo. IV, independent variable;
ROB, risk of bias.
Study or subgroup Mean SD Total Mean
Atomoxetine Placebo SMD
IV, random, 95% Cl Overall ROBSD Total Weight
SMD
IV, random, 95% Cl
TS and CTD
Allen 2005122
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.30 (p = 0.20)
4.5–2.4 –0.22 (–0.54 to 0.11)
–0.22 (–0.54 to 0.11)
74
74
–1.3 71
71
100.0%
100.0%
5.6 Low risk
TS only
Spencer 2008123
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.34 (p = 0.18)
4.5–2.5 –0.25 (–0.62 to 0.12)
–0.25 (–0.62 to 0.12)
60
60
–1.2 56
56
100.0%
100.0%
5.8 Low risk
–2 –1 0 1 2
Favours atomoxetine Favours placebo
FIGURE 87 Standardised change in YGTSS vocal tic score for children with TS or CTD or with TS alone for atomoxetine compared with placebo. IV, independent variable;
ROB, risk of bias.
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Study or subgroup Mean SD Total Mean
Change atomoxetine Change placebo SMD
IV, random, 95% Cl Overall ROBSD Total Weight
SMD
IV, random, 95% Cl
TS and CTD
Allen 2005122
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 3.19 (p = 0.001)
1.2–0.7 –0.54 (–0.87 to 0.21)
–0.54 (–0.87 to 0.21)
74
74
–0.1 71
71
100.0%
100.0%
1 Low risk
TS only
Spencer 2008123
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 3.29 (p = 0.001)
1.2–0.7 –0.63 (–1.00 to –0.25)
–0.63 (–1.00 to –0.25)
60
60
0 56
56
100.0%
100.0%
1 Low risk
–2 –1 0 1 2
Favours atomoxetine Favours placebo
FIGURE 88 Standardised change in CGI score for children with TS or CTD or with TS alone for atomoxetine compared with placebo. IV, independent variable; ROB, risk of bias.
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Study or subgroup Events Total Events
Atomoxetine Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% Cl
Headache
Allen 2005122
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.24 (p = 0.81)
16
16 14
1.08 (0.57 to 2.05)
1.08 (0.57 to 2.05)
76
76
14 72
72
100.0%
100.0%
Low risk
Vomiting
Allen 2005122
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.35 (p = 0.18)
12
12 6
1.89 (0.75 to 4.78)
1.89 (0.75 to 4.78)
76
76
6 72
72
100.0%
100.0%
Low risk
Upper abdominal pain
Allen 2005122
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.64 (p = 0.52)
7
7 9
0.74 (0.29 to 1.87)
0.74 (0.29 to 1.87)
76
76
9 72
72
100.0%
100.0%
Low risk
Decreased appetite
Allen 2005122
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.33 (p = 0.02)
12
12 2
5.68 (1.32 to 24.52)
5.68 (1.32 to 24.52)
76
76
2 72
72
100.0%
100.0%
Low risk
Cough
Allen 2005122
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.50 (p = 0.13)
4
4 9
0.42 (0.14 to 1.31)
0.42 (0.14 to 1.31)
76
76
9 72
72
100.0%
100.0%
Low risk
0.005 0.1 1 10 200
Favours atomoxetine Favours placebo
FIGURE 89 Proportion of children experiencing adverse events for atomoxetine compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias. (continued )
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Study or subgroup Events Total Events
Atomoxetine Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% Cl
Nausea
Allen 2005122
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.37 (p = 0.02)
12
12 1
11.37 (1.52 to 85.22)
11.37 (1.52 to 85.22)
76
76
1 72
72
100.0%
100.0%
Low risk
Fatigue
Allen 2005122
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.62 (p = 0.11)
9
9 3
2.84 (0.80 to 10.08)
2.84 (0.80 to 10.08)
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100.0%
Low risk
Pharyngitis
Allen 2005122
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.78 (p = 0.07)
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0.32 (0.09 to 1.12)
76
76
9 72
72
100.0%
100.0%
Low risk
Diarrhoea
Allen 2005122
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.58 (p = 0.12)
3
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0.36 (0.10 to 1.29)
0.36 (0.10 to 1.29)
76
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100.0%
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Low risk
0.005 0.1 1 10 200
Favours atomoxetine Favours placebo
FIGURE 89 Proportion of children experiencing adverse events for atomoxetine compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Clonidine
Leckman 1991116
Kurlan 2002113
Subtotal (95% CI) 
Heterogeneity: τ2 = 0.00, χ2 = 0.12, df = 1 (p = 0.73), I2 = 0%
Test for overall effect: z = 3.53 (p = 0.0004)
–0.62 (–1.26 to 0.02)
–0.76 (–1.26 to –0.26)
–0.71 (–1.10 to –0.31)
–0.62
–0.76
0.342
0.255
24.7%
39.9%
64.7%
Low risk
Low risk
Guanfacine
Cummings 2002121
Scahill 2001120
Subtotal (95% CI) 
Heterogeneity: τ2 = 0.00, χ2 = 0.02, df = 1 (p = 0.89), I2 = 0%
Test for overall effect: z = 2.70 (p = 0.007)
–0.78 (–1.61 to 0.05)
–0.70 (–1.39 to –0.01)
–0.73 (–1.26 to –0.20)
–0.778
–0.669
0.423
0.353
14.5%
20.8%
35.3%
Low risk
Low risk
–2 –1 0 1 2
Favours noradrenergic Favours placebo
Total (95% CI) 
Heterogeneity: τ2 = 0.00, χ2 = 0.14, df = 3 (p = 0.99), I2 = 0%
Test for overall effect: z = 4.44 (p < 0.00001)
Test for subgroup differences: χ2= 0.01, df = 1 (p = 0.94), I2= 0%
100.0% –0.72 (–1.03 to –0.40)
FIGURE 90 Standardised total tic/global scores for noradrenergic agents compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of bias;
SE, standard error.
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Impairment Three parallel studies reported changes in TS-related impairment using the YGTSS impairment
score113,121 and the Shapiro TSSS school and occupational function score.116 The SMD for impairment was
–0.32 (95% CI –0.84 to 0.20; n= 130) (Figure 91), but there was some evidence of a between-subgroup
difference (I2 for subgroup differences= 69%).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Only one parallel trial of clonidine measured changes in overall clinical outcome
(CGI-Severity) and results are presented in the clonidine compared with placebo (see Clonidine
versus placebo).
Long-term outcome No relevant studies reported long-term outcomes.
Safety See relevant sections for each drug above.
Clinical evidence summary for noradrenergic agents
Clonidine
There was moderate-quality evidence (see Appendix 4, Table 23) from two studies in children113,116
suggesting that clonidine produced a medium-sized to large-sized effect in terms of tic severity/impairment
and overall clinical outcome, but was associated with increased rates of adverse effects,115 particularly
sedation116 following 12–16 weeks of treatment.
Guanfacine
There was moderate-quality evidence (see Appendix 4, Table 24) from two studies in children (n= 58)120,121
that guanfacine, when compared with placebo, produced a large effect in tics following 4–8 weeks of
treatment and did not appear to be associated with serious adverse effects.
Clonidine patch
In one study in 437 children,117 there was moderate-quality evidence (see Appendix 4, Table 25) that
clonidine patch did not improve tics following 4 weeks of treatment. Another study in children,118 in which
results were presented in terms of percentage changes (and, therefore, the two studies could not be
combined), showed improvements in tics, impairment and overall clinical outcome, but this evidence was
graded as very low quality and there is large uncertainty around these findings. Both studies showed
similar rates of adverse effects for clonidine patch compared with a placebo patch.
Atomoxetine
There was moderate-quality evidence (see Appendix 4, Table 38) from one study with 145 children122
suggesting that atomoxetine gave a small/moderate improvement in tics and overall clinical outcome, but
gave higher rates of decreased appetite and nausea following 18 weeks of treatment.
All noradrenergic agents
Overall, four studies in children113,116,120,121 (n= 164) provided moderate-quality evidence (see Appendix 4,
Table 26) that noradrenergic agents (clonidine or guanfacine) improved tics by the end of 4–16 weeks
of treatment. The adverse effect profile may differ for different noradrenergic agents.
Conclusion
Noradrenergic agents are effective in the short term in reducing tics and tic-related impairments in children
and young people with TS. The most effective noradrenergic agents in reducing tics appear to be the
alpha-2-noradrengic agonists, clonidine and guanfacine. Adverse effects of these agents are generally mild
(e.g. sedation, dizziness, nausea) and differ between agents with guanfacine (not marketed in the UK)
having the most favourable profile. Atomoxetine is effective in reducing tics in children and young people
with comorbid TS and ADHD. There is no firm evidence that clonidine patches are effective in reducing tics
and may be associated with adverse effects including local skin irritation.
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Study or subgroup
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Clonidine
Kurlan 2002113
Leckman 1991116
Subtotal (95% CI) 
Heterogeneity: τ2 = 0.00, χ2 = 0.81, df = 1 (p = 0.37), I2 = 0%
Test for overall effect: z = 2.75 (p = 0.006)
–0.69 (–1.18 to –0.19)
–0.32 (–0.95 to 0.31)
–0.54 (–0.93 to –0.16)
–0.686
–0.32
0.253
0.319
41.1%
33.5%
74.6%
Low risk
Low risk
Guanfacine
Cummings 2002121
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.67 (p = 0.51)
0.27 (–0.53 to 1.08)
0.27 (–0.53 to 1.08)
–0.32 (–0.84 to 0.20)
0.273 0.41 25.4%
25.4%
Low risk
–4 –2 0 2 4
Favours noradrenergic Favours placebo
Total (95% CI) 
Heterogeneity: τ2 = 0.10, χ2 = 4.03, df = 2 (p = 0.13), I2 = 5 0%
Test for overall effect: z = 1.22 (p = 0.22)
Test for subgroup differences: χ2 = 3.22, df = 1 (p = 0.07), I2 = 69.0%
100.0%
SMD
FIGURE 91 Standardised impairment scores for noradrenergic agents compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of bias;
SE, standard error.
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Stimulant drugs
Pharmacology and prescribing
Central nervous system stimulant drugs are the first-line pharmacological treatment for ADHD. Similar to
the use of atomoxetine, stimulants would only be considered in the treatment of comorbid ADHD and TS.
Their mode of action is as indirect dopamine agonists, increasing dopamine activity in cortical and
subcortical brain regions. While methylphenidate and dexmethylphenidate primarily act as noradrenaline-
dopamine reuptake inhibitors, dexamphetamine also acts by releasing dopamine and noradrenaline
from presynaptic storage vesicles, making dexamphetamine a more potent dopaminergic agonist
than methylphenidate.
Methylphenidate (Ritalin®, Novartis Pharmaceuticals UK; and the modified-release preparations Concerta®
XL, Janssen; EquasymXL®, Shire Pharmaceuticals Limited and; MedikinetXL®, Flynn) is licensed in the UK
for ADHD.
Dexmethylphenidate (Non-proprietary; Focalin®, Novartis; Attenade®, Celgene) is a noradrenaline-
dopamine reuptake inhibitor and releasing agent, thereby classed as a stimulant. It is not licensed in the
UK and is most commonly used for ADHD in the USA.
Included studies
Four studies in children investigated the use of stimulant medications compared with placebo in children
with ADHD (see Appendix 2).113,124–126 Studies were of methylphenidate and dexmethylphenidate (there
were no included studies for dexamphetamine). The aim of these studies was to demonstrate that the use
of stimulant drugs did not worsen tics and could be used to treat comorbid ADHD and TS without
worsening of tics. For one study,126 the data could not be extracted. The three remaining studies involved
the following comparisons:
l methylphenidate compared with placebo: three child studies113,124,125
l clonidine and methylphenidate compared with placebo: one child study113
l immediate release dexmethylphenidate compared with placebo: one child study.127
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. One parallel113 and two crossover124,125 trials investigated
treatment with methylphenidate compared with placebo. In the parallel trial, 136 children with ADHD and TS
or with ADHD and CTD were randomised to a maximum dose of 60mg/day methylphenidate, 0.6mg/day
clonidine, methylphenidate and clonidine, or placebo for 16 (methylphenidate) or 12 (other interventions)
weeks. In one crossover trial,125 71 children with ADHD and TS or CTD (from two cohorts) underwent treatment
with various doses of methylphenidate; 0.1mg/kg/day, 0.3mg/kg/day and 0.5mg/kg/day (0.5mg/kg/day data
were used in the analysis in this review to match the dose used in the other methylphenidate study) and
placebo in a randomised order for 2 weeks each. The other crossover trial was in 11 children124 and used the
same study design (0.1, 0.3 and 0.5mg/kg/day for 2 weeks in randomised order) (0.5mg/kg/day data were
used for this review).
One crossover study investigated treatment with immediate-release dexmethylphenidate compared with
placebo in children with TS or CTD.127 Experiments were conducted over 1-day periods with subjects
having a mean dose of 7.5 mg dexmethylphenidate on one day and no medication on the other day in a
randomised order.
Risk of bias
In the parallel trial of methylphenidate,113 randomisation was computer generated and stratified on centre
and sexual maturity status. There was assurance of allocation concealment and of blinding of participants,
providers and outcome assessors. Dropout was relatively low and analysis was by intention to treat and the
risk of attrition bias was considered to be low. Overall, this study was considered to be at low risk of bias.
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For one crossover trial of methylphenidate,125 the method of randomisation and presence of allocation
concealment was unclear. There appears to have been blinding of participants, providers and outcome
assessors. There was no washout between interventions and the study was considered to be at high risk of
cross-intervention contamination. It was unclear how many participants dropped out of the study and how
many were included in the analysis and the risk of attrition bias was unclear. Overall, this study was
considered to be at high risk of bias.
For the other crossover trial of methylphenidate,124 the method of randomisation and presence of
allocation concealment was unclear. There appears to have been blinding of participants, providers and
outcome assessors. There was no washout between interventions and the study was considered to be at
high risk of cross-intervention contamination. It was unclear how many participants dropped out of the
study and how many were included in the analysis and the risk of attrition bias was unclear. Overall, this
study was considered to be at high risk of bias.
In the crossover trial of immediate release dexmethylphenidate,127 the method for randomisation and
presence of allocation concealment and patient, provider and outcome assessor blinding were unclear. The
control group had no treatment and this was not considered to be an adequate control. There was no
washout period between the intervention and control days and the risk of cross-intervention
contamination was considered to be high. Overall, the risk of bias in this study was considered to be high
owing to the unsuitable control group, lack of washout between treatments and unclear blinding of
participants, providers and outcome assessors.
Clinical evidence for stimulants
Methylphenidate and dexmethylphenidate
Tics Three studies used the YGTSS scale113,125,127 and one used the global tic rating scale124 to assess tics.
Findings were presented separately for motor and vocal tics. For the motor tic scale (Figure 92), reduction
from baseline/post-treatment motor tic score was similar for methylphenidate compared with placebo
(SMD –0.03, 95% CI –0.20 to 0.15; n= 151) and there was no heterogeneity between studies (I2= 0%).
For immediate release dexmethylphenidate,127 post-treatment motor tic score was lower than the no
treatment control (SMD –0.60, 95% CI –1.13 to –0.07; n= 10). For stimulant drugs combined, the SMD
was –0.17 (95% CI –0.46 to 0.11; n= 161). A large proportion of the difference between drugs was not
explained by random variation (I2 for subgroup differences= 76%).
For the vocal tic scale (Figure 93) there was no conclusive difference in reduction from baseline/post-
treatment vocal tic score for methylphenidate compared with placebo (SMD –0.28, 95% CI –0.73 to 0.16;
n= 151). There was heterogeneity between studies (I2= 71%). For immediate release dexmethylphenidate,
post-treatment vocal tic score was lower for dexmethylphenidate than no treatment (SMD –0.62, 95% CI
–1.15 to –0.09; n= 10). For stimulant drugs considered as a whole, there was no conclusive difference in
vocal tic score for stimulants compared with control (SMD –0.36, 95% CI –0.76 to 0.03; n= 150). All of
the difference between drugs could be explained by random variation (I2 for subgroup differences= 0%).
For the study where methylphenidate and clonidine were compared with placebo,113 there were greater
reductions from baseline in motor (SMD –0.55, 95% CI –1.05 to –0.06; n= 65) and vocal (SMD –0.59,
95% CI –1.09 to –0.10; n= 65) tic scores for methylphenidate plus clonidine than placebo.
Impairment Three of the stimulant studies reported measures of impairment with the YGTSS impairment
scale113,125,127 (Figure 94). For methylphenidate, there was no conclusive difference in reduction from
baseline impairment score for methylphenidate compared with placebo (SMD –0.29, 95% CI –0.89 to
0.30; n= 140). There was heterogeneity between methylphenidate studies (I2= 81%). For immediate
release dexmethylphenidate, there was no conclusive difference in impairment score compared with no
treatment (SMD –0.41, 95% CI –1.30 to 0.47; n= 10). For stimulant drugs considered as a whole, the
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Study or subgroup
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Methylphenidate
Kurlan 2002113
Gadow 2007125
Gadow 1992124
Subtotal (95% CI) 
Heterogeneity: τ2 = 0.00, χ2 = 1.75, df = 2 (p = 0.42), I2 = 0%
Test for overall effect: z = 0.28 (p = 0.78)
–0.32 (–0.80 to 0.16)
0.03 (–0.18 to 0.24)
–0.03 (–0.56 to 0.50)
–0.03 (–0.20 to 0.15)
–0.32
0.031
–0.027
0.243
0.106
0.27
21.4%
40.9%
18.8%
81.2%
Low risk
High risk
High risk
Dexmethylphenidate
Lyon 2010127
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.23 (p = 0.03)
–0.60 (–1.13 to –0.07)
–0.60 (–1.13 to –0.07)
–0.17 (–0.46 to 0.11)
–0.602 0.27 18.8%
18.8%
High risk
–2 –1 0 1 2
Favours stimulant Favours control
Total (95% CI) 
Heterogeneity: τ2 = 0.04, χ2 = 5.85, df = 3 (p = 0.12), I2 = 49%
Test for overall effect: z = 1.19 (p = 0.23)
Test for subgroup differences: χ2 = 4.09, df = 1 (p = 0.04), I2 = 75.6%
100.0%
SMD
FIGURE 92 Standardised motor tic score for stimulant drugs compared with control in children with ADHD and tics. df, degrees of freedom; IV, independent variable;
ROB, risk of bias; SE, standard error.
IN
T
E
R
V
E
N
T
IO
N
S
F
O
R
T
IC
S
IN
C
H
ILD
R
E
N
A
N
D
A
D
O
LE
S
C
E
N
T
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
9
6
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Methylphenidate
Kurlan 2002113
Gadow 1992124
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: τ2 = 0.11, χ2 = 6.95, df = 2 (p = 0.03), I2 = 71%
Test for overall effect: z = 1.27 (p = 0.20)
–0.51 (–0.99 to –0.03)
–0.56 (–1.13 to 0.01)
0.04 (–0.17 to 0.25)
–0.28 (–0.73 to 0.16)
–0.506
–0.557
0.039
0.245
0.29
0.106
23.8%
20.8%
33.3%
78.0%
Low risk
High risk
High risk
Dexmethylphenidate
Lyon 2010127
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.30 (p = 0.02)
–0.62 (–1.15 to –0.09)
–0.62 (–1.15 to –0.09)
–0.36 (–0.76 to 0.03)
–0.623 0.271 22.0%
22.0%
High risk
–2 –1 0 1 2
Favours stimulant Favours control
Total (95% CI) 
Heterogeneity: τ2 = 0.11, χ2 = 10.31, df = 3 (p = 0.02), I2 = 71%
Test for overall effect: z = 1.79 (p = 0.07)
Test for subgroup differences: χ2 = 0.92, df = 1 (p = 0.34), I2 = 0%
100.0%
FIGURE 93 Standardised vocal tic score for stimulant drugs compared with control in children with ADHD and tics. df, degrees of freedom; IV, independent variable;
ROB, risk of bias; SE, standard error.
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Methylphenidate
Kurlan 2002113
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: τ2 = 0.15, χ2 = 5.18, df = 1 (p = 0.02), I2 = 81%
Test for overall effect: z = 0.97 (p = 0.33)
–0.64 (–1.12 to –0.16)
–0.03 (–0.24 to 0.18)
–0.29 (–0.89 to 0.30)
–0.64
–0.028
0.247
0.106
33.6%
48.7%
82.2%
Low risk
High risk
Dexmethylphenidate
Lyon 2010127
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.91 (p = 0.36)
–0.41 (–1.30 to 0.47)
–0.41 (–1.30 to 0.47)
–0.30 (–0.76 to 0.15)
–0.411 0.452 17.8%
17.8%
High risk
–2 –1 0 1 2
Favours stimulant Favours control
Total (95% CI) 
Heterogeneity: τ2 = 0.10, χ2 = 5.57, df = 2 (p = 0.06), I2 = 64%
Test for overall effect: z = 1.30 (p = 0.19)
Test for subgroup differences: χ2= 0.05, df = 1 (p = 0.83), I2 = 0%
100.0%
FIGURE 94 Standardised YGTSS impairment score for stimulant drugs compared with a control in children with ADHD and tics. df, degrees of freedom; IV, independent
variable; ROB, risk of bias; SE, standard error.
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SMD was –0.30 (95% CI –0.76 to 0.15; n= 150) and there was no detectable difference between drugs
(I2 for subgroup differences= 0%).
For the overall YGTSS global score (Figure 95), there was no conclusive difference in global score for
methylphenidate compared with placebo (SMD –0.32, 95% CI –0.85 to 0.22; n= 140). There was
heterogeneity between methylphenidate studies (I2= 77%). For immediate release dexmethylphenidate,
there was no conclusive difference in global score for dexmethylphenidate compared with placebo
(SMD –0.66, 95% CI –1.27 to 0.04; n= 10). When considered as a whole, the global score was
SMD –0.40 (95% CI –0.84 to 0.04; n= 150) and all of the difference between drugs could be explained
by random variation (I2 for subgroup differences= 0%).
For the study where methylphenidate and clonidine were compared with placebo,113 there were greater
reductions from baseline in YGTSS impairment (SMD –0.66, 95% CI –1.16 to –0.16; n= 65) and global
(SMD –0.77, 95% CI –1.27 to –0.26; n= 65) scores for methylphenidate plus clonidine than placebo.
Psychological well-being In one study of methylphenidate,125 assessment was made with the Stimulant
Side Effects Checklist (SSEC) (Figure 96). For the SSEC mood index component, post-treatment
teacher-rated score was lower for methylphenidate compared with placebo (SMD –0.27, 95% CI –0.48 to
–0.05; n= 71). For the parent-rated SSEC mood component, post-treatment score was similar for
methylphenidate and placebo (SMD –0.10, 95% CI –0.31 to 0.10; n= 71).
Overall clinical outcome One study of methylphenidate measured overall clinical outcome using the
CGI-I scale.113 This assessment considered improvements in ADHD and tic symptoms separately.
For CGI improvement in tics, a greater proportion of children were much or very much improved for
methylphenidate compared with placebo when rated by parents (RR 0.64, 95% CI 0.42 to 0.96; n= 69)
and teachers (RR 0.54, 95% CI 0.32 to 0.89; n= 69), but the difference was inconclusive when rated by
investigators (RR 0.79, 95% CI 0.55 to 1.13; n= 69) (Figure 97) (the RR presented here is the RR of
not being much or very much improved).
For the study in which methylphenidate and clonidine were compared with placebo,113 a greater
proportion of children were rated as much or very much improved by parents (RR 0.38, 95% CI 0.21 to
0.69; n= 65), teachers (RR 0.45, 95% CI 0.26 to 0.79; n= 65) and investigators (RR 0.45, 95% CI 0.27
to 0.75; n= 65) for methylphenidate plus clonidine compared with placebo (the RR presented here is the
RR of not being much or very much improved).
Long-term outcome No relevant studies reported long-term outcomes.
Safety The study of methylphenidate and clonidine reported that medications were well tolerated and
that the methylphenidate alone group had lower rates of reported adverse effects than the clonidine,
methylphenidate plus clonidine and placebo groups. Rates of moderate-to-severe sedation were similar for
methylphenidate compared with placebo (RR 1.30, 95% CI 0.23 to 7.28; n= 69) (Figure 98).
There was also no conclusive difference when methylphenidate plus clonidine was compared with placebo
(RR 3.03, 95% CI 0.68 to 13.55; n= 65). It was reported that, for all of the interventions, there was no
overall evidence of cardiac toxicity by ECG monitoring.113
In another study of methylphenidate,125 the SSEC was used to monitor adverse effects. In the somatic
index of the SSEC (includes sleep and appetite problems, headache, upset stomach, dizziness), there was
no difference in teacher-rated score for methylphenidate compared with placebo (SMD 0.09, 95% CI
–0.12 to 0.30; n= 71) but, for parent-rated score, somatic index was higher for methylphenidate
compared with placebo (SMD 0.49, 95% CI 0.27 to 0.71; n= 71) (Figure 99).
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Favours stimulant Favours control
Study or subgroup SMD
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IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Methylphenidate
Kurlan 2002113
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: τ2 = 0.12, χ2 = 4.26, df = 1 (p = 0.04), I2= 77%
Test for overall effect: z = 1.16 (p = 0.25)
–0.64 (–1.12 to –0.16)
–0.09 (–0.29 to 0.12)
–0.32 (–0.85 to 0.22)
–0.64
–0.085
0.247
0.106
30.7%
44.2%
74.9%
Low risk
High risk
Dexmethylphenidate
Lyon 2010127
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.10 (p = 0.04)
–0.66 (–1.27 to –0.04)
–0.66 (–1.27 to –0.04)
–0.40 (–0.84 to 0.04)
–0.656 0.312 25.1%
25.1%
High risk
Total (95% CI) 
Heterogeneity: τ2 = 0.10, χ2 = 6.46, df = 2 (p = 0.04), I2 = 69%
Test for overall effect: z = 1.78 (p = 0.07)
Test for subgroup differences: χ2 = 0.66, df = 1 (p = 0.42), I2 = 0%
100.0%
FIGURE 95 Standardised YGTSS global score for stimulant drugs compared with a control in children with ADHD and tics. df, degrees of freedom; IV, independent variable;
ROB, risk of bias; SE, standard error.
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Teacher rated
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.45 (p = 0.01)
–0.27 (–0.48 to –0.05)
–0.27 (–0.48 to –0.05)
–0.265 0.108 100.0%
100.0%
High risk
–2 –1 0 1 2
Favours methylphenidate Favours placebo
Parent rated
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.99 (p = 0.32)
–0.10 (–0.31 to 0.10)
–0.10 (–0.31 to 0.10)
–0.105 0.106 100.0%
100.0%
High risk
FIGURE 96 Standardised teacher and parent-rated SSEC mood index score for immediate release methylphenidate compared with placebo in children with ADHD and tics.
IV, independent variable; ROB, risk of bias; SE, standard error.
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Study or subgroup Events Total Events
Methylphenidate Placebo RR
M–H, fixed, 95% Cl Overall ROBTotal Weight
RR
M–H, fixed, 95% Cl
Parent rated
Kurlan 2002113
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.04 (p = 0.04)
20
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1.92 (1.03 to 3.60)
1.92 (1.03 to 3.60)
37
37
9
9
32
32
100.0%
100.0%
100.0%
100.0%
Low risk
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours methylphenidate
Teacher rated
Kurlan 2002113
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.33 (p = 0.02)
24
24
1.89 (1.11 to 3.22)
1.89 (1.11 to 3.22)
37
37
11
11
32
32
Low risk
100.0%
100.0%
Investigator rated
Kurlan 2002113
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.27 (p = 0.21)
16
16
1.54 (0.79 to 2.99)
1.54 (0.79 to 2.99)
37
37
9
9
32
32
Low risk
FIGURE 97 Proportion of children much or very much improved on the CGI for methylphenidate compared with placebo in children with ADHD and tics (RRs of not being
much or very much improved). M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 98 Proportion of patients experiencing moderate or severe sedation for methylphenidate compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Teacher rated
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.84 (p = 0.40)
0.09 (–0.12 to 0.30)
0.09 (–0.12 to 0.30)
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100.0%
High risk
–2 –1 0 1 2
Favours methylphenidate Favours placebo
Parent rated
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 4.40 (p < 0.0001)
0.49 (0.27 to 0.71)
0.49 (0.27 to 0.71)
0.493 0.112 100.0%
100.0%
High risk
FIGURE 99 Stimulant Side Effects Checklist Somatic Index for immediate release methylphenidate compared with placebo in children with ADHD and tics. IV, independent
variable; ROB, risk of bias; SE, standard error.
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The study also reports that there were significant dose effects (doses of 0.1, 0.3 and 0.5 mg/kg were
given) for heart rate, diastolic BP and weight loss. Findings for the 0.5mg/kg dosage are compared here
(Figure 100). Post-treatment measures were higher for methylphenidate compared with placebo for
diastolic BP (MD 4.50, 95% CI 1.19 to 7.81; n= 71) and heart rate (MD 5.60, 95% CI 1.18 to 10.02;
n= 71). There was no conclusive difference in post-treatment systolic BP (MD 5.30, 95% CI –0.16 to
10.76; n= 71) or weight gain for methylphenidate compared with placebo (MD –1.50, 95% CI –12.01 to
9.01; n= 71).
For the study of immediate-release dexmethylphenidate,127 it is reported that participants tolerated the
procedures well and that 7 out of 10 experienced at least one minor adverse effect during the study (no
distinction made as to whether or not events occurred during the intervention or control days). The most
common adverse effects considered to possibly be related to immediate-release dexmethylphenidate were
drowsiness or sedation (20%) and stomach discomfort (20%).
Moderators of effectiveness In the study of immediate release methylphenidate,125 participants were
separated into two groups on the basis of their baseline YGTSS impairment score. The study reports that
there were similar effects of the drug on tic and ADHD symptoms for groups with low or high baseline
YGTSS impairment score.
Clinical evidence summary for stimulant drugs
Methylphenidate and dexmethylphenidate
Four studies (n= 161) provided very low-quality evidence (see Appendix 4, Tables 33–35) that the
stimulant drugs methylphenidate113,124,125 and dexmethylphenidate127 do not increase motor or vocal tics,
impairment or global tics/impairment following 0–16 weeks of treatment. One study of methylphenidate
reported increased rates of diastolic BP, systolic BP and heart rate that were dose dependent,125 but other
studies did not report adverse effects.
Conclusion
The available evidence suggests that stimulant drugs (methylphenidate and dexmethylphenidate) do not
significantly increase or exacerbate tics when used in the short term to treat comorbid ADHD and TS.
However, there are differences between stimulants in their effect on tics, with dexmethylphenidate
(a stimulant not marketed in the UK) effective in reducing tics. Overall, the combination of methylphenidate
and clonidine is well tolerated, with mild adverse effects (e.g. sedation) and no evidence of cardiac risk.
Anticonvulsant drugs
Pharmacology and prescribing
Levetiracetam (Keppra®, UCB Pharma) is licensed in the UK for monotherapy and adjunctive treatments of
focal seizures, adjunctive therapy of myoclonic seizures and primary generalised tonic–clonic seizures.
Topiramate (Topamax®, Janssen) is a broad-spectrum antiepileptic drug licensed in the UK for monotherapy
in adults, adolescents and children over 6 years of age with partial seizures with or without secondary
generalised seizures, and primary generalised tonic–clonic seizures. It is also licenced for use in adults for
the prophylaxis of migraine headache and is sometimes used in the management of headache, mood and
behavioural disorders, pain and tremors.128 Topiramate has been associated with significant adverse effects
including myopia and close angle glaucoma, fatigue, weight loss and psychosis.
Included studies
Two child studies investigated the efficacy of treatment with levetiracetam and one mixed study
investigated the efficacy of treatment with topiramate.129,130
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Study or subgroup Mean SD Total Mean
Methylphenidate Placebo MD
IV, random, 95% Cl Overall ROBSD Total Weight
MD
IV, random, 95% Cl
Systolic BP
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.90 (p = 0.06)
15.2104.3 5.30 (–0.16 to 10.76)
5.30 (–0.16 to 10.76)
71
71
99 71
71
100.0%
100.0%
17.9 High risk
Weight
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.28 (p = 0.78)
31.677.8 –1.50 (–12.01 to 9.01)
–1.50 (–12.01 to 9.01)
71
71
79.3 71
71
100.0%
100.0%
32.3 High risk
–20 –10 0 10 20
Favours methylphenidate Favours placebo
Diastolic BP
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.67 (p = 0.008)
1164.5 4.50 (1.19 to 7.81)
4.50 (1.19 to 7.81)
71
71
60 71
71
100.0%
100.0%
9 High risk
Heart rate
Gadow 2007125
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.48 (p = 0.01)
14.891.6 5.60 (1.18 to 10.02)
5.60 (1.18 to 10.02)
71
71
86 71
71
100.0%
100.0%
11.9 High risk
FIGURE 100 Post-treatment cardiovascular and weight measurements for immediate release methylphenidate compared with placebo in children with ADHD and tics.
IV, independent variable; ROB, risk of bias.
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Study characteristics
Study characteristics are shown in Appendix 3, Table 9. In one child crossover study,129 children received a
maximum 30mg/kg/day levetiracetam and placebo in a randomised order for 4 weeks each. In another
child crossover study,130 children also received levetiracetam and placebo in a randomised order but only
pooled intervention/control results appear to be presented and no efficacy data could be obtained.
One parallel mixed study investigated the use of topiramate compared with placebo.131 In this study,
29 adults and children were randomised to maximum dose of 200mg/day topiramate or placebo for
6 weeks. Because the mean age of this population was low (16.5 years, SD 9.9), it was assumed that the
majority of the participants would be < 18 years and this study was combined with the child studies in
the meta-analysis.
Risk of bias
For the study of levetiracetam with available data,129 quality assessment was conducted. Computer-generated
randomisation codes were used but the presence of allocation concealment was unclear. There was assurance
of blinding of participants, providers and outcome assessors. The risk of attrition bias was judged to be low
because although analysis was of available cases, the rate of dropout was low. The study was a crossover trial
with a 5–10 day period in which drugs were tapered between interventions and an additional 5-day washout
period and the risk of bias from cross-intervention contamination was unclear. The overall risk of bias was
considered to be unclear owing to the possibility of cross-intervention contamination.
For the study of topiramate,131 a computer-generated randomisation code was used but the presence of
allocation concealment was unclear. There was assurance of blinding of participants, providers and
outcome assessors. The risk of attrition bias was judged to be low because analysis was by intention to
treat for subjects with post-baseline measurements. The overall risk of bias for the study was considered
to be low.
Clinical evidence for anticonvulsant drugs
Levetiracetam and topiramate
Tics In both studies, tics were assessed using the YGTSS total tic scale (Figure 101). In the child study of
levetiracetam,129 change in total tic score was inconclusive for levetiracetam compared with placebo
(SMD –0.23, 95% CI –0.85 to 0.39; n= 20). In the mixed study of topiramate,131 there was a greater
reduction from baseline in total tic score for topiramate compared with placebo (SMD –0.88,
95% CI –1.68 to –0.08; n= 27).
For the study of topiramate, YGTSS motor and vocal tic scale components were presented separately.
Change from baseline suggested a benefit for topiramate compared with placebo for motor tic score
(SMD –0.86, 95% CI –1.65 to –0.06; n= 27) (Figure 102), but was not conclusively different for vocal tic
score (SMD –0.64, 95% CI –1.41 to 0.14; n= 27) (Figure 103).
Impairment In both studies, the YGTSS global tic score was assessed (total tic score and impairment
score) (Figure 104). Post-treatment global score was inconclusive for children treated with levetiracetam
compared with placebo (SMD 0.09, 95% CI –0.53 to 0.70; n= 20), but change from baseline in YGTSS
global score suggested a benefit for topiramate compared with placebo (SMD –1.19, 95% CI –2.02
to –0.36; n= 27).
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Levetiracetam
Smith-Hicks 2007129
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.73 (p = 0.47)
–0.23 (–0.85 to 0.39)
–0.23 (–0.85 to 0.39)
–0.231 0.317 100.0%
100.0%
Unclear risk
–2 –1 0 1 2
Favours anticonvulsant Favours control
Topiramate
Jankovic 2010131
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.17 (p = 0.03)
–0.88 (–1.68 to –0.08)
–0.88 (–1.68 to –0.08)
–0.88 0.406 100.0%
100.0%
Low risk
FIGURE 101 Standardised YGTSS total tic score for anticonvulsants compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
Study or subgroup Mean SD SDTotal Mean Total
Change topiramate Change placebo SMD
IV, random, 95% Cl Overall ROBWeight
SMD
IV, random, 95% Cl
Jankovic 2010131
Total (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.11 (p = 0.03)
5.67 4.3514
14
13
13
–5.79 –0.86 (–1.65 to –0.06)
–0.86 (–1.65 to –0.06)
100.0%
100.0%
–1.3 Low risk
–2 –1 0 1 2
Favours topiramate Favours placebo
FIGURE 102 Standardised change from baseline YGTSS motor tic score for topiramate compared with placebo. IV, independent variable; ROB, risk of bias.
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Study or subgroup Mean SD SDTotal Mean Total
Change topiramate Change placebo SMD
IV, random, 95% Cl Overall ROBWeight
SMD
IV, random, 95% Cl
Jankovic 2010131
Total (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.61 (p = 0.11)
6.1 8.4114
14
13
13
–8.5 –0.64 (–1.41 to 0.14)
–0.64 (–1.41 to 0.14)
100.0%
100.0%
–3.7 Low risk
–2 –1 0 1 2
Favours topiramate Favours placebo
FIGURE 103 Standardised change from baseline YGTSS vocal tic score for topiramate compared with placebo. IV, independent variable; ROB, risk of bias.
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Levetiracetam
Smith-Hicks 2007129
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.27 (p = 0.79)
0.09 (–0.53 to 0.70)
0.09 (–0.53 to 0.70)
0.085 0.316 100.0%
100.0%
Unclear risk
–2 –1 0 1 2
Favours anticonvulsant Favours control
Topiramate
Jankovic 2010131
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.81 (p = 0.005)
–1.19 (–2.02 to –0.36)
–1.19 (–2.02 to –0.36)
–1.19 0.423 100.0%
100.0%
Low risk
FIGURE 104 Standardised YGTSS global score for anticonvulsants compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
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Psychological well-being
Anxiety The study of levetiracetam assessed child anxiety using the Multidimensional Anxiety Scale for
Children (MASC). Post-treatment anxiety score was inconclusive for children treated with levetiracetam
compared with placebo (SMD –0.04, 95% CI –0.66 to 0.58; n= 20) (Figure 105).
Psychological well-being
Depression The study of levetiracetam assessed child depression using the Child Depression Inventory
(CDI) score. Post-treatment depression score was inconclusive for children treated with levetiracetam
compared with placebo (SMD 0.20, 95% CI –0.43 to 0.82; n= 20) (Figure 106).
Overall clinical outcome The study of levetiracetam assessed overall clinical outcome using the CGI
scale. Post-treatment CGI-Severity score was inconclusive for children treated with levetiracetam compared
with placebo (SMD 0.14, 95% CI –0.49 to 0.76; n= 20) (Figure 107).
Long-term outcome No relevant studies reported long-term outcomes.
Safety In the study of levetiracetam, adverse effects reported during the levetiracetam phase were
irritability that resolved with time, hyperkinesias during the initial dose escalation that resolved by the end
of the second week, insomnia, sadness, tiredness, verbal aggression, reduced school participation,
anxiousness and headache. During the placebo phase, there were complaints of headache, irritability,
aggression, low frustration tolerance, insomnia, tiredness, sadness, worry, hyperkinesias, anxiousness and
dry mouth (numbers not reported).
In the study of topiramate, the results were inconclusive for the proportion of participants experiencing at
least one adverse effect for topiramate compared with placebo (RR 0.79, 95% CI 0.56 to 1.11; n= 29)
(Figure 108). When considered separately, the results were inconclusive for the proportions of participants
experiencing any adverse effect for topiramate compared with placebo (Figure 109). The mean change in
weight from baseline was –2.1 kg in the topiramate compared with +1.9 kg in the placebo group
(precision not reported).
Clinical evidence summary for anticonvulsant drugs
Levetiracetam
There was low-quality evidence (see Appendix 4, Table 31) from one study in 20 children129 that was
inconclusive as to whether or not levetiracetam improved tics, global tic/impairment, symptoms of
anxiety or depression, or overall clinical outcome following 4 weeks of treatment, but adverse effects
were unclear.
Topiramate
One study with 27 children and adults131 provided low-quality evidence (see Appendix 4, Table 32)
suggesting that topiramate produced a large effect in terms of improving tics and global tic/impairment
following 6 weeks of treatment. There was no evidence of adverse effects.
Conclusion
There is no clear evidence that levetiracetam is an effective treatment for tics. Topiramate may be effective
in the short-term treatment of tics in children and young people with TS. However, the evidence is drawn
from a single small, mixed study and should be treated with caution. In addition, topiramate in wider use
has been associated with significant adverse effects including myopia and close angle glaucoma, fatigue,
weight loss and paraesthesia.
INTERVENTIONS FOR TICS IN CHILDREN AND ADOLESCENTS
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Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl Overall ROB
–2 –1 0 1 2
Favours Ievetiracetam Favours placebo
–0.036 –0.04 (–0.66 to 0.58)
–0.04 (–0.66 to 0.58)
0.316 100.0%
100.0%
Unclear riskSmith-Hicks 2007129
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.11 (p = 0.91)
FIGURE 105 Standardised MASC score for levetiracetam compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl Overall ROB
–2 –1 0 1 2
Favours Ievetiracetam Favours placebo
0.196 0.20 (–0.43 to 0.82)
0.20 (–0.43 to 0.82)
0.317 100.0%
100.0%
Unclear riskSmith-Hicks 2007129
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.62 (p = 0.54)
FIGURE 106 Standardised CDI score for levetiracetam compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
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Study or subgroup Events Total Events Total
Topiramate Placebo RR
M–H, random, 95% Cl Overall ROBWeight
RR
M–H, random, 95% CI
Jankovic 2010131
Total (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.37 (p = 0.17)
15
15
14
14
11
11 13
0.79 (0.56 to 1.11)
0.79 (0.56 to 1.11)
100.0%
100.0%
13 Low risk
0.2 0.5 1 2 5
Favours topiramate Favours placebo
FIGURE 108 Proportion of patients experiencing more than one adverse event for topiramate compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl Overall ROB
–2 –1 0 1 2
Favours Ievetiracetam Favours placebo
0.136 0.14 (–0.49 to 0.76)
0.14 (–0.49 to 0.76)
0.317 100.0%
100.0%
Unclear riskSmith-Hicks 2007129
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.43 (p = 0.67)
FIGURE 107 Standardised CGI score for levetiracetam compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
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Study or subgroup Events Total Events
Topiramate Placebo RR
M–H, fixed, 95% Cl Overall ROBTotal Weight
RR
M–H, fixed, 95% Cl
Headache
Jankovic 2010131
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.09 (p = 0.92)
3
3
0.93 (0.22 to 3.88)
0.93 (0.22 to 3.88)
15
15
3
3
14
14
100.0%
100.0%
Low risk
0.002 0.1 1 10 500
Favours topiramate Favours placebo
100.0%
100.0%
Kidney stone
Jankovic 2010131
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.65 (p = 0.52)
1
1
2.81 (0.12 to 63.83)
2.81 (0.12 to 63.83)
15
15
0
0
14
14
Low risk
100.0%
100.0%
Diarrhoea
Jankovic 2010131
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.94 (p = 0.35)
3
3
2.80 (0.33 to 23.86)
2.80 (0.33 to 23.86)
15
15
1
1
14
14
Low risk
100.0%
100.0%
Abdominal pain
Jankovic 2010131
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.07 (p = 0.94)
2
2
0.93 (0.15 to 5.76)
0.93 (0.15 to 5.76)
15
15
2
2
14
14
Low risk
100.0%
100.0%
Drowsiness/hypersomnia
Jankovic 2010131
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.07 (p = 0.94)
2
2
0.93 (0.15 to 5.76)
0.93 (0.15 to 5.76)
15
15
2
2
14
14
Low risk
100.0%
100.0%
Cognitive slowing
Jankovic 2010131
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.65 (p = 0.52)
1
1
2.81 (0.12 to 63.83)
2.81 (0.12 to 63.83)
15
15
0
0
14
14
Low risk
FIGURE 109 Proportion of patients experiencing adverse events for topiramate compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
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Monoamine oxidase B inhibitors
Pharmacology and prescribing
Monoamine oxidase B inhibitors act by inhibiting the action of monoamine oxidase in the metabolic
pathway of dopamine. This causes dopamine metabolism to decrease and the levels of dopamine in the
brain to increase. Use of these drugs is restricted because of serious dietary interactions that may cause
hypertensive crises and psychiatric withdrawal symptoms including depression and psychosis.
Selegiline (Eldepryl®, Orion), is licensed in the UK for the treatment of Parkinson’s disease, or
symptomatic parkinsonism.
Included studies
One study investigated the efficacy of treatment with selegiline (deprenyl) in children with ADHD and TS.132
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. In a crossover study,132 24 children were treated
with maximum dose of 5mg selegiline twice a day and placebo for 8 weeks each in a randomised order.
Data are presented as the MD of the improvement on selegiline compared with placebo (unlike most
crossover studies, change and not post-treatment scores are presented).
Risk of bias
Randomisation was generated by a Fortran computer program (with stratification by centre) but the
presence of allocation concealment and blinding of participants, providers and outcome assessors was
unclear. It was a crossover trial with a 6-week washout period between interventions and this may have
been sufficient to avoid cross-intervention contamination. The rate of dropout was reasonably high (37%).
The number included in the analysis was unclear and the risk of attrition bias was considered to be
unclear. Overall, this study was considered to be at unclear risk of bias owing to unclear participant,
provider and outcome assessor blinding and possible attrition bias.
Clinical evidence for monoamine oxidase B inhibitors
Selegiline
Tics Tics were assessed with the YGTSS tic scale. Results were inconclusive for selegiline compared with
placebo for motor (SMD –0.64, 95% CI –1.37 to 0.09; n= 15) and vocal (SMD –0.30, 95% CI –1.02 to
0.41; n= 15) tics (Figure 110).
Impairment TS-related impairment was assessed with the YGTSS impairment scale and combined tic
severity and impairment with YGTSS global scale. Reduction was greater following treatment with
selegiline compared with placebo for impairment score (SMD –0.75, 95% CI –1.49 to –0.01; n= 15) and
for global score (SMD –0.72, 95% CI –1.45 to 0.02; n= 15) (Figure 111).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome No relevant studies reported this outcome.
Long-term outcome No relevant studies reported long-term outcomes.
Safety The occurrence of adverse effects is reported over the whole study period and it is not possible to
distinguish events occurring during selegiline and placebo phases from one another. Events included rash
(n= 1), nausea (n= 4), agitation (n= 4), irritability (n= 2), drowsiness (n= 5), headache (n= 4) and
diarrhoea (n= 1) but it is reported that none of the adverse effects occurred more frequently during the
selegiline compared with the placebo phase.
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
YGTSS motor tic score
Feigin 1996132
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.71 (p = 0.09)
–0.64 (–1.37 to 0.09)
–0.64 (–1.37 to 0.09)
–0.641 0.374 100.0%
100.0%
Unclear risk
–2 –1 0 1 2
Favours selegiline Favours placebo
YGTSS vocal tic score
Feigin 1996132
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.83 (p = 0.41)
–0.30 (–1.02 to 0.41)
–0.30 (–1.02 to 0.41)
–0.305 0.367 100.0%
100.0%
Unclear risk
FIGURE 110 Standardised YGTSS motor and vocal tic score for children treated with selegiline compared with placebo. IV, independent variable; ROB, risk of bias;
SE, standard error.
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
YGTSS impairment score
Feigin 1996132
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.98 (p = 0.05)
–0.75 (–1.49 to –0.01)
–0.75 (–1.49 to –0.01)
–0.75 0.38 100.0%
100.0%
Unclear risk
–2 –1 0 1 2
Favours selegiline Favours placebo
YGTSS global score
Feigin 1996132
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.90 (p = 0.06)
–0.72 (–1.45 to 0.02)
–0.72 (–1.45 to 0.02)
–0.72 0.38 100.0%
100.0%
Unclear risk
FIGURE 111 Standardised YGTSS impairment and global score for children treated with selegiline compared with placebo. IV, independent variable; ROB, risk of bias;
SE, standard error.
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
X
X
X
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
X
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
H
o
llis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
1
1
3
Clinical evidence summary for monoamine oxidase B inhibitors
Selegiline
One study in 15 children132 provided low-quality evidence (see Appendix 4, Table 39) that was inconclusive
as to whether or not selegiline improved motor and vocal tics following 4 weeks of treatment, but the
evidence suggested some benefit in terms of impairment. The relative occurrence of adverse effects was
not reported.
Conclusion
There is little evidence that selegiline is an effective treatment for tics in children and young people
with TS.
Dopamine receptor agonists
Pharmacology and prescribing
Dopamine receptor agonists are primarily used for treating Parkinson’s disease.
Pergolide (non-proprietary) was withdrawn by the US FDA in 2007 owing to two studies indicating that
the drug could cause serious heart valve damage.133,134 It is still used in the UK, mainly as an adjunctive
treatment for Parkinson’s disease and for restless leg syndrome.
Pramipexole (Mirapexin®, Boehringer Ingelheim) is licensed in the UK for the treatment of the signs and
symptoms of idiopathic Parkinson’s disease. At the time of this review, the US FDA has not withdrawn
pramipexole from the US market but has issued a safety announcement, and is working with the
manufacturer to further clarify the risk of heart failure.
Included studies
Three studies in children investigated the efficacy of dopamine agonists compared with placebo:
l pergolide versus placebo: two studies in children135,136
l pramipexole versus placebo: one study in children137
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. One pergolide study135 was a crossover trial where
children received a maximum dose of 300 µg pergolide and placebo in a randomised order for 6 weeks
each. The other study of pergolide136 was a parallel trial where 51 children were randomised 2 : 1 to
receive 8 weeks of a maximum dose of 150 µg pergolide or placebo. The study of pramipexole137 was a
parallel trial where 63 children were randomised to a maximum dose of 0.25mg pramipexole twice a day
or placebo for 8 weeks.
Risk of bias
In the crossover study of pergolide,135 randomisation was conducted by dice roll and therefore appears to
have had poor allocation concealment. There was blinding of participants, providers and outcome assessors.
There was only a 2-week washout period between treatment phases and the risk of cross-treatment
contamination is unclear. Although analysis appears to be of available cases, there was a reasonably low
rate of drop out (21%) and there may have been a low risk of attrition bias. Overall, this study was
considered to be at unclear risk of bias owing to possible cross-treatment contamination.
In the parallel trial of pergolide,136 the method of randomisation and presence of allocation concealment
were unclear. There was blinding of participants, providers and outcome assessors. Analysis was by last
observation carried forward for participants with post-baseline measurements and the risk of attrition bias
was considered to be low. Overall, this study was considered to be at low risk of bias.
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In the parallel trial of pramipexole,137 the method of randomisation, presence of allocation concealment
and blinding of participants, providers and outcome assessors were unclear. The rates of dropout from the
study were not reported and the presence of attrition bias is unclear. Overall, this study was considered
to be at unclear risk of bias owing to the unclear presence of patient, provider and outcome
assessor blinding.
Clinical evidence
Pergolide and pramipexole
Tics One study of pergolide136 and one of pramipexole137 measured effects on tics using the YGTSS total
tic scale. Reduction from baseline tic score was greater but there was no conclusive difference for
pergolide compared with placebo (SMD –0.59, 95% CI –1.21 to 0.02; n= 51). Reduction from baseline tic
score was similar following treatment with pramipexole compared with placebo (SMD –0.00, 95% CI
–0.53 to 0.53; n= 62) (Figure 112).
For all studies, the YGTSS global scale was used to assess tic outcome (Figure 113). Global score favoured
pergolide in comparison with placebo (SMD –0.87, 95% CI –1.39 to –0.34; n= 70), with little heterogeneity
between studies (I2= 25%). Change from baseline global score was similar for pramipexole compared with
placebo (SMD –0.01, 95% CI –0.54 to 0.52; n= 62).
Impairment One study of pergolide,136 reported effects on impairment using the YGTSS impairment score
(Figure 114). Results were inconclusive for the reduction from baseline impairment score for pergolide
compared with placebo (SMD –0.53, 95% CI –1.14 to 0.08; n= 51).
Psychological well-being In the study of pramipexole,137 psychological well-being was measured using
the Child Depression Inventory – short version (CDI-S) and the MASC. Results were inconclusive for the
reduction from baseline in depression (SMD –0.44, 95% CI –0.99 to 0.11; n= 61) or anxiety scores (SMD
–0.30, 95% CI –0.85 to 0.24; n= 61) for pramipexole compared with placebo (Figures 115 and 116).
Overall clinical outcome In all studies, overall clinical outcome was measured using the CGI-Severity
scale. In the pergolide studies,135,136 change from baseline/post-treatment CGI-Severity score was
inconclusive for pergolide compared with placebo (SMD –0.28, 95% CI –0.78 to 0.23; n= 70) (Figure 117)
and there was no heterogeneity between study results (in the crossover study, first-phase data were used
for this outcome because of carry over effects).
In the study of pramipexole, results were inconclusive for the proportions of children who had an improved
(RR 1.19, 95% CI 0.42 to 3.33; n= 62) or unchanged (RR 0.95, 95% CI 0.72 to 1.26; n= 62) CGI-Severity
score for pramipexole compared with placebo (Figure 118).
Long-term outcome No relevant studies reported long-term outcomes.
Safety One study of pergolide135 and one of pramipexole137 reported the number of participants with one
or more adverse effects (Figure 119). Results were inconclusive for the proportions of participants
experienced an adverse effect for intervention compared with placebo in the study of pergolide (RR 0.88,
95% CI 0.40 to 1.93; n= 19) and in the study of pramipexole (RR 1.62, 95% CI 0.70 to 3.76; n= 62). In
the pramipexole study, the most frequent adverse effects in the pramipexole group were headache (28%),
nausea (19%), vomiting (12%), myalgia (9%) and fatigue (9%) (not reported for the placebo group).
Both studies135,136 of pergolide measured adverse effects using the STESS and patient-reported adverse
effects were recorded. STESS scores were inconclusive for pergolide compared with placebo (SMD –0.05,
95% CI –0.49 to 0.38; n= 70) (Figure 120).
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Pergolide
Gilbert 2003136
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.89 (p = 0.06)
–0.59 (–1.21 to 0.02)
–0.59 (–1.21 to 0.02)
–0.592 0.313 100.0%
100.0%
Low risk
–2 –1 0 1 2
Favours dopamine agonists Favours placebo
Pramipexole
Kurlan 2012137
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.00 (p = 1.00)
0.00 (–0.53 to 0.53)
0.00 (–0.53 to 0.53)
–0.001 0.272 100.0%
100.0%
Unclear risk
FIGURE 112 Standardised change from baseline total tic score for dopamine agonists compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
–2 –1 0 1 2
Favours dopamine agonists Favours placebo
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Pergolide
GIlbert 2003136
Gilbert 2000135
Subtotal (95% CI) 
Heterogeneity:  τ2 = 0.04, χ2 = 1.33, df =1 ( p = 0.25), I 2 = 25%
Test for overall effect: z = 3.21 ( p = 0.001)
–0.62 (–1.23 to 0.00)
–1.16 (–1.85 to –0.47)
–0.87 (–1.39 to –0.34)
–0.618
–1.16
0.313
0.351
54.3%
45.7%
100.0%
Low risk
Unclear risk
Pramipexole
Kurlan 2012137
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.04 ( p = 0.97)
–0.01 (–0.54 to 0.52)
–0.01 (–0.54 to 0.52)
–0.01 0.27 100.0%
100.0%
Unclear risk
FIGURE 113 Standardised global tic score for dopamine agonists compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of bias;
SE, standard error.
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Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl Overall ROB
–2 –1 0 1 2
Favours pergolide Favours placebo
–0.532 –0.53 (–1.14 to 0.08)
–0.53 (–1.14 to 0.08)
0.312 100.0%
100.0%
Low riskGilbert 2003136
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.71 (p = 0.09)
FIGURE 114 Standardised change from baseline YGTSS impairment score for pergolide compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
Study or subgroup Mean SD SDTotal Mean Total
Pramipexole Placebo SMD
IV, random, 95% Cl Overall ROBWeight
SMD
IV, random, 95% Cl
Kurlan 2012137
Total (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.10 (p = 0.27)
10.2 12.742
42
19
19
–1.6 –0.30 (– 0.85 to 0.24)
–0.30 (– 0.85 to 0.24)
100.0%
100.0%
1.8 Unclear risk
–2 –1 0 1 2
Favours pramipexole Favours placebo
FIGURE 116 Standardised change from baseline in MASC score for pramipexole compared with placebo. IV, independent variable; ROB, risk of bias.
Study or subgroup Mean SD SDTotal Mean Total
Pramipexole Placebo SMD
IV, random, 95% Cl Overall ROBWeight
SMD
IV, random, 95% Cl
Kurlan 2012137
Total (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.57 (p = 0.12)
0.9 2.542
42
19
19
–0.4 –0.44 (– 0.99 to 0.11)
–0.44 (– 0.99 to 0.11)
100.0%
100.0%
0.3 Unclear risk
–2 –1 0 1 2
Favours pramipexole Favours placebo
FIGURE 115 Standardised change from baseline in CDI-S score for pramipexole compared with placebo. IV, independent variable; ROB, risk of bias.
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
GIlbert 2003136
Gilbert 2000135
Total (95% CI) 
Heterogeneity: τ2 = 0.00, χ2 = 0.00, df = 1 ( p = 0.97), I2 = 0%
Test for overall effect: z = 1.08 ( p = 0.28)
–0.28 (–0.89 to 0.32)
–0.26 (–1.17 to 0.65)
–0.28 (–0.78 to 0.23)
–0.284
–0.26
0.309
0.462
69.1%
30.9%
100.0%
Low risk
Unclear risk
–2 –1 0 1 2
Favours pergolide Favours placebo
FIGURE 117 Standardised change from baseline/post-treatment CGI-Severity score for pergolide compared with placebo. df, degrees of freedom; IV, independent variable;
ROB, risk of bias; SE, standard error.
Study or subgroup Events Total Events
Pramipexole Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% Cl
Improved
Kurlan 2012137
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.33 (p = 0.74)
10
10
1.19 (0.42 to 3.33)
1.19 (0.42 to 3.33)
42
42
4
4
20
20
100.0%
100.0%
Unclear risk
100.0%
100.0%
Unchanged
Kurlan 2012137
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.35 (p = 0.73)
32
32
0.95 (0.72 to 1.26)
0.95 (0.72 to 1.26)
42
42
16
16
20
20
Unclear risk
0.1 0.2 0.5 1 2 105
Favours pramipexole Favours placebo
FIGURE 118 Proportion of children with improved and unchanged CGI-Severity scores for pramipexole compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
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Study or subgroup Events Total Events
Dopamine agonist Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% Cl
Pergolide
Gilbert 2000135
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.33 (p = 0.74)
7
7
0.88 (0.40 to 1.93)
0.88 (0.40 to 1.93)
19
19
8
8
19
19
100.0%
100.0%
Unclear risk
100.0%
100.0%
Pramipexole
Kurlan 2012137
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.12 (p = 0.26)
17
17
1.62 (0.70 to 3.76)
1.62 (0.70 to 3.76)
42
42
5
5
20
20
Unclear risk
0.1 0.2 0.5 1 2 105
Favours dopamine agonist Favours placebo
FIGURE 119 Proportion of patients with adverse events in studies of dopamine agonists compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Gilbert 2003136
Gilbert 2000135
Total (95% CI) 
Heterogeneity: τ2 = 0.00, χ2 = 0.04, df = 1 (p = 0.83), I 2 = 0%
Test for overall effect: z = 0.24 (p = 0.81)
– 0.10 (– 0.70 to 0.50)
– 0.00 (– 0.64 to 0.63)
– 0.05 (– 0.49 to 0.38)
– 0.098
– 0.004
0.307
0.324
57.7%
47.3%
100.0%
Low risk
Unclear risk
–2 –1 0 1 2
Favours pergolide Favours placebo
FIGURE 120 Standardised STESS side effect score for pergolide compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of bias; SE, standard error.
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In one study of pergolide,136 results were inconclusive for the rates of gastrointestinal adverse effects
(RR 0.98, 95% CI 0.68 to 1.42; n= 51), headaches (RR 0.74, 95% CI 0.43 to 1.29; n= 51), mild insomnia
(RR 5.62, 95% CI 0.34 to 93.94; n= 51) and rashes (RR 1.67, 95% CI 0.20 to 13.70; n= 51) for pergolide
compared with placebo (Figure 121).
In this study, ECG parameters were measured (Figure 122). Results were inconclusive for the changes from
baseline for pergolide compared with placebo for PR interval (MD 9.90, 95% CI –5.27 to 25.07; n= 51),
QT interval (MD 13.50, 95% CI –4.29 to 31.29; n= 51) and QRS width (MD 0.70, 95% CI –3.35 to
4.75; n= 51).
For the other pergolide study,135 adverse effects in the pergolide group were syncope, sedation, postural
dizziness, dizziness, nausea, stomach ache and irritability and, in the placebo group, blurry vision, fever,
hyperventilation, leg pain, nausea, rash, sedation, stomach ache, weight loss, diarrhoea and enuresis
(numbers not reported).
Clinical evidence summary
Pergolide
There was low-quality evidence (see Appendix 4, Table 36) from two studies in children (n= 70)135,136 that
pergolide produced medium-to-large effects in terms of tics and global tic/impairment, but overall clinical
outcome was inconclusive.
Pramipexole
One study in 62 children137 provided low-quality evidence (see Appendix 4, Table 37) that pramipexole was
unlikely to improve tics, global tic/impairment or overall clinical outcome (proportion of participants much
or very much improved on the CGI scale) following 6 weeks of treatment. There was an increase in
adverse effects, but the estimates were very imprecise.
Conclusion
Pergolide may be an effective agent for the reduction of tics in the short term in children and young people
with TS, but effects on global outcomes are inconclusive. While there was no apparent increase in adverse
effects in these studies, pergolide is now rarely considered for other neurological indications (Parkinson’s
disease) in the UK owing to serious concerns over the risk of long-term fibrotic reactions (i.e. pulmonary and
pericardial fibrosis). There is no clear evidence that pramipexole is an effective treatment for tics.
5HT3-receptor antagonists/antiemetic and gastroprokinetic agents
Pharmacology and prescribing
Metoclopramide (Maxolon®, AMCo) is a dopamine antagonist with a license in the UK to treat a number
of conditions including the treatment of the nausea and vomiting associated with gastrointestinal
disorders. Like other dopamine antagonists, metoclopramide antagonises dopamine D2 receptors within
the striatum.
Ondansetron (Zofran®, GSK) is a selective 5-HT3 receptor antagonist licensed in the UK for the treatment of
nausea and vomiting in relation to post-operative recovery and chemotherapy.
Included studies
One parallel trial investigated the efficacy of metoclopramide138 and one parallel trial investigated the
efficacy of ondansetron.139
INTERVENTIONS FOR TICS IN CHILDREN AND ADOLESCENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Study or subgroup Events Total Events
Pergolide Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% CI
Gastrointestinal events
Gilbert 2003136
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.08 (p = 0.93)
26
26
0.98 (0.68 to 1.42)
0.98 (0.68 to 1.42)
36
36
11
11
15
15
100.0%
100.0%
Low risk
0.01 0.1 1 10010
Favours pergolide Favours placebo
100.0%
100.0%
Headache
Gilbert 2003136
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.07 (p = 0.29)
16
16
0.74 (0.43 to 1.29)
0.74 (0.43 to 1.29)
36
36
9
9
15
15
Low risk
100.0%
100.0%
Insomnia
Gilbert 2003136
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.20 (p = 0.23)
6
6
5.62 (0.34 to 93.94)
5.62 (0.34 to 93.94)
36
36
0
0
15
15
Low risk
100.0%
100.0%
Rash
Gilbert 2003136
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.48 (p = 0.63)
4
4
1.67 (0.20 to 13.70)
1.67 (0.20 to 13.70)
36
36
1
1
15
15
Low risk
FIGURE 121 Proportion of patients experiencing various adverse events for pergolide compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
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Study or subgroup Mean SD Total Mean
Pergolide Placebo MD
IV, random, 95% Cl Overall ROBSD Total Weight
MD
IV, random, 95% Cl
PR
Gilbert 2003136
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.28 (p = 0.20)
14.890.9 9.90 (–5.27 to 25.07)
9.90 (–5.27 to 25.07)
36
36
–9 15
15
100.0%
100.0%
28.39 Low risk
QT interval
Gilbert 2003136
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.49 (p = 0.14)
25.239 13.50 (–4.29 to 31.29)
13.50 (–4.29 to 31.29)
36
36
–4.5 15
15
100.0%
100.0%
31.16 Low risk
QRS width
Gilbert 2003136
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.34 (p = 0.73)
7.161.9 0.70 (–3.35 to 4.75)
0.70 (–3.35 to 4.75)
36
36
1.2 15
15
100.0%
100.0%
6.53 Low risk
–50 –25 0 25 50
Favours pergolide Favours placebo
FIGURE 122 Change from baseline in ECG parameters for pergolide compared with placebo. IV, independent variable; ROB, risk of bias.
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Study characteristics
Study characteristics are shown in Appendix 3, Table 9. One parallel trial in children compared
metoclopramide with placebo.138 Twenty-eight children with TS or CTD were randomised to maximum
dose of 40mg/day metoclopramide or to placebo for 8 weeks.
Another parallel trial in a mixed population of adults and children compared treatment with ondansetron
with placebo.139 The original study was of 30 adults and children, but the authors were able to supply IPD
for 15 children who were randomised to 8mg/day ondansetron or placebo for 3 weeks.
Risk of bias
Neither study provided information on the method of sequence generation, allocation concealment or
statements about the presence of participant, provider or outcome assessor blinding. Neither study had a
high rate of dropout and both were considered to be at low risk of attrition bias. Overall, owing to the
unclear presence of blinding, both of these studies were considered to be at unclear risk of bias.
Clinical evidence for 5HT3-receptor antagonists/antiemetic and
gastroprokinetic agents
Metoclopramide and ondansetron
Tics Both studies measured tic changes using the YGTSS. For metoclopramide, reduction from baseline in
total tic score was greater for metoclopramide than placebo (SMD –1.43, 95% CI –2.28 to –0.59; n= 27).
For ondansetron, the reduction in total tic score was inconclusive for ondansetron compared with placebo
(SMD –0.38, 95% CI –1.42 to 0.66; n= 15) (Figure 123).
Both studies reported findings for motor and vocal tic components separately. For metoclopramide, there
was a reduction in YGTSS motor tic score compared with placebo (SMD –1.44, 95% CI –2.28 to –0.59;
n= 27). For ondansetron, the results were inconclusive when compared with placebo (SMD –0.14, 95% CI
–1.18 to 0.89; n= 15) (Figure 124).
For vocal tics, there was a reduction in YGTSS vocal tic score for metoclopramide compared with placebo
(SMD –0.79, 95% CI –1.58 to –0.01; n= 27), but findings were inconclusive for ondansetron compared
with placebo (SMD –0.69, 95% CI –1.76 to 0.37; n= 15) (Figure 125).
Impairment No measures of TS-related impairment were reported by these studies.
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome In both studies, overall clinical outcome was assessed using the CGI-Severity
scale. CGI score suggested a benefit for metoclopramide compared with placebo (SMD –1.07, 95% CI
–1.88 to –0.27; n= 27). For ondansetron compared with placebo, the results were inconclusive
(SMD –0.50, 95% –1.55 to 0.55; n= 15) (Figure 126).
Long-term outcome No relevant studies reported long-term outcomes.
Safety In the study of metoclopramide,138 the occurrence of adverse effects is shown in Figure 127 (other
adverse effects were measured but no events were reported). The results were inconclusive for rates of
sedation (RR 2.79, 95% CI 0.33 to 23.52; n= 27), dysphoria (RR 0.93, 95% CI 0.06 to 13.37; n= 27) and
increased appetite (RR 2.79, 95% CI 0.33 to 23.52; n= 27) for metoclopramide compared with placebo.
Weight gain (kg) was inconclusive for metoclopramide compared with placebo (MD 0.50, 95% CI –0.75 to
1.75; n= 27) (Figure 128) and it is reported that there was no difference in changes in any cardiac
conduction parameters (PR, QRS and QTc) or liver function measures for children treated with
metoclopramide compared with placebo.
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Metoclopramide
Nicolson 2005138
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 3.32 (p = 0.0009)
–1.43 (–2.28 to –0.59)
–1.43 (–2.28 to –0.59)
–1.434 0.432 100.0%
100.0%
Unclear risk
–4 –2 0 2 4
Favours antiemetic Favours placebo
Ondansetron
Toren 2005139
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.71 (p = 0.48)
–0.38 (–1.42 to 0.66)
–0.38 (–1.42 to 0.66)
–0.38 0.533 100.0%
100.0%
Unclear risk
FIGURE 123 Standardised change from baseline YGTSS total tic score for children treated with antiemetic or gastroprokinetic agents compared with placebo. IV, independent
variable; ROB, risk of bias; SE, standard error.
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Metoclopramide
Nicolson 2005138
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 3.32 (p = 0.0009)
–1.44 (–2.28 to –0.59)
–1.44 (–2.28 to –0.59)
–1.435 0.432 100.0%
100.0%
Unclear risk
–4 –2 0 2 4
Favours antiemetic Favours placebo
Ondansetron
Toren 2005139
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.27 (p = 0.79)
–0.14 (–1.18 to 0.89)
–0.14 (–1.18 to 0.89)
–0.143 0.528 100.0%
100.0%
Unclear risk
FIGURE 124 Standardised change from baseline YGTSS motor tic score for children treated with an antiemetic or gastroprokinetic agent compared with placebo.
IV, independent variable; ROB, risk of bias; SE, standard error.
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Metoclopramide
Nicolson 2005138
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.98 (p = 0.05)
–0.79 (–1.58 to –0.01)
–0.79 (–1.58 to –0.01)
–0.793 0.4 100.0%
100.0%
Unclear risk
–4 –2 0 2 4
Favours antiemetic Favours placebo
Ondansetron
Toren 2005139
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.28 (p = 0.20)
–0.69 (–1.76 to 0.37)
–0.69 (–1.76 to 0.37)
–0.695 0.542 100.0%
100.0%
Unclear risk
FIGURE 125 Standardised change from baseline YGTSS vocal tic score for children treated with an antiemetic or gastroprokinetic agent compared with placebo.
IV, independent variable; ROB, risk of bias; SE, standard error.
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Metoclopramide
Nicolson 2005138
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.61 (p = 0.009)
–1.07 (–1.88 to –0.27)
–1.07 (–1.88 to –0.27)
–1.074 0.412 100.0%
100.0%
Unclear risk
–4 –2 0 2 4
Favours antiemetic Favours placebo
Ondansetron
Toren 2005139
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.93 (p = 0.35)
–0.50 (–1.55 to 0.55)
–0.50 (–1.55 to 0.55)
–0.5 0.535 100.0%
100.0%
Unclear risk
FIGURE 126 Standardised change from baseline in CGI-Severity score for children treated with an antiemetic or gastroprokinetic agent compared with placebo.
IV, independent variable; ROB, risk of bias; SE, standard error.
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Study or subgroup Events Total Events
Metoclopramide Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
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Subtotal (95% CI) 
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Heterogeneity: not applicable
Test for overall effect: z = 0.94 (p = 0.35)
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Heterogeneity: not applicable
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Test for overall effect: z = 0.94 (p = 0.35)
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14
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FIGURE 127 Proportion of patients experiencing adverse events for metoclopramide compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup Mean SD SDTotal Mean Total
Metoclopramide Placebo MD
IV, random, 95% Cl Overall ROBWeight
MD
IV, random, 95% Cl
Nicolson 2005138
Total (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.78 (p = 0.43)
1.9 1.414
14
13
13
1 0.50 (– 0.75 to 1.75)
0.50 (– 0.75 to 1.75)
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100.0%
0.5 Unclear risk
–4 –2 0 2 4
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FIGURE 128 Weight gain for children for metoclopramide compared with placebo. IV, independent variable; ROB, risk of bias.
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In the study of ondansetron,139 in the whole mixed study sample, one patient from the ondansetron and
one from the placebo group experienced mild and transient abdominal pain. It is reported that adverse
effects also included gastrointestinal complaints leading to drop-out of one patient in the
ondansetron group.
Moderators of clinical effectiveness For the study of metoclopramide, no investigation into moderating
factors was conducted. In the study of ondansetron,139 in the whole mixed study population (not the child
subset used for efficacy results in this review), investigators found that there was no significant difference
in response to ondansetron for participants aged ≤ 18 years compared with those aged > 18 years, for
those with OCD compared with those without OCD and for those with ADHD compared with those
without ADHD.
Clinical evidence summary for 5HT3-receptor antagonists/antiemetic and
gastroprokinetic agents
Metoclopramide
There was low-quality evidence (see Appendix 4, Table 29) from one study with 27 children138 suggesting
that metoclopramide produced a large effect in terms of tics and overall clinical outcome following
8 weeks of treatment, by estimates of adverse effects were very imprecise.
Ondansetron
One study in 15 children139 provided very low-quality evidence (see Appendix 4, Table 30) that was
inconclusive as to whether or not ondansetron improves tics and overall clinical outcome following 3 weeks
of treatment. There was no apparent increase in adverse effects, although the study was too small to detect
relative differences.
Conclusion
Metoclopramide may be effective in the short-term treatment of tics in children and young people with TS.
However, this conclusion must be treated with caution as the evidence is drawn from a single small
study.138 There is no clear evidence that ondansetron is an effective treatment for tics.
Gamma-aminobutyric acidB receptor agonists/skeletal muscle relaxants
Pharmacology and prescribing
The GABAB receptor agonists act as muscle relaxants on the central nervous system and are usually
prescribed for chronic severe spasticity.
Baclofen (Lioresal®, Novartis) binds to GABAB receptors and inhibits the release of the excitatory
neurotransmitters glutamate and aspartate. It is licensed in the UK for the relief of spasticity of voluntary
muscle resulting from disorders such as multiple sclerosis.
Included studies
One study in children investigated treatment with baclofen compared with placebo.140
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. In one crossover study,140 10 children with TS were
randomised to receive a maximum dose of 60mg/day baclofen and placebo in a randomised order for
4 weeks each.
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Risk of bias
Methods for sequence generation and allocation concealment were unclear but participants, their parents,
providers and outcome assessors were blind to order of allocation. There was a short washout period
(2–3 weeks including drug tapering) and there was considered to be high risk of cross-treatment
contamination. Analysis was of only participants completing the study but attrition was reasonably
low (10%). Overall, this study was considered to be at unclear risk of bias owing to possible
cross-treatment contamination.
Clinical evidence for gamma-aminobutyric acidB receptor agonists/skeletal
muscle relaxants
Baclofen
Tics The effect on tics was assessed using the YGTSS total tic scale. The results were inconclusive for
baclofen compared with placebo (SMD –0.54, 95% CI –1.50 to 0.42; n= 9) (Figure 129).
Impairment Impairment was assessed with the YGTSS impairment scale. The results favoured baclofen
compared with placebo for impairment score (SMD –1.38, 95% CI –2.46 to –0.30; n= 9) (Figure 130) and
overall global score (SMD –0.95, 95% CI –1.93 to 0.02; n= 9) (Figure 131).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Overall clinical outcome was assessed with the CGI-Severity score and favoured
baclofen compared with placebo (SMD –1.05, 95% CI –2.03 to –0.07; n= 9) (Figure 132).
Long-term outcome No relevant studies reported long-term outcomes.
Safety Reported rates of abdominal pain, nausea, anxiety and headache were the same for participants
when taking baclofen and placebo (one patient for each) and rates of constipation (one vs. two),
palpitations (zero vs. one) and social phobia (zero vs. one) were similar.
Clinical evidence summary for gamma-aminobutyric acidB receptor
agonists/skeletal muscle relaxants
Baclofen
There was very low-quality evidence (see Appendix 4, Table 41) from one study140 with nine children that
baclofen improved impairment, tics and overall clinical outcome following 4 weeks of treatment.
There was no reported increase in rates of adverse effects, although the study was too small to detect
relative differences.
Conclusion
There is no clear evidence that baclofen is an effective treatment for tics in children and young people
with TS.
Tricyclic antidepressants
Pharmacology and prescribing
Tricyclic antidepressants are one of the oldest classes of antidepressants and are also used for the
management of panic and other anxiety disorders. They inhibit the reuptake of noradrenaline and
serotonin. TCAs have largely been replaced by SSRIs because of the greater cardiac risk in overdose
with TCAs.
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Study or subgroup SMD SE Weight
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–0.54 –0.54 (–1.50 to 0.42)
–0.54 (–1.50 to 0.42)
0.49 100.0%
100.0%
Singer 2001140
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.10 (p = 0.27)
FIGURE 129 Standardised YGTSS total tic score for baclofen compared with placebo. IV, independent variable; SE, standard error.
Study or subgroup SMD SE Weight
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Test for overall effect: z = 2.51 (p = 0.01)
FIGURE 130 Standardised YGTSS total impairment score for baclofen compared with placebo. IV, independent variable; SE, standard error.
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Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
–2 –1 0 1 2
Favours balcofen Favours placebo
–0.954 –0.95 (–1.93 to 0.02)
–0.95 (–1.93 to 0.02)
0.498 100.0%
100.0%
Singer 2001140
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.92 (p = 0.06)
FIGURE 131 Standardised YGTSS global score for baclofen compared with placebo. IV, independent variable; SE, standard error.
Study or subgroup SMD SE Weight
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Total (95% CI)
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Test for overall effect: z = 2.10 (p = 0.04)
FIGURE 132 Standardised CGI-Severity score for baclofen compared with placebo. IV, independent variable; SE, standard error.
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Desipramine is a noradrenergic TCA (with pharmacological similarities to atomoxetine) that has been
trialled in children with TS and comorbid ADHD, with the aim to reduce both tics and ADHD symptoms.141
The license for desipramine was withdrawn in the UK in the late 1980s following reports of sudden
unexplained deaths in children. Desipramine is still available in some countries including the USA.
Included studies
Two studies in children investigated treatment with desipramine compared with placebo.115,141
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. In both studies, children with concurrent tic
disorder and ADHD were treated. One study was a crossover, in which 37 children received 100mg/day
desipramine, 0.2mg/day clonidine and placebo in a randomised order for 6 weeks each.115 In the other
study, children were randomised in parallel to 3.5mg/kg/day desipramine or placebo for 6 weeks.141
Risk of bias
In the crossover trial,115 the methods for randomisation and allocation concealment were not reported but
there appears to have been blinding of participants, providers and outcome assessors. There was only a
1-week washout period between treatments and there may have been a high risk of cross-intervention
contamination. There appears to have been a low rate of dropout and the risk of attrition bias may be low.
Only data for outcomes with statistically significant findings were reported and, for these outcomes,
there is considered to be a high risk of selective outcome reporting bias. Overall, the study was considered
to be at high risk of bias owing to potential cross-treatment contamination and selective outcome
reporting bias.
In the parallel trial,141 randomisation was conducted stratified for pre/post adolescence and sex but the
method used was not stated. Allocation concealment was ensured through the use of sealed envelopes
and participants, providers and outcome assessors appear to have been blinded to intervention allocation.
The rate of dropout was relatively low (8%). Overall, this study was considered to be at low risk of bias.
Clinical evidence for tricyclic antidepressants
Desipramine
Tics The parallel trial141 measured tics with the YGTSS total tic scale and the crossover trial115 used the
YGTSS, Hopkins scale, Shapiro TSSS and a linear analogue scale completed by parents. In the parallel trial,
the proportion of participants with ≥ 30% reductions in the YGTSS was greater for children taking
desipramine compared with placebo for the total (RR 0.47, 95% CI 0.27 to 0.81; n= 39), motor (RR 0.59,
95% CI 0.35 to 1.00; n= 39) and vocal tic scores (RR 0.47, 95% CI 0.27 to 0.81; n= 39) (RRs of not
having a ≥ 30% reduction) (Figure 133).
In the crossover trial,115 there was no significant differences in post-treatment measures for the YGTSS
(conducted in 23 of 34 participants), or in motor or vocal measures on the Hopkins scale or the Shapiro
TSSS (data are not presented in the publication), but for a parent-completed linear analogue scale
measuring changes in tic severity and frequency, there was a greater change score for desipramine
compared with placebo.
Impairment In the parallel trial,141 the YGTSS global scale was used (measure of tic severity and
impairment). There was a greater reduction from baseline in global score for desipramine than placebo
(SMD –1.15, 95% CI –1.83 to –0.46; n= 39) (Figure 134).
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Study or subgroup Events Total Events
Desipramine Placebo RR (non-event)
M–H, fixed, 95% Cl Overall ROBTotal Weight
RR (non-event)
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>_ 30% reduction YGTSS total tic score
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Subtotal (95% CI) 
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Heterogeneity: not applicable
Test for overall effect: z = 2.72 (p = 0.007)
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0.47 (0.27 to 0.81)
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2
2
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100.0%
100.0%
Low risk
0.1 0.2 0.5 1 102 5
Favours desipramine Favours placebo
100.0%
100.0%
>_ 30% reduction YGTSS motor tic score
Spencer 2002141
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.97 (p = 0.05)
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0.59 (0.35 to 1.00)
0.59 (0.35 to 1.00)
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4
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100.0%
100.0%
>_ 30% reduction YGTSS vocal tic score
Spencer 2002141
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.72 (p = 0.007)
11
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0.47 (0.27 to 0.81)
0.47 (0.27 to 0.81)
19
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2
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Low risk
FIGURE 133 Proportion of children with ≥ 30% reductions in YGTSS total, motor and vocal tic scores for desipramine compared with placebo (RRs are the relative risk of not
having a ≥ 30% reduction). M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup SMD SE Weight
SMD
IV, random, 95% Cl
SMD
IV, random, 95% Cl 
–2 –1 0 1 2
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0.35 100.0%
100.0%
Spencer 2002141
Total (95% CI)
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Test for overall effect: z = 3.27 (p = 0.001)
FIGURE 134 Standardised change in YGTSS global scale score for desipramine compared with placebo. IV, independent variable; SE, standard error.
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For this study, the proportion of participants with ≥ 30% reductions in global score was greater for
children taking desipramine compared with placebo (RR 0.39, 95% CI 0.21 to 0.70; n= 39) (Figure 135)
(the RR presented here is the RR of not having a ≥ 30% reduction).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome The parallel trial141 reports the proportion of children that were much or very
much improved on the CGI scale. A higher proportion of participants were CGI much or very much
improved for desipramine than placebo (RR 0.44, 95% CI 0.26 to 0.76; n= 39) (the RR presented here is
the RR of not being much or very much improved) (Figure 136).
Long-term outcome No relevant studies reported long-term outcomes.
Safety In the crossover trial,115 a higher proportion of participants reported one or more drug-related
adverse effect while taking desipramine than when taking the placebo (RR 1.73, 95% CI 1.14 to 2.64;
n= 34) (Figure 137).
In the parallel trial,141 adverse effects occurring in greater than two children are shown in Figure 138.
Findings were inconclusive for decreased appetite (RR 11.55, 95% CI 0.68 to 195.63; n= 39) and difficulty
sleeping (RR 4.21, 95% CI 0.52 to 34.36; n= 39) for desipramine compared with placebo.
Clinical evidence summary for tricyclic antidepressants
Desipramine
There was low-quality evidence (see Appendix 4, Table 28) from one study with 39 children141 that
desipramine produced a large effect in terms of tics (proportion of children with ≥ 30% reduction in tics),
global tic/impairment and overall clinical outcome (CGI much or very much improved) following 6 weeks of
treatment. In two studies,115,141 adverse effects were reported and there was evidence of overall increased
rates of adverse effects and a tendency to higher rates of decreased appetite and difficulty sleeping.
Conclusion
Desipramine may be effective in the short-term treatment of tics in children and young people with
comorbid TS and ADHD; however, this conclusion must be treated with caution as the evidence is drawn
from a single small study.141 The clinical indication (i.e. treatment of comorbid TS plus ADHD), mechanism
of action and clinical effectiveness of desipramine appears broadly similar to atomoxetine. However, the
less favourable adverse effect profile of desipramine (in particular, reports of sudden unexplained deaths in
children) resulted in its withdrawal from the UK.
Selective serotonin reuptake inhibitors
Pharmacology and prescribing
Selective serotonin reuptake inhibitors selectively inhibit the reuptake of serotonin (5-hydroxytryptamine), so
that the effects of serotonin are prolonged. They are commonly used to treat depression, anxiety and OCD.
Fluoxetine (Non-proprietary; Prozac®, Lilly) is licensed in the UK for the treatment of MDD, OCD and bulimia
nervosa. It is the most common first-line medication prescribed for comorbid OCD/OCSs in children with TS.142
Included studies
Two studies, one in children143 and one in a mixed population144 of adults and children, investigated
treatment with fluoxetine compared with placebo.
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Study or subgroup Events Total Events Total
Post-treatment
desipramine
Post-treatment
placebo RR (non-event)
M–H, random, 95% Cl Overall ROBWeight
RR (non-event)
M–H, random, 95% CI
Spencer 2002141
Total (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 3.11 (p = 0.002)
19
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20
12
12 1
0.39 (0.21 to 0.70)
0.39 (0.21 to 0.70)
100.0%
100.0%
1 Low risk
0.1 0.2 0.5 1 52 10
Favours desipramine Favours placebo
FIGURE 135 Proportion of children with ≥ 30% reductions in YGTSS global score for desipramine compared with placebo (RRs are the relative risk of not having a ≥ 30%
reduction). M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup Events Total Events Total
Desipramine Placebo RR (non-event)
M–H, random, 95% ClOverall ROBWeight
RR (non-event)
M–H, random, 95% CI
Spencer 2002141
Total (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.97 (p = 0.003)
19
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20
11
11 1
0.44 (0.26 to 0.76)
0.44 (0.26 to 0.76)
100.0%
100.0%
1 Low risk
0.1 0.2 0.5 1 52 10
Favours desipramine Favours placebo
FIGURE 136 Proportion of children much or very much improved in the CGI-I scale for desipramine compared with placebo (the RR presented here is the RR of not being much
or very much improved). M–H, Mantel–Haenszel; ROB, risk of bias.
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RR
M–H, random, 95% CI
Singer 1995115
Total (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.56 (p = 0.01)
34
34
34
34
26
26 15
1.73 (1.14 to 2.64)
1.73 (1.14 to 2.64)
100.0%
100.0%
15 High risk
0.1 0.2 0.5 1 52 10
Favours desipramine Favours placebo
FIGURE 137 Proportion of children with adverse events for desipramine compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup Events Total Events
Desipramine Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% Cl
Decreased appetite
Spencer 2002141
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.69 (p = 0.09)
5
5
11.55 (0.68 to 195.63)
11.55 (0.68 to 195.63)
19
19
0
0
20
20
100.0%
100.0%
Low risk
100.0%
100.0%
Difficulty sleeping
Spencer 2002141
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.34 (p = 0.18)
4
4
4.21 (0.52 to 34.36)
4.21 (0.52 to 34.36)
19
19
1
1
20
20
Low risk
0.002 0.1 1 10 500
Favours desipramine Favours placebo
FIGURE 138 Proportion of children with adverse events occurring in more than two participants for desipramine compared with placebo. M–H, Mantel–Haenszel; ROB, risk
of bias.
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Study characteristics
Study characteristics are shown in Appendix 3, Table 9. One study was a parallel trial in 11 children with TS
of maximum dose of 40mg/day fluoxetine compared with placebo for 4 months.143 The other was a
crossover trial in a mixed population of 14 adults and children with TS of fixed dose of 20mg/day fluoxetine
compared with placebo for 8 weeks.144 Half of the participants in this study were children and results were,
therefore, combined with the child study. This study is a crossover trial but presents data at the end of the
first phase of the study and the first-phase data have been used in the analysis for this review.
Risk of bias
In the study of fluoxetine compared with placebo in children,143 the method of randomisation and presence
of allocation concealment were unclear. The study is described as double blind but there is no description of
patient, provider or outcome assessor blinding. Analysis was of available case data but, as dropout was
moderate and similar in both groups, the risk of attrition bias may have been low. Overall, the study was
considered to have unclear risk of bias owing to unclear patient, provider and outcome assessor blinding.
In the mixed study of fluoxetine compared with placebo,144 the method of randomisation and presence of
allocation concealment were unclear. There appears to have been blinding of participants, providers and
outcome assessors. Analysis was of available case data but, as dropout was moderate and similar in both
groups, the risk of attrition bias may have been low. Although this was a crossover trial, first-phase data
were available and this avoided bias from cross-treatment contamination. Overall, the study was
considered to have a low risk of bias.
Clinical evidence for selective serotonin reuptake inhibitors
Fluoxetine
Tics Tics were assessed in one study using the YGTSS total tic scale144 and in the other using the Unified
Tic Rating Scale (UTRS) and the Goetz scale.143 Using the Goetz simple motor tics for the study with
multiple tic measures,143 there was no conclusive difference in tic score for fluoxetine compared with
placebo (SMD –0.41, 95% CI –1.23 to 0.42; n= 21) (Figure 139), with no important heterogeneity
between studies (I2= 6%).
Impairment No relevant studies reported TS-related impairment.
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome No relevant studies reported this outcome.
Long-term outcome No relevant studies reported long-term outcomes.
Safety In the study of children,143 it is reported that adverse effects were mild and reported by two
children taking fluoxetine (hypomanic behaviour, irritability, fatigue and agitation) and three children
taking placebo (fatigue, irritability, hypomanic behaviour and diarrhoea). In the mixed study,144 outcomes
with events for greater than two participants are shown in Figure 140.
There was no conclusive difference in motor restlessness (RR 3.50, 95% CI 0.91 to 13.53; n= 12),
insomnia (RR 2.50, 95% CI 0.60 to 10.46; n= 12), decreased appetite (RR 7.00, 95% CI 0.40 to 122.44;
n= 12) and diarrhoea (RR 3.00, 95% CI 0.36 to 24.92; n= 12) for fluoxetine compared with placebo.
In this study, it is reported that none of the participants had clinically significant changes in vital signs or
laboratory measures.
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Study or subgroup Events Total Events
Fluoxetine Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% Cl
Motor restlessness
Scahill 1997144
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.82 (p = 0.07)
7
7
3.50 (0.91 to 13.53)
3.50 (0.91 to 13.53)
12
12
2
2
12
12
100.0%
100.0%
Low risk
0.002 0.1 1 50010
Favours fluoxetine Favours placebo
100.0%
100.0%
Insomnia
Scahill 1997144
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.25 (p = 0.21)
5
5
2.50 (0.60 to 10.46)
2.50 (0.60 to 10.46)
12
12
2
2
12
12
Low risk
100.0%
100.0%
Decreased appetite
Scahill 1997144
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.33 (p = 0.18)
3
3
7.00 (0.40 to 122.44)
7.00 (0.40 to 122.44)
12
12
0
0
12
12
Low risk
100.0%
100.0%
Diarrhoea
Scahill 1997144
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.02 (p = 0.31)
3
3
3.00 (0.36 to 24.92)
3.00 (0.36 to 24.92)
12
12
1
1
12
12
Low risk
FIGURE 140 Adverse events experienced by more than two patients for fluoxetine compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
IN
T
E
R
V
E
N
T
IO
N
S
F
O
R
T
IC
S
IN
C
H
ILD
R
E
N
A
N
D
A
D
O
LE
S
C
E
N
T
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
1
3
8
Clinical evidence summary for selective serotonin reuptake inhibitors
Fluoxetine
One study in 11 children143 provided low-quality evidence (see Appendix 4, Table 27) that was inconclusive
as to whether or not fluoxetine gives a clinically significant improvement in tics after 4 months of
treatment. Evidence from a mixed study showed fluoxetine to have a similar efficacy to placebo. The child
study reported no difference in adverse effects, but the mixed study reported higher rates of motor
restlessness, insomnia, decreased appetite and diarrhoea for fluoxetine compared with placebo.
Conclusion
There is no clear evidence that fluoxetine is effective in reducing tics in children and young people with
comorbid TS and OCD/OCSs. However, fluoxetine when used to treat comorbid OCD/OCSs does not
appear to result in tic worsening or exacerbation.
Nicotinic acetylcholine receptor antagonists
Pharmacology and prescribing
Mecamylamine (Inversine®, Targacept Inc.) has mainly been used as an antihypertensive, but is not licensed
in the UK. At lower doses, it can be used to act as a selective nicotinic receptor antagonist and has been
suggested as a potentially useful treatment for TS adjunctive to an antipsychotic drug.145,146
Included studies
One study compared treatment with mecamylamine with placebo.146
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. Sixty-one children with TS were randomised to
receive maximum dose of 7.5 mg/day mecamylamine or placebo for 8 weeks. In order to be included in
the study, behavioural and emotional TS symptoms had to be rated by the parent as more disturbing than
the tics themselves.
Risk of bias
Methods for sequence generation and allocation concealment are unclear and no details are given of
patient, provider or outcome assessor blinding. There was a high rate of dropout from the study (41% of
those on mecamylamine and 34% of those on placebo) and, although analysis was by last observation
carried forward for those with at least 3 weeks of data (86% of those on mecamylamine and 78% of
those on placebo), the risk of attrition bias was unclear. Overall, this study was considered to be at unclear
risk of bias owing to unclear participant, provider and outcome assessor blinding and possible risk of
attrition bias.
Clinical evidence for nicotinic acetylcholine receptor antagonists
Mecamylamine
Tics The YGTSS scale was used to assess tic changes but, for most results, the precision of study findings
was not reported. It is reported there was no significant difference in baseline or end point measures for
mecamylamine compared with placebo (Bonferroni adjustment; p < 0.0025 needed for statistical
significance) for the YGTSS total tic (MD of group changes 7.6, favours placebo) or vocal tic scores (MD of
group changes 2.6, favours placebo). YGTSS motor tic score was significantly different at baseline (baseline
MD 2.5; p= 0.02) and end point (post-treatment MD 4.2; p< 0.002) but it is reported that the difference
in group changes was not significant (MD of group changes 1.7, favours placebo).
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Impairment It is reported that there was no difference in baseline or end point YGTSS impairment score
for mecamylamine compared with placebo (MD of group changes 2.3, favours placebo).
Psychological well-being For the anxiety rating in the Conners’ Parent Rating Scale, it is reported
that there was no significant difference for mecamylamine compared with placebo for baseline or
post-treatment scores (MD of group changes –0.9, favours mecamylamine).
Overall clinical outcome The CGI-I was used to assess overall clinical outcome. It is reported that there
was no significant difference in clinician-rated CGI-I score for mecamylamine compared with placebo
(MD –2.2, favours mecamylamine).
Long-term outcome No relevant studies reported long-term outcomes.
Safety It is reported that adverse effects occurred more frequently in children taking mecamylamine than
those taking placebo. Adverse effects occurring in twice as many children for mecamylamine than placebo
were reported and there were no conclusive differences (Figure 141).
There were no between-group differences or changes in sitting or standing systolic or diastolic BP. When a
cut-off of 90/60mmHg was used to define hypertension, there was no conclusive difference in incidence
for mecamylamine compared with placebo (RR 9.00, 95% CI 0.51 to 158.85; n= 50) (Figure 142).
Results suggested heart rate measured at the end of the first week was higher for mecamylamine than
placebo (MD 8.50, 95% CI 2.22 to 14.78; n= 61) (Figure 143), but not at other time points. It was
reported that there were no clinically significant group differences or abnormalities in complete blood cell
count, blood chemistry or ECGs.
Moderators of effectiveness Investigators conducted a post hoc subgroup analysis of participants whose
TS was defined as moderate or severe [Tourette’s Disorder Scale – Clinician Rated (TODS-CR) score ≥ 60,
n= 32]. More children with moderate or severe TS taking mecamylamine compared with placebo had a
≥ 4 point reduction on the TODS-CR ‘sudden mood changes’ score (8/17 vs. 1/15) and the TODS-CR
‘depressed or uninterested in most things’ score (5/17 vs. 2/15). However, the opposite pattern was
observed for children with baseline TODS-CR scores of < 60.
Clinical evidence summary for nicotinic acetylcholine receptor antagonists
Mecamylamine
One study (n= 61)146 provided low-quality evidence (see Appendix 4, Table 40) that mecamylamine does
not improve tics, impairment or overall clinical outcome but may increase the risk of adverse effects.
Conclusion
There is no clear evidence that mecamylamine is an effective treatment for tics in children and young
people with TS.
Transdermal nicotine
Pharmacology and prescribing
Nicotine transdermal patches (Nicotinell®, Novartis) are licensed in the UK to relieve and/or prevent craving
and nicotine withdrawal symptoms associated with tobacco dependence.
Included studies
Two studies in children investigated the efficacy of transdermal nicotine for the treatment of tics.147,148
INTERVENTIONS FOR TICS IN CHILDREN AND ADOLESCENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
UNCORRECTED PROOF DATE: 12/09/2015 FILE: 10-142-01-2P.pdf
140
Study or subgroup Events Total Events
Mecamylamine Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% Cl
Asthenial/weakness
Silver 2001146
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.72 (p = 0.08)
8
8
2.94 (0.86 to 10.05)
2.94 (0.86 to 10.05)
29
29
3
3
32
32
100.0%
100.0%
Unclear risk
Aggressive
Silver 2001146
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.48 (p = 0.14)
7
7
2.57 (0.73 to 9.04)
2.57 (0.73 to 9.04)
29
29
3
3
32
32
100.0%
100.0%
Unclear risk
Vomiting
Silver 2001146
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.27 (p = 0.20)
5
5
2.76 (0.58 to 13.14)
2.76 (0.58 to 13.14)
29
29
2
2
32
32
100.0%
100.0%
Unclear risk
Muscle twitching
Silver 2001146
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.27 (p = 0.20)
5
5
2.76 (0.58 to 13.14)
2.76 (0.58 to 13.14)
29
29
2
2
32
32
100.0%
100.0%
Unclear risk
Hypersomnia
Silver 2001146
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.27 (p = 0.20)
5
5
2.76 (0.58 to 13.14)
2.76 (0.58 to 13.14)
29
29
2
2
32
32
100.0%
100.0%
Unclear risk
0.01 0.1 1 10 100
Favours experimental Favours control
FIGURE 141 Proportion of children experiencing adverse events for events where occurred greater than twice as often in the mecamylamine compared with the placebo group.
M–H, Mantel–Haenszel; ROB, risk of bias. (continued )
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Study or subgroup Events Total Events
Mecamylamine Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% Cl
Dysphoria
Silver 2001146
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.27 (p = 0.20)
5
5
2.76 (0.58 to 13.14)
2.76 (0.58 to 13.14)
29
29
2
2
32
32
100.0%
100.0%
Unclear risk
Mouth ulcer
Silver 2001146
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.06 (p = 0.29)
3
3
3.31 (0.36 to 30.08)
3.31 (0.36 to 30.08)
29
29
1
1
32
32
100.0%
100.0%
Unclear risk
Constipation
Silver 2001146
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.06 (p = 0.29)
3
3
3.31 (0.36 to 30.08)
3.31 (0.36 to 30.08)
29
29
1
1
32
32
100.0%
100.0%
Unclear risk
Fine tremor
Silver 2001146
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.06 (p = 0.29)
3
3
3.31 (0.36 to 30.08)
3.31 (0.36 to 30.08)
29
29
1
1
32
32
100.0%
100.0%
Unclear risk
0.01 0.1 1 10 100
Favours experimental Favours control
FIGURE 141 Proportion of children experiencing adverse events for events where occurred greater than twice as often in the mecamylamine compared with the placebo
group. M–H, Mantel–Haenszel; ROB, risk of bias.
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Study or subgroup Events Total Events Total
Mecamylamine Placebo RR
M–H, random, 95% Cl Overall ROBWeight
RR
M–H, random, 95% CI
Silver 2001146
Total (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.50 (p = 0.13)
25
25
25
25
4
4 0
9.00 (0.51 to 158.85)
9.00 (0.51 to 158.85)
100.0%
100.0%
0 Unclear risk
0.005 0.1 1 10 200
Favours mecamylamine Favours placebo
FIGURE 142 Proportion of children experiencing 90/60 BP for mecamylamine compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup Mean SD SDTotal Mean Total
Mecamylamine Placebo SMD
IV, random, 95% Cl Overall ROBWeight
SMD
IV, random, 95% Cl
Silver 2001146
Total (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.65 (p = 0.008)
12.4 12.629
29
32
32
92.1 8.50 (2.22 to 14.78)
8.50 (2.22 to 14.78)
100.0%
100.0%
83.6 Unclear risk
–50 –25 0 25 50
Favours mecamylamine Favours placebo
FIGURE 143 Heart rate after one week of treatment for mecamylamine compared with placebo. IV, independent variable; ROB, risk of bias.
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Study characteristics
Study characteristics are shown in Appendix 3, Table 9. One study was a parallel trial where children
treated with haloperidol (optimum dose titrated over 2 weeks before entering the trial) were randomised
to nicotine patches (7 mg/day) or placebo for 19 days.147 The dosage of haloperidol was reduced to 50%
after 5 days and outcomes assessed 3 hours after patch application and at 5, 19 and 33 days. The other
study was a crossover trial in which children being treated with an antipsychotic drug (96% of children)
were given a single dose of transdermal nicotine (7 mg) or placebo in a randomised order and
measurements made 7 days after treatment.148
Risk of bias
For the parallel trial,147 randomisation was conducted using a random number generator but the presence
of allocation concealment was unclear. There appears to have been blinding of providers and outcome
assessors. Blinding of participants was attempted but it is unclear as to whether or not differences in the
smell and adverse effects associated with nicotine resulted in loss of patient blinding. Analysis was of
available case data. Dropout was moderate (26%) and the risk of attrition bias was considered to be
unclear. Overall, this study was considered to be at unclear risk of bias owing to unclear risks of attrition
bias and unclear patient blinding.
For the crossover trial,148 the method for randomisation and presence of allocation concealment was
unclear. There appears to have been blinding of participants and outcome assessors but blinding of
providers was unclear. An 8-week washout period was used and this may have been long enough to avoid
cross-treatment contamination. Analysis was by available case. Dropout was high (39%) and the risk of
attrition bias was considered to be high. The presence of selective outcome reporting was unclear as some
outcomes (e.g. YGTSS) appear to be listed in the methods section as outcome measures, but are not
reported in the results. Overall, this study was considered to be at unclear risk of bias owing to risk of
attrition bias and possible selective outcome reporting.
Clinical evidence for transdermal nicotine
Nicotine transdermal patches
Tics In the parallel trial,147 tics were assessed with the YGTSS and, in the crossover trial,148 the Tourette
Syndrome Symptom List – Child’s report (TSSL-C) was used. Studies showed similar motor (SMD –0.03, 95% CI
–0.49 to 0.43; n= 70) (Figure 144) and vocal tic scores (SMD 0.34, 95% CI –0.37 to 1.05; n= 70) (Figure 145)
for transdermal nicotine plus antipsychotic drug compared with placebo plus antipsychotic drug (using the
simple motor and vocal scores from the study using the TSSL-C). There was moderate heterogeneity between
studies for motor tic score (I2= 40%) and large heterogeneity between studies for vocal tic score (I2= 73%).
Impairment In the parallel trial147 impairment was assessed with the YGTSS impairment scale and, in the
crossover study,148 impairment was assessed with the Conners’ Global Index social problems score. There
was no conclusive difference in impairment/social problems score for nicotine plus antipsychotic drug
compared with placebo plus antipsychotic drug (SMD –0.30, 95% CI –0.75 to 0.15; n= 70) (Figure 146).
There was some heterogeneity between studies (I2= 38%).
The parallel trial reported global tic outcome with the YGTSS global score and there was no conclusive
difference in change from baseline score for transdermal nicotine plus antipsychotic drug compared with
placebo plus antipsychotic drug (SMD –0.43, 95% CI –0.96 to 0.10; n= 56) (Figure 147).
Psychological well-being The crossover study used the Conners’ Parent Rating Scale.148 There were
similar post-treatment scores for anxiousness/shyness (SMD –0.08, 95% CI –0.55 to 0.39; n= 14) and
emotional liability for transdermal nicotine compared with placebo (SMD –0.29, 95% CI –0.77 to 0.19;
n= 14) (Figure 148).
INTERVENTIONS FOR TICS IN CHILDREN AND ADOLESCENTS
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Howson 2004148
Silver 2001147
Total (95% CI) 
Heterogeneity: τ2 = 0.04, χ2 = 1.67, df = 1 ( p = 0.20), I 2 = 40%
Test for overall effect: z = 0.13 ( p = 0.90)
0.19 (–0.29 to 0.66)
–0.28 (–0.81 to 0.25)
–0.03 (–0.49 to 0.43)
0.187
– 0.28
0.241
0.27
53.4%
46.6%
100.0%
Unclear risk
Unclear risk
–2 –1 0 1 2
Favours nicotine Favours placebo
FIGURE 144 Standardised motor tic score for transdermal nicotine compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of bias;
SE, standard error.
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Howson 2004148
Silver 2001147
Total (95% CI) 
Heterogeneity: τ2 = 0.19, χ2 = 3.64, df = 1 ( p = 0.06), I 2 = 73%
Test for overall effect: z = 0.95 ( p = 0.34)
0.70 (0.18 to 1.23)
–0.02 (–0.55 to 0.51)
0.34 (–0.37 to 1.05)
0.702
– 0.02
0.267
0.268
50.1%
49.9%
100.0%
Unclear risk
Unclear risk
–2 –1 0 1 2
Favours nicotine Favours placebo
FIGURE 145 Standardised vocal tic score for transdermal nicotine compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of bias;
SE, standard error.
Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Howson 2004148
Silver 2001147
Total (95% CI) 
Heterogeneity: τ2 = 0.04, χ2 = 1.60, df = 1 ( p = 0.21), I 2 = 38%
Test for overall effect: z = 1.32 ( p = 0.19)
– 0.09 (– 0.56 to 0.38)
– 0.55 (– 1.09 to – 0.01)
– 0.30 (– 0.75 to 0.15)
– 0.09
– 0.55
0.24
0.273
54.0%
46.0%
100.0%
Unclear risk
Unclear risk
–2 –1 0 1 2
Favours nicotine Favours placebo
FIGURE 146 Standardised impairment/social problems score for transdermal nicotine compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of
bias; SE, standard error.
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Study or subgroup SMD
SMD
IV, random, 95% Cl Overall ROBSE Weight
SMD
IV, random, 95% Cl
Anxious/shy
Howson 2004148
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 0.33 (p = 0.74)
–0.08 (–0.55 to 0.39)
–0.08 (–0.55 to 0.39)
–0.08 0.239 100.0%
100.0%
Unclear risk
–2 –1 0 1 2
Favours nicotine Favours placebo
Emotional liability
Howson 2004148
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.19 (p = 0.23)
–0.29 (–0.77 to 0.19)
–0.29 (–0.77 to 0.19)
–0.291 0.244 100.0%
100.0%
Unclear risk
FIGURE 148 Standardised Conners’ Parent Rating Scale Anxiousness/shyness and Emotional liability scores for transdermal nicotine compared with placebo. IV, independent
variable; ROB, risk of bias; SE, standard error.
Study or subgroup Mean SD SDTotal Mean Total
Change nicotine Change placebo SMD
IV, random, 95% Cl Overall ROBWeight
SMD
IV, random, 95% Cl
Silver 2001147
Total (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.60 (p = 0.11)
16.11 16.1627
27
29
29
–12.7 – 0.43 (– 0.96 to 0.10)
– 0.43 (– 0.96 to 0.10)
100.0%
100.0%
–5.6 Unclear risk
–2 –1 0 1 2
Favours nicotine Favours placebo 
FIGURE 147 Standardised change from baseline in YGTSS global score for transdermal nicotine compared with placebo. IV, independent variable; ROB, risk of bias.
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Overall clinical outcome The parallel study147 reported changes in the global improvement scale as
assessed by clinicians and parents. Global improvement ratings were better for transdermal nicotine
compared with placebo when assessed by parents (SMD –0.79, 95% CI –1.34 to –0.25; n= 56) and
clinicians (SMD –0.53, 95% CI –1.06 to 0.01; n= 56) (Figure 149).
Long-term outcome No relevant studies reported long-term outcomes.
Safety Adverse effects were reported by the parallel trial.147 For events occurring in more than 30% of
children, there were more instances of nausea (RR 4.17, 95% CI 1.95 to 8.89; n= 70), vomiting (RR 4.67,
95% CI 1.47 to 14.82; n= 70), and a similar incidence for transdermal nicotine compared with placebo of
itching at the site of the patch (RR 1.33, 95% CI 0.83 to 2.15; n= 70) and headache (RR 1.21, 95% CI
0.71 to 2.06; n= 70) (Figure 150).
Clinical evidence summary for transdermal nicotine
Two studies in children (n= 70)147,148 provided low-quality evidence (see Appendix 4, Table 42) that
transdermal nicotine did not improve motor or vocal tics by the end of 1–3 weeks of treatment. The
evidence was inconclusive as to its effects on impairment, although overall clinical outcome was improved.
There were increased rates of nausea and vomiting.
Conclusion
There is no clear evidence that transdermal nicotine is an effective treatment for tics in children and young
people with TS.
Omega-3 fatty acids
Pharmacology and prescribing
Long-chain polyunsaturated fatty acids are used for many purposes including development of nerve cells
and membranes. Omega-3 and omega-6 polyunsaturated fatty acids differ in their chemical structure and
potentially their physiological effects. Omega-3 fatty acids (fish oils) have been advocated for ameliorating
the symptoms and preventing a range of behavioural and psychiatric conditions.
Included studies
One study in children compared omega-3 fatty acids with placebo.149
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. Thirty-three children with TS were randomised to
receive maximum dose of 6000mg/day omega-3 fatty acids or olive oil (placebo) capsules for 20 weeks.149
Risk of bias
In this study, the methods for randomisation and allocation concealment are unclear. Fish oil and placebo
were administered in capsules scented with vanilla and, despite this attempt to blind study participants, the
continuation of patient blinding is unclear. Dosage was titrated on the basis of efficacy and it is unclear
whether or not blinding was maintained throughout this process. It was unclear whether or not there was
blinded outcome assessment. Analysis was by intention to treat and the risk of attrition bias appears to
be low. Measures of depression and anxiety were measured at baseline and follow-up, but the results are
not reported and the risk of outcome reporting bias is unclear. Overall, this study was considered to be
at unclear risk of bias owing to unclear patient blinding.
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Study or subgroup Mean SD Total Mean
Nicotine Placebo SMD
IV, random, 95% Cl Overall ROBSD Total Weight
SMD
IV, random, 95% Cl
Parent rated
Silver 2001147
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.85 (p = 0.04)
2.02–2.1 –0.79 (–1.34 to –0.25)
–0.79 (–1.34 to –0.25)
27
27
1.1 29
29
100.0%
100.0%
5.16 Unclear risk
–2 –1 0 1 2
Favours nicotine Favours placebo
Clinician rated
Silver 2001147
Subtotal (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 1.94 (p = 0.05)
4.19–2.5 –0.53 (–1.06 to 0.01)
–0.53 (–1.06 to 0.01)
27
27
–0.3 29
29
100.0%
100.0%
4.04 Unclear risk
FIGURE 149 Standardised clinician and parent-rated global improvement scale ratings for nicotine compared with placebo. IV, independent variable; ROB, risk of bias.
IN
T
E
R
V
E
N
T
IO
N
S
F
O
R
T
IC
S
IN
C
H
ILD
R
E
N
A
N
D
A
D
O
LE
S
C
E
N
T
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
1
4
8
Study or subgroup Events Total Events
Nicotine Placebo RR
M–H, random, 95% Cl Overall ROBTotal Weight
RR
M–H, random, 95% Cl
Nausea
Silver 2001147
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 3.69 (p = 0.0002)
25
25
4.17 (1.95 to 8.89)
4.17 (1.95 to 8.89)
35
35
6
6
35
35
100.0%
100.0%
Unclear risk
0.01 0.1 1 10010
Favours nicotine Favours placebo
100.0%
100.0%
Itching at patch site
Silver 2001147
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.18 (p = 0.24)
20
20
1.33 (0.83 to 2.15)
1.33 (0.83 to 2.15)
35
35
15
15
35
35
Unclear risk
100.0%
100.0%
Headache
Silver 2001147
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.72 (p = 0.47)
17
17
1.21 (0.71 to 2.06)
1.21 (0.71 to 2.06)
35
35
14
14
35
35
Unclear risk
100.0%
100.0%
Vomiting
Silver 2001147
Subtotal (95% CI) 
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.61 (p = 0.009)
14
14
4.67 (1.47 to 14.82)
4.67 (1.47 to 14.82)
35
35
3
3
35
35
Unclear risk
FIGURE 150 Adverse events occurring in ≥ 30% of participants for nicotine compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
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Clinical evidence for omega-3 fatty acids
Tics
Changes in tics were assessed with the YGTSS total tic scale. Reduction from baseline total tic scores was
inconclusive for omega-3 fatty acids compared with placebo (SMD –0.24, 95% CI –0.92 to 0.45; n= 33)
(Figure 151). There was no conclusive difference in the proportion of children with ≥ 30% reductions in
total tic score for omega-3 fatty acids compared with placebo (RR 0.75, 95% CI 0.40 to 1.42; n= 33)
(Figure 152) (the RR presented here is the RR of not having a ≥ 30% reduction in tic score).
Impairment Impairment was measured using the YGTSS impairment scale. Reduction from baseline
impairment score was greater for omega-3 fatty acids than placebo (SMD –0.76, 95% CI –1.47 to –0.05;
n= 33) (Figure 153). For the overall YGTSS global score, there was no conclusive difference in reduction
from baseline global score for omega-3 fatty acids compared with placebo (SMD –0.67, 95% CI –1.38 to
0.03; n= 33) (Figure 154).
There was no conclusive difference in the proportion of children with ≥ 30% reductions for omega-3
fatty acids compared with placebo for YGTSS impairment score (RR 0.55, 95% CI 0.29 to 1.04; n= 33)
(Figure 155) and YGTSS global score (RR 0.68, 95% CI 0.37 to 1.25; n= 33) (Figure 156) (RRs presented
are the relative risk of not having a ≥ 30% reduction).
Psychological well-being Depression and anxiety scores were assessed at baseline and end point using
the Children’s Depression Rating Scale-Revised and the MASC. It was reported that there was no
difference in change from baseline scores for omega-3 fatty acids compared with placebo.
Overall clinical outcome At each visit, the CGI-I was used to assess overall clinical outcome but no
results were presented in the included study.
Long-term outcome No relevant studies reported long-term outcomes.
Safety It is reported that there were no significant differences in adverse effects for omega-3 fatty acids
compared with placebo. The most frequently reported treatment-related events (reported to be tolerable
and self-limited) in the omega-3 fatty acids group were headache (n= 4), nausea/stomach ache (n= 4) and
diarrhoea/loose stool (n= 2). One subject in the omega-3 fatty acids group experienced several nosebleeds
and bruised easily and one subject in the placebo group had elevated clotting times but all follow-up
laboratory test results were within normal limits.
Clinical evidence summary for omega-3 fatty acids
One study in 33 children,149 provided low-quality evidence (see Appendix 4, Table 43) that was
inconclusive as to whether or not omega-3 fatty acids improved tics, but a medium-sized improvement in
impairment was observed and there was no increase in adverse effects compared with the control (olive
oil) following 20 weeks of treatment.
Conclusion
There is no clear evidence that omega-3 fatty acids are an effective treatment for tics in children and
young people with TS.
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FIGURE 151 Standardised change from baseline YGTSS total tic score for children treated with omega-3 fatty acids compared with placebo. FA, fatty acid; IV, independent
variable; ROB, risk of bias.
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FIGURE 152 Proportion of children treated with ≥ 30% reductions in YGTSS total tic score for omega-3 fatty acids compared with placebo (RR is relative risk of not having a
≥ 30% reduction). FA, fatty acid; M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup Mean SD SDTotal Mean Total
Omega-3 FAs Placebo SMD
IV, random, 95% Cl Overall ROBWeight
SMD
IV, random, 95% Cl
Gabbay 2012149
Total (95% CI) 
Heterogeneity: not applicable
Test for overall effect: z = 2.10 (p = 0.04)
8.6 8.317
17
16
16
–9.7 – 0.76 (– 1.47 to – 0.05)
– 0.76 (– 1.47 to – 0.05)
100.0%
100.0%
–3.1 Unclear risk
–2 –1 0 1 2
Favours omega-3 FAs Favours placebo 
FIGURE 153 Standardised change from baseline YGTSS impairment score for children treated with omega-3 fatty acids compared with placebo. FA, fatty acid; IV, independent
variable; ROB, risk of bias.
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Study or subgroup Mean SD SDTotal Mean Total
Omega-3 FAs Placebo SMD
IV, random, 95% Cl Overall ROBWeight
SMD
IV, random, 95% Cl
Gabbay 2012149
Total (95% CI) 
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Test for overall effect: z = 1.88 (p = 0.06)
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FIGURE 154 Standardised change from baseline YGTSS global score for children treated with omega-3 fatty acids compared with placebo. FA, fatty acid; IV, independent
variable; ROB, risk of bias.
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FIGURE 155 Proportion of children with ≥ 30% reductions in YGTSS impairment score for omeg-3 fatty acids compared with placebo (RR is relative risk of not having a ≥ 30%
reduction). FA, fatty acid; M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 156 Proportion of children with ≥ 30% reductions in YGTSS global score for omega-3 fatty acids compared with placebo (RR is relative risk of not having a ≥ 30%
reduction). FA, fatty acid; M–H, Mantel–Haenszel.
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Head-to-head comparisons between different classes of drugs
Included studies
Five studies made comparisons between drugs in different classes:
l risperidone (antipsychotic) compared with clonidine (noradrenergic agent)150
l sulpiride (antipsychotic) compared with fluvoxamine (antidepressant)151
l clonidine (noradrenergic agent) compared with levetiracetam (anticonvulsant)152
l clonidine (noradrenergic agent) compared with desipramine (TCA)115
l haloperidol (antipsychotic) compared with clonidine patch (noradrenergic agent).153
Study characteristics
Study characteristics are shown in Appendix 3, Table 9. A parallel trial in children compared risperidone
with clonidine.150 Twenty-one children were randomised to maximum dose of 0.06mg/kg/day risperidone
or maximum dose of 0.005mg/kg/day clonidine for 8 weeks.
A mixed parallel trial of adults and children with TS and comorbid OCD compared the efficacy of
maximum dose of 300mg/day fluvoxamine with maximum dose of 1 g/day sulpiride for 6 weeks.151
A mixed crossover study of adults and children compared clonidine with levetiracetam.152 Ten participants
were allocated to maximum dose of 0.4mg/day clonidine and maximum dose of 2500mg/day
levetiracetam in a randomised order for 6 weeks each.
A crossover study in children compared treatment with clonidine, desipramine and placebo.115 Thirty-four
children were treated with maximum dose of 0.2 mg/day clonidine, maximum dose of 100mg/day
desipramine and placebo in a randomised order for 6 weeks each.
A parallel controlled before-and-after study in children compared clonidine patch with haloperidol.153
One hundred and nineteen children were treated with clonidine patches giving doses of 1–2mg/week
(depending on body weight) or with maximum dose of 2mg/day haloperidol for 4 weeks.
Risk of bias
In the parallel study of risperidone versus clonidine,150 the method of randomisation and presence
of allocation concealment was unclear. Participants and providers appear to have been blind to
intervention allocation but the presence of outcome assessor blinding is unclear. The rate of dropout was
low and there may have been a low risk of attrition bias. Overall, this study was considered to have an
unclear risk of bias owing to unclear outcome assessor blinding.
In the crossover study of fluvoxamine compared with sulpiride,151 the randomisation method is unclear and
there is no evidence of allocation concealment. There appears to have been blinding of participants,
providers and outcome assessors but the small between-drug washout period (2 weeks) may have
introduced cross-intervention contamination. The rate of dropout was reasonably high (5/11 participants,
45%) and, although last observation carried forward was used for the analysis, the risk of attrition
bias is unclear. Overall, this study was considered to be at unclear risk of bias owing to the small
between-intervention washout period and the unclear risk of attrition bias.
In the crossover study of levetiracetam compared with clonidine,152 the sequence was generated using a
computer program but the presence of allocation concealment is unclear. Participants, providers and
outcome assessors appear to have been blind to treatment allocation sequence. There was a 2-week
washout period between interventions and there was considered to be an unclear risk of cross-treatment
contamination. The rate of dropout was low and the risk of attrition bias was considered to be low.
Overall, owing to possible cross-treatment contamination, this study was considered to be at unclear risk
of bias.
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153
In the crossover study of clonidine compared with desipramine,115 the method for randomisation and
presence of allocation concealment are unclear but there appears to be blinding of participants, providers
and outcome assessors. There was a 1-week washout period between treatments and there was
considered to be an unclear risk of cross-treatment contamination. It is reported that 3 out of 37 (8%)
participants dropped out of the study and the risk of attrition bias appears to be low. Results are presented
for significant findings only. For non-significant results, no data were presented and the study was
considered to be at high risk of selective outcome reporting bias. Overall, this study was considered to be
at high risk of bias owing to selective outcome reporting bias and possible cross-treatment contamination.
In the controlled before-and-after study of haloperidol compared with clonidine,153 the method used for
the allocation of participants to intervention groups and the presence of allocation concealment was
unclear and there was unclear blinding of participants, providers and outcome assessors. Rates of attrition
were not reported. One outcome (CGI-Severity scale) was measured but the results are not reported. This
study was considered to be at high risk of bias owing to the absence of randomisation, unclear patient,
provider and outcome assessor blinding and unclear risk of attrition and selective reporting bias.
Clinical evidence
Risperidone compared with clonidine
Tics In the parallel trial of risperidone compared with clonidine in children,150 tics and impairment were
assessed with the YGTSS global scale. Results for reduction in baseline global score were similar for
risperidone compared with clonidine (SMD 0.19, 95% CI –0.68 to 1.05; n= 21) (Figure 157) as were the
proportions of participants with a ≥ 30% reduction in YGTSS global score for risperidone compared with
clonidine (RR 0.89, 95% CI 0.35 to 2.24; n= 21) (Figure 158).
Impairment No separate impairment score was presented but the YGTSS global score (results reported
above) contains a component of impairment (50% of total score).
Psychological well-being The Hamilton Rating Scale for Depression (HAM-D) was used to assess changes
in depression. Results were inconclusive for changes from baseline in HAM-D score for risperidone
compared with clonidine (SMD 0.03, 95% CI –0.83 to 0.89; n= 21) (Figure 159).
Overall clinical outcome Overall clinical outcome was assessed using the CGI-Severity scale. There was
no conclusive difference in change from baseline CGI-Severity score for risperidone compared with
clonidine (SMD 0.65, 95% CI –0.24 to 1.54; n= 21) (Figure 160).
Long-term outcome No relevant studies reported long-term outcomes.
Safety For adverse effects, results were inconclusive for risperidone compared with clonidine (RR 0.57,
95% CI 0.20 to 1.62; n= 21) (Figure 161). The most common adverse effects with clonidine were sedation
(n= 5), dizziness (n= 2), stiffness (n= 1) and dry mouth (n= 1) and, in the risperidone group, they were
sedation (n= 1), dizziness (n= 1) and stiffness (n= 2).
There was no conclusive difference in weight gain (kg) for risperidone compared with clonidine (MD 2.00,
95% CI –1.66 to 5.66; n= 21) (Figure 162). It was reported that there were no significant differences in
changes in systolic or diastolic BP or pulse and no apparent pattern in laboratory test abnormalities for
risperidone compared with clonidine and no significant changes in ECG in either group.
Moderators of effectiveness It was reported that improvement in tic symptoms was consistent across
the range of ages and did not differ significantly between male and female participants and that the
degree of improvement in tic symptoms was not significantly related to the baseline severity of ADHD or
OCD symptoms.150
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FIGURE 157 Standardised change from baseline YGTSS global score for risperidone compared with clonidine. IV, independent variable; ROB, risk of bias.
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FIGURE 158 Proportion of patients with a ≥ 30% reduction in YGTSS global score for risperidone compared with clonidine. M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 159 Standardised change from baseline HAM-D score for risperidone compared with clonidine. IV, independent variable; ROB, risk of bias.
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FIGURE 160 Standardised change from baseline CGI-Severity score for risperidone compared with clonidine in parallel child study. IV, independent variable.
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FIGURE 161 Proportion of children experiencing clinically significant adverse events for risperidone compared with clonidine. M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 162 Weight gain for children taking risperidone compared with clonidine. IV, independent variable; ROB, risk of bias.
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Fluvoxamine versus sulpiride
Tics In the crossover study of fluvoxamine compared with sulpiride,151 the YGTSS global scale was used to
measure changes in tics and impairment. Results were inconclusive for post-treatment global score for
fluvoxamine compared with sulpiride (SMD 0.23, 95% CI –0.30 to 0.77; n= 11) (Figure 163).
Impairment Impairment was rated as part of the YGTSS global score but no separate impairment scores
were reported.
Psychological well-being No scales were used to measure outcomes of psychological well-being but it is
reported that two participants dropped out owing to severe depression while in the sulpiride phase of
the trial.
Overall clinical outcome No relevant studies reported this outcome.
Long-term outcome No relevant studies reported long-term outcomes.
Safety Adverse effects reported during fluvoxamine compared with sulpiride treatment are shown in
Figure 164. For outcomes with greater than two adverse effects, there was no conclusive difference in
rates of mild-to-moderate depression (RR 0.14, 95% CI 0.01 to 2.48; n= 11), mild and transient nausea
(RR 9.00, 95% CI 0.54 to 149.50; n= 11) and akathisia (RR 1.00, 95% CI 0.17 to 5.89; n= 11).
Levetiracetam compared with clonidine
Tics In the mixed crossover study of levetiracetam compared with clonidine,152 the effect on tics was
assessed using the YGTSS total tic scale. Post-treatment total tic score was inconclusive for levetiracetam
compared with clonidine (SMD –0.22, 95% CI –0.78 to 0.34; n= 10) (Figure 165).
Impairment No separate results for impairment are presented but results for the YGTSS global scale
(combination of tic and impairment score) were given. Results for post-treatment global score were inconclusive
for levetiracetam compared with clonidine (SMD –0.33, 95% CI –0.90 to 0.24; n= 10) (Figure 166).
Psychological well-being
Anxiety Anxiety was measured using the MASC. Post-treatment anxiety results were inconclusive for
levetiracetam compared with clonidine (SMD –0.16, 95% CI –0.72 to 0.40; n= 10) (Figure 167).
Psychological well-being
Depression. Depression was measured using the CDI-S. Post-treatment depression results were inconclusive
for levetiracetam compared with clonidine (SMD 0.08, 95% CI –0.48 to 0.63; n= 10) (Figure 168).
Overall clinical outcome Overall clinical outcome was assessed using the CGI-Severity scale.
Post-treatment CGI-Severity results were inconclusive for levetiracetam compared with clonidine
(SMD –0.16, 95% CI –0.72 to 0.40; n= 10) (Figure 169).
Long-term outcome No relevant studies reported long-term outcomes.
Safety The proportion of participants with different adverse effects for outcomes with more than four
events is shown in Figure 170. There was no conclusive difference in rates of irritability (RR 1.33, 95% CI
0.40 to 4.49; n= 10), anxiousness (RR 0.75, 95% CI 0.22 to 2.52; n= 10), aggression (RR 0.67, 95% CI
0.14 to 3.17; n= 10) or tiredness/sleepiness (RR 0.40, 95% CI 0.10 to 1.60; n= 10) for levetiracetam
compared with clonidine.
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FIGURE 163 Standardised post-treatment YGTSS global score for patients following treatment with fluvoxamine compared with sulpiride. IV, independent variable;
ROB, risk of bias; SE, standard error.
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FIGURE 164 Proportion of patients experiencing adverse events following treatment with fluvoxamine compared with sulpiride. M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 165 Standardised post-treatment YGTSS total tic score for clonidine compared with levetiracetam. IV, independent variable; ROB, risk of bias.
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FIGURE 166 Standardised post-treatment YGTSS global score for clonidine compared with levetiracetam. IV, independent variable; ROB, risk of bias; SE, standard error.
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FIGURE 167 Standardised post-treatment MASC score for levetiracetam compared with clonidine. IV, independent variable; ROB, risk of bias; SE, standard error.
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
X
X
X
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
X
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
H
o
llis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
1
5
9
Study or subgroup
SMD
IV, random, 95% Cl
SMD
IV, random, 95% ClSMD Overall ROBSE Weight
Hedderick 2009152
Total (95% Cl)
Heterogeneity: not applicable
Test for overall effect: z = 0.27 (p = 0.79)
0.077 0.283 100.0%
100.0%
Unclear risk 0.08 (–0.48 to 0.63)
0.08 (–0.48 to 0.63)
–2 –1 0 1 2
Favours clonidine Favours levetiracetam
FIGURE 168 Standardised post-treatment CDI-S score for levetiracetam compared with clonidine. IV, independent variable; ROB, risk of bias; SE, standard error.
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FIGURE 169 Standardised post-treatment CGI-Severity score for levetiracetam compared with clonidine. IV, independent variable; ROB, risk of bias; SE, standard error.
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FIGURE 170 Adverse events occurring in more than four patients during treatment with levetiracetam compared with clonidine. M–H, Mantel–Haenszel; ROB, risk of bias.
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Clonidine compared with desipramine
Tics For the crossover study of clonidine compared with desipramine,115 it was reported that there was no
significant motor or vocal tic suppression for clonidine or desipramine compared with placebo when assessed
with the Shapiro TSSS or the Hopkins scale or YGTSS scale. There was a significant effect on the parent
linear analogue scale and results for this outcome are reported. Post-treatment parent linear analogue score
favoured desipramine compared with clonidine (SMD 2.12, 1.58 to 2.66; n= 34) (Figure 171).
Impairment No relevant studies reported TS-related impairment.
Psychological well-being Results for the whole sample are not reported, but for boys aged > 12 years,
post-treatment anxious teacher subscale score was lower for desipramine than clonidine (SMD 0.40,
95% CI 0.09 to 0.71; n= 34) (Figure 172).
Overall clinical outcome No relevant studies reported this outcome.
Long-term outcome No relevant studies reported long-term outcomes.
Safety The number of adverse effects were similar for clonidine compared with desipramine (RR 1.08,
95% CI 0.84 to 1.37; n= 34) (Figure 173).
Transdermal clonidine compared with haloperidol
Tics In the study of transdermal clonidine compared with haloperidol,153 tics/impairment was measured
with a Chinese version of the YGTSS global scale. There was a greater reduction from baseline in global
score for clonidine patch than haloperidol (SMD –0.38, 95% CI –0.75 to –0.02; n= 119) (Figure 174) and
a possible greater reduction for clonidine patch than haloperidol in the proportion of children with ≥ 50%
reduction in global score (RR 0.55, 95% CI 0.29 to 1.05; n= 119) (the RR presented here is the RR of not
achieving ≥ 50% reduction) (Figure 175).
Impairment No relevant studies reported TS-related impairment.
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome No relevant studies reported this outcome.
Long-term outcome No relevant studies reported long-term outcomes.
Safety There was no conclusive difference in rates of low BP, muscle tension (RR 0.17, 95% CI 0.01 to
3.40; n= 119) or fatigue (RR 0.09, 95% CI 0.01 to 1.68; n= 119) for clonidine patch compared with
haloperidol (Figure 176).
Clinical evidence summary
Five studies made comparisons between drugs of different classes:
1. risperidone compared with clonidine150
2. sulpiride compared with fluvoxamine151
3. clonidine compared with levetiracetam152
4. clonidine compared with desipramine115
5. haloperidol compared with clonidine patch.153
The evidence for all studies was graded as low or very low quality (see Appendix 4, Tables 44–48).
All studies showed inconclusive results.
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FIGURE 171 Standardised post-treatment parent linear analogue scale for clonidine compared with desipramine. IV, independent variable; ROB, risk of bias; SE, standard error.
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FIGURE 173 Proportion of children with adverse events for clonidine compared with desipramine. M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 174 Standardised change from baseline YGTSS global score for clonidine patch compared with haloperidol. IV, independent variable; ROB, risk of bias.
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FIGURE 175 Proportion of children with ≥ 50% reductions in global score for clonidine patch compared with haloperidol (the RR presented here is the RR of not achieving
≥ 50% reduction). M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 176 Proportion of children reporting adverse events reported for clonidine patch compared with haloperidol. M–H, Mantel–Haenszel; ROB, risk of bias.
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Conclusion
It is difficult to draw firm conclusions as it is not clear whether or not these studies were adequately
powered to test non-inferiority between different drug classes. The most important findings to consider
involve comparisons between drugs that have established benefits over placebo. The comparison between
risperidone and clonidine suggests that there are unlikely to be clinically important differences between
antipsychotic drugs and noradrenergic agents in reducing tics. However, there is evidence that
noradrenergic agents may have better global outcomes and a more favourable adverse effect profile
than antipsychotics.
Overall conclusions from pharmacological intervention trials
Antipsychotics and noradrenergic agents are the only classes of drug with clear RCT evidence of short-term
clinical effectiveness for treating tics in children and young people with TS. The size of effect on tic
reduction for antipsychotics and noradrenergic agents is moderate to large and is likely to be clinically
meaningful. Among noradrenergic agents, clonidine and guanfacine have the best evidence for clinical
effectiveness; however, only clonidine is available and licensed in the UK. Overall, head-to-head studies
suggest that there are unlikely to be important clinical differences in tic reduction among antipsychotics
and between antipsychotics and noradrenergic agents. Antipsychotics are known to produce a range
of adverse effects including weight gain, metabolic and cardiac conduction disturbances and EPSs.
Furthermore, the pattern of adverse effects differs between antipsychotics. Clonidine and guanfacine have
a similar adverse effect profile that includes dose-dependent sedation, bradycardia and hypotension.
Although most studies have not been designed to be adequately powered to address moderating effects,
there is no clear evidence that the effectiveness of antipsychotics or noradrenergic agents is moderated by
either tic severity or comorbidity.
Topiramate, pergolide, metoclopramide and desipramine are other agents with RCT evidence that suggests
they may be effective in reducing tics. However, the known adverse effect profiles of these drugs, balanced
against relatively weak evidence of benefits, means that these agents are unlikely to be considered clinically
useful for the treatment of tics in children and young people with TS. Among these drugs, desipramine
has been withdrawn from use in the UK and pergolide is rarely used owing to concerns over the risk of
pulmonary and pericardial fibrosis.
A number of other agents are used primarily to treat comorbid TS and ADHD (e.g. stimulants and
atomoxetine) and comorbid TS and OCD/OCSs (e.g. fluoxetine). There is clear RCT evidence that, in the
short term, neither stimulants nor fluoxetine significantly exacerbates or worsens tics and in fact,
atomoxetine may reduce tics.
Finally, the following agents have been subjected to RCTs and have been shown not to be clinical effective
for treating tics: levetiracetam, selegiline, pramipexole, mecamylamine, ondansetron, baclofen, omega-3
fatty acids and transdermal nicotine patches.
In summary, the balance of clinical benefits to harm favours noradrenergic agents (e.g. clonidine) as first-line
drug treatments for tics, with antipsychotics (e.g. risperidone or possibly aripiprazole) reserved for treatment
of tics when clonidine is either ineffective or poorly tolerated. When treating comorbid conditions (e.g. TS
plus ADHD, and TS plus OCD/OCSs) there is no evidence that first, the presence of comorbidity moderates
the effects antitic treatment and second, that drug treatments for comorbid ADHD (e.g. with stimulants or
atomoxetine) or comorbid OCD/OCSs (e.g. with fluoxetine) worsens or exacerbates tics.
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Behavioural interventions
Introduction
Behavioural interventions aim to improve symptoms through sessions of counselling with a therapist.
These interventions have included HRT, the CBIT, ERP, negative (massed) practice, relaxation therapy, anger
control training and parent training. There have been a number of reviews and clinical guidelines of
behavioural therapies, but no quantitative meta-analyses of treatment outcomes appear to have been
conducted to date.
Habit reversal training
Habit reversal training was originally based on Azrin and Nunn’s (1973) behavioural model in which tics
were assumed to result from repetition of a normal, or trauma-induced, habit that has been reinforced by
repetition over time.154 It is proposed that tics occur in response to a premonitory urge and, by associating
another competing response with that urge, tics can be inhibited. HRT aims to equip patients with the
knowledge, skills and strategies to avoid performing tics and includes components of awareness training,
competing response practice, habit control motivation and generalisation training.154
l Awareness training aims to make the patient conscious of their tics and the accompanying premonitory
urges (uncomfortable sensory experiences that precede many tics), by describing them to the therapist
in great detail and noticing each instance of urges and tics and situations in which they are likely
to occur.154
l Competing response training involves learning competing motor and/or vocal responses which can be
prompted by tic urges, in order to physically impede tics until the urge subsides154 and a number of
established responses have been developed for use.155 These actions are designed to be inconspicuous,
able to be maintained for several minutes and act to strengthen motor or vocal responses antagonistic,
or different, to those involved in tics.154
l Habit control motivation aims to motivate patients to tic control through reviewing inconveniences and
embarrassments related to tics, praising successful control, involving family and friends and prompting
patients to maintain their practice.
l Generalisation training aims to help patients contextualise their preventative actions in everyday
situations. This involves imagining common tic-eliciting situations and performing the competing
movement in response the urge to tic.154
Comprehensive behavioural intervention for tics
Comprehensive behavioural intervention for tics is a behavioural intervention, with habit reversal as its
primary component.156 CBIT is similar to HRT but contains additional elements of relaxation training and
training to identify and modulate situations that sustain or worsen tics.156 Another difference between HRT
as it was initially introduced by Azrin and Nunn154 and the current more widely used CBIT programme is that
the competing response developed is now not necessarily an action to strengthen muscles incompatible
with tic expression. It is proposed that other responses act as activities that the individual implements as
they habituate to the premonitory urge and subsequently avoid tics. Evidence of this is given because an
implemented competing response may not always be physiologically incompatible to the identified tic.
The evidence for the link between premonitory urge and tic inhibition is inconclusive157 but it is currently the
rationale for CBIT. Current guidelines recommend HRT/CBIT for use in children and adults.158,159
Exposure and response prevention
Exposure and response prevention is based on the theory that tics are performed in order to dispel the
premonitory urge sensation that precede them.160 ERP aims to habituate patients to these sensations so
that their effect is reduced and patients can avoid performing the tic. ERP involves exposing patients to tic
eliciting prompts and sensations and encouraging them to resist their tics.160 Unlike in HRT/CBIT, no
competing response is used, but patients are repeatedly encouraged by their therapist to try harder to
resist their tics.160 Tic suppression training is first given without tic elicitation and then, in subsequent
sessions, patients are encouraged to concentrate on pre-tic sensations to induce the urge to tic.160 Social
support, relaxation and contingency management are also components included in the ERP programme.158
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Current guidelines recommend the use of ERP in adults and children.158,159
Negative (massed) practice
With a similar underlying model to that of habit reversal, negative, or massed, practice is based on the
concept that tics are initiated by some kind of trauma and, with reinforcement through association with
fear cessation, they develop as learned habitual behaviours.161 The rationale for negative practice is that
tics are behaviours that have reached their maximum habit strength and, by building an opposing habit of
not performing the tic, they can be avoided.161 In negative practice, patients are instructed to repeatedly
perform their tics for a specified period of time (e.g. 30 minutes) and, when the drive to tic dissipates, they
rest. A reduction in the drive to tic is consequently associated with not performing it and, with repeated
negative practice, a habit of not performing tics is developed.161 Currently, guidelines do not recommend
the use of negative practice.158,159
Relaxation therapy
Relaxation training has been studied for the treatment of tic disorders but mostly in combination with
other behavioural interventions162 and CBIT and ERP identify relaxation training as an adjunct treatment.
Components of relaxation training sessions may include review of the rationale behind relaxation practice
of progressive muscular relaxation and therapist-lead relaxation exercises.162
In one current guideline, relaxation therapy is recommended as a second-line behavioural therapy158 but,
in another, no recommendation regarding relaxation training is made.159
Anger control training
Anger control training has been developed for use in children. It is based on CBT and has been conducted
in a variety of settings such as schools and outpatient and inpatient facilities.163 In recent guidelines, no
recommendation regarding anger control training is made.158,159
Parent training
Parent training programmes have frequently been used for parents of children with ADHD and one study has
evaluated the use of the approach in the treatment of children with tic disorders.164 Components of treatment
may include training for effective child behaviour management, classroom behaviour modification and
academic interventions and special educational placement with family therapy in problem solving and
communication skills and the co-ordination of school resources.165 Parent training was not assessed in recent
guidelines158,159 and no recommendation regarding its use for children with tic disorders has been made.
Included studies
The search obtained seven studies of behavioural interventions for children and young people with TS
(see Appendix 3, Table 10). The search also obtained four behavioural intervention studies in adult or
mixed populations that were considered as supporting evidence.
The types of studies are shown below:
l CBIT compared with SP (one child156 and one adult study166)
l HRT compared with SP (two adult studies167,168)
l HRT compared with waiting list control (one child study169)
l HRT compared with negative practice (one mixed study170)
l HRT compared with ERP (one child study171)
l Videoconference CBIT compared with face-to-face CBIT (one child study172)
l Relaxation training compared with minimal therapy (one child study173)
l Anger control training compared with treatment as usual (one child study174)
l Parent training compared with treatment as usual (one child study164).
Study characteristics for behavioural intervention studies are given in Appendix 3, Table 10.
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Habit reversal training/comprehensive behavioural intervention for tics
Habit reversal training/comprehensive behavioural intervention for tics
compared with control
Study characteristics
Five RCTs compared HRT/CBIT with a control group (see Appendix 3, Table 10). Two of the studies
investigated CBIT156,166 and three investigated HRT.167–169 Two studies were conducted in child
populations156,169 and three in adults.166–168 In four studies, HRT or CBIT was compared with SP156,166–168
and in the other, HRT was compared with a waiting list control group.169
The four studies that compared HRT or CBIT with SP used similar methods. Treatment duration varied
between studies and lasted for 10 weeks in two studies156,166 and 20 weeks in the other two studies.167,168
Outcome was assessed post intervention and, in three studies,156,166,168 mid-way through treatment. The
study that used a waiting list as the control group169 delivered an average of 20 sessions of HRT over
8–11 months but the waiting list control was only for 3 months (in this review, outcome assessment at
3 months is used for both study arms so that intervention/control findings are compared at the same time
point). In these studies, 25–53% of participants were on other medications. In studies for which the type
of current medication was reported,156,166,168 there were most commonly antipsychotics, noradrenergic
agents (clonidine or guanfacine) or SSRIs.
All HRT/CBIT studies reported that the primary elements of the behavioural intervention were tic awareness
training, self-monitoring, relaxation training, competing response training and contingency management
and as the components of these interventions appeared to be similar, the studies were combined in the
meta-analysis.
Risk of bias
For studies of HRT/CBIT, three reported their method of randomisation156,166,169 but none of the studies had
clear evidence of allocation concealment. All studies used SP as the control group except for one,169 in
which a waiting list control was used. SP was considered to be a suitable control as it avoided some forms
of performance bias (general effect of the therapy process) but the waiting list control group was not
considered a suitable control. Because of the person-delivered nature of behavioural intervention studies,
none of the studies could blind participants and providers to intervention allocation.
Only two of the studies stated that outcome assessors were blinded to randomisation allocation156,166 and
for the remaining studies, the risk of detection bias was unclear. Four of the studies were considered to
have reasonably addressed missing outcome data. In these studies, dropout was relatively low and data for
participants with at least one post-baseline measurement,156,166 or post 8-week data,167,168 were carried
forward for the analysis. In the other study, there was considered to be some potential risk of bias as a
high proportion of participants dropped out of the study and only available data were used in the
analysis.169 It is unclear whether or not the participants dropping out were adults or children (only the child
data were used for this review) and the risk of attrition bias was, therefore, unclear.
Overall, one of the child156 and one of the adult166 studies were considered to be of low risk of bias and
the remaining child169 and two adult167,168 studies were considered to be of high or unclear risk of bias,
primarily owing to the use of a waiting list control group in the child study and to the uncertainty around
blinding of outcome assessors in the two adult studies.
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Clinical evidence for habit reversal training/comprehensive behavioural intervention
for tics compared with control
Tics As HRT and CBIT appear to have had very similar training components, for this analysis these studies
have been combined. The HRT/CBIT compared with SP studies used the YGTSS to measure tic severity after
10156,166 or 20167,168 weeks of intervention, while the study of HRT compared with a waiting list control
group169 measured tic frequency using 10-minute video records after 12 weeks of intervention. The
reduction from baseline in total tic severity/frequency was greater for HRT/CBIT compared with control in
child (SMD –0.64, 95% CI –0.99 to –0.29; n= 133) and adult studies (SMD –1.23, 95% CI –2.06 to
–0.39; n= 172) (Figure 177). There was no heterogeneity between studies of children (I2= 0%) but
significant heterogeneity between adult studies (I2= 77%). There was little evidence of a difference
between child and adult studies (I2= 38.5% for subgroup differences).
For studies measuring YGTSS total tic score, the magnitude of effect in terms of the YGTSS is shown in
Figure 178. The mean change from baseline in YGTSS total tic rating for HRT/CBIT compared with SP was
–4.1 (95% CI –6.31 to –1.8; n= 126) in children and –7.29 (95% CI –13.4 to –2.79; n= 172) in adults.
One child156 and one adult166 CBIT study presented separate data for YGTSS motor and vocal tic ratings.
Mean reduction from baseline in motor tic rating suggested a benefit for CBIT compared with SP in the
child (SMD –0.45, 95% CI –0.81 to –0.10; n= 126) and adult studies (SMD –0.62, 95% CI –1.00 to
–0.24; n= 113) (Figure 179).
For vocal tic rating, results suggested a benefit for CBIT compared with SP in the child (SMD –0.54,
95% CI –0.9 to –0.19; n= 126) and adult study (SMD –0.41, 95% CI –0.78 to –0.03; n= 113)
(Figure 180).
Impairment One child156 and two adult166,167 studies presented impairment results in terms of YGTSS
impairment score (Figure 181). The change from baseline YGTSS impairment score favoured HRT/CBIT
compared with SP in the child study (SMD –0.51, 95% CI –0.87 to –0.16; n= 126) and in the adult study
(SMD –0.50, 95% CI –0.86 to –0.15; n= 142).
Family impact and social adjustment In one study of children,156 impairments in functioning within the
family and school environment were assessed using the Family Assessment Measure-III. In one study of
children,156 impairments in functioning within the family and school environment were assessed using the
Family Assessment Measure-III (short form), Caregiver Strain Questionnaire, Social Adjustment Scale
Self-Report and subscales of the Child Behaviour Checklist (CBCL).175 There was no evidence of benefit
for CBIT compared with SP for changes from baseline in the Family Assessment Measure for children
(SMD –0.02, 95% CI –0.37 to 0.33; n= 126) or adults (SMD 0.16, 95% CI –0.19 to 0.51; n= 126), or for
the Caregiver Strain Questionnaire (SMD –0.02, 95% CI –0.37 to 0.33; n= 126), Social Adjustment Scale
Self-Report – family (SMD –0.15, 95% CI –0.50 to 0.20; n= 126), friends (SMD –0.08, 95% CI –0.43 to
0.27; n= 126) or school functioning measures (SMD 0.10, 95% CI –0.25 to 0.45; n= 126), or the CBCL
activities (SMD 0.17, 95% CI –0.18 to 0.52; n= 126), social (SMD 0.08, 95% CI –0.27 to 0.43; n= 126),
school (SMD –0.05, 95% CI –0.40 to 0.30; n= 126) or total competency (SMD 0.04, 95% CI –0.31 to
0.39; n= 126) subscales.
Psychological well-being
Anxiety In one study of children,156 results for the Screen for Child Anxiety Related Emotional Disorders
completed by children and their parents are reported in a later publication.175 There were similar changes
in anxiety scores from baseline to follow-up for CBIT compared with SP as assessed by children (SMD
–0.10, 95% CI –0.45 to 0.25; n= 126) and their parents (SMD –0.15, 95% CI –0.50 to 0.20; n= 126)
(Figure 182).
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FIGURE 177 Standardised change from baseline in tic score for HRT/CBIT compared with control in child and adult studies. df, degrees of freedom; IV, independent variable;
ROB, risk of bias.
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FIGURE 178 Standardised change from baseline in YGTSS total tic rating for HRT/CBIT compared with SP in child and adult studies. df, degrees of freedom; IV, independent
variable; ROB, risk of bias.
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FIGURE 179 Standardised change from baseline for CBIT compared with SP for YGTSS motor tic rating in children and adults. df, degrees of freedom; IV, independent variable;
ROB, risk of bias.
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FIGURE 180 Standardised change from baseline for CBIT compared with SP for YGTSS vocal tic score in children and adults. df, degrees of freedom; IV, independent variable;
ROB, risk of bias.
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FIGURE 181 Standardised change from baseline YGTSS impairment score for HRT/CBIT compared with SP in child and adult studies. df, degrees of freedom; IV, independent
variable; ROB, risk of bias.
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FIGURE 182 Standardised change from baseline Screen for Child Anxiety Related Emotional Disorders rating for CBIT compared with SP as rated by children and parents.
df, degrees of freedom; IV, independent variable; ROB, risk of bias.
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Psychological well-being
Depression One study in children175 and one in adults168 report changes in patient depression. The child study
used the Children’s Depression Inventory and the adult study used the Beck Depression Inventory. There were
similar changes in depression scores for HRT/CBIT compared with SP in the study of children (SMD –0.22, 95%
CI –0.57 to 0.13; n= 126) and adults (SMD 0.01, 95% CI –0.70 to 0.73; n= 30) (Figure 183).
Overall clinical outcome One study in children and two in adults reported the proportions of participants
showing improvements on the CGI-I scale. A greater number of participants were much or very much
improved for HRT/CBIT compared with SP for the child (RR 2.84, 95% CI 1.62 to 4.99; n= 126) and adult
(RR 5.39, 95% CI 2.42 to 11.9; n= 152) studies (Figure 184). There was no important heterogeneity
between the two adult studies.
One study presented continuous data for the CGI-I scale (1= very much improved, 7= very much
worse).167 After the 20-week intervention, mean CGI-I score was better for HRT than SP (SMD –1.32,
95% CI –2.18 to –0.46; n= 27) (Figure 185).
Long-term outcomes No studies in children have reported long-term outcomes but two of the adult
studies reported YGTSS total tic rating167,168 and one study reported YGTSS impairment rating167 at
10 months. Results were analysed including only participants retained in the study at 10 months but, by
this time, approximately one-third of participants had dropped out. Treatment effect size remained similar
to post-treatment effects for both outcomes. HRT showed improvement from baseline compared with SP
for YGTSS total tic score (SMD –1.11, 95% CI –1.80 to –0.42; n= 39) (Figure 186).
However, for YGTSS impairment score, there was no conclusive difference in change from baseline for HRT
compared with SP (SMD –0.42, 95% CI –1.29 to 0.45; n= 21) (Figure 187).
Safety Adverse effects are reported in one child156 and one adult study.166 There were no significant
differences in event rates apart from a higher incidence of falls/athletic injuries for children undergoing
SP compared with CBIT (19 vs. 7; p= 0.02) and a higher incidence of irritability in adults undergoing SP
compared with CBIT (6 vs. 0; p= 0.01).
Moderators of effectiveness
Tic severity One adult study conducted a regression analysis to examine the relationship between
baseline tic severity and response to treatment.168 There was no significant correlation between baseline
YGTSS total tic severity score and post-treatment response (r= 0.17; p= 0.55).
Age One adult study conducted a regression analysis to examine the relationship between age at tic
onset and response to treatment.168 There was no significant correlation between age at onset and
post-treatment response (r= 0.15; p= 0.60).
Comorbidity There are no published RCTs investigating the effects of comorbidity on the outcome of
behavioural interventions in children or adults with tic disorders.
Medication There are no published RCTs investigating the effects of medication in addition to
behavioural therapy in children or adults with tic disorders.
Mode of delivery One study investigated whether or not CBIT was as effective when delivered via video
conference when compared with face-to-face delivery.172 Twenty children were randomly assigned to
receive eight sessions of CBIT over 10 weeks with a therapist via teleconference or with traditional
face-to-face interaction. The primary components of the CBIT intervention in both modes of delivery were
psychoeducation, HRT, function-based assessment and intervention and relaxation training. Each week,
a new tic was targeted and children were encouraged to practice therapeutic activities every day.
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FIGURE 183 Standardised change from baseline in depression rating for HRT/CBIT compared with SP in child and adult studies. df, degrees of freedom; IV, independent
variable; ROB, risk of bias.
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FIGURE 184 Proportion of patients rated as much or very much improved on the CGI-I scale for HRT/CBIT compared with SP in child and adult studies. df, degrees of freedom;
M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 185 Standardised CGI-I score for HRT compared with SP (1= very much improved, 7= very much worse) in adults. IV, independent variable; ROB, risk of bias.
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FIGURE 186 Standardised change in YGTSS total tic score from baseline to 10-month follow-up for HRT compared with SP in adults. df, degrees of freedom; IV, independent
variable; ROB, risk of bias.
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FIGURE 187 Standardised change in YGTSS impairment rating from baseline to 10-month follow-up for HRT compared with SP in adults. IV, independent variable;
ROB, risk of bias.
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In the quality assessment of this study, methods for randomisation and allocation concealment were
unclear. It was not possible to blind study participants or providers delivering interventions and, although
both were delivered with a similar time frame and intensity, the risk of performance bias is unclear.
Outcome assessors were blinded to intervention allocation. Two participants dropped out of the
face-to-face group during the 10-week intervention and one dropped out after the post-test assessment
(during follow-up). None dropped out of the video conference group and the risk of attrition bias is
unclear (analysis was of available case data). Overall, this study was considered to be at low risk of bias.
This study reports changes in tics in terms of the YGTSS total tic score and overall clinical improvement
with the CGI scale. Results were inconclusive for changes from baseline in total tic score (SMD –0.18,
95% CI –1.11 to 0.75; n= 18) (Figure 188) and numbers of children with CGI scored as improved or very
much improved (RR 1.07, 95% CI 0.64, 1.77; n= 18) (Figure 189) for video conference compared with
face-to-face delivery.
At the 4-month follow-up, the same pattern was observed. For video conference compared with
face-to-face delivery, results were inconclusive for changes from baseline in total tic score (SMD –0.32,
95% CI –1.32 to 0.67; n= 16) (Figure 190) and for proportions of children who were CGI-I much or very
much improved (RR 1.30, 95% CI 0.46 to 3.65; n= 16) (Figure 191).
Length of intervention HRT/CBIT studies varied in length and some measured outcomes at different
time points during the intervention. One child156 and one adult166 10-week CBIT study also measured
outcomes at 5 weeks and one adult168 20-week HRT intervention also measured outcome at 10 weeks.
For both 10-week intervention studies,156,166 the effect on YGTSS total tic score in favour of CBIT was
smaller at 5 weeks (SMD –0.32, 95% CI –0.64 to 0.00; n= 239; p= 0.08) compared with the final
10-week assessment (SMD –0.62, 95% CI –0.88 to –0.36; n= 239) (Figure 192) (for this comparison, child
and adult study data were combined).
In the 20-week adult study,168 findings were similar at both 10 and 20 weeks (Figure 193). There was an
advantage of HRT over SP at 10 (SMD –1.53, 95% CI –2.35 to –0.70; n= 30) and 20 (SMD –1.82, 95% CI
–2.69 to –0.95; n= 30) weeks.
Habit reversal training versus negative (massed) practice
Study characteristics
One mixed study of 22 adults and children (aged 11–62 years) measured changes in the number of tics per
day following HRT compared with negative practice therapy.170 In this study, HRT was delivered in one or
two sessions of around 2.5 hours. The primary HRT component was considered to be competing response
training, but the treatment also included a review of inconveniences caused by tics, identification of people
or situations associated with tics, awareness training and relaxation training. Methods were to be practised
and utilised at home between sessions. After the training sessions, telephone contact was maintained,
with reducing contact over time.
For negative practice, in a 2.5-hour session, participants reviewed the difficulties caused by tics, the origins
of their habits and previous treatments. They were given written instructions for the negative practice
technique and discussed the underlying rationale. They were to purposefully perform tics for 30 second
periods with rests over 1 hour, saying to themselves ‘this is what I’m supposed not to do’. They were to
continue the practice each day until their tics subsided and to restart if tics returned. The study does not
report whether or not telephone contact was maintained for participants undergoing treatment with
negative practice. For HRT and negative practice, outcome was assessed after 4 weeks.
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FIGURE 188 Standardised change from baseline to post-intervention in YGTSS total tic rating for video conference CBIT compared with face-to-face CBIT. IV, independent
variable; ROB, risk of bias.
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Test for overall effect: z = 0.25 (p = 0.80)  
Overall ROB
Low risk
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FIGURE 189 Proportion of children rated as much or very much improved on the CGI-I scale for video conference CBIT compared with face-to-face CBIT. M–H,
Mantel–Haenszel; ROB, risk of bias.
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FIGURE 190 Standardised change from baseline to 4-month follow-up in YGTSS total tic rating for video conference CBIT compared with face-to-face CBIT. IV, independent
variable; ROB, risk of bias.
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FIGURE 191 Proportion of children rated as much or very much improved on the CGI-I scale for videoconference CBIT compared with face-to-face CBIT at 4-month
follow-up. M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 192 Standardised change from baseline in YGTSS total tic score in child and adult studies with outcome measured at 5 and 10 weeks for CBIT compared with SP.
df, degrees of freedom; IV, independent variable.
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FIGURE 193 Standardised change from baseline in YGTSS total tic score in adult study with outcome measured at 10 and 20 weeks for HRT compared with SP. df, degrees of
freedom; IV, independent variable; ROB, risk of bias.
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Risk of bias
The method of randomisation was stated but the study was unclear in its use of allocation concealment.
Providers of interventions could not be blinded to treatment allocation and, although this could not be
avoided, the risk of performance bias is unclear. Participants were asked to estimate their own frequency
of tics and there was, therefore, no blinded outcome assessment. At 4 weeks, there was no attrition from
the study and the risk of attrition bias at this time point was low. Overall, the study was considered to be
at unclear risk of bias owing to the lack of patient, provider and outcome assessor blinding.
Clinical evidence for habit reversal training compared with negative (massed) practice
Tics Tic severity was assessed by counts of tic frequency per day by participants. At baseline, median tic
frequency was 425 (range 50–5000) and 450 (range 6–9000) per day in the HRT and negative practice
groups, respectively. At 4 weeks, estimated tics per day reduced by 92% in the HRT group (size of
reduction not reported for negative practice group) and tic reduction was greater for HRT compared with
negative practice (SMD –1.74, 95% CI –2.72 to –0.76; n= 22) (Figure 194).
At the end of the intervention, more participants in the HRT group had tic counts of < 1 per day compared
with participants in the negative practice group (RR 0.21, 95% CI 0.06 to 0.77; n= 22) (Figure 195).
Impairment No relevant studies reported TS-related impairment.
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome No relevant studies reported this outcome.
Long-term outcome Long-term outcome was reported for HRT at 18 months but not for negative
practice. At 18 months, one-half of the HRT participants (5/10) remained in the study. For these participants,
the intervention-associated reduction in tics was maintained and was 97% lower than at baseline.
Habit reversal training compared with exposure and response prevention
Study characteristics
One mixed study of children and adults compared 10 weeks of HRT with 12 weeks of ERP.171 The authors
provided IPD and results could therefore be calculated for the child subset (25 out of 43 participants).
In this study, participants were randomised to 10 weekly treatment sessions of HRT or 12 sessions of ERP
(two training and 10 treatment sessions). HRT consisted of awareness and competing response training,
in which participants learnt to detect and describe each tic and then to apply a competing response for
1 minute when a tic was about to occur. In the ERP training sessions, participants were trained to suppress
their tics for increasing lengths of time. In the next 10 ERP treatment sessions, participants were to apply
the response prevention technique over 2 hours and, during these sessions, tics were provoked by asking
participants to concentrate on the sensory experiences of their tics and to take tic-eliciting objects into the
sessions. For both interventions, participants were encouraged to practice exercises at home.
Risk of bias
For this study, the method of randomisation and presence of allocation concealment was unclear.
Providers of interventions could not be blinded to treatment allocation and although this could not be
avoided, the risk of performance bias is unclear. Outcome assessors were blind to intervention allocation so
there was a low risk of detection bias. The risk of attrition bias was low because the rate of dropout of
children was relatively small (4% at mid-point, 20% at end point) and, in the analysis of the subgroup
of child data, intention to treat by last observation carried forward was used. Overall, the study was rated
as low risk of bias but, as this review does not utilise the whole randomised sample of participants
(only the subset of child data), some caution may be necessary when interpreting the findings.
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FIGURE 194 Standardised change from baseline for number of tics per day for HRT compared with negative practice. IV, independent variable; NP, negative practice; ROB, risk
of bias.
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FIGURE 195 Proportion of patients with < 1 tic per day in patients for negative practice compared with HRT. M–H, Mantel–Haenszel; NP, negative practice; ROB, risk of bias.
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Clinical evidence for habit reversal training/comprehensive behavioural intervention
for tics
As this review171 does not utilise the whole randomised sample of participants, the subset of child data
used was checked for baseline similarity. There were no significant differences at baseline in age, sex, age
at onset, duration of disease or use of other medications. However, baseline measure of YGTSS total tic
score approached being significantly different for the different intervention groups [mean HRT 21.9
(SD 7.0), ERP 17.9 (SD 4.1); p= 0.08].
Tics The Dutch version of the YGTSS was used to assess patient outcome. This is similar to the standard
YGTSS (motor and tic severity are scored out of 25 each and total tic severity is the sum of both) except
that impairment is scored out of 5 (50 for the standard YGTSS) to give a total score out of 55 (100 for the
standard YGTSS). There was no conclusive difference in change from baseline total tic score for ERP
compared with HRT (SMD –0.43, 95% CI –1.23 to 0.37; n= 25) (Figure 196).
For vocal tic score, there was a greater reduction from baseline for ERP compared with HRT but the
difference was not conclusive (SMD –0.73, 95% CI –1.55 to 0.09; n= 25) (Figure 197).
For motor tic score, there were similar changes from baseline for ERP compared with HRT (SMD 0.08,
95% CI –0.71 to 0.87; n= 25) (Figure 198).
The proportion of children showing ≥ 30% reductions in total tic score was compared. There were similar
numbers of children showing ≥ 30% reductions in YGTSS total tic score for ERP compared with HRT
(RR 1.48, 95% CI 0.70 to 3.15; n= 25) (Figure 199).
Impairment Impairment was rated with the Dutch version of the YGTSS (scored out of five) and there
were similar reductions from baseline in impairment score for ERP compared with HRT (SMD 0.04, 95% CI
–0.75 to 0.83; n= 25) (Figure 200).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome No relevant studies reported this outcome.
Long-term outcome Follow-up was conducted 3 months after the intervention period. However, for over
half of the participants (58%), this was assessed after they had crossed over and undergone the other
treatment arm (HRT or ERP). The interpretation of these longer-term findings is therefore unclear.
Safety No results for adverse effects were reported for this study.
Moderators of effectiveness IPD were available for this study but, owing to the small sample size
(n= 25), investigation into moderating factors was not considered appropriate.
Clinical evidence summary for habit reversal training/comprehensive
behavioural intervention for tics
There was moderate-quality evidence (see Appendix 4, Table 49) from one study in 126 children,156
suggesting that CBIT produced a medium-sized effect in terms of tics and impairment following a 10-week
intervention. These favourable effects are supported by findings in three studies of adults (n= 172).166–168
The intervention did not produce improvements in measures of social functioning and psychological
well-being (anxiety and depression) in comparison with SP.
The optimum length of intervention is currently unclear but the child study156 provided moderate-quality
evidence that after 5 weeks of treatment there was a small-sized to medium-sized effect on tics and there
was no statistical difference between results after 5 and 10 weeks of intervention (I2 for subgroup
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FIGURE 196 Standardised change from baseline in YGTSS total tic score for ERP compared with HRT. IV, independent variable; ROB, risk of bias.
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FIGURE 197 Standardised change from baseline in YGTSS vocal tic score for ERP compared with HRT. IV, independent variable; ROB, risk of bias.
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FIGURE 198 Standardised change from baseline in YGTSS motor tic score for ERP compared with HRT. IV, independent variable; ROB, risk of bias.
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FIGURE 199 Proportion of children with ≥ 30% reduction in YGTSS total tic score for ERP compared with HRT. M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 200 Standardised change from baseline in Dutch YGTSS impairment score for ERP compared with HRT. IV, independent variable; ROB, risk of bias.
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difference= 0%; p= 0.51). This was not consistent with a study in adults,166 for which intervention at
10 weeks, but not 5 weeks was effective.
One study in 22 adults and children of negative practice compared with HRT170 provided very low-quality
evidence (see Appendix 4, Table 49) that HRT was more effective than negative practice in treating
tic disorders.
One study in 18 children,172 provided low-quality evidence (see Appendix 4, Table 49) for the impact of
delivering CBIT by video conference compared with face to face. There were similar changes in tics and
overall clinical change for CBIT when delivered by video conference compared with face-to-face therapy
(the size of changes in both groups were similar to those observed in Piacentini 2010156) and comparable
efficacy was maintained at the 4-month follow-up.
One mixed study in adults and children compared HRT with ERP.171 For the subsample of 25 children, the
study provided low-quality evidence (see Appendix 4, Table 49) that was inconclusive with regard to
whether or not ERP and HRT were similar in their efficacy.
Conclusion
There is clear RCT evidence that HRT/CBIT is an effective treatment for tics in children and young people
with TS. In head-to-head studies, HRT appears more effective than negative massed practice but there is
no evidence of meaningful differences in clinical effectiveness between HRT and ERP. There is no evidence
that HRT/CBIT is effective in reducing associated symptoms of anxiety and depression in TS. In children and
young people the optimal duration of treatment appears to be between 5 and 10 sessions, with the
suggestion that remotely-delivered CBIT (video consultation) may be as effective as face-to-face therapy.
There is currently no evidence available regarding the potential moderating effects of comorbidity and
medication on HRT/CBIT.
Relaxation training
Relaxation training compared with minimal therapy
Study characteristics
One study of 23 children compared relaxation training with a control group of minimal therapy.173 Relaxation
training consisted of six weekly 1-hour sessions covering awareness training, diaphragmatic breathing,
behavioural relaxation training, applied relaxation techniques and electromyographic biofeedback. Children
were expected to spend 25 minutes per day on exercises including self-monitoring of tics, practising relaxation
exercises with an audiotape guide and reading on topics related to breathing, relaxation and biofeedback.
Minimal therapy was also conducted in six 1-hour sessions. Sessions covered awareness training and quiet
time training, in which children listened to tapes of music or environmental sounds. Participants in this group
were also expected to spend 25 minutes per day on exercises. These included daily self-monitoring and
practice logs. Regardless of their assigned treatment group, participants and their families were given the
rationale for their treatment and encouraged with positive expectations of improvement in tics.
Risk of bias
For this study, the method for randomisation is reported but the presence of allocation concealment is
unclear. Minimal therapy was considered to be a suitable control group and attempts were made to ensure
that participants in each group had the same expectations for improvements from therapy. Participants and
providers could not be blinded to treatment allocation and the risk of patient or provider performance bias
is unclear. Outcome assessors were blind to treatment allocation. Sixteen out of 23 randomised children
completed the study. Only data from those completing were analysed and, therefore, there was considered
to be a risk of attrition bias. Overall, largely due to the high rate of attrition, this study was considered to
have an unclear risk of bias.
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Clinical evidence for relaxation training compared with minimal therapy
Tics Changes in tics were assessed with the YGTSS and results reported as the proportion of children
improving/staying the same/getting worse.173 For the global score, the evidence was inconclusive regarding
the proportion of children improving following relaxation training compared with minimal therapy
(RR 0.43, 95% CI 0.06 to 3.28; n= 16) (Figure 201) (the RR presented here is the RR of not improving).
Impairment No separate results for patient impairment were reported but the YGTSS global score
(reported above) includes an impairment rating that constitutes half of the score.173
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome No relevant studies reported this outcome.
Long-term outcome Longer-term outcome was assessed 3 months after baseline measurements
(about 9 weeks post intervention).173 For the YGTSS global score, the evidence was inconclusive for the
proportions of children who were improved for relaxation therapy compared with minimal therapy
(RR 0.64, 95% CI 0.16 to 2.56; n= 16) (Figure 202) (the RR presented here is the RR of not improving).
Safety No relevant studies reported this outcome.
Moderators of effectiveness Investigators tested whether or not the ability of children to learn relaxation
techniques affected the rate of improvement in measures of the CBCL (no comparison with YGTSS).173
When children across both treatment groups with improved behavioural relaxation scores (measure of
ability to relax) (n= 8) were compared with those with unchanged behavioural relaxation scores (n= 6),
there was no significant difference in change from baseline scores for any of the elements of the CBCL.
Clinical evidence summary: relaxation training
There was very low-quality evidence (see Appendix 4, Table 53) from one study in 16 children173 that was
inconclusive with regard to the effect of relaxation therapy compared with minimal therapy.
Conclusion
There is no clear evidence that relaxation therapy, when delivered in isolation, is an effective treatment for
tics in children and young people with TS.
Anger control training
Anger control training compared with treatment as usual
Study characteristics
One study in 26 young people with both TS and disruptive behaviour compared the efficacy of anger
control training with treatment as usual.174 The young people were randomised to attending 10 weekly
1-hour sessions of anger control training, or to continue with their usual treatment. Anger control training
consisted of 10 1-hour sessions including, in sessions one to three, education about anger triggers,
experience and expression followed by practice of common arousal management skills such as deep
breathing, muscle relaxation and positive imagery; in sessions four to six, cognitive restructuring and
practising problem solving skills; and, in session seven to nine, behavioural practice of skills for preventing
or resolving potentially anger-provoking situations with friends, siblings, parents and teachers. Children
allocated to treatment as usual, as well as those allocated to anger control training, continued to see their
treating clinicians and were treated according to usual practice, commonly including patient education,
clinical monitoring, medication management and school consultations as needed.
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FIGURE 201 Proportion of children with improved YGTSS global score for relaxation training compared with minimal therapy (the RR presented here is the RR of not
improving). M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 202 Proportion of children with improved in YGTSS global score for relaxation training compared with minimal therapy at 9 weeks’ follow-up (the RR presented here
is the RR of not improving). M–H, Mantel–Haenszel; ROB, risk of bias.
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Risk of bias
The method for randomisation was stated for this study but the presence of allocation concealment was
unclear. The control group, treatment as usual, was not considered to be suitable as it did not include
elements of the intervention that were not specific to anger control training (e.g. time spent in counselling,
attention given, etc.) and was likely to have led to some performance bias. Participants and providers
could not be blinded to treatment allocation and, although this could not be avoided, the further risk of
performance bias from the actions/perceptions of participants or providers is unclear. Outcome was
assessed by an evaluator who was blind to treatment allocation. It is stated that this evaluator conducted
measurement of the CGI-I scale rating and it seems likely that this was also the case for the measurement
of the YGTSS. However, for outcomes assessed by parents (CBCL, Family Assessment Device, etc.) who
were not blind to treatment allocation, outcome assessment was not blind to treatment allocation. It was
reported that there were no dropouts from the study and the risk of attrition bias may be low. Overall,
largely due to the unsuitability of the control group and no blinded outcome assessment for parent-rated
outcomes, this study was considered to have an unclear risk of bias.
Clinical evidence for anger control training
Tics Changes in tics were assessed with the YGTSS total tic score. There was no conclusive difference in
reduction from baseline total tic score for anger control training compared with treatment as usual
(SMD –0.58, 95% CI –1.37 to 0.20; n= 26) (Figure 203).174
Impairment The CBCL was used to measure intervention effects on behavioural change and the
total competence component measures competence in social, school and community activity. CBCL total
competence score showed greater improvement in the anger control training compared with the
treatment as usual group (SMD –1.18, 95% CI –2.01 to –0.35; n= 26) (Figure 204).
The Family Assessment Device general functioning scale was rated by parents to assess family functioning.
There were similar changes from baseline in family functioning for the anger control compared with the
treatment as usual group (SMD –0.42, 95% CI –1.20 to 0.35; n= 26) (Figure 205).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Overall clinical outcome (based on improvements in all types of behaviour and
not specific to improvements in TS) was assessed using the CGI-I scale. A greater proportion of children
were rated much or very much improved following anger control training compared with treatment as
usual (RR 0.36, 95% CI 0.16 to 0.85; n= 26) (Figure 206) (the RR presented here is the RR of not being
much nor very much improved).
Long-term outcomes At 3 months’ post intervention, follow-up findings were reported but only for the
group that underwent anger control training (n= 13). Eight of these children were still rated as much or
very much improved on the CGI-I scale.
Safety No relevant studies reported this outcome.
Clinical evidence summary for anger control training
One study in 26 young people with TS and disruptive behaviour174 provided low-quality (for tics) or very
low-quality evidence (for other outcomes) (see Appendix 4, Table 54) for the efficacy of anger control
training compared with treatment as usual. Findings favoured anger control training for tics, total
competence (CBCL total competence score) and overall clinical outcome (CGI much or very much improved).
Conclusion
Anger control training may be an effective treatment for improving overall outcomes and tics in children
and young people with comorbid TS and disruptive behavioural disorders. However, the low quality of
evidence means that caution must be applied to this finding.
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FIGURE 203 Standardised change from baseline in YGTSS total tic score for anger control training compared with treatment as usual. AC, anger control; IV, independent
variable; SE, standard error; TAU, treatment as usual.
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FIGURE 204 Standardised change from baseline in CBCL total competence score for anger control training compared with treatment as usual. AC, anger control;
IV, independent variable; SE, standard error; TAU, treatment as usual.
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Study or subgroup
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FIGURE 206 Proportion of children assessed as much or very much improved on the CGI-I scale for anger control training compared with treatment as usual (the RR presented
here is the RR of not being much or very much improved). AC, anger control; M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup
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FIGURE 205 Standardised change from baseline in Family Assessment Device general functioning score for anger control training compared with treatment as usual. AC, anger
control; IV, independent variable; SE, standard error; TAU, treatment as usual.
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Parent training
Parent training compared with treatment as usual
Study characteristics
One RCT evaluated parent training in children with both tic disorders and disruptive behaviour.164
Twenty-four children with TS or CTD and moderate-to-severe disruptive behaviour were randomised to a
structured 10-session programme for parent management in addition to their usual treatment, or to
treatment as usual.
Parent training consisted of 10 sessions in which skills were taught through the use of modelling, role play
and corrective feedback. Training aimed to improve parental competence in dealing with their child’s
behavioural problems, increase caregivers’ understanding of the origins of non-compliant and defiant
behaviour, improve the child’s compliance with parental instructions and decrease family conflict. Core
skills that were taught included providing positive reinforcement for appropriate behaviour, communicating
directions effectively and being consistent with consequences for disruptive behaviour, as well as
techniques of positive attending, selective ignoring, token economies and timeout. Assignments to
implement skills at home were given after each session.
Treatment as usual was maintained for children in both groups, in which they continued to be treated
according to usual practice, commonly including patient education, clinical monitoring, medication
management and school consultations as needed. Study participants were also allowed to receive other
community clinical services, such as child individual psychotherapy and school-based mental health services,
but were asked not to initiate new treatments, or stop existing treatments, during the course of the study.
Risk of bias
The method for randomisation and the presence of allocation concealment was unclear. The control group
(treatment as usual) was not considered to be suitable as it did not include elements of the intervention
not specific to parent training (e.g. time spent in counselling, attention given, etc.) and was likely to have
caused aspects of performance bias. Participants and providers could not be blinded to treatment
allocation and although this could not be avoided, the further risk of performance bias from the
actions/perceptions of participants or providers is unclear. It is unclear whether or not outcome assessors
of all measures were blind to treatment allocation (it is only stated that assessment of CGI-I was blinded).
Of 24 randomised children, 23 completed the study and, although data analysis was of available cases, the
risk of attrition bias was considered to be low. Overall, largely due to the unsuitability of the control group
and unclear blinded outcome assessment, this study was considered to have an unclear risk of bias.
Clinical evidence for parent training versus treatment as usual
Tics Changes in tics were assessed with the YGTSS total tic score. There were similar changes from
baseline in total tic score for parent training, compared with treatment as usual (SMD 0.29, 95% CI –0.53
to 1.12; n= 23) (Figure 207).
Impairment No results for patient impairment were reported for this study but the family impact of the
tic disorder was assessed using the Parenting Stress Index-Short Form. There were similar changes in
parenting stress scores for parent training compared with treatment as usual (SMD –0.12, 95% CI –0.94
to 0.70; n= 23) (Figure 208).
Psychological well-being No relevant studies reported this outcome.
Overall clinical outcome Overall clinical outcome (based on improvements in all types of behaviour and
not specific to improvements in TS) was assessed using the CGI-I scale. A greater number of children were
CGI much or very much improved following parent training compared with treatment as usual (RR 0.44,
95% CI 0.19 to 0.99; n= 23) (Figure 209) (the RR presented here is the RR of not being much or very
much improved).
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FIGURE 207 Standardised change from baseline in YGTSS total tic score for parent training compared with treatment as usual. IV, independent variable; SE; standard error;
TAU, treatment as usual.
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FIGURE 208 Standardised change from baseline in Parenting Stress Index for parent training compared with treatment as usual. IV, independent variable; SE; standard error;
TAU, treatment as usual.
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FIGURE 209 Proportion of children assessed as much or very much improved on the CGI-I scale for parent training compared with treatment as usual (the RR presented here is
the RR of not being much or very much improved). M–H, Mantel–Haenszel; ROB, risk of bias.
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Long-term outcome No relevant studies reported long-term outcomes.
Safety No relevant studies reported this outcome.
Clinical evidence summary for parent training
One study of 23 children164 provided very low-quality evidence (see Appendix 4, Table 55) for the use of
parent training compared with treatment as usual. There was no clear difference in overall tic/impairment
outcome, but parent training improved overall clinical outcome. The aim of this intervention primarily
seems to have been to address behavioural issues and overall clinical outcome related to changes in
behaviour as well as TS symptoms.
Conclusion
Although parent training may improve general behavioural outcomes, there is no clear evidence that
parent training is an effective treatment for tics in children and young people with TS.
Overall conclusions from behavioural intervention trials
There is clear evidence that HRT/CBIT produces improvements in tics that may be clinically meaningful.
Shorter intervention than the standard 10-session CBIT course may be effective but the optimum length of
treatment is currently unclear. There is some evidence that delivering HRT/CBIT via video consultation
(telemedicine) may be as effective as face-to-face therapy; however, further research is required before
firm conclusions can be drawn. There is no evidence that the effects of HRT/CBIT are moderated by tic
severity. However, there remain important gaps in the evidence concerning the benefits of behavioural
interventions in the presence of comorbid conditions and the effects of combining behavioural and drug
interventions for tic disorders. There is little evidence for the effect of behavioural interventions on QoL and
longer-term outcomes.
There are no RCTs of negative massed practice or ERP compared with control interventions. However,
head-to-head comparisons suggest that HRT is a more effective intervention than negative practice, while
HRT and ERP may be equally effective interventions for tics.
Currently, there is no clear evidence to suggest that relaxation therapy in isolation is an effective treatment
for tics. Anger control training may be a useful intervention for young people with tics and comorbid
disruptive behaviour and behaviour problems may be improved by parent training, although there is no
evidence that parent training is an effective treatment for tics.
Overall, the quality of evidence for behavioural interventions other than HRT/CBIT is low and, therefore,
conclusions drawn from this evidence must be treated with caution. In summary, future research will
need to consider how behavioural interventions are best combined with medication, the potential for
alternatives to face-to-face delivery of therapy and whether or not the effects of behavioural interventions
are sustained over time.
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Physical interventions
Introduction
A number of physical interventions have been used to treat TS, including DBS, rTMS, intravenous (i.v.)
immunoglobulin, botulinum toxin and acupuncture.
Deep brain stimulation
Deep brain stimulation is an invasive procedure that has been used to treat movement disorders such as
Parkinson’s disease, essential tremor and dystonia.176 It has also, more recently, been used to treat
psychiatric disorders such as resistant depression and OCD.177 DBS aims to correct disorders by sending
electrical impulses to the brain to modulate brain activity in specific regions. Surgery is performed to make
a small hole in the skull through which an electrode is positioned on the brain using imaging techniques,
stereotactic atlases and microelectrode recordings.178 A lead connects the electrode to a pulse generator
inserted under the skin in the chest or abdomen. The generator transmits tiny electric pulses to the
electrode resulting in stimulation of the surrounding brain. This stimulation interrupts the brain signals that
are thought to be responsible for the unwanted behaviour. The generator is programmed by a transdermal
unit that can be adjusted to vary settings and optimise therapy.178
Deep brain stimulation has been applied for the treatment of TS in place of ablative neurosurgery. It was
first used in 1997179 and it has been estimated that around 100 DBS operations have been conducted to
date.180 DBS has predominantly been performed in adults – the youngest patients treated for TS being
16 years of age.181 DBS has been applied to different areas of the basal ganglia and nearby structures, but
the optimum target has been a source of controversy. It appears that, although many different targets may
be used,180 different patients may benefit from stimulation of different areas of the brain.181 There is little
reported on adverse effects177 but surgery-associated morbidity (e.g. haemorrhage, infection and fracture)
for all indications has been estimated at 3–4% of patients.178 There is little information on other adverse
effects affecting cognition and emotional well-being and the long-term impacts are currently unknown.
Current guidelines recommend DBS for use in patients with:
l chronic and severe TS (YGTSS total tic score of > 35)
l severe functional impairment
l previous failed treatment with conventional TS medications and previous consideration/treatment with
behavioural therapy
l stable, optimised, treatment of comorbidities
l no medical, physical or social contraindications for DBS.159,177,182,183
Although DBS has been performed in TS patients < 18 years of age,181 TS guidelines only recommend its
use in adults. There is some variation in the lowest recommended age for DBS; patients > 25 years,182
> 20 years177 and > 18 years.183
Repetitive transcranial magnetic stimulation
Transcranial magnetic stimulation is a non-invasive method of brain stimulation in which an electric coil is
used to induce a magnetic field over the scalp. This induces circular electrical (eddy) currents in the brain
that in turn cause stimulation of neurons and muscle activity.184 Repeated stimulation with short bursts
of high-frequency stimulation has been shown to be effective in inducing long-term changes in the
excitability of synapses of the motor system in animal studies and rTMS has been applied for the treatment
of movement disorders in humans.184 Very high intensity rTMS can induce seizures and guidelines
recommend limits on the maximum stimulation intensity.184 The intensity of stimulation is often determined
relative to a person’s resting motor threshold (minimum intensity needed to cause a response in the
target muscle)184 reducing intensity settings to safe limits. The use of rTMS has mainly been focused on
application to Parkinson’s disease but it has also been used for dystonia and TS.184
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Repetitive transcranial magnetic stimulation is considered to be safe159,184 and suitable for use in children.185
Current guidelines do not recommend the use of rTMS for treatment of children with TS but only for use
in the context of research studies.159
Intravenous immunoglobulin
Intravenous immunoglobulin been proposed for the treatment of children with PANDAS. For this
population, where infection is believed to trigger an autoimmune reaction that precedes the onset of
symptoms, i.v. immunoglobulin may be administered to remove the infection with the aim of subsequently
reducing TS-like or OCD-like symptoms. It has been proposed that infection may be implicated more widely
in childhood-onset TS and OCD186 and intervention with immune modulating agents in a more general
tic disorder/OCD population may be effective.187 Owing to the risks associated with treatment, this
approach is not currently recommended and its use is limited to children with associated evidence of severe
encephalopathy or evidence of immune mediated disorder, such as positive antineuronal antibodies.188
Botulinum toxin
Botulinum toxin (Botox®, Allergan) is an agent produced by the bacteria Clostridium botulinum. It has the
ability to impede nerve function, resulting in reduced contraction of muscle fibres189 and has been used to
induce temporary muscle weakness for the treatment of movement disorders.190 Injections of botulinum
toxin have been used to treat motor tics in people with TS, particularly those with a singular, problematic
tic, or tics in a singular muscle group.190
Botulinum toxin has been considered reasonably safe but risks may be associated with errors in dosing or
injection site189 and injection into some areas may be particularly vulnerable (e.g. laryngeal and soft-palette
botulinum toxin can lead to complications in swallowing). It is considered to be effective for the treatment of
some movement disorders and has been recommended as a possible treatment for tics;191,192 however, recent
TS guidelines give no recommendations on its use.159,183
Acupuncture
Acupuncture is an ancient form of treatment that originated in China. Very thin metal needles are inserted
into specific points on the surface of the body with the aim of improving health and well-being.193 There
is no consensus on the proposed mechanism of action. Although some propose biological mechanisms,
Chinese tradition claims a non-biological role, in which acupuncture replenishes a person’s vital essence
by restoration of the balance between Yin and Yang.193 Acupuncture is used to treat a wide variety of
physical and mental conditions; however, acupuncture was not assessed for recommendation in recent
TS guidelines.159,183
Included studies
The search obtained nine RCTs of physical treatments; one in children and eight studies in adults or mixed
adult and child populations that were considered as supporting evidence. The types of studies are
shown below:
l DBS compared with sham therapy (three adult studies)194–196
l rTMS compared with sham therapy (three adult studies)197–199
l i.v. immunoglobulin compared with i.v. saline (one mixed study)187
l botulinum toxin compared with placebo (one mixed study)200
l acupuncture and Chinese herbs compared with haloperidol and artane (one child study).201
In separate sections below, studies for each intervention are presented.
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Deep brain stimulation
Study characteristics
No studies of DBS in children were identified. Three studies of DBS in adults were obtained and these are
presented as supporting evidence (see Appendix 3, Table 11).194–196 Participants included in these studies
had severe TS with typical YGTSS total tic scores of around 40 and the majority were on medication at the
time of treatment. All these studies were randomised controlled crossover trials, where participants
received both DBS and sham (control) treatments and the order of treatments was randomised.
In a 3-month study,194 participants underwent two study phases: DBS of the centromedian nucleus-substantia
periventricularis-nucleus ventro-oralis internus crosspoint in the thalamus compared with sham treatment.
In a 2-month study,195 participants underwent four study phases in a randomised crossover (n of one study)
design: (i) DBS treatment with thalamic stimulation; (ii) DBS treatment with pallidal stimulation; (iii) DBS
treatment with thalamic plus pallidal stimulation; and (iv) sham treatment. Each study phase was compared
with YGTSS pre-operative assessment. In a 4-week randomised crossover double-bind study,196 participants
underwent four study phases lasting 1 week each: (i) DBS of the thalamus on the left side; (ii) DBS of the
thalamus on the right side; (iii) DBS of the thalamus on the right plus left sides; (iv) sham treatment. Each study
phase was compared with YGTSS pre-operative assessment.
Risk of bias
None of the studies reported the method of randomisation or had clear evidence of allocation
concealment. In one study, owing to ethical constraints, participants appear to have been allowed to
switch their order of treatments.194 This resulted in five out of six participants undergoing the DBS before
the sham treatment and only one out of six undergoing sham before DBS. The sham treatment in all
studies was considered to be an appropriate control group.
Only one of the studies appeared to have conducted the study with both the participants and providers
blind to the order of DBS and sham treatments.196 In one study, participants, but not providers, appear to
have been blinded195 and, in the final study194 it appears that neither participants nor providers were blind
to intervention order. In one of the studies in which DBS and sham treatments were each given for a 1-week
period,196 there was no washout between treatments and the risk of bias owing to cross-intervention
contamination was considered high. In the other two studies, the intervention periods were reasonably long
(2 months195 and 3 months194) and although there was no washout period between treatments, there may
have been enough time for effects from the previous period to washout by the end of the next period. For
these studies, the risk of bias owing to contamination was considered unclear.
All studies used blinded outcome assessment. The impact of dropout from some studies was unclear. In
the 3-month intervention study,194 a high proportion of participants did not undergo treatment for the full
treatment period. Data from the last observation were carried forward for the analysis but the risk of bias
from this assumption is unclear. In the 2-month study,195 only data from participants undergoing both DBS
and sham treatments were presented and it was unclear whether or not there were any dropouts. In the
1-week study,196 it is reported that all participants completed both treatments and there were no dropouts
during the crossover intervention period.
Overall, one of the studies195 was considered to have an unclear risk of bias owing to the possibility of
cross-treatment contamination. The remaining two studies were considered to be at high risk of bias
owing to imbalance of allocation groups194 and a high risk of cross-treatment contamination.196
Clinical evidence for deep brain stimulation
Tics
All three studies compared DBS with sham treatment and measured tic severity with the YGTSS total tic
scale. However, meta-analysis was not possible and very small sample sizes (≤ 6 participants) in these
studies makes any comparison between groups unreliable (all comparisons were inconclusive).
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Safety
In these studies, safety outcomes are largely reported uncontrolled. That is, adverse effects are discussed in
relation to treatments but no distinction is made between events owing to intervention compared with
sham phases. Most adverse effects appear to be owing to the associated surgery, rather than the action
of DBS.
In the study for which various DBS treatments were given over 1-week periods,196 one participant had an
episode of acute psychosis at the end of the crossover phase but this was attributed to life stress and a
personal and family history of psychiatric illness. No other adverse effects were reported in the study.
In the study for which participants were treated with 2 months of different DBS protocols,195 thalamic
stimulation caused transient (few minutes) ‘cheiro-oral or arm parenthesis’ and pallidal stimulation caused
lethargy for 3–4 days (number of participants undergoing adverse effects not reported). With increasing
pallidal stimulation intensity, two participants reported having nausea and vertigo and one patient reported
having anxiety. In addition, one patient reported a libido decrease when under thalamic stimulation.
In the study in which participants underwent 3 months of DBS and sham treatment, three people had
adverse effects that were related to their surgery.194 One participant had a small parenchymal haemorrhage
deep at the tip of the left electrode that resulted in vertical gaze palsy. This resolved after 6 months but
persistent subjective slowing of vertical fixation and pursuit on stimulation remained and led to the patient
choosing to have the stimulator switched off. Another participant developed a staphylococcus aureus
infection in the infraclavicular region. Another participant had symptoms including lethargy, binge eating,
dysarthria, apathy, gait disturbances and frequent falls but switching off the simulator did not affect these
symptoms. One year after surgery, all participants reported substantial restriction in their daily activities
because of a lack of energy. Three years after surgery, one patient developed severe multidirectional
nystagmus when the stimulation was turned off. When interviewed, all participants reported visual
disturbances that varied from blurred vision to fixation problems but no objective abnormalities could be
detected by an optometrist and neuro-ophthalmologist. Participants were tested for vestibular and
oculomotor function and all showed no signs of central pathology except for one patient who showed
impaired vertical gaze with normal vertical vestibular ocular reflexes, indicating a supranuclear deficit.
Clinical evidence summary for deep brain stimulation
Three small crossover RCTs (n= 3, 5 and 6)194–196 of DBS compared with sham treatment in adults with
severe TS provided very low-quality evidence that could not be meaningfully interpreted.
Conclusion
It is unknown if DBS is an effective treatment in highly selected adults with severe TS. There is uncertainty
regarding the most effective neuroanatomical targets for DBS. Various adverse effects have been reported,
generally as a consequence of surgery rather than brain stimulation. There is no evidence available
regarding the clinical effectiveness and safety of DBS in children and young people with TS.
Repetitive transcranial magnetic stimulation
Study characteristics
No studies of rTMS in children were identified. Three studies of rTMS in adults were obtained and these
are presented as supporting evidence (see Appendix 3, Table 11).197–199 All of these studies were crossover
trials in which participants received both rTMS and sham treatment and the order of treatments was
randomised. Participants included in these studies had moderate-to-severe TS. In one study,197 baseline
YGTSS total tic score was 23 and in the other two studies, baseline YGTSS global scores (baseline total tic
score not reported) were 70198 and 57.199 Most participants were on medication at the time of treatment.
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In one study,198 participants underwent five treatment phases on five consecutive days with no washout
between treatments: (i) rTMS of the pre-frontal cortex at high frequency; (ii) rTMS of the pre-frontal cortex
at at low frequency; (iii) rTMS of the motor cortex at high frequency; (iv) rTMS of the motor cortex at low
frequency; (v) sham treatment. All phases were compared with pre-treatment baseline. In another study,199
participants underwent treatment on two consecutive days for each of three treatment phases with a
2-week washout period between phases: (i) rTMS of the motor cortex; (ii) rTMS of the pre-motor cortex;
(iii) sham treatment. All phases were compared with pre-treatment baseline. In another study,197
participants underwent treatment on two consecutive days for each of three treatment phases with a
4-week washout period between phases: (i) rTMS of the pre-motor cortex on the left-hand side; (ii) rTMS
of the pre-motor cortex on the left plus right-hand side; (iii) sham treatment. All phases were compared
with pre-treatment baseline.
Risk of bias
None of the studies reported the method of randomisation or had clear evidence of allocation
concealment. The sham treatment in all studies was considered to be an appropriate control group. In all
of the studies, the participants but not the providers appeared to be blinded to the order of rTMS and
sham treatments. Two of the studies used washout periods between treatments197,199 but one study did
not.198 In one study, the outcome assessor was blinded to treatment order.198 Another study also had
blinded outcome assessment as outcomes were patient-rated and participants were blind to treatment
order.199 In the other study, outcomes were measured by investigators but the presence of blinded
outcome assessment was not reported.197 For all studies, it was unclear whether or not there was dropout
from the studies because only data from participants undergoing both rTMS and sham treatments
were presented.
Overall, one of the studies199 was considered to have an unclear risk of bias from contamination and the
remaining two studies were considered to be at high risk of bias owing to contamination from inadequate
washout198 and unclear risk of contamination and unclear blinded outcome assessment.197
Clinical evidence for repetitive transcranial magnetic stimulation
Tics
Two studies used the YGTSS and reported data for results for rTMS applied at different treatment
sites.197,198 However, meta-analysis was not possible and very small sample sizes (≤ 16 participants) in these
studies makes any comparison between groups unreliable (all comparisons were inconclusive).
Safety
In the rTMS study with five consecutive days of successive treatments, there were no significant differences
in ratings for pain and discomfort between treatments.198 Three headaches were reported (study does not
report under which rTMS/sham treatment they occurred). In one participant, high frequency motor cortex
stimulation resulted in an increase in excitability that was manifested by a progressive increase in evoked
twitch and motor evoked potential amplitude. In this study, there is no comparative (rTMS compared with
sham treatment) safety analysis but there was no significant change in the AIMS from baseline (mean
13.9, SD 8.8) to the end of the treatment period (mean 9.6, SD 6.8; p= 0.11). The mean motor threshold
in participants did not significantly change (p= 0.12) from baseline (51.9, SD 11.4) to the end of the
treatment period (50.6, SD 10.3).
The study that administered each treatment for two 20-minute sessions on two consecutive days (with a
2-week washout between treatments),199 reported that rTMS was well tolerated. One participant reported
a mild headache following pre-motor rTMS and two participants reported excessive tiredness after both
pre-motor and motor rTMS that lasted for about 1 day. As with the first study, the active motor threshold
did not significantly change after any of the rTMS treatments.
In the study for which rTMS treatments were administered on two consecutive days (with a 4-week
washout between treatments),197 findings related to adverse effects were not reported.
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Clinical evidence summary for repetitive transcranial magnetic stimulation
Three small crossover RCTs (n= 5, 8 and 16)197–199 of rTMS at different treatment sites compared with
sham treatment in adults with severe TS provided very low-quality evidence that could not be
meaningfully interpreted.
Conclusion
It is unknown if rTMS is an effective treatment for tics in adults with severe TS. No evidence is available for
the use of rTMS in children and young people with TS.
Intravenous immunoglobulin versus placebo
Study characteristics
One parallel trial investigated the efficacy of i.v. immunoglobulin in 29 children and adults with TS (90%)
or CTD (10%) (see Appendix 3, Table 11).187 The study used i.v. albumin as the control group and
measured outcome at various time points from 2 to 14 weeks post intervention.
Risk of bias
The method of randomisation was not reported and there was no statement about allocation
concealment. The study used a suitable control group (i.v. albumin) that allowed participants and providers
to be blinded to treatment allocation and there was blinding of outcome assessors. Only data from
participants completing treatment were analysed but the dropout rate was low (3%). Overall, the study
was considered to have a low risk of bias.
Clinical evidence for intravenous immunoglobulin
Tics
The YGTSS total tic scale was used to assess tic severity at 2, 4, 6, 10 and 14 weeks.187 There was variation
in differences in change from baseline tic score for i.v. immunoglobulin compared with placebo at different
time points (Figure 210). At 14 weeks, there was no conclusive difference in change from baseline tic
score for i.v. immunoglobulin compared with placebo (SMD –0.51, 95% CI –1.25 to 0.23; n= 29).
Impairment
No relevant studies reported TS-related impairment.
Psychological well-being
No relevant studies reported this outcome.
Overall clinical outcome
This study reported the proportion of participants much or very much improved on the CGI-I scale. The
proportion of participants who were CGI much or very much improved for i.v. immunoglobulin compared
with placebo varied at the different time points assessed (Figure 211). At 14 weeks post treatment, there
was no conclusive difference in the proportion of participants who were much or very much improved for
i.v. immunoglobulin compared with placebo (RR 0.77, 95% CI 0.54 to 1.09; n= 29) (the RR presented
here is the RR of not being much or very much improved).
Long-term outcome
No relevant studies reported long-term outcomes.
Safety
This study compared the number of participants with adverse effects for i.v. immunoglobulin compared
with i.v. saline. There was an increased rate of adverse effects for participants undergoing i.v.
immunoglobulin compared with i.v. saline (RR 3.48, 95% CI 1.49 to 8.16; n= 29) (Figure 212). Adverse
effects included headache (n= 11), nausea (n= 7), chills (n= 6), fever (n= 5), vomiting (n= 4) and
dizziness (n= 3).
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Clinical evidence summary for intravenous immunoglobulin
One parallel RCT (n= 29) in adults and children with tic disorders187 provided low-quality evidence
(see Appendix 4, Table 56) for the efficacy of i.v. immunoglobulin. i.v. immunoglobulin was ineffective for
the treatment of tic disorders and overall clinical outcome and was associated with an increased risk of
adverse effects.
Conclusion
There is no clear evidence that i.v. immunoglobulin is an effective treatment for tics in children or adults
with TS.
Botulinum toxin compared with placebo
Study characteristics
One crossover study compared the efficacy of botulinum toxin with placebo in a mixed population of
18 adults and children (age range 15–55 years, median 31.5 years) (see Appendix 3, Table 11).200
Participants had TS (78%) or CTD (22%) of moderate severity (median YGTSS motor tic score 9, range
≈5–14). Participants were injected with botulinum toxin and placebo (substance not reported) in the area
of the body affected by motor tics in a randomised order. Outcome was assessed after 2 weeks and
there was an 8-week (or more) washout period between treatments.
Risk of bias
An adequate method of sequence generation was reported and there appears to have been allocation
concealment of the randomisation code. The nature of the placebo was unclear but, as for the
intervention, it was given as an i.v. injection and was, therefore, considered to be a suitable control.
Participants, providers and outcome assessors were blinded to treatment order but, owing to the paralyses
associated with botulinum toxin injections, maintenance of blinding appears unlikely. Although analysis
was done only of participants completing the study, there was a low rate of dropout and bias from
attrition may have been low. The primary outcome measure was reduction in treated tics. A motor tic for
each patient was selected for treatment and botulinum/placebo injections were made into the relevant
area of the body. The use of this outcome makes overall assessment of the efficacy of botulinum toxin on
all tics difficult. In some cases, the effect on other tics was also reported but this was not done consistently
across outcomes and the study was judged to be at risk of selective reporting bias. The overall risk of bias
for this study was considered to be unclear owing to unclear patient, provider and outcome assessor
blinding and possible selective outcome reporting bias.
Clinical evidence for botulinum toxin
Findings for this study are presented as net changes from baseline (baseline measured just before the
intervention or control treatment). Because net change scores only are presented, the data for this study
are not analysed as for other cross-sectional studies in this review (comparison of end points) but data are
reported for net changes from pre-treatment to post treatment.
Tics
Measures of YGTSS motor tic score were reported, but only for treated tics. Three aspects of the YGTSS
motor tic scale were reported (Figure 213). The data were inconclusive for reductions from baseline for
botulinum toxin compared with placebo for motor tic frequency (SMD –0.14, 95% CI –0.80 to 0.51;
n= 18) and interference (SMD –0.05, 95% CI –0.70 to 0.61; n= 18) but botulinum toxin was associated
with greater reduction in the intensity of the treated tic compared with placebo (SMD –0.91, 95% CI
–1.59 to –0.22; n= 18).
Overall tic score (both treated and untreated tics) were reported for the Shapiro TSSS. Results were
inconclusive for reductions from baseline in overall tic score for botulinum toxin compared with placebo
(SMD 0.02, 95% CI –0.63 to 0.67; n= 18) (Figure 214).
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Impairment
No relevant studies reported TS-related impairment.
Psychological well-being
No relevant studies reported this outcome.
Overall clinical outcome
Participants assessed their own outcome as better, unchanged or worse on the Patient Global Impressions
of Change. There was no conclusive difference in the proportion of participants feeling better (RR 0.82,
95% CI 0.63, 1.08; n= 18) (the RR presented here is the RR of not feeling better), unchanged or worse for
botulinum toxin compared with placebo (Figure 215).
Long-term outcome
No relevant studies reported long-term outcomes.
Safety
Pain score for the treated tic area (scale not reported) was greater for botulinum toxin compared with
placebo but the effect was inconclusive (SMD 0.52, 95% CI –0.15 to 1.18; n= 18) (Figure 216).
There was no conclusive difference for other adverse effects (Figure 217), but there was increased
weakness in the injected muscle (RR 6.00, 95% CI 1.56 to 23.07; n= 18) for botulinum toxin compared
with placebo.
Clinical evidence summary for botulinum toxin
One crossover RCT (n= 18) in children and adults with tic disorders200 provided very low-quality evidence
(see Appendix 4, Table 57) for the efficacy of botulinum toxin. When the effect on all tics was considered
(not just treated tics), there was no improvement for botulinum toxin compared with placebo. For the
treated motor tic, there was no difference in YGTSS motor tic frequency or interference but there was a
large improvement in tic intensity and there was a tendency to greater patient-reported improvement.
Botulinum toxin was associated with increased rates of adverse effects compared with placebo, particularly
an increased likelihood of muscle weakness in the injected area and there was a tendency towards
increased pain score.
Conclusion
Botulinum toxin may decrease the intensity of tics in the local area treated but there is no evidence of
reduced tic frequency or improvements in untreated tics. Adverse effects, including reports of local muscle
weakness and pain, may reduce the acceptability of this intervention.
Acupuncture and Chinese herbs
Study characteristics
One randomised parallel study in 60 children (4–20 years) with TS investigated the combined use of
acupuncture and Chinese herbs compared with a combination of haloperidol and artane (trihexyphenidyl
hydrochloride) (see Appendix 3, Table 11).201 Children were randomised to receive 20 half-hour sessions
of acupuncture and Chinese herbs (dosage not reported) or to haloperidol at a maximum dose of
1.5–8.0mg/day with artane of the same dosage given to alleviate adverse effects (length of intervention
period not reported).
Risk of bias
The study reports no methods for random sequence generation or allocation concealment and there is no
statement about blinding of participants, providers or outcome assessors. It is unclear whether or not the
control group, haloperidol and artane, is suitable. Some participants in the study were young children
(minimum age 4 years) and maximum doses of 1.5–8.0mg/day were used (starting dose for 4 year olds
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Study or subgroup
Subtotal (95% Cl)
Weight Overall ROB
Marras 2001200
Subtotal (95% Cl)
Marras 2001200
Marras 2001200
Subtotal (95% Cl)
Events
1
1Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.40 (p = 0.16)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.02 (p = 0.31)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.00 (p = 1.00)
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
1.00 (0.79 to 1.26)
1.00 (0.79 to 1.26)
1.60 (0.65 to 3.96)
1.60 (0.65 to 3.96)
0.82 (0.63 to 1.08)
0.82 (0.63 to 1.08)
Unclear risk
Unclear risk
Unclear risk
Proportion felt worse
Proportion felt unchanged
Proportion felt better
2
2
2
2
18
18
18
18
18
18
18
18
18
18
18
18
10
10
4
4
TotalTotal Events
PlaceboBotulinum toxin
13
13
RR (non-event)
M–H, random, 95% CI
RR (non-event)
M–H, random, 95% CI
Favours botulinum toxin Favours placebo
5210.50.2
FIGURE 215 Proportion of patients feeling better, unchanged or worse for botulinum toxin compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
Study or subgroup SESMD
SMD
IV, random, 95% Cl
SMD
IV, random, 95% ClWeight
Total (95% Cl)
100.0%
100.0%
0.52 (–0.15 to 1.18)
0.52 (–0.15 to 1.18)
–2 –1 0 1 2
Favours placeboFavours botulinum
Unclear risk
Overall ROB
0.517 0.339Marras 2001200
Heterogeneity: not applicable
Test for overall effect: z = 1.53 (p = 0.13)
FIGURE 216 Standardised pain score for treated tics for botulinum toxin compared with placebo. IV, independent variable; ROB, risk of bias; SE, standard error.
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6.00 (1.56 to 23.07)
6.00 (1.56 to 23.07)Unclear risk
Unclear risk
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Unclear risk
Overall ROB
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Neck discomfort
Blurry vision
Swallowing difficulty
Total events
Total events
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Total events
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M–H, fixed, 95% CI
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Weight
Botulinum toxin
0.002 0.1 1 10 500
Favours botulinum Favours placebo
FIGURE 217 Proportion of patients experiencing adverse events for botulinum toxin compared with placebo injections. M–H, Mantel–Haenszel; ROB, risk of bias. (continued )
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FIGURE 217 Proportion of patients experiencing adverse events for botulinum toxin compared with placebo injections. M–H, Mantel–Haenszel; ROB, risk of bias.
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0.5 mg/day, for 5 year olds 1mg twice a day). Artane of the same dosage was given to decrease adverse
effects but it is unclear if this type of treatment strategy would be beneficial and if this control group
provides a reasonable group for comparison. Attrition from the study is not reported and it is unclear
whether or not there were any dropouts. For outcome measurements, only the YGTSS score is reported
and it is unclear whether or not this was selectively reported in favour of other measurements if they were
made. Overall, this study was considered to be at high risk of bias.
Clinical evidence for acupuncture and Chinese herbs
Tics
Within-person changes in tics/impairment were presented as the proportion of children with ≥ 30% and
≥ 60% reductions from baseline in YGTSS global score. There was a greater proportion of children
showing ≥ 60% reductions from baseline for acupuncture and Chinese herbs compared with haloperidol
and artane (RR 0.62, 95% CI 0.39 to 0.99; n= 60) (Figure 218) (RRs are for relative risk of not achieving
30 or 60% reductions from baseline) but no conclusive difference in the proportion of children showing
≥ 30% reductions (RR 0.29, 95% CI 0.06 to 1.26; n= 60).
Impairment
Impairment score was reported as part of the YGTSS global score as described under Tics above.
Psychological well-being
No relevant studies reported this outcome.
Overall clinical outcome
No relevant studies reported this outcome.
Long-term outcome
No relevant studies reported long-term outcomes.
Safety
No relevant studies reported this outcome.
Clinical evidence summary for acupuncture and Chinese herbs
One parallel RCT (n= 60) in children with TS201 provided very low-quality evidence (see Appendix 4, Table 58)
for the efficacy of a combination of acupuncture and Chinese herbs compared with a combination of
haloperidol and artane (described as western medicine). The study showed some evidence of a benefit
of acupuncture and Chinese herbs compared with haloperidol and artane for the treatment of tics.
Conclusion
Acupuncture may be an effective treatment for tics in children and young people with TS. However, the
limitations in the quality of the available evidence and lack of information on adverse effects do not allow
firm conclusions to be drawn.
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Study or subgroup
Acupuncture plus Chinese herbs
Total Weight
Subtotal (95% Cl)
Subtotal (95% Cl)
Heterogeneity: not applicable
Heterogeneity: not applicable
Test for overall effect: z = 1.99 (p = 0.05)
Test for overall effect: z = 1.65 (p = 0.10)
100.0%
100.0%
100.0%
100.0%
High risk
High risk
Overall ROB
Proportion with > 60% reduction in YGTSS global score
Proportion with > 30% reduction in YGTSS global score
0.62 (0.39 to 0.99)
0.29 (0.06 to 1.26)
0.29 (0.06 to 1.26)
0.62 (0.39 to 0.99)
Haloperidol plus artane
30 9
9
30
17
17
28
28
30
30
30
30
30
30
23
23
EventsEvents Total
Chi 2003201
Chi 2003201
Total events
Total events
RR (non-event)
M–H, fixed, 95% Cl
RR (non-event)
M–H, fixed, 95% Cl
0.02 0.1 1 10 50
Acupunture plus herbs Haloperiodol plus artane
FIGURE 218 Proportion of children with ≥ 30% and ≥ 60% reductions from baseline in YGTSS global score for acupuncture and Chinese herbs compared with haloperidol and
artane (the RR presented here is the RR of not achieving 30 or 60% reductions from baseline). M–H, Mantel–Haenszel; ROB, risk of bias.
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Overall conclusions from physical intervention trials
It is unknown if DBS is a useful treatment for selected adults with severe TS. Future parallel trials may
provide better evidence on which to base judgements. Studies in children have yet to be conducted, but
the invasive nature of treatment is likely to make DBS an unacceptable intervention for children and young
people with TS except in very exceptional circumstances.
Currently, there is no clear evidence that rTMS is an effective treatment for tics and the predominance of
crossover trials with the potential for carry-over effects makes it difficult to drawn any firm conclusions.
Future parallel trials may provide better evidence on which to base judgements. Although rTMS is a less
invasive a procedure than DBS, there remains uncertainty over its safety and suitability for use in children
and young people.
Overall, there is no clear evidence that i.v. immunoglobulin is an effective treatment for tics in children and
young people with TS.
Botulinum toxin may reduce intensity of treated tics; however, the low quality of evidence makes it difficult
to draw firm conclusions regarding benefits. Furthermore, reports of adverse effects mean that botulinum
toxin may not be a suitable treatment for tics in children and young people with TS.
The evidence of benefit for acupuncture and Chinese herbs is of extremely low quality and, therefore,
there remains uncertainty about the effectiveness of this intervention.
In summary, there is currently no evidence to suggest that the physical interventions reviewed (DBS, rTMS,
i.v. immunoglobulin, botulinum toxin and acupuncture) are sufficiently effective and safe to be considered
as treatments for tics in children and young people with TS.
Paediatric Autoimmune Neuropsychiatric Disorders Associated
with Streptococcal infection
Introduction
Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infection describes
disorders that have been identified in pre-pubescent children who are thought to have developed OCD, a
tic disorder, or both, that is associated with a group A streptococcal infection. PANDAS has been defined
by temporal association (infection precedes symptoms), dramatic symptom onset, infection-related
exacerbations and concurrent neurological abnormalities during exacerbations.202 However, the concept of
PANDAS remains controversial.203
The PANDAS population does not fall under the population set out in the review protocol (children and
young people with TS or CTD) as some PANDAS-defined children do not experience tics (only OCD
symptoms). The proposed cause and aetiology of illness is also different from that of childhood tic
disorders and this population would not necessarily be included in this review. However, the question of
whether or not supposed PANDAS can be successfully treated was considered to be a clinically relevant
and important question and these studies have therefore been included in the review. Their findings are
not applicable to the general child tic disorder population and vice versa.
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Included studies
The studies identified use different intervention strategies but have the same underlying principle of
intervention: treatment of streptococcal infection and or the removal of streptococcus A immunoglobulin
that is hypothesised to bring about PANDAS symptoms. Three studies in children were identified:
l i.v. immunoglobulin compared with i.v. saline (one child study204)
l plasma exchange compared with i.v. saline (one child study204)
l penicillin compared with placebo (one child study)205
l penicillin compared with azithromycin (one child study).206
Intravenous immunoglobulin and plasma exchange versus placebo
Study characteristics
One study investigated the efficacy of i.v. immunoglobulin and plasma exchange in children with PANDAS
(see Appendix 3, Table 12).204 Twenty-nine children defined as having PANDAS [tic disorder, OCD (or both)
onset before puberty, history of sudden onset or episodic course, evidence of association with streptococcal
infection] and with a current severe exacerbation were randomised to i.v. immunoglobulin, plasma
exchange or i.v. saline (placebo). i.v. immunoglobulin was given at 1 g/kg body weight and administered
on two consecutive days. i.v. saline was also administered on two consecutive days with a similar volume
to that as for i.v. immunoglobulin. Children undergoing i.v. immunoglobulin or i.v. saline were given
diphenhydramine and paracetamol to alleviate adverse effects of treatment. Children undergoing plasma
exchange had treatment consisting of five to six procedures conducted over 10–12 days (treatment on
alternative days) with one plasma volume (45ml/kg body weight) exchanged during each procedure.
Children in all treatment arms were followed up at 1 month. After this point, children originally allocated to
the placebo group were started on i.v. saline or plasma exchange and, together with children originally
allocated to those groups, they were followed up at 1 year.
Risk of bias
The method of randomisation was reported but there was no clear evidence of allocation concealment and
groups were markedly different at baseline, with mean tic scores of 6.8 (SD 9.2), 11.0 (SD 9.5) and 21.7
(SD 14.7) for i.v. immunoglobulin, placebo and plasma exchange, respectively. There was a suitable control
group for comparison with i.v. immunoglobulin (i.v. saline) but this was not a suitable control for the
plasma exchange intervention as this has a different mode of administration and, for this treatment arm,
participants and providers could not be blinded to treatment allocation. It was unclear if outcome
assessment was blinded for i.v. immunoglobulin or plasma exchange groups. Both studies analysed only
data from participants who had completed the treatments but the dropout rate was low (3%).
Overall, the study results were considered to be at high risk of bias for i.v. immunoglobulin owing to
imbalances at baseline and unclear blinded outcome assessment and to be at particularly high risk of bias
for plasma exchange owing to baseline imbalances, lack of patient and provider blinding and unclear
blinded outcome assessment.
Clinical evidence for intravenous immunoglobulin and plasma exchange
Tics
The effect of i.v. immunoglobulin and plasma exchange on the severity of tics was measured using the
UTRS.204 For i.v. immunoglobulin, there was the same change from baseline tic score for i.v.
immunoglobulin compared with i.v. saline (SMD 0.00, 95% CI –0.90 to 0.90; n= 19). For plasma
exchange, there was a greater but inconclusive reduction from baseline for plasma exchange compared
with i.v. saline (SMD –0.88, 95% CI –1.81 to 0.05; n= 20) (Figure 219).
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FIGURE 219 Standardised change from baseline TS unified rating scale score for children undergoing i.v. immunoglobulin and plasma exchange compared with control
(i.v. saline). IV, independent variable; ROB, risk of bias.
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Impairment
The study measured changes in impairment using the National Institute for Mental Health (NIMH) global
impairment scale. Compared with those undergoing i.v. saline, there were greater reductions in
impairment score for participants undergoing i.v. immunoglobulin (SMD –1.87, CI –3.00 to –0.75; n= 19)
and plasma exchange (SMD –1.42, 95% CI –2.42 to –0.41; n= 20) (Figure 220).
Emotional well-being
Anxiety Changes in anxiety were measured using the NIMH anxiety scale. Compared with i.v. saline,
there were greater reductions in anxiety score for i.v. immunoglobulin (SMD –1.03, CI –2.00 to –0.05;
n= 19) and plasma exchange (SMD –1.24, 95% CI –2.21 to –0.26; n= 20) (Figure 221).
Depression Changes in depression were reported using the NIMH depression scale. Plasma exchange
showed an improvement in depression score compared with i.v. saline (SMD –1.06, 95% CI –2.00 to –0.11;
n= 20) (Figure 222) but i.v. immunoglobulin was not conclusively different (SMD –0.64, CI –1.57 to 0.29;
n= 19).
Overall clinical outcome
Overall clinical outcome was measured with the CGI scale and results are presented as improvement scores
(1= very much improved, 7= very much worse). CGI-I score was better for i.v. immunoglobulin (SMD –1.86,
95% CI –2.98 to –0.74; n= 19) and plasma exchange (SMD –2.38, 95% CI –3.58 to –1.18; n= 20) than
i.v. saline (Figure 223).
Long-term outcome
Children were followed up at 1 year but, following the controlled trial period, blinding was broken and
children who had received placebo were offered treatment with an intervention. At 1 year, mean scores
were similar to post-treatment levels for the UTRS for i.v. immunoglobulin [5.5 (SD 7.7) and 5.8 (SD 8.7)
for 1 month and 1 year, respectively] and plasma exchange [11.0 (SD 9.2) and 8.9 (SD 9.6) for 1 month
and 1 year, respectively]. The mean CGI-I score was also similar to post-treatment scores for i.v.
immunoglobulin [2.4 (SD 1.1) and 2.3 (SD 1.1) for 1 month and 1 year, respectively] and plasma exchange
[1.9 (SD 1.1) and 1.75 (SD 0.9) for 1 month and 1 year, respectively].
Safety
The numbers of children experiencing adverse effects for the active intervention compared with i.v. saline
were compared. There were higher rates of adverse effects but the difference was not conclusive for
children undergoing i.v. immunoglobulin (RR 3.33, 95% CI 0.89 to 12.51; n= 19) or plasma exchange
(RR 3.50, 95% CI 0.95 to 12.90; n= 20) compared with i.v. saline (Figure 224). Adverse effects in the i.v.
immunoglobulin group included nausea and vomiting (n= 5), mild-to-moderately severe headache (n= 3),
and low-grade fever (n= 4). In the plasma exchange group, adverse effects included pallor, dizziness and
nausea (n= 7), vomiting (n= 2) and anxiousness (n= 3).
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FIGURE 220 Standardised change from baseline NIMH global impairment score for children undergoing i.v. immunoglobulin or plasma exchange compared with control
(i.v. saline). IV, independent variable; ROB, risk of bias.
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FIGURE 221 Standardised change from baseline NIMH anxiety score for children undergoing i.v. immunoglobulin and plasma exchange compared with control (i.v. saline).
IV, independent variable; ROB, risk of bias.
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FIGURE 222 Standardised change from baseline NIMH depression score for children undergoing i.v. immunoglobulin or plasma exchange compared with control (i.v. saline).
IV, independent variable; ROB, risk of bias.
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FIGURE 223 Standardised CGI-I rating for children undergoing i.v. immunoglobulin or plasma exchange compared with control (i.v. saline). IV, independent variable;
ROB, risk of bias.
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FIGURE 224 Proportion of children experiencing adverse events for i.v. immunoglobulin and plasma exchange compared with control (i.v. saline). M–H, Mantel–Haenszel;
ROB, risk of bias.
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Penicillin versus placebo
Study characteristics
One crossover study compared penicillin prophylaxis with placebo in children assessed as having
PANDAS.205 Thirty-seven children were assigned to receive 4 months of penicillin (250mg tablets twice a
day) and 4 months of placebo (tablets twice daily) in a randomised order.
Risk of bias
For this study, no methods of sequence generation or allocation concealment were reported, although
baseline characteristics for children randomised to each intervention order were similar. Participants were
blinded to treatment order but blinding of treatment providers was unclear. There was no statement about
blinding of outcome assessors and the risk of assessment bias is unclear. There was no washout period
between treatments and there may have been some risk of cross-treatment contamination. Analysis was
restricted to children completing the study but there was a low rate of dropout and the risk of attrition
bias may be low. Overall, this study was considered to be at unclear risk of bias owing to the presence of
unclear blinded outcome assessment.
Clinical evidence for penicillin
Tics
Tics were assessed with the YGTSS. There was no conclusive difference in changes in total tic score for
penicillin compared with placebo (SMD –0.26, 95% CI –0.72 to 0.21; n= 37) (Figure 225).
Scores were also similar when motor (SMD –0.14, 95% CI –0.61 to 0.32; n= 37) and vocal (SMD –0.23,
95% CI –0.69 to 0.24; n= 37) tic scores were considered separately (Figures 226 and 227).
Rates of streptococcal infections were not conclusively different for the placebo compared with the
penicillin group (RR 0.70, 95% CI 0.43 to 1.15; n= 37) (Figure 228) as were rates of neuropsychiatric
exacerbations (RR 1.00, 95% CI 0.64 to 1.57; n= 37) (Figure 229).
Impairment
Impairment was measured using the C-GAS. Post-treatment impairment score was inconclusive following
penicillin compared with placebo (SMD –0.20, 95% CI –0.66 to 0.27; n= 37) (Figure 230).
Psychological well-being
Anxiety Anxiety was measured using the NIMH anxiety scale. Anxiety scores favoured penicillin over
placebo (SMD –0.52, 95% CI –0.99 to –0.05; n= 37) (Figure 231).
Depression Depression was measured using the NIMH depression scale. Depression scores favoured
penicillin over placebo (SMD –0.62, 95% CI –1.10 to –0.15; n= 37) (Figure 232).
Overall clinical outcome
Overall clinical outcome was assessed with the CGI-I. CGI-I score was similar for overall global
improvement (SMD –0.07, 95% CI –0.53 to 0.39; n= 37) (Figure 233) and for CGI TS-specific
improvement score (SMD –0.01, 95% CI –0.47 to 0.45; n= 37) for penicillin compared with placebo
(Figure 234).
Long-term outcome
No relevant studies reported long-term outcomes.
Safety
No relevant studies reported this outcome.
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FIGURE 225 Standardised post-treatment YGTSS total tic score for penicillin compared with placebo. IV, independent variable; SE, standard error.
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FIGURE 226 Standardised post-treatment YGTSS motor tic score for penicillin compared with placebo. IV, independent variable; SE, standard error.
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FIGURE 227 Standardised post-treatment YGTSS vocal tic score for penicillin compared with placebo. IV, independent variable; SE, standard error.
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FIGURE 228 Rate of streptococcal infection penicillin compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
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FIGURE 229 Rate of neuropsychiatric exacerbations for penicillin compared with placebo. M–H, Mantel–Haenszel; ROB, risk of bias.
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–0.195
–1 0 1 2
Favours penicillin Favours placebo
FIGURE 230 Standardised post-treatment C-GAS scores for penicillin compared with placebo. IV, independent variable; SE, standard error.
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Study or subgroup
SMD
IV, random, 95% ClSMD
SMD
IV, random, 95% ClWeightSE
Garvey 1999205
Total (95% Cl)
Heterogeneity: not applicable
Test for overall effect: z = 2.18 (p = 0.03)
0.24 100.0%
100.0%
–0.52 (–0.99 to –0.05)
–0.52 (–0.99 to –0.05)
–2
–0.522
–1 0 1 2
Favours penicillin Favours placebo
FIGURE 231 Standardised post-treatment NIMH anxiety scores for penicillin compared with placebo. IV, independent variable; SE, standard error.
Study or subgroup
Garvey 1999205
Total (95% Cl)
Heterogeneity: not applicable
Test for overall effect: z = 2.59 (p = 0.01)
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100.0%
SMD
IV, random, 95% Cl
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IV, random, 95% ClSMD SE Weight
–0.624 0.241 –0.62 (–1.10 to –0.15)
–0.62 (–1.10 to –0.15)
–2 –1 0 1 2
Favours penicillin Favours placebo
FIGURE 232 Standardised post-treatment NIMH depression scores for penicillin compared with placebo. IV, independent variable; SE, standard error.
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Study or subgroup
Garvey 1999205
Total (95% Cl)
Heterogeneity: not applicable
Test for overall effect: z = 0.04 (p = 0.97)
100.0%
100.0%
SMD
IV, random, 95% Cl
SMD
IV, random, 95% ClSMD SE Weight
–0.009 0.236
–0.01 (–0.47 to 0.45)
–0.01 (–0.47 to 0.45)
–2 –1 0 1 2
Favours penicillin Favours placebo
FIGURE 234 Standardised post-treatment CGI-TS improvement score for penicillin compared with placebo. IV, independent variable; SE, standard error.
Study or subgroup
Garvey 1999205
Total (95% Cl)
Heterogeneity: not applicable
Test for overall effect: z = 0.31 (p = 0.76)
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100.0%
SMD
IV, random, 95% Cl
SMD
IV, random, 95% ClSMD SE Weight
–0.072 0.236
–0.07 (–0.53 to 0.39)
–0.07 (–0.53 to 0.39)
–2 –1 0 1 2
Favours penicillin Favours placebo
FIGURE 233 Standardised post-treatment CGI-I score for children following 4 months of treatment with penicillin compared with placebo. IV, independent variable;
SE, standard error.
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Penicillin compared with azithromycin
Study characteristics
One study compared the efficacy of penicillin with azithromycin in children assessed as having PANDAS
(see Appendix 3, Table 12).206 Children were randomised to 12 months of penicillin or azithromycin and
tablets were taken twice on one day a week (placebo tablets taken on the other days). Children were aged
from 5–10 years and comorbid disease included ADHD (26%) and OCD (69%).
Risk of bias
For this study, methods of sequence generation and allocation concealment were not reported.
Participants and providers appear to have been blinded throughout the study period but blinding of the
outcome assessors is unclear. Although analysis was done only of children completing the study, there was
a low rate of dropout and bias from attrition may have been low. During the intervention period, the
YGTSS and the Yale–Brown Obsessive–Compulsive Scale were used by investigators to monitor
participants. These results are not reported in the publication and the study was therefore considered at
high risk of selective outcome reporting bias. Overall, this study was considered to be at high risk of bias
owing to unclear blinded outcome assessment and potential selective outcome reporting bias.
Clinical evidence for penicillin compared with azithromycin
Unlike for the analysis of other parallel-group trials in this review (for which change from baseline is
assessed), for this study, because the event rates at follow-up were very small compared with the
between-group differences at baseline, results are analysed as differences at end point.
Tics
No measurement of tic outcomes were reported but investigators measured the number of
neuropsychiatric symptom exacerbations. These were defined as an exacerbation of tic or OCD symptoms
and were based on child/parent reports obtained at the end of the year. There was no conclusive
difference in rates of reported exacerbations for the penicillin compared with the azithromycin group
(SMD –0.77, 95% CI –1.63 to 0.08; n= 23) (Figure 235).
The number of streptococcal infections over the study year was measured. There was no conclusive
difference in the mean number of streptococcal infections per child in the year of study for those treated
with penicillin compared with azithromycin (SMD 0.00, 95% CI –0.82 to 0.82; n= 23) (Figure 236).
Impairment
No relevant studies reported TS-related impairment.
Psychological well-being
No relevant studies reported this outcome.
Overall clinical outcome
No relevant studies reported this outcome.
Long-term outcome
No relevant studies reported long-term outcomes.
Safety
No relevant studies reported this outcome.
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Study or subgroup
Snider 2005206
Heterogeneity: not applicable
Test for overall effect: z = 1.77 (p = 0.08)
Total (95% Cl)
Favours azithromycinFavours penicillin
100.0%
100.0%
SMD
IV, fixed, 95% Cl
SMD
IV, fixed, 95% ClWeight
0.5 –0.77 (–1.63 to 0.08)
–0.77 (–1.63 to 0.08)
–2 –1 0 1 2
Overall ROB
High risk
TotalTotal
12
12
SDSD MeanMean
0.90.5 0.5
Post-treatment penicillin Post-treatment azithromycin
11
11
FIGURE 235 Standardised mean number of post-treatment neuropsychiatric symptom exacerbations for penicillin compared with azithromycin. IV, independent variable;
ROB, risk of bias.
Study or subgroup
SMD
IV, fixed, 95% Cl
SMD
IV, fixed, 95% ClWeightSDSD Overall ROB
Snider 2005206
Total (95% Cl)
Heterogeneity: not applicable
Test for overall effect: z = 0.00 (p = 1.00)
0.30.1 0.1 0.3 100.0%
100.0% 0.00 (–0.82 to 0.82)
0.00 (–0.82 to 0.82)
–2 –1 0 1 2
Favours penicillin Favours azithromycin
High risk12
12
Post-treatment penicillin Post-treatment azithromycin
TotalTotal MeanMean
11
11
FIGURE 236 Standardised mean number of post-treatment streptococcal infections for penicillin compared with azithromycin. IV, independent variable; ROB, risk of bias.
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Summary of Paediatric Autoimmune Neuropsychiatric Disorders Associated
with Streptococcal infection trials
Intravenous immunoglobulin
One study in 19 children defined as having PANDAS204 provided very low-quality evidence (see Appendix 4,
Table 59) of no conclusive benefit of i.v. immunoglobulin compared with i.v. saline on tics, but there was a
large effect in terms of impairment, symptoms of anxiety and depression and improved overall clinical
outcome. There was a tendency towards increased rates of adverse effects of treatment.
Plasma exchange
One study in 20 children defined as having PANDAS204 provided very low-quality evidence (see Appendix 4,
Table 60) of possible benefits for plasma exchange compared with i.v. saline on tic symptoms, impairment,
symptoms of anxiety and depression and overall clinical outcome. Plasma exchange was associated with
increased rates of adverse effects.
Penicillin
One study investigated the use of penicillin compared with placebo to treat 72 children defined as having
PANDAS.205 The study provided low-quality evidence (see Appendix 4, Table 61) of no effect of penicillin
on neuropsychological exacerbations, tics or symptoms of anxiety and depression. No findings for adverse
effects were reported by this study.
One study compared the use of penicillin with azithromycin for treating 23 children defined as having
PANDAS.206 The study provided low-quality evidence (see Appendix 4, Table 62) of no conclusive
difference in the rates of streptococcal infections, but there was lower rates of neuropsychological
exacerbations for penicillin.
Overall conclusions from Paediatric Autoimmune Neuropsychiatric Disorders
Associated with Streptococcal infection trials
There is no clear evidence that i.v. immunoglobulin is an effective treatment of tics in children and young
people identified with PANDAS. Plasma exchange may be an effective treatment of tics in children and
young people identified with PANDAS. However, the low-quality of the available evidence means that
there is a high degree of uncertainty with respect to the benefits and harms of plasma exchange in this
population. Finally, there is no clear evidence that penicillin is an effective treatment for tics in children and
young people with PANDAS.
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Chapter 3 Qualitative Study of Experiences of
Services and Treatments
Very little is known about the views of young people with TS and their parents on their experiences oftreatment and what outcomes they value most. The QuEST aims to capture qualitative and descriptive
data on young people’s experiences of treatment and to evaluate the outcomes that are important to
parents and young people. Three sources of information will be used: (1) systematic review of qualitative
and descriptive studies examining experience of treatment; (2) survey of parents of children and young
people with TS; and (3) in-depth interviews of children and young people with TS. A systematic review of
qualitative and descriptive studies examining health professionals’ parents’ and children’s experience of
treatment for TS will summarise and synthesise the extent of existing knowledge. As we know that few
studies have specifically explored perceived clinical effectiveness of treatment, we will collect primary data
from parents of children with TS using an online survey.
A survey methodology was considered appropriate and pragmatic to collect data from a large sample of
parents of children with a wide range of ages. Parents of children with chronic conditions are key drivers
of adherence to treatment for children with chronic conditions207 and are able to give a longitudinal
perspective. A combination of structured questions and text boxes gave flexibility and allowed us to probe
important issues in more depth while retaining the advantages of an online survey.
The views of children aged 10–17 years were explored using in-depth interviews.
Semistructured interviews were felt to be most appropriate method to capture the views of young people
because, apart from enhancing the richness of data, we could be sure that the information was from the
young person himself or herself and that communication was not constrained by their level of literacy.
Interviews have the flexibility to prompt and encourage responses when participants may lack confidence
or are reflecting on more challenging issues.
The results are presented separately for each study and the findings are synthesised in the discussion to
address the issues of experience of access to care and the process of diagnosis, experiences of treatment
and treatment expectations.
Systematic review of qualitative studies
Methods
Search strategy
In addition to the searches undertaken for intervention studies, additional searching was generated for
qualitative studies and survey literature in the following databases: major bibliographic – EMBASE,
MEDLINE, PREMEDLINE In-Process & Other Non-Indexed Citations and PsycINFO; education databases –
AEI, BREI and ERIC; social care databases – ASSIA, IBSS, SSCI, SSA, Sociological Abstracts and Web of
Science; grey literature databases – HMIC, PsycBOOKS, PsycEXTRA; and additional sources – BCI, CINAHL.
Search terms comprised text word and subject headings for tic* and tourette* to identify populations with
TS or with chronic phonic or motor tics (all referred to as TS in this review). Searches were limited to
qualitative systematic reviews, qualitative primary studies and survey literature and generated from 1995
to January 2013. No language restrictions were applied at the searching stage. Search results for the
intervention searches were also screened for any literature relevant to the review. The search strategy is
provided in Appendix 1.
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Selection of studies
Study selection consisted, first, of screening the titles and abstracts of all citations obtained from the
searches. For articles that appeared relevant on screening, or for articles that had insufficient information in
the title or abstract to determine their relevance, full-paper copies were obtained. These papers were
then screened thoroughly, using pre-defined inclusion/exclusion criteria to determine the final set of
included studies.
Inclusion/exclusion criteria
Full-paper articles were screened for inclusion by one reviewer, with reference to a second reviewer in
cases of uncertainty around their eligibility. The selection criteria used for inclusion of studies into this part
of the review were based on the study population and outcomes.
Population
Included studies were to have been conducted in populations of children/young people with TS or their
carers or in health professionals with experience of treating TS.
Outcomes
Included studies were to have examined the views of patients or carers about one or more of the
interventions (medication or diet, behavioural/psychological or psychosocial, physical) or to provide
information on patient/carer/health professional experiences of health-care services for TS. Studies
of the following were considered for inclusion:
l attitudes, or perceived barriers, towards the use of interventions
l experiences of access to care
l experiences of assessment and diagnosis
l experiences of treatment services and community care
l interventions for improving service user experience.
Excluded studies
Studies of non-health-care experiences of TS patients were excluded. For example, studies on the
experiences of bullying or alienation, school performance or self-esteem of children with TS were excluded.
Studies of patient anxiety and stress were also excluded unless these emotions were in relation to, or as a
result of, their care or treatments. Although the review included studies of patient access to care, it did not
aim to review current treatment practices and studies of intervention usage, such as the prevalence of
different medication use, were excluded from the review. In addition, although studies of interventions
aimed at improving care for TS were eligible for inclusion, descriptions of current care projects, with no
assessment of change in patient experience, were not.
Data synthesis
As there was only one qualitative study identified208 and surveys presented different types of outcomes,
neither formal qualitative or quantitative synthesis was attempted. However, results are presented under
theme headings, to group information from different studies on similar outcomes or themes. For the
qualitative study, relevant themes highlighted by study authors are presented. Related participant
quotations are presented to illustrate the themes but no exploration or synthesis of the original quotes
from the primary study was performed.
Results
The searches identified 6345 citations (5434 from the RCT/systematic review/observational study and grey
literature search and 911 from the qualitative/survey search). On title and abstract screening, 14 were
selected and, on full-paper review, four studies were considered as relevant to some aspect of the review
and included. Ten studies were excluded on full-paper review and details of these are given in Appendix 6.
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Included studies
The characteristics of the four included studies are given in Appendix 3, Table 13. Three were surveys of
TS patients and their carers and one was a qualitative study of health professionals and TS patients and
their relatives. Two studies208,209 included information on patient/parent experiences of the diagnostic
process, one on parents’ concerns about the adverse effects of antipsychotic drugs210 and one on parents’
perceived barriers to their child undergoing treatment for TS and also, specifically, to undergoing
behavioural therapy.211
Mol Debes et al.,209 examined the TS diagnostic process by conducting a structured interview on
314 children with TS and their parents attending a TS clinic in Denmark. The survey included questions
about the professionals consulted prior to diagnosis and the professional who made the final TS diagnosis.
Rivera-Navarro et al.208 also investigated the adequacy of TS diagnosis in a qualitative study with five focus
groups: (1) five doctors, (2) six young people with TS, (3) six adults with TS, (4) six parents of young people
with TS and (5) six parents of adults with TS. Focus groups used an initiating question but, after that, they
were unstructured and topics were guided by the experiences of participants. For doctors, the initiating
question related to their perception of the main problems encountered in TS while for patients, it related
to the support provided by health professionals and, for relatives, it related to their opinion of the Spanish
social and medical system.
Kompoliti et al.210 surveyed 100 consecutive TS adult patients and the parents of TS child patients
attending a TS tertiary referral clinic in the USA. The study aimed to assess the use of antipsychotic drugs
for TS and the level of awareness and concern about their adverse effects. For the measurement of relative
concern, subjects were given a list of nine adverse effects and were asked to rate their concern from 0–10
(0 no concern, 10 extremely concerned).
Woods et al.211 conducted an internet survey of adults and parents of young people with TS in the USA.
This was part of a larger survey,212 that assessed the impact of TS on patients, but the current study
specifically reports the results for questions on treatment utilisation, barriers to care and factors affecting
the use of behavioural therapy. For the assessment of barriers to care, participants (465 adults and 487
children) were provided with a list of different statements to mark as yes or no according to whether or
not they considered that item to be a barrier. Additionally, adults or parents of children who had not
undergone behavioural therapy for their TS (327 children and 385 adults), were asked to provide reasons
for this and these reasons were grouped by the investigators into common areas.
Evidence summary
Difficulty in Tourette Syndrome diagnosis/health professional knowledge
In Mol Debes et al.’s survey of TS diagnosis in children,209 participants reported that the number of
professionals they had consulted before diagnosis was between 0 and 16. The majority saw
two professionals prior to consulting the professional who diagnosed TS and these were mostly GPs
(77%), psychologists (47%) and paediatricians (31%). They were also diagnosed by psychiatrists (12%),
ophthalmologists (11%), ear/nose/throat physicians (10%) and professionals from other disciplines, such
allergists and speech and language therapists (31%). When a diagnosis was made, in most cases it had
been done by a child neurologist (76%) and, less frequently, diagnosis was made by a paediatrician (16%),
psychiatrist (5%) or another type of physician (4%). The median time from the first appearance of
symptoms until diagnosis was 5.5 years (range 0–16.7 years) and, from the onset of tics until diagnosis,
was 2.8 years (range 0–12.3 years).
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Difficulties in diagnosis was also identified as a theme in the focus groups in Rivera-Navarro’s qualitative
study of doctors, patients and parents of TS patients.208 Doctors said that diagnosis was difficult owing to
the complex symptoms and confusion with other psychological disorders such as hyperactivity, depression,
anxiety and behavioural disorders:
I suppose sometimes TS symptoms stay hidden because of hyperactivity, mobility, or other problems
such as behavioural disorders, until there is finally a professional who is able to determine what is
really happening to that person.
Doctor (quoted in Rivera-Navarro et al.,208 p. 18)
The theme was also identified in the TS patient focus groups in which patients (children and young people
with TS) related that poor symptom interpretation by doctors caused mistakes in diagnosis. Patients also
thought that lack of doctors’ knowledge about TS was a problem:
Because they have never given me a diagnosis or explained exactly what it was . . . I have visited
several doctors but they did not diagnose TS, perhaps by the lack of knowledge of physicians.
Adult patient (quoted in Rivera-Navarro et al.,208 p. 18)
Focus groups in the parents of TS patients in this study, similarly, identified a lack of doctors’ knowledge as
a problem in recognising symptoms and diagnosing TS. This perception was also identified in the survey of
Woods et al.,211 in which the barrier to treatment of ‘finding a provider who understood tics’ was agreed
with by 42% of parents of TS children.
In the qualitative study by Rivera-Navarro et al.,208 a problem identified by parents of TS children was that
doctors implied that they were overoccupied by their child’s behaviour and exaggerated their symptoms:
I have not had a bad experience with physicians it is only that I think they did not know it . . . I have
suffered from the lack of credibility as a mother and from accusations because they told me I was
extremely obsessed with my son.
Mother of teenage patient (quoted in Rivera-Navarro et al.,208 p. 19)
Barriers to seeking treatment
Fear of stigmatisation
In the study of Rivera-Navarro et al.,208 the focus group of doctors identified the problem of parents’ fears
of associated stigmatisation if their child was diagnosed with TS. This was thought, in some cases, to delay
or inhibit them going to the doctors:
I think that many families stopped visiting doctors because they were afraid of the fact that TS is an
inherited disease.
Doctor (quoted in Rivera-Navarro et al.,208 p. 19)
In this study, patients and parent focus groups also agreed about the stigma caused by identifying TS as a
mental disorder. However, in the survey of Woods et al.,211 a relatively small proportion of parents of TS
children (5%) agreed with the barrier to treatment of ‘Don’t want to be labelled or have a diagnosis’.
Concerns about drug adverse effects
In the parents of TS children surveyed by Woods et al.,211 the barrier to treatment most commonly
agreed with was ‘worry about the adverse effects of medication’ (43% of parents). In the survey by
Kompoliti et al.210 of adults with TS and parents of children with TS, from the list of antipsychotic drug
adverse effects that participants were given, participants identified that they were most concerned with the
risk of seizures, tardive dyskinesia, disturbances of thinking and emotion and cardiac disturbances and
the median concern rating for each of these was 10 (extreme concern). Other adverse effects of concern
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were gastrointestinal (median 9), movement disorders (median 8), sexual function (median 7) and body
image (median 6). In this study, patients who had taken antipsychotic drugs in the past (45%), or their
parents, were less concerned about adverse effects than those who had not (χ2 test; p= 0.004). In
addition, those who claimed to know nothing about neuroleptics were more concerned (Mann–Whitney
U-test; p= 0.002) and the well-informed were less concerned (Mann–Whitney U-test; p= 0.027) about
adverse effects than other participants.
Concerns about negative impacts of behavioural therapy
In the survey by Woods et al.,211 for those who had never undergone behavioural therapy, when asked
their reasons for not receiving therapy, participants identified that they were worried that tic suppression
would cause a later ‘rebound’ effect, when tics became worse (14%), cause other tics to start (12%),
make other activities such as schoolwork more difficult (15%) and that tics would get worse if they were
focused on (12%).
Other barriers
Other barriers to general treatment and, specifically, to treatment with behavioural therapy were identified
in the survey of Woods et al.211 General barriers, proposed by investigators and agreed with by
participants, were the financial cost (41%), the time needed to receive treatment (26%) and not having a
treatment specialist in a close locality (33%). Some patients/parents indicated that they did not feel the
need for treatment as tics did not interfere with life (32.4%) or they considered that they had never been
very bad (35.2%).
For behavioural therapy, regarding children who had never undergone that type of treatment, when asked
to give the reasons as to why not the most commonly identified were that patients/parents had not heard
of behavioural therapy (21%) and they did not know where to go to receive it (28%). Some participants
did not feel that behavioural therapy was necessarily the right approach and worried that behavioural
issues would interfere with therapy (12%) or that it would not treat the underlying problem (5%). As for
barriers to general treatment, participants identified that there were not behavioural therapy services in a
close locality (13%) and that it was too difficult to travel the distance for these services (7%).
Online survey of parents of children with Tourette syndrome and other
tic disorders
Methods
Participants
Participants were parents or carers of children and young people with TS or any tic disorder. Exclusion
criterion was children or young people aged > 17 years.
Measures
The QuEST survey was designed to gather information about parents’ experiences of treatment for their
children’s tics. Survey questions were developed by consulting the existing literature (e.g. Roessner et al.;94
Verdellen et al.158), including the systematic review (see Systematic review of qualitative studies) and in
consultation with the TEG, which included 11 clinicians working with this population, academics and two
service users. A survey draft was presented to and discussed with the TEG, which provided suggestions of
question presentation, wording and inclusion or removal of items. After revisions were made, the survey
was placed in SurveyMonkey® (CA, USA; www.surveymonkey.com) and three parents recruited through TA
completed the survey to ensure that questions were clear and comprehensible. Parents’ comments and
suggestions were integrated into the survey and a final version was prepared and approved by all
the authors.
The survey included forced choice tick box responses (e.g. yes/no), rating scales, ranking scales and text
boxes for open comments. Areas covered were (1) clinical characteristics of the child and demographic
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characteristics of both the child and the parent or carer, (2) psychoeducation (i.e. information about tics to
parents and carers, and information about tic management to the child’s school), (3) behavioural
interventions for tics, (4) medication for tics, (5) other treatments used for tics (i.e. alternative/
complementary therapies), and (6) desired outcomes of treatment for tics. Skip patterns were used to
move participants past questions that were not applicable.
For the child’s clinical characteristics, parents and carers were asked to report the child’s age of tic onset,
diagnosis of tic disorders and diagnosis of coexisting conditions. Open questions probed responses to
access to treatment and diagnosis of TS. To assess the child’s tic-related impairment, parents and carers
were asked to rate the impact of tics on their child’s self-esteem, social relationships and academic
performance using the overall impairment scale of the YTGSS,213 adapted for online presentation.
Specifically, parents and carers were asked to rate the impact of tics over the previous week using a
0- (‘none’) to 5- (‘severe’) point scale with slightly modified descriptors for ease of comprehension.
Descriptors that made reference to the impact of tics in occupational settings (e.g. job functioning or job
performance) were not included.
To assess whether or not the young person had ever received a behavioural intervention for tics,
participants were presented with a brief description of the CBIT that was developed based on the therapist
guide for behavioural intervention for children and adults.214 The description included components of habit
reversal and function-based intervention (i.e. contingency management). Relaxation training was excluded
from the description on the advice of the expert panel to avoid confusing participants whose child had
used relaxation training in isolation as a complementary therapy (i.e. not as part of a comprehensive
behavioural intervention). The description read:
Here we would like to ask you about behaviour treatment for tics. Behaviour treatment for tics may
include one or both of the following: (please read these treatment descriptions before answering the
question below)
l the child is taught how to identify and change or avoid situations or triggers that make tics more
likely to happen – for example, some places, people or thoughts. (health care professionals may
call this treatment function-based intervention or contingency management)
l the child is taught how to recognise the urges or feelings that can precede tics, and practises
responding to these with a competing or opposite response—such as briefly tensing some muscles
or breathing deeply so that the tics cannot occur. (health care professionals may call this
treatment HRT)
Has your child ever received any of the treatments described above?
The QuEST survey assessed parents’ views on treatment (10 drugs were listed for tics). The target drugs
[(clonidine, risperidone, aripiprazole, sulpiride, haloperidol, olanzapine (Zyprexia®, Lilly), quetiapine
(Seroquel®, AstraZeneca) pimozide (Orap®, Janssen), clonazepam (Rivotril®, Roche) and lorazepam
(non-proprietary)] were selected based on a 2011 survey of choice of medication for tics among members
of the European Society for the Study of Tourette Syndrome94 and expert panel reports of everyday
practice in the UK. Parents were also prompted for additional drugs used in the treatment of tics.
Participants were presented a list of treatments other than medication and behavioural interventions
(e.g. yoga, fish oils, massage, relaxation training and aromatherapy) and were asked to select all the
therapies that the child had tried with the intention of helping with his or her tics.
To examine what outcomes of treatment are hoped for, parents were presented with two open-ended
questions: (1) ‘What would you most hope a treatment for tics would do for your child?’ and (2) ‘Are there
any other benefits from treatment that you would like to see’. In addition, parents were asked to rank,
from most important to least important, seven preselected outcomes of treatment for tics (e.g. ‘School is
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better able to manage your child’s tics’, ‘Your child gets on better with friends’, ‘Your child is better able
to cope with his or her tics’).
Procedure
Participants were recruited through study adverts that were posted on the UK TA website (www.tourettes-
action.org.uk) and on its electronic newsletter. In addition, invitation e-mails that included a link to the
survey were sent by TA to its members and study leaflets were distributed in TA events such as
conferences and group meetings. The survey was available for six consecutive months, from December
2012 to May 2013. Participants gave online consent to participate and the survey was anonymous.
After completing the survey, participants’ responses were automatically stored in the research team’s
SurveyMonkey account, which required a password to be accessed. Participants were then were directed
to a different web page (created with SurveyMonkey) that invited them to take part in the second part of
the QuEST. The study was approved by the Medical School Ethics Committee of the University
of Nottingham.
Statistical analysis
The percentages, means and SDs reported were calculated based on the number of responses to each
item and exclude missing values.
Results
Demographic and clinical characteristics
A total of 358 respondents consented to participate in the survey, of whom 297 answered at least one
question concerning treatment utilisation, which was the minimum response criterion for inclusion.
Two entries were identified as repeat respondents based on their responses to demographic questions and
were removed from the data analysis, resulting in 295 participants with usable data.
Of the 295 participants, 276 (93.6%) reported that their child had received a diagnosis of TS, eight (2.7%)
reported a diagnosis of one or more tic disorders (i.e. chronic motor tic disorder, chronic vocal tic disorder
or transient tic disorder) and 11 (3.7%) did not report a diagnosis of TS or tic disorder or had missing
values on these items. All 11 reported age of onset for tics and were included in the survey. The majority
of participants were biological mothers (92.2%) and the mean age of the sample was 44.0 (SD= 6.3). The
sample was predominantly married (78.2%) and 40% were educated to graduate level (see Appendix 9).
Young people’s demographic and clinical characteristics as reported by parents and carers are presented in
Appendix 9. Young people’s mean age was 12.4 years (SD= 3.0 years; range 5–17 years), 79.3% were
males and the mean age of tic onset was 5.9 years (SD= 2.8 years; range 1–17 years). The mean age at
diagnosis of TS was 9.1 years (SD= 2.7 years; range 3–17 years). On average, parents and carers reported
that in the last 7 days, their child’s tic-related impairment was mild.
Access to care
Open text boxes probed parents’ perceptions of access to care and the process of receiving a diagnosis.
Of the 295 participants, 195 made codeable comments. The pathway into treatment for tics was frustrating
and difficult for many parents as testified by 100 free text comments.
We went to see a Doctor twice and was told it was a habit. It took a year before a Doctor referred our
son to a consultant Paediatrician.
Parent ID 125
It was very difficult to get someone to believe my son had a problem.
Parent ID 49
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At first our concerns were not taking seriously, and we were advised to go away and explore self-help
therapies such as ‘tapping’. We wouldn’t have been asking for help if we could have managed the
problem our selves!
Parent ID 266
Getting referred for specialist treatment and access to appropriate treatment was slow and difficult for
many unless parents opted for a private referral. GP knowledge or attitudes were explicitly blamed by
31 parents.
We went to a GP at our local practice three times within the first year and were told it was a phase
and nothing to worry about – despite the fact that the tics (vocal and motor) were frequent and
having a pronounced impact on my son’s school and home life.
Parent ID 70
It took 18 months before my child was seen and several visits to GP.
Parent ID 9
I started with my GP as I didn’t know where else to go, when I said I thought he had TS he laughed
saying I don’t think so. I left feeling stupid, but had to go back as things got worse and insisted he
refer me somewhere, which he did; to CAMH. I was told I had to wait a year before they could assess
the situation. They only started seeing him regularly because I phoned in tears as he was suicidal.
Parent ID 5
GP dismissed our concerns. Told us to ignore them (tics) and not to focus on them. We had already
monitored the tics ourselves for six months and so didn’t want to wait any longer. Used private
medical insurance to see consultant, then by chance someone we knew mentioned X Hospital. We
managed to get a referral there to their Tourette’s Clinic.
Parent ID 61
In response to an open question about the receiving a diagnosis of TS, 39 parents commented on a lack of
support or inadequate information. Specifically in relation to receiving a diagnosis of TS, qualitative data
from the survey suggested that many parents felt unsupported and would have liked more information.
I was surprised at the absolute lack of information received from them about the condition following
their diagnosis, and total lack of support for child and family in dealing with Tourettes. Most of our
subsequent knowledge of Tourettes and dealing with this has come from Tourettes Action.
Parent ID 76
I had already guessed my child had Tourettes from research I had done on the internet, but when he
was diagnosed I was expecting to be referred to experts who could help and give us advice, we
weren’t offered any support or advice, not even a leaflet!
Parent ID 143
We were told by our GP he would grow out of this habit and we were given antihistamines.
Parent ID 27
GPs show no knowledge or awareness of Tics and have told me to offer reward charts to stop the
‘behaviour’! It was purely my husband researching our son’s movements on the internet that led us to
realising that he suffers with tics/tourettes.
Parent ID 203
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Primary care physicians are not well educated re tourettes and services available. I feel especially
qualified to make this statement being a GP myself. Often children are referred to local community
paeds who often have insufficient knowledge to manage this condition. We were also referred to
neurology who again were not best placed to manage all the psychosocial implications but who
fortunately directed us to child and adolescent specialist psychiatry services at [X].
Parent ID 34
There were also other barriers to treatment and many parents struggled to get paediatric services to take
the child’s difficulties seriously.
Hard work! Tests for epilepsy inconclusive, so ‘off you go’ was the attitude from the paediatrician.
Was a battle to get to see the correct person and took nearly 18 months to do.
Parent ID 77
A substantial number of comments referred (n= 49) to the difficulty of getting a diagnosis.
Neurology gave us the diagnosis of chronic motor tic disorder. I feel there is a lot of stigma around the
use of the term Tourette’s and subsequent fear of using the term-something the media does not help.
Child and adolescent psychiatry were the first service to use the term.
Parent ID 34
Frustrating for us as parents that it took so long. Once diagnosed everything made sense and we felt
that we could help our son.
Parent ID 90
Many parents felt they had to pressurise services to make a diagnosis, resorting to strategies such as
filming the child’s tics.
We had to demand to our GP to send him to a hospital referral but I myself had a video of him with
his tics and he was diagnosed straight away.
Parent ID 27
Lack of support for diagnosis
Once a diagnosis had been made, many parents (n= 45) commented in the lack of support to help them
cope with the diagnosis.
They never at any point sat us down and explained a diagnosis, they just dropped it into a casual
conversation one day as if I knew. If you have cancer or something a doctor sits with you and explains
everything, with mental health it seems different. WHY?
Parent ID 5
We also felt lost and scared. Like being sent home to get on with something we didn’t really know
how to get on with.
Parent ID 11
For many parents the diagnosis did not seem to provide a pathway to treatment.
Very direct, told us the diagnosis whilst my son was in the room. He was very upset once we got
outside. Told us that he may or may not grow out of it, that his Tourettes was mild (did not seem that
way to us) and that there was no treatment unless it got worse.
Parent ID 46
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Psychoeducation
Information about tics to parents and carers More than two-thirds (68.5%, n= 202) of parents and
carers reported that a health-care professional had given them information about tics. If participants
reported that they received information about tics, they were asked how helpful they perceived the
information to be, which service provided the information and how was the information provided. Among
those parents and carers who received information about tics (157/202; 77.7%) considered that the
information was somewhat helpful or very helpful. Less than one-third (21.3%, n= 43) were neutral and
only 1% (n= 2) considered that the information made things worse. Parents also reported receiving
information about tics through different services, of which the two most commonly reported were CAMHS
(58.7%, n= 118) and paediatric services (37.3%, n= 75). Fewer than 10% of parents received information
from an adult neurology service (6.5%, n= 13) or from private practice and only 3.5% (n= 7) received
information from a GP. The most frequently reported way of receiving the information was through a
conversation with the health-care professional (82.1%, n= 165) and about half (52.2%, n= 105) of
participants received the information in written form and 37.8% (n= 76) were directed to a website.
Only seven parents (3.5%) reported that they had received information about tics from GP. Seventy-seven
participants gave open comments about the information they had received. Many parents (n= 26) felt that
they had had to search out information for themselves, often on the web or through TA.
No info as such just directed to websites that we have already found ourselves.
Parent ID 96
My research has been more enlightening than anything I’ve learned through my son’s doctors.
Parent ID 172
Most helpful was being directed to the Tourette Action.
Parent ID 105
Comments suggested there was a gap in information provision at the primary care level.
Two years after the diagnosis, I don’t always feel that I have somebody to go to for an update/review.
Our GP is unashamedly unfamiliar with the syndrome.
Parent ID 31
When information had been given, particularly from specialist services, parents appreciated its value.
No real information given to us about tics until we were referred to the consultant specialist team . . .
approx. 6 months after our son’s initial diagnosis. Once we were with the specialist team, we were
given lots of information, both practical and information based. Our son’s habit reversal therapist also
helped with explaining about tics.
Parent ID 160
Information about tic management to the child’s school
From the survey participants, just over one-third of parents/carers (111/291; 38.1%) reported that a
health-care professional ever contacted their child’s school to give information about managing tics at
school. Among those parents/carers whose child’s school was contacted, most of them (77/111; 70.0%)
reported that the information given to the school was somewhat helpful or very helpful; 22.7% (25/111)
felt that the information was neither helpful nor unhelpful and 7.3% (8/111) reported that the information
made things worse.
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Of the parents/carers who reported that their child’s school was contacted, 60 (54.1%) provided
comments elaborating on the information that their child’s school received. An inductive content analysis
of these comments revealed that parents/carers felt that the information provided by the health-care
professional helped others at school understand the condition better.
she [health care professional] visited the school and spoke to the class and made the children aware of
my child’s disorder as it was quite severe and he was the only one in the school with the condition. It
helped the children to understand and they accepted it fully.
Parent ID 99
Helped the teachers to understand the condition. believe it or not, some teachers have got no idea
what it involves.
Parent ID 109
However, parents/carers also felt that schools were not receptive to the information provided by the
health-care professional.
Our healthcare professional has tried her best to explain to my son school about his condition but it’s
the school that hasn’t been that interested and not really taken much notice.
Parent ID 120
The school didn’t take any notice and used their own methods . . . They wouldn’t adapt to meet my
child’s needs.
Parent ID 94
Furthermore, parents/carers felt that schools have difficulties disseminating the information among
the teachers.
The teachers change so often at his school that many are still unaware of the issues.
Parent ID 25
The school had no knowledge of how to help kids with tic disorders or TS but were willing although
as they passed through the school years each teacher got less info and seemed to have no handover
so we had to raise the issue ourselves.
Parent ID 210
There is evidence from the survey that informed schools also have a part to play in improving access to
care for TS. When asked about accessing treatment for tics many people gave examples of how the
process had been difficult. Of the 29 parents who gave neutral or positive responses about accessing care
for TS, seven parents specifically mentioned the role of the school suggesting that better informed schools
could reduce barriers to care.
The school where my child went had also had a massive impact with this as they were noticing
unusual behaviours in my child. This is what really stemmed it off!
Parent ID 26
Our school referred us to the local paediatrician, was very thorough and have been well supported.
Parent ID 192
It seems that for many parents, GPs are the gatekeepers to services and children are often referred back to
primary care following diagnosis.
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Other treatments
As shown in Table 2, more than three-quarters of participants (78.5%, n= 219) reported that the child
had tried at least one other (alternative/complementary) treatment to help with tics. Of these other
treatments, the three most commonly reported were relaxation training (39.8%, n= 111), exercise
(34.1%, n= 95) and fish oils (30.5%, n= 85). Between 20% and 25% of parents reported that their child
had tried individual counselling, diet and massage; whereas fewer than 10% of parents reported that their
child has tried therapies such as yoga, homeopathy and aromatherapy. Of the other treatments, the two
that were least frequently reported were dental therapies (2.2%, n= 6) and neurolinguistic programming
(1.1%, n= 3).
Medication for tics
More than half (54.7%, n= 202) of parents and carers reported that their child has taken medication for
tics. The three most frequently reported drugs for tics were risperidone (27.7%, n= 77), clonidine (26.3%,
n= 73) and aripiprazole (19.9%, n= 55).
For each target drug, the survey included questions to assess (1) perceived helpfulness (‘How helpful has
this medicine been for your child’s tics?’, scored on a 5-point Likert scale from –2 (unhelpful tics got a lot
worse) to 2 (very helpful) and (2) adverse effects [‘Has this medicine had unwanted effects [side-effects]
on your child?’, scored on a 4-point scale from 0 (none) to 3 (severe)]. The doses of each target drug were
not known and as a consequence it is not possible to determine to what extent dosage influenced
participants’ reports of helpfulness and adverse effects.
Table 3 presents how parents and carers perceived the helpfulness and adverse effects of medication for
tics. Mean helpfulness scores ranged between –0.2 and 1.0, indicating that parents and carers felt that
drugs were neither helpful nor unhelpful for tics or somewhat helpful. The drug with the highest mean
helpfulness score was aripiprazole (mean= 1.0), indicating that, on average, participants perceived that
this drug was somewhat helpful for their child’s tics. To calculate the proportion of participants who
considered that a drug was helpful, for each drug the number of participants who reported that it was
‘somewhat helpful’ or ‘very helpful’ were counted. As Table 3 shows, the proportion of participants who
TABLE 2 Other treatments (alternative/complementary) for tics as reported by parents and carers
Other treatment n %
One or more other treatments 219 78.5
Relaxation training 111 39.8
Exercise 95 34.1
Fish oils (omega-3 fatty acids) 85 30.5
Individual counselling 69 24.7
Diet 63 22.6
Massage 58 20.8
Martial arts 40 14.3
Yoga 19 6.8
Homeopathy 18 6.5
Aromatherapy 17 6.1
Hypnotherapy 12 4.3
Dental therapies 6 2.2
Neurolinguistic programming 3 1.1
Other 28 10.0
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considered that a drug was helpful ranged between 15.4% (for sulpiride) and 69.1% (for aripiprazole).
For most of the drugs examined, fewer than 50% of parents and carers felt that the drug was helpful for
their child’s tics. An exception to this was aripiprazole; of the 55 parents who reported that their child took
this drug, almost 70% considered that aripiprazole was somewhat helpful or very helpful for the child’s tics.
Of the five parents who reported that their child took lorazepam, three (60%) of them considered that
lorazepam was somewhat helpful or very helpful.
Mean adverse effects scores ranged from 0.9 to 2.0, indicating that, in general, parents and carers
perceived that medication for tics had mild-to-moderate adverse effects. The drug with the lowest mean
adverse effect score was aripiprazole (M= 0.9), indicating that, on average, participants felt that this drug
had mild adverse effects. Table 3 shows that the proportion of participants who reported moderate or
severe adverse effects ranged from 25.5% (for aripiprazole) to 70.8% (for haloperidol). For most of the
drugs examined, more than 45% of participants reported that the drug had moderate-to-severe adverse
effects. For aripiprazole, however, of the 55 parents who reported that their child took this drug about
25% of them felt that the drug had moderate-to-severe adverse effects.
For each medication examined, the survey also included an open-ended question that probed respondents’
views on the target drugs (i.e. ‘Are there any comments you would like to make about this medicine?’).
Examination of parents’ responses to each of these questions revealed that between 14.3% and 60% of
parents commented on some aspect of drug adverse effects. Although parents mentioned a wide variety
of adverse effects, those frequently described were sleepiness, tiredness or drowsiness, and weight gain.
Table 4 shows the number of parents who commented on adverse effects, frequently described adverse
effects and example comments.
TABLE 3 Medication and behavioural interventions for tics
Helpfulness Adverse effects
Mean helpfulness
(–2 to 2 scale)
Proportion
who found it
helpful for
child’s tics
Mean adverse
effects (0 to 3 scale)
Proportion
who reported
moderate or
severe adverse
effects
Treatment N % Mean SD n % Mean SD n %
Medication
Risperidone 77 27.7 0.1 1.3, n= 76 30 39.5 1.9 1.1, n= 76 48 63.2
Clonidine 73 26.3 0.1 1.1, n= 73 30 41.1 1.5 1.1, n= 73 34 46.6
Aripiprazole 55 19.9 1.0 1.0, n= 55 38 69.1 0.9 1.1, n= 55 14 25.5
Haloperidol 24 8.7 –0.1 1.2, n= 24 6 25.0 1.9 1.3, n= 24 17 70.8
Sulpiride 13 4.7 –0.2 1.0, n= 13 2 15.4 1.3 1.4, n= 13 6 46.2
Pimozide 7 2.5 0.3 1.3, n= 7 3 42.9 1.7 1.4, n= 7 4 57.1
Clonazepam 7 2.5 –0.1 1.5, n= 7 3 42.9 2.0 1.4, n= 7 5 71.4
Lorazepam 5 1.8 0.2 1.3, n= 5 3 60.0 1.6 1.5, n= 5 3 60.0
Behavioural
interventions for tics
74 25.9 0.4 1.0, n= 70 34 48.6 0.4 0.8, n= 70 8 11.4
Reproduced from © 2015 Cuenca et al.;215 licensee BioMed Central. This is an Open Access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
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TABLE 4 Adverse effects of medication as described by parents and carers
Medication
Number
received
medication
Parents
commenting
on adverse
effects
Frequently described
adverse effectsa (number of
parents describing adverse
effect, % among those
who received medication) Example commentn %
Risperidone 77 32 41.6 Weight gain/increase of
appetite (9, 11.7)
He only took it for 3 weeks as he
developed a monstrous appetite and
gained rapid weight . . .
Other (21, 27.3) My son became more agitated and
impulsive on this medicine. It was
a nightmare!
Clonidine 73 17 23.3 Depression (5, 6.8) Our son became depressed on
clonidine – extremely weepy . . .
Sleepy/tired/drowsy (5, 6.8) He was very sleepy on this medicine and
it didn’t help
Other (10, 13.7) Make his blood pressure very low and
was told by hospital doctor to stop
taking it
Aripiprazole 55 14 25.5 Sleepy/tired/drowsy (4, 7.3) He has been on this med for approx.
16 months. Was very sleepy to
begin with
Weight gain/increase of
appetite (4, 7.3)
Have to watch what he eats, makes him
hungry . . .
Other (e.g. nausea, akathisia/
tremor) (8, 14.5)
. . . she had very bad nausea and unable
to eat in the beginning but that has now
gone sometimes she gets a bit shaky
when taking it mainly shaky hands . . .
Haloperidol 24 12 50.0 Sleepy/tired/drowsy (n= 5,
20.8)
. . . is very sleepy at times, he often falls
asleep at school
Other (e.g. dystonia) (6, 25.0) Only took this medication for a couple
of days. Caused breathing problems and
muscle spasms
Sulpiride 13 5 38.5 Sleepy/tired/drowsy (2, 15.4) Became easily fatigued when he first
started taking medication . . .
Weight gain/increase of
appetite (2, 15.4)
. . . she put on weight . . .
Other (3, 23.1) Took it at age 6. Only took it for 10 days.
Vomited every day he took it . . .
Pimozide 7 1 14.3 Mixed (weight gain, insomnia) . . . caused weight gain and insomnia
and tiredness in the day unable to get
up in the morning also caused dizziness
Clonazepam 7 2 28.6 Mixed Only took on one occasion but had such a
horrible almost hallucinogenic effect we
didn’t use again
Lorazepam 5 3 60.0 Sleepy/tired/drowsy (2, 40.0) Too sleepy unable to think
Other (2, 40.0) Caused increase in anxiety . . .
a Some parents described more than one adverse effect.
Reproduced from © 2015 Cuenca et al.;215 licensee BioMed Central. This is an Open Access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
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Behavioural intervention for tics
About one-quarter of participants (25.9%, n= 74) reported that their child had received a behavioural
intervention for tics. Participants reported that behavioural interventions for tics were mostly delivered by
CAMHS (71.4%, 50/70), followed by paediatric services (15.7%, n= 11), private practice (7.1%, n= 5)
and adult neurology (4.3%, n= 3). Among participants who reported that their child had received a
behavioural intervention for tics, 52.2% (36/69) reported that the child received fewer than five sessions,
23.2% (n= 16) reported receiving between 5 and 10 sessions, and 24.6% (n= 17) received more than
10 sessions. As shown in Table 3, participants who reported that their child received a behavioural
intervention (n= 74) felt, on average, that it was neither helpful nor unhelpful for tics (mean= 0.4). Of
those participants who reported that their child had received a behavioural intervention, 48.6% (40/74)
reported that the behavioural intervention was ‘somewhat helpful’ or ‘very helpful’ for the child’s tics.
Examination of mean helpfulness scores by number of sessions received showed that participants who
received more than 10 sessions had slightly higher scores (n= 17; mean= 0.8, SD= 0.6) than participants
who received 5–10 (n= 16; mean= 0.3, SD= 1.4) or < 5 sessions (n= 36; mean= 0.3, SD= 1.0), although
there were no significant differences between the groups at p < .05.
Regarding adverse effects, participants felt that behavioural interventions had none or mild adverse effects
(mean= 0.4). Given that adverse effects are often not reported for behavioural intervention trials, it is
interesting to note that eight participants (8/70; 11.4%) reported that behavioural interventions had
moderate or severe adverse effects, such as worsening of tics attributed to treatment exercises.
Desired outcomes of treatment
Participants were asked to rank seven preselected outcomes of treatment for tics, with 1 being the most
important and 7 being the least important. As shown in Table 5, reduction in severity and frequency of the
child’s tics was ranked as most important (i.e. received the lowest mean score). The child being better able
to cope with tics was ranked as second in importance and the school being better able to manage the
child’s tics was ranked as third in importance. Of note, the child can take part in more leisure activities was
ranked as least important.
Parents were also asked to describe in free text their desired outcomes of treatment for tics. The two
questions presented read: ‘What would you most hope a treatment for tics would do for your child?’ and
‘Are there any other benefits from treatment that you would like to see?’. A total of 247 parents answered
at least one of these questions and parents’ responses were examined for commonalities and coded/
divided into nine categories. Some parents described more than one desired outcome of treatment for tics.
Table 6 shows the nine categories, the number and percentage of parents who endorse each category and
typical responses.
TABLE 5 Parental ranking of desired outcomes of treatment for tics
Desired outcome M SD, n
Importance of outcome:
mode ranked score
Reduction in severity and frequency of your child’s tics 1.8 1.3, 253 1
Your child is better able to cope with his or her tics 1.9 1.0, 252 2
School is better able to manage your child’s tics 4.3 1.4, 253 3
Your child gets on better with friends 4.4 1.4, 253 5
Your child gets on better at school 4.7 1.4, 253 6
Your family is better able to cope with your child’s tics 5.0 1.6, 253 7
Your child can take part in more leisure activities 6.0 1.3, 252 7
Outcomes are listed in the mean rank order, 1 being the most important and 7 being the least important.
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Although the most common desired outcome of treatments were stopping or reducing the child’s tics
(41.0%), many identified emotionally focused outcomes such as reducing anxiety or increasing self-esteem.
Reducing or managing negative emotions such as anxiety was the second most frequently reported desired
outcome of treatment for tics, accounting for almost 22% of responses. Yet, participants also described
more behaviourally oriented outcomes such as managing or controlling tics, which were reported by a
notable portion of participants (19.3%). Although less frequently reported, about 12% of participants
described desiring outcomes that increase knowledge and understanding of TS and tics.
Psychoeducation by type of treatment
To examine delivery of psychoeducation and use of other treatments beyond medication and behavioural
intervention, the sample was divided in three groups: (1) medication only, (2) medication and behavioural
intervention and (3) behavioural intervention only. The medication only group consisted of participants
who had only received medication for tics. The medication and behavioural intervention group consisted of
participants who had received medication and a behavioural intervention for tics, whereas the behaviour
only group consisted of participants who had only received a behavioural intervention. Table 7 shows
delivery of psychoeducation and use of other treatments as a function of type of main treatment
(medication and/or behavioural) received for tics.
TABLE 6 Desired outcomes of treatment for tics as reported by parents and carers
Category
n parents who
endorsed each
category % (overall sample) Example comment
Reduce or stop tics 121 41.0 Bring them to a tolerable level or even stop them
Ideally I would like a treatment that would eliminate his
tics with no side effects
Manage or reduce
negative emotions
associated with tics
64 21.7 Reduce feelings of anxiety and frustration
A feeling of being less anxious, so as to not worry about
everything . . .
Child controls/
manages tics
57 19.3 For him to be able to control them at his instigation
Give him control over them and be able to substitute
one for a less noticeable/harmful type
Increase self-esteem
and confidence
46 15.6 Help him overcome his lack of self-confidence
Boost his self-esteem, make him feel ‘normal’ and not
as inadequate in social situations
Increase knowledge
and acceptance of
condition
35 11.9 Just give us a better understanding of why they happen
and how to deal with them
A place where doctors send children with tics where the
practitioner understands what you are describing and
can give you a straight answer would be nice
Enhance general QoL 18 6.1 Raising of quality of life through an ability to spend time
on other activities when time lots of time is spent
ticcing . . .
Social integration 16 5.4 . . . being able to have a good social life without being
self-conscious about his condition
Reduce physical pain
associated with tics
16 5.4 Reduce the pain caused by constant tics and jerks
Other 43 14.6
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Although most participants across the different treatment groups reported that a health professional gave
them information about tics, the group with the lowest proportion of participants who received tic-related
information was the medication only group (72.8%). Among participants whose child had received
medication and/or behavioural intervention, provision of tic-related information to schools was consistently
less common than provision of information to parents and carers. Just over half (55.1%) of participants
whose child had received medication and/or behavioural intervention reported that a health professional
provided information to their child’s school. The behavioural intervention only group had the lowest
proportion of participants who reported that the child’s school received tic-related information (38.1%).
In-depth qualitative interviews with young people with Tourette syndrome
Methods
Participants
Participants were children and young people with TS between 10 and 17 years of age. Participants were
recruited via the QuEST online survey by asking parents who completed the survey if their child would be
interested in taking part in an interview that explored young people’s views on treatments for tics. In
addition, recruitment was conducted through study announcements that were posted on the TA website
and social media, and study leaflets that were handed out at information sharing and social events
organised by TA. The target sample size was flexible and aimed to include up to 50 young people
depending on the number of participants needed to achieve saturation of themes. This sample size was
considered feasible within the study period and sufficient to ensure participation of young people with
different treatment and service experiences. As the systematic review has identified barriers to treatment
for tics among young people with TS, participants who were in the process of receiving treatment or who
have not received treatment at the time of the interview were included in the analysis. This allowed
exploring young people’s experiences of access to care and perceived barriers towards the use of different
treatments for tics.
Interview schedule
The interviews aimed to explore young people’s thoughts and experiences concerning services and
treatments for tics. Interviews were conducted by telephone or, when practical, face to face. The interview
schedule, which was developed by members of the research team and the TEG, explored three main areas:
(1) experiences concerning tics and TS, including factors that are perceived as improving or worsening
tics and aspects of tics that are considered problematic, (2) experiences of services and treatments for tics,
including positive and negative experiences, as well as views on information about tics, medication for
tics and behavioural interventions for tics, and (3) desired outcomes of treatment.
TABLE 7 Psychoeducation and other treatments by main intervention received (medication and/or behavioural)
YGTSS tic-related
impairment score
(0 to 5 scale)
Information
about tics to
parent/carer
Information
about tic
management to
child’s school
One or
more other
treatments
Treatment N % M SD n % n % n %
No medication or
behavioural intervention
105 37.8 1.9 1.2, n= 105 56 53.3 27 25.7 68 64.8
Medication only 103 37.1 2.6 1.6, n= 101 75 72.8 43 41.7 83 80.6
Medication and behavioural
intervention
49 17.6 2.6 1.5, n= 49 43 87.8 27 55.1 46 93.9
Behavioural intervention only 21 7.6 2.0 1.2, n= 20 19 90.5 8 38.1 21 100
YGTSS tic-related impairment scale: 0, none; 1, minimal; 2, mild; 3, moderate; 4, marked; 5, severe.
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For young people who reported not having received medication and/or behavioural intervention for tics,
the interview schedule included a short description of each of these treatments (see Appendix 8) that were
read aloud to the participant to explore his or her views. As with the QuEST survey, the description of
behavioural interventions for tics excluded the relaxation training component to avoid confusion with
relaxation exercises delivered in isolation and not part of a more comprehensive behavioural intervention.
Procedure
After parents and carers completed the QuEST survey, they were automatically directed to a different
website (developed with the software SurveyMonkey) that presented information about the interviews
with young people. This website explained that the interviews were conducted with young people with TS
and asked parents and carers if they would be interested in their child taking part in the study. Parents and
carers who reported being interested in the study were then asked for their contact details (e.g. e-mail
address and telephone number) so that a member of the research team could contact them to provide
more information about the study. Parents’ and carers’ contact details were kept confidential and separate
from their QuEST survey responses.
The study announcements and leaflets used to advertise the study included the web address of a website
similar to the one described above, but with the option for young people between 16 and 17 years of age
to provide their contact details. In addition, this website included information for young people below
16 years of age on how their parents and carers could contact the researchers in case they were interested
in taking part in the study.
Parents and young people between 16 and 17 years of age who provided their contact details were then
contacted to discuss the study in more detail and to answer any further questions. They were then sent
the information sheet in print, a consent form and a freepost envelope to facilitate the return of the
consent form. Interviews were carried out at least 1 week after the initial contact was made.
On the day of the interview, parents and carers of young people aged 10–15 years were asked to provide
verbal informed consent, which was digitally recorded with their permission. In addition, after explaining
and answering any questions about the study, their children were asked to provide verbal consent to take
part in the study and this was digitally recorded. Young people aged 16–17 years provided verbal informed
consent on the day of the interview.
After completing the interview and with the participant’s permission, parents were asked follow-up
questions about the child’s treatment if the young person had been unable to recall specific information
(e.g. drug dose). Interviews were digitally recorded and transcribed verbatim following completion. Any
personal identifiers were removed from the transcript. The study was approved by the Medical School
Ethics Committee of the University of Nottingham.
Analysis
The interviews were analysed using thematic analysis and the development of themes was conducted as
described by Boyatzis.216 The purpose of the analysis was to explore young people’s needs and perceptions
of treatments for tics. Thematic analysis was chosen because it is a flexible method that results in a
detailed description and organisation of the data;217 allowing full exploration of young people’s needs and
perceptions of treatments for tics without the constraints that other theoretically bounded methods impose.
Theme analysis encourages maximum variation sampling whereby the population of interest is represented
by a heterogeneous sample and thus tends to require a relatively large number of participants in order to
ensure saturation of themes.216 We wanted to capture views of young people from early adolescence to
adulthood and with a range of tic severity. A method such as interpretative phenomenological analysis,
which obtains very dense experiential data from small homogenous samples, would not have been
sufficiently flexible to capture this range. To become familiar with the data, the interview transcripts were
read repeatedly and ideas about important features or segments of the data were noted down to develop
QUALITATIVE STUDY OF EXPERIENCES OF SERVICES AND TREATMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
UNCORRECTED PROOF DATE: 12/09/2015 FILE: 10-142-01-2P.pdf
248
initial codes. These codes helped to organise the data into more meaningful groups and they were
reviewed, combined or discarded to identify potential themes. The themes were developed inductively and
based on the raw data because past research has not examined experiences of treatments for tics among
young people with TS. This inductive approach is considered appropriate when previous research findings
do not allow developing theory driven or research driven themes.216 Each thematic code was labelled using
five elements: (1) a label or name, (2) a definition of what the theme concerned, (3) a description of how to
know when a theme occurred, (4) a description of any qualifications or exclusion and (5) examples,
including positive and negative examples.216 This allowed examining the reliability of the themes.
Results
A total of 40 interviews were conducted (38 by telephone, two face to face) (see Appendix 7). The data
were reviewed to determine that saturation of themes had been achieved. Young people’s demographic
characteristics are presented in Table 8.
Eight main themes were identified, of which seven had subthemes. To examine the trustworthiness of the
themes and subthemes, a code book was prepared which included for each theme and subtheme:
(1) a descriptive label, (2) a definition of the theme, (3) pointers to look for when identifying the theme,
(4) any examples of aspects which would exclude an extract from the theme and (5) an illustrative sample
extract.216 An experienced qualitative researcher who was not involved in the study used the code book to
recode 26 unlabelled extracts of text. Her ratings were compared with the original coding conducted by
the study research fellow (JC) and agreement was excellent (24/26, 92.3%).
Theme 1: need for access to informed and expert care
This theme describes young people’s perceptions about the importance of receiving care from health
professionals who were knowledgeable about the condition including the challenges of accessing expert
care and the consequences of receiving ill-informed care.
TABLE 8 Summary characteristics of young people who participated in the interviews
Characteristic n % Median Range
Age (years) 13.0 10–17
Sex
Male 31 77.5
Female 9 22.5
Ethnicity
White British 34 85.0
Mixed/multiple ethnic groups 6 15.0
Co-occurring conditions as reported by child’s parent
(may be more than one)
18 45.0
ADHD 8 20.0
OCD 7 17.5
ASD 4 10.0
Anxiety 4 10.0
Other 4 10.0
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Perceived lack of understanding of TS among health professionals Young people perceived that
some health professionals have limited or no knowledge of TS and tics, as well as about treatments or
interventions for tics. Furthermore, some health professionals were perceived as unsupportive or not
understanding of the condition. There was a feeling they lacked adequate training in providing treatment
for tics. Young people often described health professionals as having little knowledge about their condition,
both when seeking medical help for tics and while receiving treatment. Young people remembered visiting
different services to receive treatment for tics, often finding that knowledge of TS and tics was limited.
YP ID 40: . . . most of the places we have been to about my Tourettes like it seems like no one actually
knows about it, like we know more than them . . . when we go there they usually ask us about it
more than we ask them.
Interviewer: How does that make you feel?
YP ID 40: Ermm quite annoyed . . . because like we have been asked to go there by someone saying
they know a lot about it but they barely know anything.
Another participant described their experience of treatment:
. . . I saw him [a healthcare professional] for two years and on the second year he told me to do habit
reversal and then habit reversal didn’t work so we didn’t know if that was cos he had given us the
wrong information or what, so we decided to go elsewhere and then we thought we would give him
a second chance cos he was just in training for the habit helping at the time. All that he said was sort
of out of a text book or something that he thought might have helped.
YP ID 39
Some young people described wanting to receive more information about TS and tics, as well as
information about their treatment.
I would like to know what the Clonidine does, simply because the yeah, the doctor that prescribed it
said and I quote ‘I am not really sure about this, so I can’t really say for definite that it is Tourettes’. So
I don’t really kind of trust what he says.
YP ID 2
Difficulties accessing or maintaining specialist care This subtheme describes how young people
perceive that there have been difficulties or delays in receiving specialist care. It can also include
perceptions that the information received about the condition did not meet expectations, or was not
perceived as relevant or sufficient to understand more about TS or tics.
. . . After I got diagnosed 2 years after that, that’s when I started to get information about it. . . .
I would have liked it to have been just more of a frequent thing when I actually needed the help
more. Some sort of like guidance on things I could do, instead of just finding out that I had to deal
with it all on my own.
YP ID 32
Importance of receiving informed specialist care This subtheme captures how young people perceive
benefits to be treated by health professionals who are knowledgeable and was represented in one-quarter
of the interviews. Perceived benefits included feeling understood and more confident, as well as feeling
that health professionals can provide useful information about TS.
. . . I can talk to my parents about anything but she [health professional] was just like another person,
who, I don’t know but just who knows a bit more about Tourettes you know what I mean. So she
knows she has some knowledge of Tourettes so she knows what message could help me . . .
YP ID 9
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. . . he [health professional] has had a few, not interview, sessions with me, and talked to me about
how, he has tried to understand, he is verbally very good he has explained to me about what he
knows about Tourettes and he and another member he explained what’s happening and from that he
suggested ways of being able to not necessarily prevent the twitches but to limit them. Which I did
find very helpful.
YP ID 38
. . . I think the psychologist that I was talking to was very understanding about my Tourettes and it
kind of reassured me that there are people that do understand it and didn’t make me feel so bad
about it really.
YP ID 13
Theme 2: need to manage emotional responses associated with tics
This theme captures young people’s experience of negative emotions in relation to tics, such as
self-reported anxiety, worries, anger or frustration, and young people’s attempts and interest to manage
or reduce these emotions.
Negative emotions as contributing to tics Young people spoke about experiencing negative emotions
associated with tics. These emotions were described variously as ‘worries’, ‘anxiety’ and ‘stress’.
These emotions were considered to worsen tics, which in turn contributed to experiencing further
negative emotions.
. . . it makes me worried and then because I am worried I do it [tic] more and then because I am doing
it more and people are looking I do it even more than that.
YP ID 19
. . . at one point they [tics] just kind of like fade off but then the next point you think it’s all gone and
you have anxiety levels build up and it starts all over again.
YP ID 21
. . . I try to not do them [tics] but I find it a bit hard when we are doing something and I am nervous
like when we are doing something and I am a bit nervous about it, it is a bit worse.
YP ID 34
Interest and attempts to reduce negative emotions associated with tics For some young people, the
subjective emotional responses associated with tics were sometimes considered more troublesome than
actual tics, and they tried different practices to help them manage their emotions and to reduce their tics.
. . . I am fine with the tics it is more the stuff that comes along with the tics like the emotion that’s
worse I find.
YP ID 14
. . . I have got some relaxation CD’S, they seem to make it better, yeah and when mum comes into me
cos I am twitching really bad. Mum comes in to calm me down and that makes me feel a lot better.
. . . She [mum] like just like talks to me and tries to make me think about something else and just
calms me down.
YP ID 19
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When asked about what they would hope a treatment for tics to achieve, some young people spoke about
having a treatment or intervention that could help them feel calmer.
. . . it (treatment) could make you feel more relaxed so then, then you wouldn’t be well you would be
less stressed so then I wouldn’t have done them [tics] as much.
YP ID 18
Say some day I had an important exam I could just like have some of that treatment or that
medication or something and then that could like calm me down, it would be like a way to get me
more focused for something like if I had an exam.
YP ID 32
Theme 3: the importance of gaining a sense of control over Tourette syndrome
This theme captures how young people feel they have little or no control over their tics and how they feel
they would like to have or learn to have control over tics. It also includes attempts to control tics, as well as
interest in treatment for tics that is perceived as helping to gain control over tics.
Perceived lack of control over TS and tics Young people described feeling little or no control over their
tics as if TS had its own will or personality or as being something foreign or alien to them.
. . . one of the things about tics is it is something that your body is doing that you don’t really have
any control of but it is kind of a major physical thing. [Pause] cos a lot of your body functions you
don’t have any control over like digestion and stuff like that but with this yeah it is something you feel
you should have control over but your body is not letting you control and being able to control it is a
good thing I think.
YP ID 16
. . . sometimes I lose like all control and my Tourettes takes over and does what it wants to do.
YP ID 13
Need to gain control over TS and tics Young people considered that gaining a sense of control over
them was a desired outcome of treatment. This sense of control was described as an ability to stop the tics
when the young people wanted to and as a general sense of having control over oneself.
To almost be able to control my tics so like I could hold them in but then like let some of them out at
different times.
YP ID 40
Just personally, really, to know that I can be able to control myself, as well as you know be able to be
a normal person.
YP ID 32
In relation to this, young people spoke about behavioural interventions as something that could help them
gain a sense of control over tics.
I just like to feel that I am in control of it myself. Rather than something else doing it for me, which is
why, I like habit reversal because I like to be in control.
YP ID 5
It [behavioural intervention for tics] sounds good because it is a different way of trying to stop the tics.
Trying to do something else to resist the kind of urge to do it. I personally quite like that idea more
because you, the person who has tics has to do something to try and stop it and it’s really ermm well
it is a way of doing something else . . .
YP ID 34
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Theme 4: desire for a treatment to stop or reduce tics and the urge to tic
Not surprisingly, wanting an intervention that would stop or reduce their tics, as well the urge to tic,
was a strong theme that emerged from the data.
Wanting to stop or reduce tics This subtheme reflects how young people would like their tics to be
stopped, cured, taken away or eliminated, as well as how they would like their tics to be reduced
or ameliorated.
So something that could reduce or eliminate tics, even if it is only at night or in certain situations or
things like that, that would probably be my ideal treatment.
YP ID 29
Wanting to reduce urges to tic The urge to tic was perceived as uncomfortable and reducing the urge
to tic was seen as an important outcome of treatment.
. . . I would want the urge to twitch to be reduced. Also if my Tourettes could go overall that would be
fantastic, I don’t know how realistic that is, but I would certainly want the urge to be less.
YP ID 38
Theme 5: concerns and limitations about taking medication for tics
This theme describes young people’s negative perceptions of medication for tics, based on their direct
experience with medication or on their understanding of this treatment. Perceived adverse effects of
medication for tics were frequently mentioned by young people.
Concerns about taking medication for tics In this subtheme, the young person who has not taken
medication perceives potential difficulties or drawbacks about taking medication for tics, including adverse
effects, difficulties to remember to take the drug, the need to take medication for a prolonged period of
time and bad taste of medication. There is a general perception that medicines cannot be good and some
young people described an interest in other forms of treatment.
. . . they [drugs] do have side effects and they make you drowsy and stuff like that and maybe you feel
weird when you have that drowsiness.
YP ID 25
I wouldn’t want to be taking that much drugs . . . it can’t really be good for you.
YP ID 16
. . . I would probably prefer to learn to suppress them [tics] almost, I don’t really want to be taking
tablets . . . I just wouldn’t like to take them everyday almost and like with most tablets if you suddenly
stop them as well you can get ill from them and that.
YP ID 40
Perceived adverse effects of medication This subtheme captures young people’s actual experience of
taking medication for tics, often the feeling that medication caused adverse effects. These effects, which
were associated with different types of medication, included drowsiness, tiredness, self-reported
depression, nightmares, weight gain and a sense of not being oneself.
I used to get really hungry so I put on loads of weight or I used to get tired. . . . It was horrible because
I could just go to sleep in the middle of the day in class and that, and I put on quite a bit of weight
as well.
YP ID 8
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For some young people, adverse effects were the main reason to stop taking medication, or for changing
to a different one, even if they perceived an improvement in tics.
YP ID 7: . . . I was happy that my tics weren’t as bad when I was on them [clonidine tablets] but I just
wasn’t happy about being so depressed all the time.
Interviewer: And you said that you stopped taking it, why did you stop?
YP ID 7: Just because it wasn’t just making me depressed it was also giving me really scary dreams.
Young people described seeking a balance between the adverse effects associated with certain drugs and
the positive benefits of tic reduction. When seeking this balance, young people spoke about seeking
advice from their parents and health professionals.
. . . I found that [aripiprazole] gave me the kind of dizzy feeling so I always got light headed when
I stood up and stuff . . . I was very tired as well. So we have decided with the doctor that I would do
one [5 milligram tablet of aripiprazole] in the morning and one [5 milligram tablet of aripiprazole] in
the evening and we kept that going for a bit but then eventually when the dizziness wasn’t going
I decided that I would go back down to one tablet but have a few more tics but I didn’t mind.
YP ID 12
. . . when we are making decisions about Tourettes I usually talk it over with my mum and dad first
because obviously I don’t know everything that is best for me. So if I am planning on reducing a
medication or increasing it or changing it or if I think I have got a new Tourette or tic I always tell my
parents and see what they think of it and everything just to make sure it’s not something I didn’t think
it was.
YP ID 39
Perceived limited or lack of benefit of medication for tics This subtheme captures how young people
feel that medication left the tics unchanged, or had a positive effect on tics for only a limited period of
time. It can also include young people’s perception that medication worsened tics.
. . . it [aripiprazole] wasn’t really doing much I stopped taking it and they said if you feel like you want
to start taking it again you can but then I didn’t.
YPar ID 18
I was on a medication called risperidone for a while, which was helpful to start off with, it certainly
had a noticeable effect but once I had got the level, my risperidone level sort of steady after about a
year or after about 6 months it stopped being so effective so I went off it . . .
YP ID 29
Theme 6: positive experiences of medication for tics
This theme describes how young people felt that medication for tics can help them to reduce their tics and
to have better control over them.
. . . it [risperidone] has helped me, it hasn’t completely like stop them (tics) but it has helped me.
Before I was on the tablets I was ticcing really, really loads and the medication has controlled them a
better, so I don’t really tic that much anymore.
YP ID 27
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For some young people medication for tics allowed them to feel less self-conscious about their tics and to
dissimulate them better when in public.
It [clonidine] makes them better . . . sort of makes them easier to control . . . they just don’t sort of
happen as much . . . It’s good because it is easier and I don’t have to feel at all self-conscious at school.
YP ID 24
[On aripiprazole] Basically ermm I probably say I still do it at school but I can easily make it look like I
am just looking at something cos all it is really is a tensing of the muscle in the neck. It is not doing
the movement it is just straining a muscle to get rid of a burning feeling. That’s it, I just look around
and that’s what I do really, just make it look like nothing.
YP ID 22
Theme 7: behavioural intervention for tics is a ‘natural’ intervention that could be
incorporated into daily life
This theme captures positive perceptions of behavioural intervention for tics either from direct experience
or based on their understanding of what the treatment involves. The perception that it is ‘natural’ and fits
with their existing strategies used to manage tics.
Perceived potential helpfulness of behavioural interventions for tics In response to a description of
behavioural interventions, young people perceive that such an intervention involves doing something that
they have tried before and that makes sense to them. However, of the 40 participants, 33 young people
had not received a behavioural intervention. Of the 33 young people who had not received a behavioural
intervention, 14 endorsed this subtheme, while a small number (n= 4) perceived both potential benefits
and difficulties with this intervention.
Young people’s responses to the description of behavioural interventions suggested that many perceived
that this treatment was similar to some of the behavioural strategies they have previously used when
attempting to reduce or manage their tics. As such, behavioural interventions for tics were described as
‘natural’ with few or no adverse effects that, if learned adequately, could be incorporated into daily life.
I don’t really think it will be difficult. I think it will be like something I have done in the past, I think
getting myself out of the habit of it could slow the process down a bit . . .
YP ID 32
That sounds like it makes sense, like it doesn’t sound like a magical cure, it sounds natural and that it
would eventually work.
YP ID 22
It is good because it is behaviour it is not like taking a pill or doing something to you like making you
dizzy or changing your mind set it is just to do with your behaviour.
Participant ID 25
Positive experiences of behavioural interventions for tics Although young people who received a
behavioural intervention for tics described engaging in a process that took time, the process was perceived as
being positive. They describe from experience how they are able to practice exercises or techniques and how a
behavioural intervention is generally a helpful approach. Seven participants received some form of behavioural
intervention and some of them (n= 3) described both positive and negative experiences related to this
treatment. Of the seven participants who received a behavioural intervention, five endorsed this subtheme.
So it wasn’t anything at all troubling about it [behavioural intervention for tics], it was not anything
physically painful, it wasn’t anything mentally stressing, I didn’t find it stressing what so ever.
Participant ID 38
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. . . it took me a while but now it works more. Like I don’t think about it. I don’t have to think oh I
must bite my lip I just do it without thinking, but at the time I was just like oh this isn’t going to work
but it got better.
Participant ID 5
Theme 8: limitations of behavioural interventions for the treatment of tics
This theme captures how young people perceive potential limitations or difficulties in practising a
behavioural intervention or in the limited helpfulness of this treatment. Other direct experiences of
behavioural interventions suggest they could be unhelpful or difficult.
Perceived potential difficulties of behavioural interventions for tics When asked about their views
on the description of behavioural interventions for tics, some young people also perceived that this
treatment might require considerable effort and support from others. Young people also perceived that a
behavioural intervention could be a slow process that involved several sessions with a health professional,
and some of them anticipated difficulties remembering to practice treatment exercises. Thirteen of the
33 young people who had not received a behavioural intervention endorsed this subtheme.
It [behavioural intervention] requires a lot of proactivity on the person’s behalf so they need to make
sure that they have got the support around them, that they have got a doctor that understands this
therapy, which might be easier said than done. It is not easy to think about what you are doing and to
change your behaviour, you know it is not an easy thing.
Participant ID 4
Well, [pause] I don’t mind going once but I probably wouldn’t want to go loads of times because
when I get home . . . I would probably want to do something else like watch some telly or play with
my mates. I don’t mind going once and then trying it out, but if it is going loads of times I probably
wouldn’t want to do that.
Participant ID 20
Some young people felt that a behavioural intervention for tics would not be helpful for ‘major’ or strong
tics, and one young person perceived that having to think about tics while receiving this treatment could
worsen his tics.
Just having to think about it, you know when someone says this is what you think about when you
have a tic, and then it makes you think about it more, so then you tic more.
Participant ID 8
Negative experiences of behavioural intervention for tics Those young people who had received a
behavioural intervention sometimes felt that it had not helped. Of the seven young people who had
received behavioural intervention, five endorsed this subtheme. They described difficulties identifying and
executing competing or antagonistic responses for motor or vocal tics, and one young person remembered
developing a tic from a competing response.
. . . I thought habit reversal did work for a while and I thought yeah it is helping a lot and I am quite
enjoying this, you know cos it is getting a lot better and it is helping my Tourettes go away. A week
after I started to see improvements I started to do the habit that I was reversing.
Participant ID 39
When she [health professional] was telling me of the ways of how I could transfer my tics from like
being a big massive leg flick to just like scrunching my hand up or something, I just couldn’t do it,
I didn’t know how.
Participant ID 6
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Qualitative evidence summary
Evidence summary from the systematic review of qualitative studies
The main themes emerging from the systematic review concerned access to care, lack of knowledge
among health professionals regarding TS and difficulties and delays in obtaining a diagnosis.
Difficulties in accessing care
The qualitative review identified a number of barriers to treatment for tics among parents of young people
with TS, such as difficulties finding well-informed treatment providers and concerns about the adverse
effects of treatment, including medication and behavioural intervention. Some health professionals
reported concerns that stigmatisation of the TS diagnosis may act as barrier to treatment among parents of
young people with TS. However, there was little evidence from parents’ reports that they had not sought
treatment because of concerns about being labelled or having a TS diagnosis.
Difficulties and delays in obtaining a Tourette syndrome diagnosis
The qualitative review suggested problems regarding the diagnosis of TS, including delays in receiving a
diagnosis and perceived lack of knowledge of health professionals in recognising symptoms. Mol Debes
et al.209 identified delays in receiving a diagnosis of TS among young people, with a median of 2.8 years
from age of tic onset until diagnosis.
Medications for tics
There was evidence from the qualitative review that concerns about adverse effects affects medication
adherence. The survey conducted by Woods et al.211 found that 43% of parents reported that an
important reason for their child not receiving treatment were worries about the adverse effects
of medication.
Evidence summary from the Qualitative study of Experiences of Services and
Treatment survey of parents and carers of young people with Tourette
syndrome
The key topic areas that emerged from the results of the survey are as follows.
Difficulties accessing care
The survey results identified that many parents and carers of young people with TS experienced problems
accessing specialist care, including delays in being referred to specialist treatment and perceived a lack of
knowledge and understanding from health professionals, particularly at primary care level.
Difficulties and delays in obtaining the diagnosis of Tourette syndrome
In the QuEST survey, the mean age at onset of tics was 5.9 years and the mean age of diagnosis was
9.1 years, giving an average delay of just over 3 years between symptom onset and diagnosis. The survey
results showed that parents and carers of young people with TS experienced difficulties in accessing a TS
diagnosis, inadequate information was given at diagnosis and lack of support from health professionals
after a diagnosis was given.
Importance of providing information to parents and schools
The survey results supported the importance of providing comprehensive information about TS and tics to
parents and carers of young people and to schools. More than two-thirds (68.5%) of parents and carers
reported that a health-care professional had given them information about tics. Of those who received
information, over three-quarters (77.7%) considered that the information was somewhat helpful or very
helpful. The majority of parents who received information received this from CAMHS (58.7%) and
paediatric services (37.3%). Rarely was information on TS provided to parents by primary care (3.5%).
DOI: 10.3310/hta19XXX HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. X
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Hollis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
UNCORRECTED PROOF DATE: 12/09/2015 FILE: 10-142-01-2P.pdf
257
Only just over one-third of parents/carers (38.1%) reported that a health-care professional had given
information about TS and managing tics to their child’s school. When schools were given information, the
majority of parents (70%) felt that this had been either helpful or very helpful. Parents commented that
information given to schools had increased teachers’ knowledge and understanding of TS and about
management strategies they could employ. In addition, this information was felt also to help teachers to
better recognise tics and potentially access help for other children and young people with tics.
Parents’ experiences of medication for tics
Just over half of the parents (54.7%) reported that their child had received medication for tics. The most
commonly prescribed drugs were two antipsychotics [risperidone (27.7%) and aripiprazole (19.9%)] and
the noradrenergic agent clonidine (26.3%). The helpfulness (reported as somewhat helpful/very helpful) of
medications varied, being greatest for aripiprazole (69.1%), intermediate for risperidone (39.5%) and
clonidine (41.1%) and least for the older antipsychotics including haloperidol (25.0%) and sulpiride
(15.4%). Adverse effects were also reported for all medications, with the fewest reports of moderate/
severe adverse effects for aripiprazole (25.5%), intermediate for clonidine (46.6%) and greatest for
risperidone (63.2%) and haloperidol (70.8%). Specific adverse effects were reported by parents for different
drugs: risperidone – increased appetite, weight gain; clonidine – tiredness/fatigue, depression; and
aripiprazole – tiredness/fatigue, weight gain, nausea, tremor/shakiness. However, the survey was not able to
assess the prescribed dosage of particular medications and this limits the interpretation of the parents’ reports
of both helpfulness and adverse effects.
Parents’ experiences of behavioural intervention for tics
Just over one-quarter of parents (25.9%) reported that their child had received a behavioural intervention
for tics. Just under half of parents (48.6%) reported that their child’s behavioural intervention had been
helpful (i.e. somewhat helpful/very helpful). Interestingly, adverse effects of behavioural interventions were
reported by just over 10% of parents. Behavioural interventions were most commonly delivered by CAMHS
(71.4%), followed by paediatric services (15.7%). Just over half (52.2%) of parents reported that their
child had received fewer than five sessions, with just under one-quarter (23.2%) receiving between 5 and
10 sessions, and a similar proportion (24.6%) receiving more than 10 sessions.
Parents’ experiences of other treatments
A total of 78.5% of parents reported that their child had tried at least one additional treatment approach
other than medication or a behavioural intervention (i.e. HRT/CBIT). The three most commonly reported
were relaxation training (delivered in isolation from a comprehensive behavioural intervention, 39.8%),
exercise (34.1%) and fish oils (30.5%).
Parents’ desired outcomes of treatment
For parents and carers of young people with TS, there was clear evidence that the most important
outcome was reduction in their child’s tics and their child gaining greater control over their tics. Parents
also mentioned the importance of managing their child’s anxiety and emotions associated with tics and
increasing their child’s self-esteem. Interestingly, other broader outcomes such as the effect of tics on their
child’s friendships, school functioning, leisure activities and family functioning were rated as significantly
less important than tic reduction.
Evidence summary from in-depth interviews with young people with Tourette
syndrome
The following key themes emerged from the interviews.
Perceived limited knowledge and understanding of TS by health professionals
Young people with TS described limited knowledge and understanding of TS among the health professionals
they encounter. This theme was associated with difficulties accessing expert care, receiving insufficient
information about the condition and problems trusting the adequacy of the treatment that was offered.
When young people described being treated by knowledgeable health professionals, they felt understood,
more confident and perceived that the advice given by health professionals was helpful.
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Young people’s direct experience of medication for tics
Just over half (55%) of young people interviewed had received medication for tics. Among those that had
received medication, there was a range of views expressed regarding both experiences of benefits (e.g. tic
reduction and greater control over tics) as well as adverse effects. These adverse effects, which were
associated with different types of medication, included drowsiness, tiredness, self-reported depression,
nightmares, weight gain and a sense of not being oneself.
Young people’s perceived potential difficulties of medication for tics
Among those young people who had not taken medication for tics, the qualitative interviews identified
concerns about taking medication, including adverse effects, difficulties remembering to take medication
and a general perception that drugs cannot be ‘good’ and are not an appropriate way of managing behaviour.
Young people’s direct experience with behavioural interventions for tics
Less than one-fifth (17.5%) of young people interviewed had received a behavioural intervention for tics.
Among this group with direct experience of a behavioural intervention, there were mixed views. Some
young people felt they were able to practice the techniques learned and spoke about experiencing more
control over their tics, and that the behavioural intervention built on previous strategies developed by the
young people themselves to manage their tics. However, others found it difficult to practice behavioural
strategies and one young person described a competing response that developed into a tic.
Young people’s perceived potential benefits and limitations of behavioural
interventions for tics
The majority of young people interviewed had not received a behavioural intervention and generally held
positive views about this type of approach. Behavioural intervention was perceived as being ‘natural’ and
easy to engage with. However, some young people expressed reservations concerning behavioural
intervention including the perception that behavioural intervention could be cumbersome and may not be
effective with more severe tics.
Young people’s desired outcomes of treatment for tics
For young people, the most important outcomes of treatment were reducing or stopping tics and urges to
tic, being able to manage emotions associated with tics (e.g. self-reported anxiety, stress and worries) and
of gaining a sense of control over tics.
Discussion
Overall, the results of the part 2 study (QuEST) provide a unique insight into the perspectives of young
people with TS, and their parents, concerning their experiences of care and treatment. The three
components of QuEST (systematic review of qualitative studies, national online survey of parents, and
in-depth interviews with young people) produced converging findings. The results are discussed below
with recommendations for practice and further research.
Access to care and knowledge of Tourette syndrome among
health professionals
All three components of QuEST highlighted difficulties and delays in both obtaining an initial referral to a
specialist from primary care and then receiving a timely diagnosis and relevant information, appropriate
treatment and follow-up once referred. The average delay of 3 years between onset of tics and diagnosis
illustrates this problem. Some young people and parents reported feeling abandoned after receiving a
diagnosis and were returned, in their view, prematurely to primary care without further follow-up
and support.
Tourette syndrome is a condition that does not fit easily within the traditional partition of physical health
and mental health services. We found that children and young people receiving care from a range of
services including CAMHS, paediatrics, neurology, private practice and primary care. TS is often referred to
as a ‘neurological disorder’ with the assumption that it will be managed within paediatric/neurology
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services. However, skilled management of disabling associated symptoms (e.g. anxiety, OCSs), common
comorbidities (e.g. ADHD, OCD, ASD) and the provision of behavioural interventions typically falls within
the remit of CAMHS. Clearly, a more integrated approach is required with the provision of information,
diagnostic and evidence-based interventions for TS available from a single specialist service in a local area.
Recommendations
Those working in primary care should be aware of the prevalence and clinical features of children and
young people presenting with tics and suspected TS. Local care pathways for children with suspected TS
need to be established to accelerate access to expert assessment and diagnosis. It is important that health
commissioners recognise that skilled assessment and treatment of TS should be provided by specialist
CAMHS. Further health services research is required to identify barriers to care and unmet need for services
for young people with TS and to develop targeted interventions to improve referral practice and reduce
the delay between onset of tics and diagnosis.
Psychoeducation and information on Tourette syndrome
Young people and their parents valued the provision of clear information on TS and its treatment. While
information on TS and its treatment was offered to the majority of parents, this was not universal, with up
to 25% not receiving information from their clinical service.
There is a significant unmet need for provision of information on TS and its management designed
for schools.
Recommendations
Information in various formats [written, digital versatile disc (DVD), internet and mobile applications
(‘apps’)] should be made available for young people, parents and teachers. Research is required to
investigate the impact of providing structured information on treatment adherence/engagement,
self-efficacy and management of TS in schools.
Recognition of the role of anxiety and emotional symptoms in
Tourette syndrome
Both young people and their parents consistently raised the issue of anxiety as both a cause and associated
feature of TS. Young people described both anticipatory anxiety associated with tics (e.g. fears of ticcing in
front of friends or in public places), anxious and tense feelings associated with ‘urges’ and tic suppression
and the impact of extraneous stressors (e.g. exams) that exacerbate tics. Young people felt that
interventions that targeted and reduced anxiety were particularly important.
Recommendations
Assessment of anxiety symptoms should be incorporated into routine assessments and outcome measures.
The role of behavioural interventions and medication in reducing anxiety should be the subject of
future research.
Medication for tics
Young people requested better understanding/information about how drugs work and their adverse
effects. Findings from the systematic review of qualitative research suggested that lack of accurate
information about medication and adverse effects was associated with less acceptance and uptake of
medication, potentially leading to poorer outcomes. From the perspective of parents, aripiprazole was
viewed as most helpful with least adverse effects. Regarding adverse effects associated with other drugs,
clonidine was intermediate with the adverse effect most commonly reported with risperidone and the
older antipsychotic drugs.
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Recommendations
Better information should be provided with respect to both the rationale for using medication to treat tics
and potential adverse effects. Given the positive perception of aripiprazole, RCTs are needed to evaluate
clinical effectiveness and safety and the impact of dosage on outcome.
Behavioural interventions for tics
Access to behavioural interventions for young people with TS is clearly limited. Only one-quarter of young
people in the online survey and less than one-fifth of young people interviewed had experience of a
behavioural intervention. All of those young people had received medication in addition to behavioural
interventions. Parents perceived that the helpfulness of behavioural interventions was similar to medication
such as clonidine but with fewer adverse effects. The perception of behavioural interventions was generally
positive, particularly among those young people that had not received this treatment. A particular
attraction of HRT/CBIT for young people appeared to be that it involved learning techniques that built on
their own efforts to manage tics and could then be practised so they became automatic responses.
However, more than half of parents indicated that their child received fewer than five sessions of a
behavioural intervention, which is below the recommended number of eight or more sessions for CBIT.214
Overall, the limited access to behavioural interventions and the suggestion that young people may receive
a shorter course of therapy than provided in clinical trials indicates that different forms of delivery,
including greater use of technology, may be required.
Recommendations
Increased access to evidence-based behavioural interventions for tics is required for young people with TS.
Future research should explore the potential for delivering behavioural interventions (e.g. HRT/CBIT) via
video consultation and developing computerised interactive treatment HRT/CBIT packages that could
widen access to behavioural interventions. The acceptability, feasibility and efficacy of alternative modes of
delivery for behavioural interventions should be investigated through RCTs.
Important outcomes of treatment from the perspective of young people
with Tourette syndrome and their parents
Both young people and their parents placed greatest importance on tic reduction and gaining control over
tics. This concurs with the primary clinical trial outcomes that focus on tic reduction using scales such as
the YGTSS. However, young people also indicated that reduction in anxiety and stress was also important
and should be considered as a relevant outcome.
Recommendation
Existing outcome scales such as the YGTSS that focus on tics are clearly relevant from the perspective of
young people and their parents. However, measuring reductions in anxiety and stress should also be
considered as a relevant outcome of treatment and these measures incorporated into clinical trials.
Strengths and limitations
An anonymous online survey gave parents the opportunity to describe both positive and negative
perceptions of treatment for tics. Internet access has increased rapidly and the Office for National Statistics
has reported that in 2013, 83% of households had internet access. Text boxes provided the opportunity to
express views with more breadth and depth and a large number of parents took advantage of this option.
Parents were recruited through TA membership and through the TA website, which may have biased the
sample towards those who are better informed, more concerned or more proactive in seeking information
which is a limitation. A further limitation is that we cannot estimate the response rate of the survey as we
do not know how many people accessing the TS website would be eligible for the survey. However, the
sample size is a strength meeting the target recruitment.
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The use of in-depth, semistructured interviews to explore young people’s views was a strength. The
majority of interviews were conducted by telephone and it has been suggested that telephone interviews
may be shorter and contain proportionately more prompting by the interviewer than face-to-face
interviews.218 However, telephone interviews provide more geographic heterogeneity and allow for a more
inclusive sampling strategy. Young people are arguably comfortable using phone technology and the
medium can give an enhanced sense of anonymity. Some young people chose to be interviewed with their
parent present, which might have influenced responses; however, young people seemed to talk openly
and to consult the parent only when they were unable to remember details of treatment, such as a drug
name or the time when they received an intervention. The failure to include health professionals in the
study could be considered a limitation but the views of clinicians were represented by the TEG.
Furthermore, the focus of the research was to explore the experiences and perceptions of young people
with TS and parents.
Conclusion
The perspective of young people with TS and their parents on their experience of treatment and care had
previously received little attention. Therefore, these findings should lay the foundations for future research
and contribute to the development of patient-centred treatment guideline.
Overall discussion
This report combined a systematic review and meta-analysis of interventions for TS with a qualitative study
of young people with TS and their parents regarding their experiences and perceptions of care
and treatment.
To our knowledge, this is the first comprehensive systematic review and meta-analysis of pharmacological,
behavioural and physical interventions for children and young people with TS. It is also the first qualitative
study involving in-depth interviews with young people with TS exploring their experiences of care
and treatment.
Detailed discussion of the results from the part 1 and part 2 studies has followed the individual sections
above, therefore, the aim of this overall discussion is to draw together and integrate the main findings
from both studies and discuss implications for practice and future research.
Key findings
Pharmacological interventions
Qualitative study of Experiences of Services and Treatment national survey and
qualitative study
l The online national survey found that just over half of young people with TS had received medication
for tics. The most commonly used drugs were risperidone, clonidine and aripiprazole.
l Young people and parents reported that medication could be helpful in reducing tics but frequently
expressed concerns about adverse effects and lack of provision of relevant information explaining the
rationale for using medication for tics and possible adverse effects.
l Of the medications surveyed, aripiprazole was perceived by parents of young people with TS as being
most helpful with least troublesome adverse effects.
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Systematic review and meta-analysis
l Antipsychotics and noradrenergic agents are the only classes of drug with clear RCT evidence
suggesting short-term clinical effectiveness for treating tics in children and young people with TS. The
size of effect on tic reduction for antipsychotics and noradrenergic agents is moderate to large and is
likely to be clinically meaningful.
l There are no RCTs of aripiprazole compared with placebo. However, head-to-head comparisons
suggest that aripiprazole may be equally effective as other antipsychotics for tics. The main differences
between antipsychotic drugs concerns their adverse-effect profiles.
l Among noradrenergic agents, clonidine and guanfacine (not available in UK) have the best evidence for
clinical effectiveness. However, there are unlikely to be important clinical differences in tic reduction
among antipsychotics and between antipsychotics and noradrenergic agents. There is no clear evidence
that the clinical effectiveness of antipsychotics or noradrenergic agents is moderated by either tic
severity or comorbidity.
l Topiramate, pergolide, metoclopramide and desipramine are other agents with RCT evidence that
suggests they may be effective in reducing tics. However, the known adverse effect profiles of these
drugs, balanced against relatively weak evidence of benefits, means that these agents are unlikely to
be considered clinically useful for the treatment of tics in children and young people with TS.
l There is clear RCT evidence that, in the short term, neither stimulants and atomoxetine (used to treat
comorbid TS and ADHD) nor fluoxetine (used to treat comorbid TS and OCD) significantly exacerbate or
worsen tics and atomoxetine may reduce tics.
l A number of other agents were reviewed and were found unlikely to be clinically effective for treating
tics: levetiracetam, selegiline, pramipexole, mecamylamine, ondansetron, baclofen, omega-3 fatty acids
and transdermal nicotine patches.
Behavioural interventions
Qualitative study of Experiences of Services and Treatment national survey
and qualitative study
l The online national survey found that about one-quarter of young people with TS had received a
behavioural intervention (broadly conforming to HRT/CBIT) for tics. Behavioural interventions were
almost always delivered together with medication.
l Young people with TS and parents reported that behavioural interventions (HRT/CBIT) could be helpful
in reducing tics and adverse effects were rarely reported. Young people reported that they valued the
opportunity to learn behavioural techniques that helped them control their tics and build on strategies
that they had developed themselves. However, some young people found these approaches could be
difficult to use and were not always helpful.
Systematic review and meta-analysis
l There is clear evidence that HRT/CBIT produces improvements in tics that may be clinically meaningful.
There is no evidence that the effects of HRT/CBIT are moderated by tic severity.
l There is some preliminary evidence that delivering HRT/CBIT remotely via video consultation
(telemedicine) may be as effective as face-to-face therapy.
l There are no RCTs of negative massed practice or ERP compared with control interventions. However,
head-to-head comparisons suggest that HRT is a more effective intervention than negative practice,
while HRT and ERP may be equally effective interventions for tics. The quality of evidence for
interventions other than HRT/CBIT is low and so conclusions drawn from this evidence should be
treated with caution.
l There is no clear evidence to suggest that relaxation therapy in isolation is an effective treatment for
tics. Anger control training may be a useful intervention for young people with tics and comorbid
disruptive behaviour and behaviour problems may be improved by parent training, although there is no
evidence that parent training is an effective treatment for tics.
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Physical interventions and Paediatric Autoimmune Neuropsychiatric Disorders
Associated with Streptococcal infection
Systematic review and meta-analysis
l There is no evidence to suggest that the physical interventions reviewed – DBS, rTMS, i.v.
immunoglobulin, botulinum toxin and acupuncture – are sufficiently effective and safe to be
considered as treatments for tics in children and young people with TS.
l There is no evidence that i.v. immunoglobulin or penicillin are an effective treatments for tics in
children and young people identified with PANDAS.
l There is a high degree of uncertainty with respect to the benefits and harms of plasma exchange
treatment of tics in children and young people identified with PANDAS.
Access to care and delay in diagnosis
l Young people with TS and their parents frequently reported concerns about lack of knowledge of TS
and its treatment among health professionals both in primary care (GPs) and secondary care (CAMHS
and paediatrics).
l Delays in recognition and referral for diagnosis were common with the average delay of 3 years from
onset of tics to diagnosis of TS.
l There appeared to be a lack of clear care pathways for children and young people with tics and TS.
Inadequate care for children and young people with TS may result from a lack of integration in the
commissioning and provision of physical and mental health services for children and young people with
TS care falling between this gap.
Provision of information and psychoeducation
Qualitative study of Experiences of Services and Treatment national survey
and qualitative study
l Young people with TS and their parents placed great emphasis on the provision of information about
TS and its management. Often this information was not provided by health services or was viewed as
inadequate. An important finding was the lack of information provided by health services to schools on
TS and its management. In only one-quarter of children and young people surveyed with TS had health
professionals contacted and provided information to the school.
Recognition of associated emotional symptoms including anxiety
Qualitative study of Experiences of Services and Treatment national survey and
qualitative study
l Young people with TS and their parents highlighted the importance of recognising and managing
anxiety symptoms associated with TS. This is a complex issue as anxiety can be both a cause and
consequence of tics and is also related to premonitory urges.
What treatment outcomes are important to young people with TS and
their parents?
Qualitative study of Experiences of Services and Treatment national survey
and qualitative study
l Young people with TS and their parents regarded reducing the frequency and intensity of tics and
increasing control over tics as the most important outcomes of treatment.
l Reducing anxiety and stress associated with tics was also viewed by young people in particular as
being important.
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Implications of findings for practice and research
Drawing together the results from the part 1 and part 2 study, there are a number of implications for
practice as well as identified gaps in the evidence requiring further research. Detailed research
recommendations are presented in Recommendations for further research.
l It is clear that both medication (antipsychotics and noradrenergic agents) and behavioural intervention
(HRT/CBIT) can be effective in treating tics. However, the order in which these treatments should be
delivered, and if they are more effective in combination, is unclear. Therefore, RCTs are required
comparing the effectiveness of pharmacological and behavioural interventions delivered alone with a
combined pharmacological/behavioural intervention.
l Aripiprazole was perceived by parents of young people with TS as the most helpful medication with a
relatively favourable adverse effect profile. However, lack of information on dosing and comparison
with a control intervention means that this cannot be interpreted as evidence of effectiveness or lack of
harm. Currently, there are no placebo controlled studies available for aripiprazole in the treatment of
tics, although trials may be ongoing. Therefore, evidence from controlled trials is needed for
aripiprazole before firm conclusions regarding its clinical effectiveness and cost-effectiveness and safety
can be drawn.
l There remains uncertainty regarding the clinical effectiveness and cost-effectiveness of pharmacological
and behavioural interventions for tics in the presence of comorbidities (e.g. ADHD, OCD, ASD). So far,
clinical trials have been inadequately designed to address moderation of outcome by comorbidity and
tic severity. Clinically, this is an important question as comorbidity is the rule with TS rather than
the exception.
l Behavioural intervention (HRT/CBIT) is effective and well received by young people with TS and their
parents. However, access is limited with up to three-quarters of young people with TS surveyed not
receiving this intervention. Factors affecting access are likely to be limited availability of trained
HRT/CBIT therapists, as well as travel to specialist centres and the need for frequent appointments
(e.g. up to 10–12 face-to-face sessions of HRT/CBIT). Access to treatment may be increased if the
behavioural intervention could be delivered remotely (via video consultation/telemedicine) and/or in
digital formats using apps available through mobile devices. An important question for research is
whether or not these forms of delivery of behavioural interventions are practicable and acceptable,
genuinely increase access and are cost-effective.
l The findings highlight difficulties in accessing specialist services and delays in diagnosis. Health services
research is required to understand the key processes and barriers in the referral and care pathway in
order to target health service system change. Furthermore, the factors contributing to delayed
diagnosis need to be better understood as well as the impact of duration of untreated tics on outcome.
l Current lack of provision of information to schools should be addressed by health services. However,
further research is also needed to identify what aspect of information on TS and its management are
most relevant to schools, who it should be delivered to, in what format and what outcomes are
important. Cluster RCTs will be needed to evaluate the clinical effectiveness and cost-effectiveness of
information packages for schools.
l The importance placed on tic reduction by young people with TS and their parents suggests that
current outcome measures, such as the YGTSS, remain relevant and appropriate tools for clinical
practice and research trials. However, the findings also highlight the importance of anxiety symptoms
and further research is required to determine how these symptoms are best measured in children and
young people with TS. Finally, the clinical importance of changes on rating scales can be difficult to
interpret – both in clinical practice and from the results of trials. Therefore, research is needed to
confirm what constitutes clinically meaningful change using rating scales such as the YGTSS.
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Overall conclusions
The findings of this systematic review and evidence synthesis show that there are effective pharmacological
(e.g. antipsychotics and noradrenergic agents) and behavioural interventions (e.g. HRT/CBIT) available for the
treatment of tics in children and young people with TS. However, the number and quality of clinical trials is
low and this downgrades the strength of the evidence and conclusions. Larger and better conducted trials
addressing important clinical uncertainties are required. Access to behavioural interventions is currently
limited and delays in diagnosis of TS are common. Knowledge of TS and its management among health
professionals is often inadequate and information provision to schools is generally poor. Information
packages for schools should be developed and evaluated. The relevance of associated anxiety and emotional
symptoms is often overlooked and requires greater attention from both clinical practice and research.
Further research is needed to inform the development of clinical guidelines for children and young people
with TS, in particular to answer questions about the order in which interventions should be given, how
interventions should be combined and how their clinical effectiveness is affected by comorbidity and tic
severity. Aripiprazole appears a promising drug treatment for tics; however, further clinical trial evidence is
required to establish its efficacy, dosing strategy and safety. Poor access to behavioural interventions is an
important issue and research is needed to test whether or not technological innovations (e.g. mobile digital
and video technology) can be used to widen access while maintaining the effectiveness of the intervention.
Tic reduction is a relevant primary outcome for both clinical practice and research trials and secondary
outcomes should include associated anxiety, stress and self-esteem.
Recommendations for further research
The TEG has made the following recommendations for research, based on its review of evidence:
1. Is the combination of a behavioural intervention together with medication management more clinically
effective and cost-effective in the short term than either behavioural intervention alone or medication
management alone for the treatment of moderate and severe tics in children and young people with
Tourette syndrome?
The behavioural intervention would be an eight-session manualised therapy package that includes HRT,
psychoeducation, relaxation training and contingency management. Medication management would be
protocol-based and allow use of either clonidine, risperidone or aripiprazole. The key outcomes should
include symptoms, impairment, QoL, treatment acceptability, experience of care, level of psychosocial
functioning and the cost-effectiveness of the interventions.
The programme of research would compare the clinical effectiveness and cost-effectiveness of behavioural
intervention alone, compared with medication management alone, and compared with a behavioural
intervention and medication management combined, for the treatment of moderate and severe tics in
children and young people with TS. The study would use a randomised controlled superiority trial design.
The trial would be adequately powered to evaluate the moderating effects of (1) common co-morbid
conditions (e.g. ADHD, OCD) and (2) symptom severity on outcome.
Why is this important?
Currently, about half of children and young people receive medication as treatment for TS (the most
commonly prescribed medications are clonidine, risperidone or aripiprazole), and about one-quarter receive
some form of behavioural intervention (e.g. HRT). Medication carries the risk of adverse effects and is often
required for the long term as treatment is symptomatic. Therefore, psychological interventions tailored for
treatment of tics (e.g. HRT) may either be an effective alternative treatment or in combination with
medication allow lower effective doses to be used, and potentially the combination treatment may result in
better outcomes. RCTs have shown modest benefits of behavioural interventions based on HRT and for
medication (noradrenergic and antipsychotic drugs). However, it is unclear (1) if a combination of a
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behavioural intervention and medication is superior to either intervention alone, (2) if a behavioural
intervention alone is as effective as medication alone, and (3) whether or not the clinical effectiveness of
these interventions (a behavioural intervention, medication and combination therapy) is moderated by
comorbid conditions (e.g. ADHD, OCD) and tic severity.
The suggested programme of research would need to test out, using an adequately powered, randomised
placebo controlled design, the clinical effectiveness and cost-effectiveness of using aripiprazole, compared
with (1) a noradrenergic agent (clonidine) and with (2) placebo plus standard care, for the treatment of
moderate and severe tics in children and young people with TS. The outcomes considered should include
QoL, symptomatic and functional improvements, treatment acceptability and adverse effects.
2. What is the feasibility, acceptability, clinical effectiveness and cost-effectiveness of a behavioural
intervention for tics that is delivered remotely [e.g. via telemedicine/video conference or Skype™
(Microsoft Corporation, Redmond, WA, USA)] compared with traditional face-to-face delivery
of therapy?
The suggested programme of research would need to test out, using an adequately powered, randomised
controlled design, the clinical effectiveness and cost-effectiveness of using remotely delivered behavioural
interventions (e.g. via telemedicine/video conference or Skype) compared with standard face-to-face delivery
of behaviour therapy. The feasibility and acceptability of a remotely delivered behavioural intervention
would need to be established first before evaluating clinical effectiveness and cost-effectiveness of the
intervention using a non-inferiority trial design. The outcomes considered should include QoL, symptomatic
and functional improvements, number of sessions received, treatment acceptability and cost-effectiveness.
Why is this important?
Behavioural interventions (CBIT) have been shown to be effective for reducing tics in children with TS.
Unfortunately, there remain significant barriers to behavioural intervention with no more than one-quarter
of young people with TS accessing behavioural intervention in the UK. Behavioural intervention is delivered
over 8–10 weekly sessions, which is challenging for routine NHS practice to achieve and in a national
survey, almost half of young people received fewer than five sessions. There is low-quality evidence that
video conference CBIT is acceptable and equally effective in reducing tics as face-to-face CBIT. Therefore,
remote delivery of a behavioural intervention may increase both access and adherence to it and allow the
intervention to be delivered to more young people at less cost.
3. What is the feasibility, acceptability, clinical effectiveness and cost-effectiveness of a behavioural
intervention (HRT/CBIT) and self-monitoring mobile app for tics compared with traditional face-to-face
delivery of therapy?
The suggested programme of research would need to test out, using an adequately powered, randomised
controlled design, the clinical effectiveness and cost-effectiveness of using a HRT/CBIT mobile app
compared with standard face to face delivery of behavioural therapy. The first phase of programme of
research would develop an app (computerised version of CBIT – eCBIT) that could be accessed on a
personal computer (PC), tablet and smartphone platforms. The feasibility and acceptability of the HRT/CBIT
app for tics would need to be established first before evaluating clinical effectiveness and cost-effectiveness
of the intervention in an adequately powered clinical trial using a non-inferiority design. The outcomes
considered should include QoL, symptomatic and functional improvements, number of sessions received,
treatment acceptability and cost-effectiveness.
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Why is this important?
Computerised delivery of behavioural therapy is increasingly available for conditions such as depression.
Young people (16- to 24-year olds) have the greatest smartphone usage in the population.219 Therefore,
the advantages of a behavioural intervention and monitoring app include increased accessibility, more
frequent opportunities for rehearsal and practice, and self-pacing. Furthermore, monitoring of tics by
traditional rating scales is subjective and retrospectively averaged over the previous 7 days. The
development of automated tic monitoring via a webcam on a mobile telephone, tablet or PC has the
potential to allow the impact of computerised behaviour therapy to be assessed in real time and fed back
to the young person and their therapist.
4. What is the clinical effectiveness and cost-effectiveness of aripiprazole for the treatment of tics in
children and young people with TS?
The suggested programme of research would need to test out, using an adequately powered, randomised
placebo controlled design, the clinical effectiveness and cost-effectiveness of using aripiprazole, compared
with (1) a noradrenergic agent (clonidine) and with (2) placebo plus standard care, for the treatment of
moderate and severe tics in children and young people with TS. The outcomes considered should include
QoL, symptomatic and functional improvements, treatment acceptability and adverse effects.
Why is this important?
Currently, aripiprazole is prescribed in about one-quarter of children and young people receiving
medication for tics. Survey data from parents and young people suggests that aripiprazole may be an
effective treatment and is better tolerated than either clonidine or risperidone. Despite its increasing use,
there is only one low-quality randomised head-to-head trial of aripiprazole in children and young people
with TS and no RCT with a placebo control arm, which is necessary to establish clinical effectiveness.
5. What is the clinical effectiveness and cost-effectiveness of a psychoeducation/information package on
TS and its management designed for schools?
The suggested programme of work involves developing a TS information package for schools in
collaboration with clinical experts, teachers and service users. Different modes of delivery will be piloted.
The outcomes considered should include both the uptake of the package as well as its impact on tic
management in schools, knowledge and attitudes of teachers, school performance/attendance and
acceptance/reduced victimisation by peers. Following development and piloting of the package, its
clinical effectiveness and cost-effectiveness should be evaluated using both a cluster RCT and
qualitative research.
Why is this important?
Less than half of parents/carers (38%) in a national survey reported that a health-care professional
contacted their child’s school to give information about managing tics at school. Among those
parents/carers whose child’s school was contacted, most of them (70%), reported that the information
given to the school was somewhat helpful or very helpful.
6. What are the barriers to care, including diagnosis and treatment, for children and young people
with TS?
This programme of health services research would involve analysis of routes of referral, types of care and
barriers to care for tics and the common comorbidities of TS, as well as access to liaison for educational
and social liaison. The methodology would be similar to that used by Sayal et al.220 for ADHD and would
explore services accessed by children identified in an epidemiological sample and establish their care
and outcomes.
QUALITATIVE STUDY OF EXPERIENCES OF SERVICES AND TREATMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
UNCORRECTED PROOF DATE: 12/09/2015 FILE: 10-142-01-2P.pdf
268
Why is this important?
Findings from the qualitative literature review and national survey (QuEST) show that delays in referral to
specialist services are common, with an average duration of 3 years between onset of tics and diagnosis
of TS.
7. What is the clinical effectiveness and cost-effectiveness of an exercise programme for the treatment of
tics in children and young people with TS?
The suggested programme of research would need to test out, using an adequately powered, randomised
controlled design, the clinical effectiveness and cost-effectiveness of using an exercise programme plus
treatment as usual compared with usual care for treatment of tics in children and young people with TS.
The first phase of programme of research would develop an exercise programme that is acceptable and
enjoyable for young people of different ages as well as effective in reducing tics. The outcomes considered
should include QoL, symptomatic and functional improvements (both short and long term), number of
sessions received, treatment acceptability and cost-effectiveness.
Why is this important?
Many young people with tics report that exercise is helpful in reducing tics and anxiety levels and increases
well-being and self-confidence. Furthermore, young people with tics may be excluded (or exclude
themselves) from traditional forms of exercise and sport at school, while medications for tics can also cause
overweight and reduce exercise tolerance. Currently, it is unclear which forms of exercise are most helpful
in reducing tics and whether or not the benefits are sustained outside the periods of exercise.
8. What constitutes a clinical meaningful change on the YGTSS from the perspective of children and
young people with TS and their carers?
The suggested programme of research would establish the minimum change in tic score on the YGTSS
that is associated with a clinically meaningful change in function from the perspective of children and
young people with TS and their carers. An adequately powered study would collect longitudinal
observational data from the YGTSS and independent measures of clinical change (e.g. CGI-I scale) rated by
children, young people and carers.
Why is this important?
The YGTSS is the most widely used outcome scale used in clinical practice and research trials. Currently,
there is no clear consensus of what constitutes a clinically meaningful change on the YGTSS when results
are reported from clinical trials. Furthermore, what work that does exist on this topic has focused on
assessing meaningful clinical change from the perspective of clinicians only.
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Appendix 1 Search strategies
Search summary
A systematic search strategy was developed to locate all of the relevant evidence. The balance between
sensitivity (the power to identify all studies on a particular topic) and specificity (the ability to exclude
irrelevant studies from the results) was carefully considered and a decision made to utilise a broad
approach to searching to maximise retrieval of evidence to all parts of the review. The sensitivity of
this approach was aimed at minimising the risk of overlooking relevant publications owing to potential
weaknesses that result from more focused search strategies. The search strategies were initially developed
for MEDLINE before being translated for use in other databases/interfaces.
Study design filters
To aid retrieval of relevant and sound studies, study design filters were used to limit the results of searches
to evidence of systematic reviews, RCTs, observational studies, qualitative studies and survey literature. For
standard mainstream bibliographic databases, search terms for the population were combined with filters
for each of the study designs under review. For searches generated in The Cochrane Library (CENTRAL,
CDSR, DARE, HTA) and HMIC, search terms for the population were used without the appendage of a filter.
The study design filters for systematic reviews and RCTs are adaptations of filters of designed by the CRD
and the Health Information Research Unit of McMaster University, Ontario. The study design filters for
observational studies, qualitative studies and survey literature were developed in-house. Each filter
comprises index terms relating to the study type(s) and associated text words for the methodological
description of the design(s).
Date and language restrictions
Searches for RCTs and observational studies were generated from the inception of the databases to
January 2013. Searches for systematic reviews, primary qualitative studies and survey literature were
limited to research published from 1995 as older research was thought to be less useful.
No language restrictions were applied at the searching stage.
Other search methods
Other search methods involved: (1) scanning the reference lists of all eligible publications (systematic
reviews and included studies) for more published reports and citations of unpublished research, (2) sending
lists of studies meeting the inclusion criteria to subject experts (identified through searches and expert
group members) and asking them to check the lists for completeness, and to provide information of any
published or unpublished research for consideration, (3) checking the tables of contents of key journals for
studies that might have been missed by the database and reference list searches, and (4) tracking key
papers in the Science Citation Index (prospectively) over time for further useful references.
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Databases searched
AEI.
Allied and Complementary Medicine Database.
ASSIA.
BCI.
BREI.
CDSR (The Cochrane Library).
NHS DARE (The Cochrane Library).
ERIC.
CENTRAL (The Cochrane Library).
CINAHL.
HMIC.
HTA database (The Cochrane Library).
EMBASE.
IBSS.
MEDLINE.
PREMEDLINE In-Process & Other Non-Indexed Citations.
PsycBOOKS.
PsycEXTRA.
PsycINFO.
SSA.
Sociological Abstracts.
SSCI.
Web of Science.
Full details of the search strategies and filters used for the systematic review of clinical evidence are
provided below.
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Search strategies used in the major electronic databases
Population search terms
EMBASE, MEDLINE, PREMEDLINE In-Process & Other Non-Indexed Citations,
PsycINFO (via Ovid)
1. exp tic/ or gilles de la tourette syndrome/
2. 1 use emez
3. exp tic disorders/
4. 3 use mesz, prem
5. tics/ or tourette syndrome/
6. 5 use psyh
7. (tic or tics or tourette$).ti,ab,id.
8. or/2,4,6-7
Allied and Complementary Medicime Database (via Ovid)
1. exp tic/
2. (tic or tics or tourette$).ti,ab.
3. 1 or 2
The Cochrane Library (Wiley)
1. mesh descriptor tics, this term only
2. mesh descriptor tourette syndrome, this term only
3. (tic or tics or tourette*):ti or (tic or tics or tourette*):ab
4. (#1 or #2 or #3)
Cumulative Index to Nursing and Allied Health Literature (EBSCOhost)
1. ( s1 or s2 )
2. ti ( tic or tics or tourette* ) or ab ( tic or tics or tourette* )
3. (mh “tic+”)
Australian Education Index, Applied Social Sciences Index and Abstracts,
British Education Index, Education Resources in Curriculum, International
Bibliography of Social Science, Social Services Abstracts, Sociological
Abstracts (ProQuest)
su=((tics) or (tourette’s syndrome) or (vocal tics)) or ti=(tic or tics or tourette*) or ab=(tic or tics
or tourette*)
1. ( s1 or s2 )
2. ti ( tic or tics or tourette* ) or ab ( tic or tics or tourette* )
3. (mh “tic+”)
4. ( s1 or s2 )
5. ti ( tic or tics or tourette* ) or ab ( tic or tics or tourette* )
6. (mh “tic+”)
Biosis Citation Index, Web of Science (Thomson Reuters)
1. topic=(tic or tics or tourette*) or title=(tic or tics or tourette*)
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Health Management Information Consortium (Healthcare Databases
Advanced Search)
1. (tic or tics or tourette*).af.
PsycBOOKS, PsycEXTRA (via OvidSP)
1. (tic or tics or tourette$).ti,ab,hw.
Study design filters
Systematic review filters
EMBASE, MEDLINE, PREMEDLINE In-Process & Other Non-Indexed Citations,
PsycINFO (via Ovid)
Quantitative systematic review
1. meta analysis/ or systematic review/
2. 1 use emez
3. meta analysis.sh,pt. or “meta-analysis as topic”/ or “review literature as topic”/
4. 3 use mesz, prem
5. (literature review or meta analysis).sh,id,md. or systematic review.id,md.
6. 5 use psyh
7. (exp bibliographic database/ or (((electronic or computer$ or online) adj database$) or bids or cochrane
or embase or index medicus or isi citation or medline or psyclit or psychlit or scisearch or science
citation or (web adj2 science)).ti,ab.) and (review$.ti,ab,sh,pt. or systematic$.ti,ab.)
8. 7 use emez
9. (exp databases, bibliographic/ or (((electronic or computer$ or online) adj database$) or bids or
cochrane or embase or index medicus or isi citation or medline or psyclit or psychlit or scisearch or
science citation or (web adj2 science)).ti,ab.) and (review$.ti,ab,sh,pt. or systematic$.ti,ab.)
10. 9 use mesz, prem
11. (computer searching.sh,id. or (((electronic or computer$ or online) adj database$) or bids or cochrane
or embase or index medicus or isi citation or medline or psyclit or psychlit or scisearch or science
citation or (web adj2 science)).ti,ab.) and (review$.ti,ab,pt. or systematic$.ti,ab.)
12. 11 use psyh
13. ((analy$ or assessment$ or evidence$ or methodol$ or quantitativ$ or systematic$) adj2 (overview$ or
review$)).tw. or ((analy$ or assessment$ or evidence$ or methodol$ or quantitativ$ or systematic$).ti.
and review$.ti,pt.) or (systematic$ adj2 search$).ti,ab.
14. (metaanal$ or meta anal$).ti,ab.
15. (research adj (review$ or integration)).ti,ab.
16. reference list$.ab.
17. bibliograph$.ab.
18. published studies.ab.
19. relevant journals.ab.
20. selection criteria.ab.
21. (data adj (extraction or synthesis)).ab.
22. (handsearch$ or ((hand or manual) adj search$)).ti,ab.
23. (mantel haenszel or peto or dersimonian or der simonian).ti,ab.
24. (fixed effect$ or random effect$).ti,ab.
25. ((pool$ or combined or combining) adj2 (data or trials or studies or results)).ti,ab.
26. or/2,4,6,8,10,12-25
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Qualitative systematic review
1. (cross case analys$ or eppi approach or metaethno$ or meta ethno$ or metanarrative$ or meta
narrative$ or meta overview or metaoverview or metastud$ or meta stud$ or metasummar$ or meta
summar$ or qualitative overview$).ti,ab.
2. (((critical interpretative or evidence or meta or mixed methods or multilevel or multi level or narrative or
parallel or realist) adj synthes$) or metasynthes$).ti,ab.
3. (qualitative$ and (metaanal$ or meta anal$ or synthes$ or systematic review$)).ti,ab,hw,pt.
4. or/1-3
Allied and Complementary Medicine Database (via Ovid)
Quantitative systematic review
1. meta analysis/
2. (databases bibliographic/ or (((electronic or computer$ or online) adjdatabase$) or bids or cochrane or
embase or index medicus or isi citation or medline or psyclit or psychlit or scisearch or science citation
or (web adj2 science)).ti,ab.) and (review$.ti,ab,pt. or systematic$.ti,ab.)
3. ((analy$ or assessment$ or evidence$ or methodol$ or qualitativ$ or quantativ$ or systematic$) adj2
(overview$ or review$)).tw. or ((analy$ or assessment$ or evidence$ or methodol$ or quantativ$ or
qualitativ$ or systematic$).ti. and review$.ti,pt.) or (systematic$ adj2 search$).ti,ab.
4. (evidence synthesis or meta anal$ or metaanal$ or meta ethnograph$ or metaethnograph$ or meta
study or metastud$ or meta synthesis or metasynthesis or (qualitative and synthesis) or realist
synthesis).ti,ab.
5. (research adj (review$ or integration)).ti,ab.
6. reference list$.ab.
7. published studies.ab.
8. relevant journals.ab.
9. selection criteria.ab.
10. (data adj (extraction or synthesis)).ab.
11. (handsearch$ or ((hand or manual) adj search$)).ti,ab.
12. (mantel haenszel or peto or dersimonian or der simonian).ti,ab.
13. (fixed effect$ or random effect$).ti,ab.
14. or/1-13
Cumulative Index to Nursing and Allied Health Literature (EBSCOhost)
Quantitative systematic review
s33 s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 or s15 or s16 or s22 or s23 or
s26 or s27 or s28 or s29 or s30 or s31 or s32
s32 ti ( analy* n5 review* or assessment* n5 review* or evidence* n5 review* or methodol* n5 review* or quantativ*
n5 review* or systematic* n5 review* ) or ab ( analy* n5 review* or assessment* n5 review* or evidence* n5
review* or methodol* n5 review* or quantativ* n5 review* or systematic* n5 review* )
s31 ti ( analy* n5 overview* or assessment* n5 overview* or evidence* n5 overview* or methodol* n5 overview* or
quantativ* n5 overview* or systematic* n5 overview* ) or ab ( analy* n5 overview* or assessment* n5 overview* or
evidence* n5 overview* or methodol* n5 overview* or quantativ* n5 overview* or systematic* n5 overview* )
s30 ti ( pool* n2 results or combined n2 results or combining n2 results ) or ab ( pool* n2 results or combined n2 results
or combining n2 results )
s29 ti ( pool* n2 studies or combined n2 studies or combining n2 studies ) or ab ( pool* n2 studies or combined n2
studies or combining n2 studies )
s28 ti ( pool* n2 trials or combined n2 trials or combining n2 trials ) or ab ( pool* n2 trials or combined n2 trials or
combining n2 trials )
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s27 ti ( pool* n2 data or combined n2 data or combining n2 data ) or ab ( pool* n2 data or combined n2 data or
combining n2 data )
s26 s24 and s25
s25 ti review* or pt review*
s24 ti analy* or assessment* or evidence* or methodol* or quantativ* or systematic*
s23 ti “systematic* n5 search*” or ab “systematic* n5 search*”
s22 (s17 or s18 or s19) and (s20 or s21)
s21 ti systematic* or ab systematic*
s20 tx review* or mw review* or pt review*
s19 (mh "cochrane library")
s18 ti ( bids or cochrane or index medicus or “isi citation” or psyclit or psychlit or scisearch or “science citation” or web
n2 science ) or ab ( bids or cochrane or index medicus or “isi citation” or psyclit or psychlit or scisearch or “science
citation” or web n2 science )
s17 ti ( “electronic database*” or “bibliographic database*” or “computeri?ed database*” or “online database*” ) or
ab ( “electronic database*” or “bibliographic database*” or “computeri?ed database*” or “online database*” )
s16 (mh "literature review")
s15 pt systematic* or pt meta*
s14 ti ( “fixed effect*” or “random effect*” ) or ab ( “fixed effect*” or “random effect*” )
s13 ti ( “mantel haenszel” or peto or dersimonian or “der simonian” ) or ab ( “mantel haenszel” or peto or dersimonian
or “der simonian” )
s12 ti ( handsearch* or "hand search*" or "manual search*" ) or ab ( handsearch* or "hand search*" or "manual
search*" )
s11 ab "data extraction" or "data synthesis"
s10 ab "selection criteria"
s9 ab "relevant journals"
s8 ab "published studies"
s7 ab bibliograph*
s6 ab "reference list*"
s5 ti ( “research review*” or “research integration” ) or ab ( “research review*” or “research integration” )
s4 ti ( metaanal* or “meta anal*”) or ab ( metaanal* or “meta anal*”)
s3 (mh "meta analysis")
s2 (mh "systematic review")
s1 (mh "literature searching+")
s33 s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 or s15 or s16 or s22 or s23 or
s26 or s27 or s28 or s29 or s30 or s31 or s32
s32 ti ( analy* n5 review* or assessment* n5 review* or evidence* n5 review* or methodol* n5 review* or quantativ*
n5 review* or systematic* n5 review* ) or ab ( analy* n5 review* or assessment* n5 review* or evidence* n5
review* or methodol* n5 review* or quantativ* n5 review* or systematic* n5 review* )
s31 ti ( analy* n5 overview* or assessment* n5 overview* or evidence* n5 overview* or methodol* n5 overview* or
quantativ* n5 overview* or systematic* n5 overview* ) or ab ( analy* n5 overview* or assessment* n5 overview* or
evidence* n5 overview* or methodol* n5 overview* or quantativ* n5 overview* or systematic* n5 overview* )
s30 ti ( pool* n2 results or combined n2 results or combining n2 results ) or ab ( pool* n2 results or combined n2 results
or combining n2 results )
s29 ti ( pool* n2 studies or combined n2 studies or combining n2 studies ) or ab ( pool* n2 studies or combined n2
studies or combining n2 studies )
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s28 ti ( pool* n2 trials or combined n2 trials or combining n2 trials ) or ab ( pool* n2 trials or combined n2 trials or
combining n2 trials )
s27 ti ( pool* n2 data or combined n2 data or combining n2 data ) or ab ( pool* n2 data or combined n2 data or
combining n2 data )
s26 s24 and s25
s25 ti review* or pt review*
s24 ti analy* or assessment* or evidence* or methodol* or quantativ* or systematic*
s23 ti “systematic* n5 search*” or ab “systematic* n5 search*”
s22 (s17 or s18 or s19) and (s20 or s21)
s21 ti systematic* or ab systematic*
s20 tx review* or mw review* or pt review*
s19 (mh "cochrane library")
s18 ti ( bids or cochrane or index medicus or “isi citation” or psyclit or psychlit or scisearch or “science citation” or web
n2 science ) or ab ( bids or cochrane or index medicus or “isi citation” or psyclit or psychlit or scisearch or “science
citation” or web n2 science )
s17 ti ( “electronic database*” or “bibliographic database*” or “computeri?ed database*” or “online database*” ) or
ab ( “electronic database*” or “bibliographic database*” or “computeri?ed database*” or “online database*” )
s16 (mh "literature review")
s15 pt systematic* or pt meta*
s14 ti ( “fixed effect*” or “random effect*” ) or ab ( “fixed effect*” or “random effect*” )
s13 ti ( “mantel haenszel” or peto or dersimonian or “der simonian” ) or ab ( “mantel haenszel” or peto or dersimonian
or “der simonian” )
s12 ti ( handsearch* or "hand search*" or "manual search*" ) or ab ( handsearch* or "hand search*" or "manual
search*" )
s11 ab "data extraction" or "data synthesis"
s10 ab "selection criteria"
s9 ab "relevant journals"
s8 ab "published studies"
s7 ab bibliograph*
s6 ab "reference list*"
s5 ti ( “research review*” or “research integration” ) or ab ( “research review*” or “research integration” )
s4 ti ( metaanal* or “meta anal*”) or ab ( metaanal* or “meta anal*”)
s3 (mh "meta analysis")
s2 (mh "systematic review")
s1 (mh "literature searching+")
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Qualitative systematic review
s1 ti (“cross case analys*” or “eppi approach” or metaethno* or “meta ethno*” or metanarrative* or “meta narrative*”
or “meta overview” or metaoverview or metastud* or “meta stud*” or metasummar* or “meta summar*” or
“qualitative overview*”) or ab (“cross case analys*” or “eppi approach” or metaethno* or “meta ethno*” or
metanarrative* or “meta narrative*” or “meta overview” or metaoverview or metastud* or “meta stud*” or
metasummar* or “meta summar*” or “qualitative overview*”)
s2 ti (((“critical interpretative” or evidence or meta or “mixed methods” or multilevel or “multi level” or narrative or
parallel or realist) n1 synthes*) or metasynthes*) or ab (((“critical interpretative” or evidence or meta or “mixed
methods” or multilevel or “multi level” or narrative or parallel or realist) n1 synthes*) or metasynthes*)
s3 ti qualitative* or ab qualitative* or mw qualitative* or pt qualitative*
s4 ti (metaanal* or “meta anal*” or synthes* or “systematic review*”) or ab (metaanal* or “meta anal*” or synthes* or
“systematic review*”) or mw (metaanal* or “meta anal*” or synthes* or “systematic review*”) or pt (metaanal* or
“meta anal*” or synthes* or “systematic review*”)
s5 s3 and s4
s6 s1 or s2 or s5
s1 ti (“cross case analys*” or “eppi approach” or metaethno* or “meta ethno*” or metanarrative* or “meta narrative*”
or “meta overview” or metaoverview or metastud* or “meta stud*” or metasummar* or “meta summar*” or
“qualitative overview*”) or ab (“cross case analys*” or “eppi approach” or metaethno* or “meta ethno*” or
metanarrative* or “meta narrative*” or “meta overview” or metaoverview or metastud* or “meta stud*” or
metasummar* or “meta summar*” or “qualitative overview*”)
s2 ti (((“critical interpretative” or evidence or meta or “mixed methods” or multilevel or “multi level” or narrative or
parallel or realist) n1 synthes*) or metasynthes*) or ab (((“critical interpretative” or evidence or meta or “mixed
methods” or multilevel or “multi level” or narrative or parallel or realist) n1 synthes*) or metasynthes*)
s3 ti qualitative* or ab qualitative* or mw qualitative* or pt qualitative*
s4 ti (metaanal* or “meta anal*” or synthes* or “systematic review*”) or ab (metaanal* or “meta anal*” or synthes* or
“systematic review*”) or mw (metaanal* or “meta anal*” or synthes* or “systematic review*”) or pt (metaanal* or
“meta anal*” or synthes* or “systematic review*”)
s5 s3 and s4
s6 s1 or s2 or s5
Australian Education Index, Applied Social Sciences Index and Abstracts,
British Education Index, Education Resources in Curriculum, International
Bibliography of Social Science, Social Services Abstracts, Sociological
Abstracts (ProQuest)
Quantitative systematic review
1. su.exact(“literature reviews”)
2. su.exact(“meta-analysis”)
3. su.exact(“systematic reviews”)
4. ti ((analy* or assessment* or evidence* or methodol* or quantitativ* or systematic*) near/2
(overview* or review*)) or (systematic* near/2 search*) or ab ((analy* or assessment* or evidence* or
methodol* or quantitativ* or systematic*) near/2 (overview* or review*)) or (systematic* near/
2 search*)
5. ti ((analy* or assessment* or evidence* or methodol* or quantitativ* or systematic*) and review*
6. ti (metaanal* or “meta anal*”) or ab (metaanal* or “meta anal*”)
7. ti (research near/1 (review* or integration)) or ab (research near/1 (review* or integration))
8. ti “reference list*” or ab “reference list*”
9. ti bibliograph* or ab bibliograph*
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10. ti “published studies” or ab “published studies”
11. ti “relevant journals” or ab “relevant journals”
12. ti “selection criteria” or ab “selection criteria”
13. ti (data near/1 (extraction or synthesis)) or ab (data near/1 (extraction or synthesis))
14. ti (handsearch* or ((hand or manual) near/1 search*)) or ab (handsearch* or ((hand or manual) near/
1 search*))
15. ti (mantel haenszel or peto or dersimonian or “der simonian”) or ab (mantel haenszel or peto or
dersimonian or “der simonian”)
16. ti (fixed effect* or “random effect*”) or ab (fixed effect* or “random effect*”)
17. ti ((pool* or combined or combining) near/2 (data or trials or studies or results)) or ab ((pool* or
combined or combining) near/2 (data or trials or studies or results))
18. s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 or s15 or s16
or s17
Qualitative systematic review
1. ti (“cross case analys*” or “eppi approach” or metaethno* or “meta ethno*” or metanarrative* or
“meta narrative*” or “meta overview” or metaoverview or metastud* or “meta stud*” or
metasummar* or “meta summar*” or qualitative overview*) or ab (“cross case analys*” or “eppi
approach” or metaethno* or “meta ethno*” or metanarrative* or “meta narrative*” or “meta
overview” or metaoverview or metastud* or “meta stud*” or metasummar* or “meta summar*” or
qualitative overview*)
2. ti (((“critical interpretative” or evidence or meta or “mixed methods” or multilevel or “multi level” or
narrative or parallel or realist) near/1 synthes*) or metasynthes*) or ab (((“critical interpretative” or
evidence or meta or “mixed methods” or multilevel or “multi level” or narrative or parallel or realist)
near/1 synthes*) or metasynthes*)
3. ti (qualitative* and (metaanal* or “meta anal*” or synthes* or “systematic review*”)) or ab
(qualitative* and (metaanal* or “meta anal*” or synthes* or “systematic review*”))
4. s1 or s2 or s3
Biosis Citation Index, Web of Science (Thomson Reuters)
Quantitative systematic review filter
#1 title=(“electronic database*” or “computer* database*” or “online database*” or bids or cochrane or embase or
“index medicus” or “isi citation” or medline or psyclit or psychlit or scisearch or “science citation” or “web of
science”)
#2 title=(review* or systematic*) or topic=(review* or systematic*)
#3 #1 and #2
#4 topic=((systematic* near search* or metaanal* or “meta anal*” or “research review*” or “research integration” or
“reference list*” or bibliograph* or “published studies” or “relevant journals” or “selection criteria” or “data
extraction” or “data synthesis” or handsearch* or “hand search*” or “manual search*” or “mantel haenszel” or
peto or dersimonian or “der simonian” or “fixed effect*” or “random effect*” or ((pool* or combined or combining)
near (data or trials or studies or results)))) or title=((systematic* near search* or metaanal* or “meta anal*” or
“research review*” or “research integration” or “reference list*” or bibliograph* or “published studies” or “relevant
journals” or “selection criteria” or “data extraction” or “data synthesis” or handsearch* or “hand search*” or
“manual search*” or “mantel haenszel” or peto or dersimonian or “der simonian” or “fixed effect*” or “random
effect*”) or ((pool* or combined or combining) near (data or trials or studies or results))))
#5 topic=(((analy* or assessment* or evidence* or methodol* or quantitativ* or systematic*) near (overview* or
review*))) or title=(((analy* or assessment* or evidence* or methodol* or qualitativ* or quantitativ* or systematic*)
near (overview* or review*)))
#6 #3 or #4 or #5
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#1 title=(“electronic database*” or “computer* database*” or “online database*” or bids or cochrane or embase or
“index medicus” or “isi citation” or medline or psyclit or psychlit or scisearch or “science citation” or “web of
science”)
#2 title=(review* or systematic*) or topic=(review* or systematic*)
#3 #1 and #2
#4 topic=((systematic* near search* or metaanal* or “meta anal*” or “research review*” or “research integration” or
“reference list*” or bibliograph* or “published studies” or “relevant journals” or “selection criteria” or “data
extraction” or “data synthesis” or handsearch* or “hand search*” or “manual search*” or “mantel haenszel” or
peto or dersimonian or “der simonian” or “fixed effect*” or “random effect*” or ((pool* or combined or combining)
near (data or trials or studies or results)))) or title=((systematic* near search* or metaanal* or “meta anal*” or
“research review*” or “research integration” or “reference list*” or bibliograph* or “published studies” or “relevant
journals” or “selection criteria” or “data extraction” or “data synthesis” or handsearch* or “hand search*” or
“manual search*” or “mantel haenszel” or peto or dersimonian or “der simonian” or “fixed effect*” or “random
effect*”) or ((pool* or combined or combining) near (data or trials or studies or results))))
#5 topic=(((analy* or assessment* or evidence* or methodol* or quantitativ* or systematic*) near (overview* or
review*))) or title=(((analy* or assessment* or evidence* or methodol* or qualitativ* or quantitativ* or systematic*)
near (overview* or review*)))
#6 #3 or #4 or #5
Qualitative systematic review filter
#1 topic=((“cross case analys*” or “eppi approach” or metaethno* or “meta ethno*” or metanarrative*
or “meta narrative*” or “meta overview” or metaoverview or metastud* or “meta stud*” or
metasummar* or “meta summar*” or “qualitative overview*”)) or title=((“cross case analys*” or
“eppi approach” or metaethno* or “meta ethno*” or metanarrative* or “meta narrative*” or “meta
overview” or metaoverview or metastud* or “meta stud*” or metasummar* or “meta summar*” or
“qualitative overview*”))
#2 topic=((((“critical interpretative” or evidence or meta or “mixed methods” or multilevel or “multi
level” or narrative or parallel or realist) near synthes*) or metasynthes*)) or title=((((“critical
interpretative” or evidence or meta or “mixed methods” or multilevel or “multi level” or narrative or
parallel or realist) near synthes*) or metasynthes*))
#3 topic=((qualitative* and (metaanal* or “meta anal*” or synthes* or “systematic review*”))) or title=
((qualitative* and (metaanal* or “meta anal*” or synthes* or “systematic review*”)))
#4 #1 or #2 or #3
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Randomised controlled trial filters
EMBASE, MEDLINE, PREMEDLINE In-Process & Other Non-Indexed Citations,
PsycINFO (via Ovid)
1. exp “clinical trial (topic)”/ or exp clinical trial/ or crossover procedure/ or double blind procedure/ or
placebo/ or randomization/ or random sample/ or single blind procedure/
2. 1 use emez
3. exp clinical trial/ or exp “clinical trials as topic”/ or cross-over studies/ or double-blind method/ or
placebos/ or random allocation/ or single-blind method/
4. 3 use mesz, prem
5. (clinical trials or placebo or random sampling).sh,id.
6. 5 use psyh
7. (clinical adj2 trial$).ti,ab.
8. (crossover or cross over).ti,ab.
9. (((single$ or doubl$ or trebl$ or tripl$) adj2 blind$) or mask$ or dummy or doubleblind$ or singleblind$
or trebleblind$ or tripleblind$).ti,ab.
10. (placebo$ or random$).ti,ab.
11. treatment outcome$.md. use psyh
12. animals/ not human$.mp. use emez
13. animal$/ not human$/ use mesz, prem
14. (animal not human).po. use psyh
15. (or/2,4,6-11) not (or/12-14)
Allied and Complementary Medicine Database (via Ovid)
1. (clinical trials or double blind method or placebos or random allocation).sh.
2. (clinical adj2 trial$).ti,ab.
3. (crossover or cross over).ti,ab.
4. (((single$ or doubl$ or trebl$ or tripl$) adj5 blind$) or mask$ or dummy or singleblind$ or doubleblind$
or trebleblind$ or tripleblind$).ti,ab.
5. (placebo$ or random$).ti,ab.
6. or/1-5
Cumulative Index to Nursing and Allied Health Literature (EBSCOhost)
s10 s9 not s8
s9 s1 or s2 or s3 or s4 or s5 or s6 or s7
s8 (mh "animals") not (mh "human")
s7 (pt "clinical trial") or (pt "randomized controlled trial")
s6 ti ( placebo* or random* ) or ab ( placebo* or random* )
s5 ti ( single blind* or double blind* or treble blind* or mask* or dummy* or singleblind* or doubleblind* or
trebleblind* ) or ab ( single blind* or double blind* or treble blind* or mask* or dummy* or singleblind* or
doubleblind* or trebleblind* )
s4 ti ( crossover or cross over ) or ab ( crossover or cross over )
s3 ti clinical n2 trial* or ab clinical n2 trial*
s2 (mh "crossover design") or (mh "placebos") or (mh "random assignment") or (mh "random sample")
s1 (mh "clinical trials+")
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s10 s9 not s8
s9 s1 or s2 or s3 or s4 or s5 or s6 or s7
s8 (mh "animals") not (mh "human")
s7 (pt "clinical trial") or (pt "randomized controlled trial")
s6 ti ( placebo* or random* ) or ab ( placebo* or random* )
s5 ti ( single blind* or double blind* or treble blind* or mask* or dummy* or singleblind* or doubleblind* or
trebleblind* ) or ab ( single blind* or double blind* or treble blind* or mask* or dummy* or singleblind* or
doubleblind* or trebleblind* )
s4 ti ( crossover or cross over ) or ab ( crossover or cross over )
s3 ti clinical n2 trial* or ab clinical n2 trial*
s2 (mh "crossover design") or (mh "placebos") or (mh "random assignment") or (mh "random sample")
s1 (mh "clinical trials+")
Australian Education Index, Applied Social Sciences Index and Abstracts,
British Education Index, Education Resources in Curriculum, International
Bibliography of Social Science, Social Service Abstracts, Sociological
Abstracts (ProQuest)
1. su.exact.explode(“clinical randomized controlled trials” or “cluster randomized controlled trials” or
“double blind randomized controlled trials” or “randomized consent design” or “randomized
controlled trials” or “single blind randomized controlled trials” or “urn randomization”)
2. su.exact(“clinical trials”)
3. su.exact(“crossover trials”)
4. su.exact(“placebos”)
5. su.exact(“random sampling”)
6. su.exact(“randomization”)
7. su.exact(“random samples”)
8. su.exact(“placebo effect”)
9. ti (clinical near/2 trial*) or ab (clinical near/2 trial*)
10. ti (crossover or “cross over”) or ab (crossover or “cross over”)
11. ti (((single* or doubl* or trebl* or tripl*) near/2 blind*) or mask* or dummy or doubleblind* or
singleblind* or trebleblind* or tripleblind*) or ab (((single* or doubl* or trebl* or tripl*) near/2 blind*)
or mask* or dummy or doubleblind* or singleblind* or trebleblind* or tripleblind*)
12. ti (placebo* or random*) or ab (placebo* or random*)
13. s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12
Biosis Citation Index, Web of Science (Thomson Reuters)
#1 topic=(((clinical near trial* or crossover or “cross over”) or ((single* or doubl* or trebl* or tripl*) near (blind* or
mask* or dummy)) or (singleblind* or doubleblind* or trebleblind* or tripleblind* or placebo* or random*))) or title=
(((clinical near trial* or crossover or “cross over”) or ((single* or doubl* or trebl* or tripl*) near (blind* or mask* or
dummy)) or (singleblind* or doubleblind* or trebleblind* or tripleblind* or placebo* or random*)))
#1 topic=(((clinical near trial* or crossover or “cross over”) or ((single* or doubl* or trebl* or tripl*) near (blind* or
mask* or dummy)) or (singleblind* or doubleblind* or trebleblind* or tripleblind* or placebo* or random*))) or title=
(((clinical near trial* or crossover or “cross over”) or ((single* or doubl* or trebl* or tripl*) near (blind* or mask* or
dummy)) or (singleblind* or doubleblind* or trebleblind* or tripleblind* or placebo* or random*)))
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Observational study filters
EMBASE, MEDLINE, PREMEDLINE In-Process & Other Non-Indexed Citations,
PsycINFO (via Ovid)
1. exp case control study/ or cohort analysis/ or cross-sectional study/ or follow up/ or longitudinal
study/ or observational study/ or prospective study/ or
2. retrospective study/
3. 1 use emez
4. exp case control studies/ or exp cohort studies/ or cross-sectional studies/ or epidemiologic studies/
5. 3 use mesz, prem
6. (cohort analysis or followup studies or longitudinal studies or prospective studies or retrospective
studies).sh,id. or (followup study or longitudinal study or
7. prospective study or retrospective study).md.
8. 5 use psyh
9. ((epidemiologic$ or observational) adj (study or studies)).ti,ab.
10. (cohort$1 or cross section$ or crosssection$ or followup$ or follow up$ or followed or longitudinal$
or prospective$ or retrospective$).ti,ab.
11. (case adj2 (control or series)).ti,ab.
12. or/2,4,6-9
Allied and Complementary Medicine Database (via Ovid)
1. case control studies/ or cohort studies/ or follow up studies/ or longitudinal studies/ or prospective
studies/ or retrospective studies/
2. ((epidemiologic$ or observational) adj (study or studies)).ti,ab.
3. (cohort$1 or cross section$ or crosssection$ or followup$ or follow up$ or followed or longitudinal$ or
prospective$ or retrospective$).ti,ab.
4. (case and (control$ or series)).ti,ab.
5. or/1-4
Cumulative Index to Nursing and Allied Health Literature (EBSCOhost)
s4 s1 or s2 or s3
s3 ti ( “case control” or cohort* or “cross sectional” or followup* or “follow up*” or followed or longitudinal or
prospective* or retrospective* ) or ab ( “case control” or cohort* or “cross sectional” or followup* or “follow up*”
or followed or longitudinal or prospective* or retrospective* )
s2 ti ( “cross sectional” n2 study or “cross sectional” n2 studies or epidemiologic* n2 study or epidemiologic* n2 studies
or observational* n2 study or observational* n2 studies ) or ab ( “cross sectional” n2 study or “cross sectional” n2
studies or epidemiologic* n2 study or epidemiologic* n2 studies or observational* n2 study or observational* n2
studies )
s1 (mh “correlational studies”) or (mh “case control studies+”) or (mh “cross sectional studies”) or (mh “prospective
studies+”)
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Australian Education Index, Applied Social Sciences Index and Abstracts,
British Education Index, Education Resources in Curriculum, International
Bibliography of Social Science, Social Services Abstracts, Sociological Abstracts
1. su.exact(“case controlled studies”)
2. su.exact(“case studies”)
3. su.exact(“cohort analysis”)
4. su.exact(“cohorts”)
5. su.exact(“cross sectional analysis”)
6. su.exact(“cross sectional studies”)
7. su.exact(“followup”)
8. su.exact(“followup studies”)
9. su.exact(“longitudinal analysis”)
10. su.exact(“longitudinal studies”)
11. su.exact(“prospective controlled trials”)
12. su.exact(“prospective studies”)
13. su.exact(“retrospective studies”)
14. ti ((epidemiologic* or observational) near/1 (study or studies)) or ((epidemiologic* or observational)
near/1 (study or studies))
15. ti (cohort* or “cross section*” or crosssection* or followup* or “follow up*” or followed or
longitudinal* or prospective* or retrospective*) or ab (cohort* or “cross section*” or crosssection* or
followup* or “follow up*” or followed or longitudinal* or prospective* or retrospective*)
16. ti (case near/2 (control or series)) or ab (case near/2 (control or series))
17. s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 or s15 or s16
Biosis Citation Index, Web of Science (Thomson Reuters)
1. topic=(((epidemiologic* or observational) near (study or studies)) or cohort* or cross section* or
crosssection* or followup* or “follow up*” or followed or longitudinal* or prospective* or
retrospective* or (case near (control or series))) or title=(((epidemiologic* or observational) near (study
or studies)) or cohort* or cross section* or crosssection* or followup* or “follow up*” or followed or
longitudinal* or prospective* or retrospective* or (case near (control or series)))
Primary qualitative studies/survey literature filter
EMBASE, MEDLINE, PREMEDLINE In-Process & Other Non-Indexed Citations,
PsycINFO (via Ovid)
1. cluster analysis/ or constant comparative method/ or content analysis/ or cultural anthropology/ or
discourse analysis/ or ethnographic research/ or ethnography/ or ethnology/ or ethnonursing research/ or
field study/ or grounded theory/ or information processing/ or nursing methodology research/ or personal
experience/ or phenomenology/ or purposive sample/ or qualitative research/ or exp recording/ or semi
structured interview/ or storytelling/ or structured interview/ or thematic analysis/ or theoretical sample/
2. 1 use emez
3. anthropology, cultural/ or focus groups/ or exp tape recording/ or interview/ or personal narratives/ or
exp interviews as topic/ or narration/ or nursing methodology research/ or observation/ or qualitative
research/ or sampling studies/ or cluster analysis/ or videodisc recording/
4. 3 use mesz, prem
5. “culture (anthropological)”/ or cluster analysis/ or content analysis/ or discourse analysis/ or ethnography/
or “experiences (events)”/ or grounded theory/ or interviews/ or life experiences/ or narratives/ or
observation methods/ or phenomenology/ or qualitative research/ or structured clinical interview/ or exp
tape recorders/ or storytelling/ or (field study or interview or focus group or qualitative study).md.
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6. 5 use psyh
7. (action research or audiorecord$ or ((audio or tape or video$) adj5 record$) or colaizzi$ or (constant adj
(comparative or comparison)) or content analy$ or critical social$ or (data adj1 saturat$) or discourse
analys?s or emic or ethical enquiry or ethno$ or etic or fieldnote$ or (field adj (note$ or record$ or stud$
or research)) or (focus adj4 (group$ or sampl$)) or ((focus$ or structured) adj2 interview$) or giorgi$ or
glaser or (grounded adj (theor$ or study or studies or research)) or heidegger$ or hermeneutic$ or
heuristic or human science or husserl$ or ((life or lived) adj experience$) or maximum variation or merleau
or narrat$ or ((participant$ or nonparticipant$) adj3 observ$) or ((philosophical or social) adj research$) or
(pilot testing and survey) or purpos$ sampl$ or qualitative$ or ricoeur or semiotics or shadowing or
snowball or spiegelberg$ or stories or story or storytell$ or strauss or structured categor$ or tape record$
or taperecord$ or testimon$ or (thematic$ adj3 analys$) or themes or theoretical sampl$ or unstructured
categor$ or van kaam$ or van manen or videorecord$ or video record$ or videotap$ or video tap$).ti,ab.
8. or/2,4,6-7
9. (((adult$ or attender$ or carer$ or caregiv$ or care giv$ or client$ or community based or consumer$
or couples or customer$ or daughter$ or famil$ or father$ or friend$ or (home adj2 (care or caring or
nurs$)) or home based or husband$ or individual$ or ((informal or non professional) adj5 (care or
nursing)) or marital$ or men or mentor$ or mother$ or multifam$ or neighbo?r$ or next of kin or
niece or nephew$ or parent$1 or partner$1 or patient$ or people$ or person$ or relative or relatives
or sibling$ or significant other$ or spous$ or step relationship$ or teacher$ or wife$1 or wives or
women or user$) or (adolescen$ or boy$ or child$ or delinquen$ or girl$ or graders or infant$ or
junior$ or juvenile$ or kindergarten or minors or p?ediatric$ or postpubert$ or postpubescen$ or
preadolescen$ or prepubert$ or prepubescen$ or preschool$ or preteen$ or pubert$ or pubescen$ or
school$ or teen$ or toddler$ or (young$ adj1 (people or person$ or patient$ or population$)) or
youngster$ or youth$)) adj3 (account$ or anxieties or attitude$ or barriers or belief$ or buyin or buy in
$1 or cooperat$ or co operat$ or expectation$ or experienc$ or feedback or involv$ or opinion$ or
participat$ or perceived need$ or (perception$ not speech perception) or perspective$ or preferen$ or
satisf$ or view$ or voices or worry)).ti,ab.
10. ((information adj (need$ or requirement$ or support$)) or health information).ti,ab.
11. (service$ adj2 (acceptab$ or unacceptab$)).ti,ab.
12. or/8-11
13. health care survey/ or health survey/
14. 13 use emez
15. health care surveys/ or exp health surveys/
16. 15 use mesz, prem
17. exp surveys/
18. 17 use psyh
19. (survey$ or question$).ti,ab.
20. exp attitude/ or exp patient acceptance of health care/ or exp patient attitude/ or patient-centered
care/ or patient education/ or patient satisfaction/
21. 20 use emez
22. exp attitude to health/ or exp patient acceptance of health care/ or patient-centered care/ or patient
education/ or patient education handout/ or patient satisfaction/
23. 22 use mesz, prem
24. exp client attitudes/ or client education/ or exp consumer attitudes/ or exp health
25. attitudes/ or exp patient attitude/ or patient-centered care/ or patient education/ or
26. patient satisfaction/
27. 24 use psyh
28. (account$ or anxieties or attitude$ or barriers or belief$ or buyin or buy in$1 or
29. cooperat$ or co operat$ or expectation$ or experienc$ or feedback or involv$ or
30. opinion$ or participat$ or perceived need$ or (perception$ not speech perception)
31. or perspective$ or preferen$ or satisf$ or view$ or voices or worry).ti,ab.
32. (or/14,16,18,19) and (or/21,23,25-26)
33. or/12,27
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Cumulative Index to Nursing and Allied Health Literature (EBSCOhost)
s43 S28 or s39 or s40 or s41 or s42
s42 ti ( ( (service* n2 (acceptab* or unacceptab*)) ) ) or ab ( ( (service* n2 (acceptab* or unacceptab*)) ) )
s41 ti ( ( ((information n1 (need* or requirement* or support*)) or patient information) ) ) or ab ( ( ((information n1
(need* or requirement* or support*)) or patient information) ) )
s40 ti (((adult* or attender* or carer* or caregiv* or “care giv*” or client* or “community based” or consumer* or
couples or customer* or daughter* or famil* or father* or friend* or (home n2 (care or caring or nurs*)) or
“home based” or husband* or individual* or ((informal or “non professional”) n5 (care or nursing)) or marital*
or men or mentor* or mother* or multifam* or neighbo?r* or “next of kin” or niece or nephew* or parent* or
partner* or patient* or people* or person* or relative or relatives or sibling* or “significant other*” or spous*
or “step relationship*” or teacher* or wife* or wives or women or user*) or (adolescen* or boy* or child* or
delinquen* or girl* or graders or infant* or junior* or juvenile* or kindergarten or minors or p?ediatric* or
postpubert* or postpubescen* or preadolescen* or prepubert* or prepubescen* or preschool* or preteen* or
pubert* or pubescen* or school* or teen* or toddler* or (young* n1 (people or person* or patient* or
population*)) or youngster* or youth*)) n3 (account* or anxieties or attitude* or barriers or belief* or buyin or
"buy in*" or cooperat* or "co operat*" or expectation* or experienc* or feedback or involv* or opinion* or
participat* or perceived need* or (perception* not "speech perception") or perspective* or preferen* or satisf*
or view* or voices or worry)) or ab (((adult* or attender* or carer* or caregiv* or “care giv*” or client* or
“community based” or consumer* or couples or customer* or daughter* or famil* or father* or friend* or
(home n2 (care or caring or nurs*)) or “home based” or husband* or individual* or ((informal or
“non professional”) n5 (care or nursing)) or marital* or men or mentor* or mother* or multifam* or neighbo?r*
or “next of kin” or niece or nephew* or parent* or partner* or patient* or people* or person* or relative or
relatives or sibling* or “significant other*” or spous* or “step relationship*” or teacher* or wife* or wives or
women or user*) or (adolescen* or boy* or child* or delinquen* or girl* or graders or infant* or junior* or
juvenile* or kindergarten or minors or p?ediatric* or postpubert* or postpubescen* or preadolescen* or
prepubert* or prepubescen* or preschool* or preteen* or pubert* or pubescen* or school* or teen* or
toddler* or (young* n1 (people or person* or patient* or population*)) or youngster* or youth*)) n3 (account*
or anxieties or attitude* or barriers or belief* or buyin or "buy in*" or cooperat* or "co operat*" or
expectation* or experienc* or feedback or involv* or opinion* or participat* or perceived need* or (perception*
not "speech perception") or perspective* or preferen* or satisf* or view* or voices or worry))
S39 ti (#29 or #30) and (#31 or #32 or #33 or #34 or #35 or #36 or #37 or #38)
S38 ti ( (account* or anxieties or attitude* or barriers or belief* or buyin or "buy in*" or cooperat* or "co operat*"
or expectation* or experienc* or feedback or involv* or opinion* or participat* or perceived need* or
(perception* not "speech perception") or perspective* or preferen* or satisf* or view* or voices or worry) ) or
ab ( (account* or anxieties or attitude* or barriers or belief* or buyin or "buy in*" or cooperat* or "co operat*"
or expectation* or experienc* or feedback or involv* or opinion* or participat* or perceived need* or
(perception* not "speech perception") or perspective* or preferen* or satisf* or view* or voices or worry) )
S37 (mh "consumer attitudes")
S36 (mh "consumer satisfaction")
s35 (mh "patient satisfaction")
s34 (mh "patient education (iowa nic) (non-cinahl)")
s33 (mh "patient education") or (mh "hiv education") or (mh "patient discharge education")
s32 (mh "patient centered care")
s31 (mh "attitude to health+")
s30 ( (survey* or question*) ) or ab ( (survey* or question*) )
S29 (mh "surveys")
s28 s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 or s15 or s16 or s17 or s18
or s19 or s20 or s21 or s22 or s23 or s24 or s25 or s26 or s27
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s27 ti (qualitative* or ethno* or emic or etic or heuristic or semiotics or ((focus* or structured) n2 interview*)
or ((audio or tape or video*) n5 record*) or audiorecord* or taperecord* or videorecord* or videotap*
or story or stories or storytell* or “story tell*” or testimon* or (focus n4 (group* or sampl*)) or narrat*
or ((life or lived) n1 experience*) or ((participant* or nonparticipant*) n3 observ*) or (constant n1
(comparative or comparison)) or “content analy*” or (field n1 (note* or record* or stud* or research)) or
fieldnote* or (data n1 saturat*) or “discourse analys?s” or (grounded n1 (theor* or study or studies or
research)) or hermeneutic* or heidegger* or husserl* or colaizzi* or giorgi* or glaser or spiegelberg* or
strauss or “maximum variation” or snowball or “purpos* sampl*” or “structured categor*” or
“unstructured categor*” or ((thematic* n3 analys*) or themes) or “theoretical sampl*” or ricoeur or
spiegelberg* or merleau or “van kaam*” or “van manen” or “constant compar*” or “action research”
or “human science” or “critical social*” or “ethical enquiry” or (“pilot testing” and survey) or
shadowing or ((philosophical or social) n1 research*)) or ab (qualitative* or ethno* or emic or etic or
heuristic or semiotics or ((focus* or structured) n2 interview*) or ((audio or tape or video*) n5 record*)
or audiorecord* or taperecord* or videorecord* or videotap* or story or stories or storytell* or “story
tell*” or testimon* or (focus n4 (group* or sampl*)) or narrat* or ((life or lived) n1 experience*) or
((participant* or nonparticipant*) n3 observ*) or (constant n1 (comparative or comparison)) or “content
analy*” or (field n1 (note* or record* or stud* or research)) or fieldnote* or (data n1 saturat*) or
“discourse analys?s” or (grounded n1 (theor* or study or studies or research)) or hermeneutic* or
heidegger* or husserl* or colaizzi* or giorgi* or glaser or spiegelberg* or strauss or “maximum
variation” or snowball or “purpos* sampl*” or “structured categor*” or “unstructured categor*” or
((thematic* n3 analys*) or themes) or “theoretical sampl*” or ricoeur or spiegelberg* or merleau or
“van kaam*” or “van manen” or “constant compar*” or “action research” or “human science” or
“critical social*” or “ethical enquiry” or (“pilot testing” and survey) or shadowing or ((philosophical or
social) n1 research*))
s26 (mh "theoretical sample")
s25 (mh "purposive sample")
s24 (mh "observational methods+")
s23 (mh "methodological research")
s22 (mh "grounded theory")
s21 (mh "information processing (iowa noc)")
s20 (mh "focus groups")
s19 (mh "field studies")
s18 (mh "ethnonursing research")
s17 (mh "ethnological research")
s16 (mh "ethnography")
s15 (mh "thematic analysis")
s14 (mh "content analysis")
s13 (mh "cluster analysis")
s12 (mh "discourse analysis")
s11 (mh "constant comparative method")
s10 (mh "attitude+")
s9 (mh "audiorecording")
s8 (mh "videorecording")
s7 (mh "storytelling+")
s6 (mh "narratives")
s5 (mh "life change events")
s4 (mh "life experiences")
s3 (mh "qualitative studies+")
s2 (mh "qualitative validity")
s1 (mh "phenomenology")
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Australian Education Index, Applied Social Sciences Index and Abstracts,
British Education Index, Education Resources in Curriculum, International
Bibliography of Social Science, Social Services Abstracts, Sociological
Abstracts (ProQuest)
1. su.exact(“cluster analysis”)
2. su.exact(“content analysis”)
3. su.exact(“cultural anthropology”)
4. su.exact(“discourse analysis”)
5. su.exact(“ethnography”)
6. su.exact(“focus groups”)
7. su.exact(“focused interviews”)
8. su.exact(“grounded theory”)
9. su.exact(“narration”)
10. su.exact(“narratives”)
11. su.exact(“personal narratives”)
12. su.exact.explode(“phenomenology” or “phenomenoological analysis”)
13. su.exact(“qualitative analysis”)
14. su.exact(“qualitative data”)
15. su.exact(“qualitative methods”)
16. su.exact(“qualitative research”)
17. su.exact(“qualitative studies”)
18. su.exact(“semi structured interviews”)
19. su.exact(“semistructured interviews”)
20. su.exact(“semistructured questionnaires”)
21. su.exact(“story telling”)
22. su.exact(“storytelling”)
23. su.exact(“tape recordings”)
24. su.exact.explode(“tape recordings” or “selfhelp tape recordings”)
25. su.exact(“videodisc recordings”)
26. su.exact(“videotape recording”)
27. su.exact(“videotape recordings”)
28. ti (“action research” or audiorecord* or ((audio or tape or video*) near/5 record*)
29. or colaizzi* or (constant near/1 (comparative or comparison)) or “content analy*” or “critical
social*” or (data near/1 saturat*) or “discourse analys?s” or emic or “ethical enquiry” or ethno* or
etic or fieldnote* or (field near/1 (note* or record* or stud* or research)) or (focus near/4 (group*
or sampl*)) or ((focus* or
30. structured) near/2 interview*) or giorgi* or glaser or (grounded near/1 (theor* or study or studies or
research)) or heidegger* or hermeneutic* or heuristic or “human science” or husserl* or ((life or
lived) near/1 experience*) or “maximum variation” or merleau or narrat* or ((participant* or
nonparticipant*) near/3 observ*) or ((philosophical or social) near/1 research*) or (“pilot testing”
and survey) or “purpos* sampl*” or qualitative* or ricoeur or semiotics or shadowing or snowball
or spiegelberg* or stories or story or storytell* or strauss or “structured categor*” or “tape
record*” or taperecord* or testimon* or (thematic* near/3 analys*) or themes or “theoretical
sampl*” or “unstructured categor*” or “van kaam*” or “van manen” or videorecord* or “video
record*” or videotap* or “video tap*”) or ab (“action research” or audiorecord* or ((audio or tape
or video*) near/5 record*) or colaizzi* or (constant near/1 (comparative or comparison)) or “content
analy*” or “critical social*” or (data near/1 saturat*) or “discourse analys?s” or emic or “ethical
enquiry” or ethno* or etic or fieldnote* or (field near/1 (note* or record* or stud* or research)) or
(focus near/4 (group* or sampl*)) or ((focus* or structured) near/2 interview*) or giorgi* or glaser or
(grounded near/1 (theor* or study or studies or research)) or heidegger* or hermeneutic* or heuristic
or “human science” or husserl* or ((life or lived) near/1 experience*) or “maximum variation” or
merleau or narrat* or ((participant* or nonparticipant*) near/3 observ*) or ((philosophical or social)
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near/1 research*) or (“pilot testing” and survey) or “purpos* sampl*” or qualitative* or ricoeur or
semiotics or shadowing or snowball or spiegelberg* or stories or story or storytell* or strauss or
“structured categor*” or “tape record*” or taperecord* or testimon* or (thematic* near/3 analys*) or
themes or “theoretical sampl*” or “unstructured categor*” or “van kaam*” or “van manen” or
videorecord* or “video record*” or videotap* or “video tap*”)
31. ti (((adult* or attender* or carer* or caregiv* or “care giv*” or client* or
32. “community based” or consumer* or couples or customer* or daughter* or famil*
33. or father* or friend* or (home near/2 (care or caring or nurs*)) or “home based”
34. or husband* or individual* or ((informal or “non professional”) near/5 (care or
35. nursing)) or marital* or men or mentor* or mother* or multifam* or neighbo?r*
36. or “next of kin” or niece or nephew* or parent* or partner* or patient* or people*
37. or person* or relative or relatives or sibling* or “significant other*” or spous* or
38. “step relationship*” or teacher* or wife* or wives or women or user*) or
39. (adolescen* or boy* or child* or delinquen* or girl* or graders or infant* or
40. junior* or juvenile* or kindergarten or minors or p?ediatric* or postpubert* or
41. postpubescen* or preadolescen* or prepubert* or prepubescen* or preschool* or
42. preteen* or pubert* or pubescen* or school* or teen* or toddler* or (young*
43. near/1 (people or person* or patient* or population*)) or youngster* or youth*))
44. near/3 (account* or anxieties or attitude* or barriers or belief* or buyin or “buy
45. in*” or cooperat* or “co operat*” or expectation* or experienc* or feedback or
46. involv* or opinion* or participat* or perceived need* or (perception* not “speech
47. perception”) or perspective* or preferen* or satisf* or view* or voices or worry))
48. or ab (((adult* or attender* or carer* or caregiv* or “care giv*” or client* or
49. “community based” or consumer* or couples or customer* or daughter* or famil*
50. or father* or friend* or (home near/2 (care or caring or nurs*)) or “home based”
51. or husband* or individual* or ((informal or “non professional”) near/5 (care or
52. nursing)) or marital* or men or mentor* or mother* or multifam* or neighbo?r*
53. or “next of kin” or niece or nephew* or parent* or partner* or patient* or people*
54. or person* or relative or relatives or sibling* or “significant other*” or spous* or
55. “step relationship*” or teacher* or wife* or wives or women or user*) or
56. (adolescen* or boy* or child* or delinquen* or girl* or graders or infant* or
57. junior* or juvenile* or kindergarten or minors or p?ediatric* or postpubert* or
58. postpubescen* or preadolescen* or prepubert* or prepubescen* or preschool* or
59. preteen* or pubert* or pubescen* or school* or teen* or toddler* or (young*
60. near/1 (people or person* or patient* or population*)) or youngster* or youth*))
61. near/3 (account* or anxieties or attitude* or barriers or belief* or buyin or “buy
62. in*” or cooperat* or “co operat*” or expectation* or experienc* or feedback or
63. involv* or opinion* or participat* or perceived need* or (perception* not “speech
64. perception”) or perspective* or preferen* or satisf* or view* or voices or worry))
65. ti ((information near/1 (need* or requirement* or support*)) or “health
66. information”) or ab ((information near/1 (need* or requirement* or support*)) or
67. “health information”)
68. ti (service* near/2 (acceptab* or unacceptab*)) or ab (service* near/2 (acceptab*
69. or unacceptab*))
70. s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14
71. or s15 or s16 or s17 or s18 or s19 or s20 or s21 or s22 or s23 or s24 or s25 or s26
72. or s27 or s28 or s29 or s30 or s31
73. ti ((survey* or question*) and (account* or anxieties or attitude* or barriers or
74. belief* or buyin or “buy in*” or cooperat* or co operat* or expectation* or
75. experienc* or feedback or involv* or opinion* or participat* or perceived need*
76. or perspective* or preferen* or satisf* or view* or voices or worry)) or ab
77. ((survey* or question*) and (account* or anxieties or attitude* or barriers or
78. belief* or buyin or “buy in*” or cooperat* or co operat* or expectation* or
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79. experienc* or feedback or involv* or opinion* or participat* or perceived need*
80. or perspective* or preferen* or satisf* or view* or voices or worry))
81. 32 or 33
Biosis Citation Index, Web of Science (Thomson Reuters)
1. topic=((“action research” or audiorecord* or ((audio or tape or video*) near record*) or colaizzi* or
(constant near (comparative or comparison)) or “content analy*” or “critical social*” or (data near saturat*)
or “discourse analys?s” or emic or “ethical enquiry” or ethno* or etic or fieldnote* or (field near (note* or
record* or stud* or research)) or (focus near (group* or sampl*)) or ((focus* or structured) near interview*)
or giorgi* or glaser or (grounded near (theor* or study or studies or research)) or heidegger* or
hermeneutic* or heuristic or “human science” or husserl* or ((life or lived) near experience*) or “maximum
variation” or merleau or narrat* or ((participant* or nonparticipant*) near observ*) or ((philosophical or
social) near research*) or (“pilot testing” and survey) or “purpos* sampl*” or qualitative* or ricoeur or
semiotics or shadowing or snowball or spiegelberg* or stories or story or storytell* or strauss or “structured
categor*” or “tape record*” or taperecord* or testimon* or (thematic* near analys*) or themes or
“theoretical sampl*” or “unstructured categor*” or “van kaam*” or “van manen” or videorecord* or
“video record*” or videotap* or “video tap*”)) or title= ((“action research” or audiorecord* or ((audio or
tape or video*) near record*) or colaizzi* or (constant near (comparative or comparison)) or “content
analy*” or “critical social*” or (data near saturat*) or “discourse analys?s” or emic or “ethical enquiry” or
ethno* or etic or fieldnote* or (field near (note* or record* or stud* or research)) or (focus near (group* or
sampl*)) or ((focus* or structured) near interview*) or giorgi* or glaser or (grounded near (theor* or study
or studies or research)) or heidegger* or hermeneutic* or heuristic or “human science” or husserl* or ((life
or lived) near experience*) or “maximum variation” or merleau or narrat* or ((participant* or
nonparticipant*) near observ*) or ((philosophical or social) near research*) or (“pilot testing” and survey) or
“purpos* sampl*” or qualitative* or ricoeur or semiotics or shadowing or snowball or spiegelberg* or
stories or story or storytell* or strauss or “structured categor*” or “tape record*” or taperecord* or
testimon* or (thematic* near analys*) or themes or “theoretical sampl*” or “unstructured categor*” or
“van kaam*” or “van manen” or videorecord* or “video record*” or videotap* or “video tap*”))
2. topic= (((adult* or attender* or carer* or caregiv* or “care giv*” or client* or “community based” or
consumer* or couples or customer* or daughter* or famil* or father* or friend* or (home near (care or
caring or nurs*)) or “home based” or husband* or individual* or ((informal or “non professional”) near
(care or nursing)) or marital* or men or mentor* or mother* or multifam* or neighbo?r* or “next of
kin” or niece or nephew* or parent* or partner* or patient* or people* or person* or relative or
relatives or sibling* or “significant other*” or spous* or “step relationship*” or teacher* or wife* or
wives or women or user*) or (adolescen* or boy* or child* or delinquen* or girl* or graders or infant*
or junior* or juvenile* or kindergarten or minors or p?ediatric* or postpubert* or postpubescen* or
preadolescen* or prepubert* or prepubescen* or preschool* or preteen* or pubert* or pubescen* or
school* or teen* or toddler* or (young* near (people or person* or patient* or population*)) or
youngster* or youth*)) near (account* or anxieties or attitude* or barriers or belief* or buyin or “buy
in*” or cooperat* or “co operat*” or expectation* or experienc* or feedback or involv* or opinion* or
participat* or perceived need* or (perception* not “speech perception”) or perspective* or preferen*
or satisf* or view* or voices or worry)) or title= (((adult* or attender* or carer* or caregiv* or “care
giv*” or client* or “community based” or consumer* or couples or customer* or daughter* or famil*
or father* or friend* or (home near (care or caring or nurs*)) or “home based” or husband* or
individual* or ((informal or “non professional”) near (care or nursing)) or marital* or men or mentor* or
mother* or multifam* or neighbo?r* or “next of kin” or niece or nephew* or parent* or partner*
or patient* or people* or person* or relative or relatives or sibling* or “significant other*” or spous* or
“step relationship*” or teacher* or wife* or wives or women or user*) or (adolescen* or boy* or child*
or delinquen* or girl* or graders or infant* or junior* or juvenile* or kindergarten or minors or p?
ediatric* or postpubert* or postpubescen* or preadolescen* or prepubert* or prepubescen* or
preschool* or preteen* or pubert* or pubescen* or school* or teen* or toddler* or (young* near
(people or person* or patient* or population*)) or youngster* or youth*)) near (account* or anxieties
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or attitude* or barriers or belief* or buyin or “buy in*” or cooperat* or “co operat*” or expectation*
or experienc* or feedback or involv* or opinion* or participat* or perceived need* or (perception* not
“speech perception”) or perspective* or preferen* or satisf* or view* or voices or worry))
3. topic= ((information near (need* or requirement* or support*)) or “health information”) or title=
((information near (need* or requirement* or support*)) or “health information”)
4. topic= (service* near (acceptab* or unacceptab*)) or title= (service* near (acceptab* or unacceptab*))
5. 1 or 2 or 3 or 4
6. topic= ((survey* or question*) and (account* or anxieties or attitude* or barriers or belief* or buyin or
“buy in*” or cooperat* or co operat* or expectation* or experienc* or feedback or involv* or opinion*
or participat* or perceived need* or perspective* or preferen* or satisf* or view* or voices or worry)) or
title= ((survey* or question*) and (account* or anxieties or attitude* or barriers or belief* or buyin or
“buy in*” or cooperat* or co operat* or expectation* or experienc* or feedback or involv* or opinion*
or participat* or perceived need* or perspective* or preferen* or satisf* or view* or voices or worry))
7. 5 or 6
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Appendix 2 Preferred Reporting Items for
Systematic Reviews and Meta-Analyses flow diagram
Pharmacological/dietary child
(n = 35) and adult/mixed
studies (n = 12)
• Antipsychotics, n = 11
• Noradrenergic agents, n = 8
• Stimulants, n = 4
• Anticonvulsants, n = 3
• MAO-B inhibitors, n = 1
• Dopamine receptor agonists,
   n = 3
• 5HT3-receptor antagonists, n = 2
• GABAB receptor agonists, n = 1
• TCA antidepressants, n = 2
• SSRI antidepressants, n = 2
• Nicotinic acetylcholine receptor
   antagonists, n = 1
• Transdermal nicotine, n = 2
• Omega-3 fatty acids, n = 1
• Across-group comparisons,
   n =  6
Behavioural child (n =  7)
and adult (n = 4)
studies
• HRT/CBIT, n = 6
• Negative practice, n = 1
• ERP, n = 1
• Relaxation training, n = 1
• Anger control training,
   n = 1
• Parent training, n = 1
Physical child (n = 1)
and adult/mixed (n = 8)
studies
• DBS, n = 3
• rTMS, n = 3
• i.v. immunoglobulin,
   n = 1
• Botulinum toxin, n = 1
• Acupuncture, n = 1
PANDAS child (n = 3)
studies
• i.v. immunoglobulin
   and plasma exchange,
   n = 1
• Penicillin, n = 1
• Azithromycin, n = 1
Records excluded (n = 6148)
Full-text articles excluded (n = 123)
• Wrong intervention, n = 7
• Wrong population, n = 8
• Wrong study design, n = 95
• Wrong outcomes, n = 12
• Paper retracted, n = 1
Studies included in qualitative synthesis
(n = 4)
Studies included in quantitative synthesis
(n = 70)
Records identified through database searching
(n = 8295) 
Records screened after duplicates removed
(n = 6345) 
Full-text articles assessed for eligibility
(n = 197)
FIGURE 237 A PRISMA flow diagram of included studies. MAO-B, monoamine oxidase type B.
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Appendix 3 Study characteristics
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TABLE 9 Study characteristics for trials of pharmacological interventions
Study Study design Population Treatment Attrition
Antipsychotics
Sallee 199798 Haloperidol and pimozide vs. placebo
Crossover RCT (2 weeks’ washout)
Inclusion criteria:
l YGTSS global score of > 20
l no current use of other antipsychotic drugs
(washout 2 weeks)
22 children
Mean age 10.2 years, SD 2.5 years
Age range 7–16 years
77% male, 100% TS
59% ADHD, 23% OCD
0% on medication
TSGS 28.5, SD 14.5
Haloperidol
Mean dose of 3.5mg/day, SD 2.2mg/day
Range 1–8mg/day
Start dose of 1mg/day
Pimozide
Mean dose of 3.4mg/day, SD 1.6mg/day
Range 1–6mg/day
Start dose of 1mg/day
Administered 1×day
6 weeks’ duration
95% completed
100% analysed
Shapiro 198999 Haloperidol and pimozide vs. placebo
Parallel RCT (crossover but first-phase data used)
Inclusion criteria:
l no use of other medications (3 weeks’ washout)
57 adults and children
Mean age 21.1 years, SD 11 years
Age range NR
72% male, 100% TS
19% ADHD, % OCD NR
0% on medication
Shapiro TSSS 4.1, SD 2.0
Haloperidol
Maximum dose of 10 mg/day
Start dose of 0.5mg/day
Pimozide
Maximum dose of 0.3mg/kg/day or
20mg/day
Start dose of 1mg/day
Administered 1 × day
6 weeks’ duration
84% completed
84% analysed
Included studies
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Study Study design Population Treatment Attrition
Shapiro 1984100 Pimozide vs. placebo
Crossover RCT (2 weeks’ washout)
Inclusion criteria:
l multiple motor and vocal tics for > 2 years
l no other medication (2 weeks’ washout)
20 adults and children
Mean age 24.7 years, SE 2.7 years
Age range 11–53 years
65%male
100% TS
30% ADHD, % OCD NR
0% on medication
Maximum dose of 20mg/day for adults,
10mg/day or ≈ 0.2mg/kg/day for children
aged ≤ 12 years
Start dose of 1mg/day
Administered 1 × day
6 weeks’ duration
83% completed
83% analysed
Ross 1978106 Pimozide vs. haloperidol
Crossover RCT (6 day washout)
Inclusion criteria:
l TS
l no use of other medications (4 days’ washout)
Nine adults and children
Mean age 18.7 years, SD NR
Age range 8–28 years
78% male
100% TS
% ADHD, % OCD NR
0% current medication
Mean tic frequency 44 per
5 minutes, SD 26 tics
Pimozide
Maximum dose of 12mg/day
Start dose of 2mg/day
Haloperidol
Maximum dose of 12mg/day
Start dose of 2mg/day
Administered 1 × day
12 days’ duration
Only available
cases reported
continued
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Gulisano 2011109 Pimozide vs. aripiprazole
Parallel controlled before-and-after study
Inclusion criteria:
l TS
l aged 6–18 years
l not on other medications (washout duration NR)
50 children
Mean age 11.1 years, SD 2.1 years
Age range 6–18 years
86% male, 100% TS
56% ADHD, 48% OCD
0% on medication
YGTSS global score 49.3, SD 2.7
Pimozide mean dose of 4.4mg/2 × day,
SD 1.5mg/2 × day
Aripiprazole mean dose of 5.3mg/2 × day,
SD 2.4mg/2 × day
24 months’ duration
% completed NR
% analysed NR
Scahill 2003101 Risperidone vs. placebo
Parallel RCT
Inclusion criteria:
l YGTSS score ≥ 22
l no other psychotropic drug use (2 weeks’ washout)
26 children
Mean age 11.1 years, SD 2.2 years
Age range 6–NR years
96% male, 100% TS
42% ADHD, 15% OCD
0% on medication
YGTSS total tic score 27.9, SD 6.7
Maximum dose of 3mg/day, 4mg/day for
older adolescents
Start dose of 0.5mg/day
Administered 2 × day
8 weeks’ duration
92% completed
100% analysed
Dion 2002102 Risperidone vs. placebo
Parallel RCT
Inclusion criteria:
l TSSS at least 3 (moderate)
l no other psychotropic drug use (washout varied
depending on the drug)
48 adults and children
Median age 32 years
Age range 14–49 years
18% male, 100% TS
% ADHD NR, % OCD NR
0% on medication
Shapiro TSSS 5.3, SD 1.3
Maximum dose of 6mg/day
Start dose of 0.25mg/day
Administered 2 × day
8 weeks’ duration
81 completed
96% analysed
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Study Study design Population Treatment Attrition
Sallee 2000103 Ziprasidone vs. placebo
Parallel RCT
Inclusion criteria:
l tic symptoms that, in the clinical judgement of the
investigator, were severe enough to warrant
treatment with medication
l no psychotropic drug use (4–8 weeks’ washout
depending on medication)
28 children
Mean age 11.6 years, SD NR
Age range 7–16 years
79% male
96% TS, 4% CTD
54% ADHD, 36% OCD
0% on medication
YGTSS global score 46.9, SD 16
Maximum dose of 20mg/day
Start dose of 5mg/day
Administered 2 × day
8 weeks’ duration
86% completed
96% analysed
Gilbert 2004104 Risperidone vs. pimozide
Crossover RCT (2 weeks’ washout)
Inclusion criteria:
l TS or CTD
l CGI-tic score ≥ 4
l aged 7–17 years
l no use of other medications for tics or other
neurological or psychiatric disorders
(2 weeks’ washout)
19 children
Mean age 11 years, SD 2.5 years
Age range 7–17 years
79% male
84% TS, 16% CTD
37% ADHD, 2% OCD
0% current medication
Mean YGTSS global score 43.3,
SD 17.5
Risperidone
Maximum dose of 4mg/day
Start dose of 1mg/day
Split into two equal doses per day
administered morning and night time
Pimozide
Maximum dose of 4mg/day
Start dose of 1mg/day
Administered 1 × day (+ placebo 1 × day)
4 weeks’ duration
68% completed
68% analysed
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
X
X
X
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
X
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
H
o
llis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
3
1
9
TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Bruggerman 2001105 Risperidone vs. pimozide
Parallel RCT
Inclusion criteria:
l TS
l ≥ 3 on Shapiro TSSS (moderate)
l ≥ 3 on CGI-severity (moderately ill)
l aged 10–65 years
l no use of other medications (1–5 weeks’ washout
depending on medication)
50 adults and children
Median age 22 years
Range 11–50 years
88% male
4% ADHD, 46% OCD
0% current medicate
Mean Shapiro TSSS total score 4.3
Risperidone
Maximum dose of 6mg/day
Start dose of 1mg/day
Pimozide
Maximum dose of 6mg/day
1mg/week increments
Administered 1 × day
8 weeks’ duration
82% completed
100% analysed
Liu 2011107 Aripiprazole vs. tiapride
Parallel quasi-randomised trial
Inclusion criteria:
l TS
l aged 5–17 years
l YGTSS global score ≥ 25
200 children
Mean age 10.1 years, SD 2.7 years
Range 5–17 years
80% male
100% TS
% on current medication NR
Mean YGTSS global score 52.5,
SD 14.7
Aripiprazole
Maximum dose of 15–25mg/day
Start dose of 2.5–5mg/day
Tiapride
Maximum dose of 300–500mg/day
Start dose of 25–50mg/day
12 weeks’ duration
98% completed
95% analysed
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Study Study design Population Treatment Attrition
Yoo 2011108 Aripiprazole vs. haloperidol
Parallel comparative
(non-randomised) study
Inclusion criteria:
l TS or CTD
l aged 6–15 years
l Korea YGTSS ≥ 22
l no use of psychotropic medications
(2 weeks’ washout)
48 children
Mean age 10.3 years, SD 3.5 years
Range 6–15 years
69% male
54% TS, 22% CTD
31% ADHD, 6% OCD
% on current medication NR
YGTSS total tic score 26.9, SD 5.8
Aripiprazole
Maximum dose of 20mg/day
Start dose of 5mg/day
Haloperidol
Maximum dose of 4.5mg/day
Start dose of 0.75mg/day
8 weeks’ duration
77% competed
100% analysed
Ji 2005110 Olanzapine vs. haloperidol
Parallel RCT
Inclusion criteria:
l TS
l aged 8–16 years
l use of other antipsychotic medications
(3 days’ washout)
60 children
Mean age 10.5 years, SD 3.7 years
Range 8–16 years
95% male
100% TS
% on current medication NR
YGTSS total tic score 31, SD 9
Olanzapine
Maximum dose of 10mg/day
Start dose of 2.5–5mg/day
Haloperidol
Maximum dose of 12mg/day
Start dose of 2–4mg/day
4 weeks’ duration
90% completed
90% analysed
continued
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Noradrenergic agents
Kurlan 2002113 Clonidine and methylphenidate and
clonidine+methylphenidate vs. placebo
Parallel RCT
Inclusion criteria:
l TD and CTD
l ADHD
l C-GAS ≤ 70
l no use of medications for ADHD, tics
or associated behavioural symptoms
(2 weeks’ washout)
136 children
Mean age 10.2 years, SD 2 years
Age range 7–14 years
85% male
94% TS 6% CTD
100% ADHD, 16% OCD
0% on other medication
YGTSS global score 40.6, SD 18
Clonidine
Maximum dose of 0.6mg/day
Start dose of 0.2mg/day
Methylphenidate
Maximum dose of 60mg/day
Both clonidine and methylphenidate
Administered 1 × day
16 weeks’ duration
Outcome assessed at 4, 8, 12 and
16 weeks
89% completed
100% analysed
Leckman 1991116 Clonidine vs. placebo
Parallel RCT
Inclusion criteria:
l YGTSS global ≥ 20
l TS
l no use of any other psychoactive medication
(2 months’ washout)
47 adults and children
Mean age 15.6 years,
SD 10.4 years
Age range 7–48 years
80% male
100% TS
55% ADHD, 20% OCD
0% on other medication
TSGS 35.7, SD 8.3
0.25mg/day
Start dose of 4–5mg/kg/day
Increased over 2 weeks and maintained
for 10 weeks
Administered 2, 3 or 4 times/day
12 weeks’ duration
Outcomes assessed at 12 weeks
89% completed
85% analysed
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Study Study design Population Treatment Attrition
Goetz 1987114 Clonidine vs. placebo
Crossover RCT (1 week of washout)
Inclusion criteria:
l TS
l no previous clonidine exposure
l stable doses of other medications
24 child [IPD from mixed study
(n= 30)]
Mean age 12.9 years, SD 2.6 years
Age range 8–17 years
79% male
100% TS
8% ADHD, 8% OCD
46% on other medication
Motor: 8 severe, 17 moderate,
5 mild
Vocal: 1 severe, 4 moderate,
16 mild (for n= 30 population)
Maximum dose of 0.0075mg/kg/day or
0.015mg/kg/day
Start dose of 0.0025mg/kg/day, escalated
over 6 weeks and maintained for 6 weeks
Administered 1 × day
12 weeks’ duration
% completed NR
% analysed NR
Singer 1995115 Clonidine and desipramine vs. placebo
Crossover RCT (1 week of washout)
Inclusion criteria:
l TS
l ADHD
l no use of other medications (washout period NR)
37 children
Mean age 10.6 years, SD NR
Age range 7–14 years
91% male
100% TS
100% ADHD, 0% OCD
Baseline severity NR
Clonidine
Maximum dose of 0.2mg/day
Start dose of 0.05mg/day
Desipramine
Maximum dose of 100mg/day
Start dose of 25mg/day
Administered up to 4 × day
6 weeks’ duration
92% completed
92% analysed
continued
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Du 2008117 Clonidine patch vs. placebo patch
Parallel RCT
Inclusion criteria:
l TD and CTD
l no use of antipsychotic/antidepressant/mood
stabilising and/or antiepileptic medications
(4 weeks’ washout)
437 children
Mean age 10.1 years, SD 2.8 years
Age range 6–18 years
85% male
% ADHD NR, % OCD NR
YGTSS motor tic score 15.6, SD 5
1mg, 1.5mg or 2mg for body weight
< 20 kg, 20–40 kg or 40–60 kg, respectively
Patch applied 1 × day
4 weeks’ duration
87% completed
100% analysed
Zhong 2007118 Clonidine patch vs. placebo patch
Parallel RCT
Inclusion criteria:
l TS
l aged 6–18 years
l no use of antitic medications
76 children
Median age 8–9 years
Age range 6–18 years
82% male
% ADHD or OCD NR
YGTSS global tic score 56, SD 14
1mg, 1.5mg or 2mg for body weight
< 20 kg, 20–40 kg or 40–60 kg, respectively
Patch applied 1 × day
4 weeks’ duration
% completed NR
% analysed NR
Gancher 1990119 Clonidine patch vs. placebo patch
Crossover RCT (2 weeks’ washout)
Inclusion criteria:
l TS
l no use of other medications (oral clonidine tapered
and discontinued at least 2 weeks before start)
10 adults and children
Mean age adults 28 years,
children 12 years, SD NR
Age range NR
100% TS
% ADHD NR, % OCD NR
0% on other medication
TSGS 8.5, range 6–19
Maximum dose of 0.4mg/day
Start dose of 0.1mg/day
Patch applied once a week
2 months’ duration
90% completed
90% analysed
A
P
P
E
N
D
IX
3
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
3
2
4
Study Study design Population Treatment Attrition
Cummings 2002121 Guanfacine vs. placebo
Parallel RCT
Inclusion criteria:
l TS and CTD patients
l no use of treatments for OCD, ADHD or tics (apart
from intervention) (no washout for OCD and ADHD
treatments, 6 months’ washout for tic treatments)
24 children
Mean age 10.4 years, SD 2.3 years
Age range NR
83% male
96% TS, 4% CTD
0% on other medication
17% ADHD, 0% OCD
YGTSS global score 32.2, SD 13
Maximum dose of 2mg/day
Start dose of 0.5mg/day
Administered 2 × day
4 weeks’ duration
% completed NR
% analysed NR
Scahill 2001120 Guanfacine vs. placebo
Parallel RCT
Inclusion criteria:
l TS and CTD
l ADHD
l no use of other medications (washout varied
depending on drug)
34 children
Mean age 10.4 years, SD 2.0 years
Age range 7–14 years
91% male
59% TS, 35% CTD
100% ADHD, % OCD NR
0% on other medication
YGTSS global score 15.3, SD 6.7
Maximum dose of 4mg/day
Start dose of 0.5mg/day
Administered 1, 2 or 3 times/day
8 weeks’ duration
% completed NR
100% analysed
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
SSRI antidepressants
Kurlan 1993143 Fluoxetine vs. placebo
Parallel RCT
Inclusion criteria:
l TS
l Leyton Obsessional Inventory ≥ 14
l at least one obsession or compulsion that
significantly interfered with daily activities
l not on antipsychotic medications (but allowed to
take haloperidol or clonidine for tic suppression)
11 children
Mean age 13.1 years, SD 2.6 years
Age range 10–18 years
100% male
100% TS
% ADHD NR, 100% OCD
symptoms (LOI-CV≥ 14, OCD
cut-point ≥ 20)
Six patients on haloperidol and/or
clonidine
Goetz motor tic frequency 5.4,
SD 2.6
Maximum dose of 40mg/day
Initial dose of 20mg/day
4 months’ duration
82% competed
82% analysed
Scahill 1997144 Fluoxetine vs. placebo
Crossover RCT (4 weeks’ washout) but first-phase
data used
Inclusion criteria:
l TS
l CGI-tic score 4 or more (at least moderate
severity)
l not on any psychotropic medication (1 month
washout)
Seven adults and seven children
Mean age 19 years, SD 8.2 years
Age range 9–34 years
64% male
100% TS
43% ADHD, 36% OCD
0% on other medication
YGTSS total tic score 25.4, SD 5.8
Fixed dose of 20mg/day
8 weeks’ duration
71% completed
71% analysed
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Study Study design Population Treatment Attrition
TCA
Singer 1995115 Desipramine (and clonidine) vs. placebo
Crossover RCT (1 week of washout)
Inclusion criteria:
l TS
l ADHD
l no use of other medications (washout period NR)
37 children
Mean age 10.6 years SD NR
Age range 7–14 years
91% male, 100% TS
100% ADHD, 0% OCD
Baseline severity NR
Desipramine
Maximum dose of 100mg/day
Start dose of 25mg/day
Administered up to 4 × day
6 weeks’ duration
92% completed
92% analysed
Spencer 2002141 Desipramine vs. placebo
Parallel RCT
Inclusion criteria:
l TD and CTD
l ADHD
l not on any other psychotropic drugs
(1 month of washout)
39 children (with tics, two without
tics not included in tic outcomes)
Mean age 10.9 years, SD 3 years
Age range NR
83% male
87% TS, 13% CTD
100% ADHD, 29% OCD
0% on other medication
YGTSS global score 64.0, SD 17
Maximum dose of 3.5mg/kg/day
Administered 2 × day
6 weeks’ duration
95% completed
100% analysed
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Antiemetic and gastroprokinetic agents
Nicolson 2005138 Metoclopramide vs. placebo
Parallel RCT
Inclusion criteria:
l TS or CTD
l subjects with tic disorder judged severe enough to
warrant medication
l not taking other medications (2 weeks’ washout)
27 children
Mean age 11.5 years,
SD ≈2.6 years
Age range 7–18 years
70% male
96% TS, 4% CTD
67% ADHD, % OCD NR 0%
On other medications for tics or
comorbidities
YGTSS total tic score 22.4, SD ≈6
Maximum dose of 40mg/day
Start dose of 5mg/day
Administered 2 or 3 times/day
8 weeks’ duration
86% completed
96% analysed
Toren 2005139 Ondansetron vs. placebo
Parallel RCT
Inclusion criteria:
l TS
l had to have previously failed on haloperidol
(side effects or no effect after 8 weeks of treatment)
15 children (IPD from mixed
n= 30 sample)
Mean age 14 years, SD 2.9 years
Age range 12–18 years
60% male, 100% TS
20% ADHD, 13% OCD
YGTSS total tic score 26.3, SD 8.2
Maximum dose of 24mg/day
Start dose of 8mg/day
Administered 3 × day (increased from
1 to 2 to 3 times/day)
3 weeks’ duration
87% completed
87% analysed
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Study Study design Population Treatment Attrition
Anticonvulsants
Smith-Hicks 2007129 Levetiracetam vs. placebo
Crossover RCT (2 weeks’ washout)
Inclusion criteria:
l TS
l YGTSS total tic score ≥ 20
l stable medication for previous 2 months
and kept constant during study
22 children
Mean age 12.2 years, SD 2.3 years
Age range 8–16 years
95% male
100% TS
50% ADHD, 9% OCD, 45% OCD
behaviours
50% on other medications
Maximum dose of 30mg/kg/day
Start dose of 10mg/kg/day
Administered 2 × day
4 week duration
91% completed
91% analysed
Jankovic 2010131 Topiramate vs. placebo
Parallel RCT
Inclusion criteria:
l TS
l YGTSS global score ≥ 19
l CGI score ≥ 4
l not on other medications for tics or comorbidities
(30 day washout)
29 adults and children
Mean age 16.5 years, SD 9.9 years
Age range 7–65 years
90% male
100% TS
34% ADHD,% OCD NR
0% on other medications
Maximum dose of 200mg/day
Start dose of 25mg/day
Administered 1 × day
6 week duration
67% completed
93% analysed
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Stimulants
Kurlan 2002113 Methylphenidate (and clonidine and
clonidine+methylphenidate) vs. placebo
Parallel RCT
Inclusion criteria:
l TS or CTD
l C-GAS ≤ 70
l ADHD
l not taking other medications for ADHD, tics or
associated behavioural symptoms (2 weeks’ washout)
136 children (in three arms)
Mean age 10.2 years,
SD ≈1.9 years
Age range 7–14 years
85% male
94% TS, 6% CTD
100% ADHD, 16% OCD
0% on medications for tics, ADHD
or other behavioural symptoms
YGTSS global score 40.6, SD 18
Methylphenidate
Maximum dose of 60mg/day
Clonidine
Maximum dose of 0.6mg/day
Methylphenidate and clonidine
Administered 1 × day
16 weeks’ duration
Outcome assessed at 4, 8, 12 and
16 weeks
86% completed
(117/136)
100% analysed
Castellanos 1997126 Methylphenidate (and dextroamphetamine) vs. placebo
Crossover RCT (no washout)
Inclusion criteria:
l TS
l ADHD
l no use of other medications (4 children continued
on haloperidol) (4 weeks’ washout)
12 children mean age 9.4 years,
SD 2 years
Range 6–13 years
100% male
95% TS, 5% CTD
100% ADHD, 10% OCD
25% (n= 3) subjects taking
haloperidol
Mean YGTSS global score 37.3,
SD 14.9
Methylphenidate
Maximum dose of 1.2mg/kg
Start dose of 0.43mg/kg/day
Dextroamphetamine
Maximum dose of 0.64mg/kg
Start dose of 0.2mg/kg
Administered 2 × day
3 weeks’ duration
83% completed
83% analysed
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Study Study design Population Treatment Attrition
Gadow 2007125 Immediate release methylphenidate vs. placebo
Crossover RCT (no washout)
Inclusion criteria:
l TS or CTD patients
l ADHD
l not taking other medications (washout: stimulants
1 week, antipsychotic drugs or SSRIs 3 weeks,
clonidine 2 weeks)
71 children
Mean age 9.0 years, SD 1.4 years
Age range 6–12 years
80% male
96% TS, 4% CTD
100% ADHD, 4% OCD
0% on other medications
YGTSS global score 36.9, SD 14.6
Maximum dose of 0.1mg/kg/day,
0.3mg/kg/day and 0.5mg/kg/day
Administered 2 × day
2 weeks’ duration
% completed NR
% analysed NR
Gadow 1992124 Methylphenidate vs. placebo
Crossover RCT (no washout)
Inclusion criteria:
l TS or CTD
l ADHD
l no other medications (washout: stimulants
1 week, antipsychotic drugs 3 weeks)
11 children
Mean age 8.3 years, SD 1.96 years
Range 6–11 years
100% male
91% TS, 9% CTD
100% ADHD, % OCD NR
0% on other medications
YGTSS global score 40.6, SD 16.6
Maximum dose of 0.1mg/kg/day,
0.3mg/kg/day and 0.5mg/kg/day
Administered 2 × day
2 weeks’ duration
% completed NR
% analysed NR
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Lyon 2010127 Immediate release dexmethylphenidate vs. no treatment
Crossover RCT (1 day washout)
Inclusion criteria:
l TS or CTD
l ADHD
l YGTSS total tic sore ≥ 14 for TS and ≥ 10 for CTD
l not taking other stimulant medications
(48 hour washout)
l level of tic medication remains stable during study
l no OCD or anxiety disorder requiring treatment
13 children
Mean age 12.7 years, SD 2.6 years
Age range 8–16 years
90% male
100% TS
100% ADHD, 0% OCD
70% on other medications
YGTSS global score 41.8, SD 13.4
0.15mg/kg
One-off dose
Studied on 1 day
77% completed
77% analysed
Dopamine agonists
Gilbert 2000135 Pergolide vs. placebo
Crossover RCT (2 weeks’ washout)
Inclusion criteria:
l TS or CTD
l YGTSS global score ≥ 20
l not on medications for tics or other neurological or
psychiatric disorders (2 weeks’ washout)
24 children
Mean age NR
Age range 7–17 years
79% male
% TS NR
68% ADHD, 32% OCD
0% on other medication
YGTSS global score 48.0, SD 13.3
Maximum dose of 300 µg/day
Start dose of 25 µg
Administered 1 × day
6 weeks’ duration
Outcome assessed at 6 weeks
79% completed
79% analysed
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Study Study design Population Treatment Attrition
Gilbert 2003136 Pergolide vs. placebo
Parallel RCT
Inclusion criteria:
l TS or CTD
l YGTSS global score ≥ 30
l not on medications for tics or other neurological or
psychiatric disorders (2 weeks’ washout)
57 children
Mean age 10.7 years, SD 2.4 years
Age range 7–17 years
73% male
% TS NR
24% ADHD, 19% OCD
0% on other medication
YGTSS global score 49.0, SD 13
Maximum dose of 150 µg/day
Start dose of 25 µg/day
Administered 3 × day
8 weeks’ duration
84% completed
89% analysed
Kurlan 2012137 Pramipexole vs. placebo
Parallel RCT
Inclusion criteria:
l TS
l YGTSS total tic sore ≥ 22
l not on any medication for ADHD, tics or OCD
(4 weeks’ washout)
63 children
Mean age NR
Age range 6–17 years
% male NR
% ADHD, % OCD NR
0% on other medication
Baseline tic severity NR
Maximum dose of 0.5mg/day
Start dose of 0.0625mg 2× day
Administered 2 × day
6 weeks’ duration
% completed NR
98% analysed
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Atomoxetine
Allen 2005122 Atomoxetine vs. placebo
Parallel RCT
Inclusion criteria:
l YGTSS total tic score ≥ 5
l TS and CTD patients
l ADHD
l no other psychotropic drug use (2 weeks’ washout)
148 children
Mean age 11.2 years, SD 2.5 years
Age range 7–17 years
88.5% male
79% TS, 21% CTD
100% ADHD, 3% OCD
0% on other medication
YGTSS total tic score 22, SD 8
Maximum dose of 1.5mg/kg
Start dose of 0.5mg/kg
Administered 1 × day
18 weeks’ duration
70% completed
98% analysed
Spencer 2008123
(subgroup of Allen
2005122)
Atomoxetine vs. placebo
Parallel RCT
Inclusion criteria:
l YGTSS total tic score ≥ 5
l TS
l ADHD
l no other psychotropic drug use (2 weeks’ washout)
117 children
Mean age 11.2 years, SD 2.4 years
Age range 7–17 years
87% male
100% TS
100% ADHD, % OCD NR
0% on other medication
YGTSS total tic score 23.3, SD 8
Maximum dose of 1.5mg/kg
Start dose of 0.5mg/kg
Administered 1 × day
18 weeks’ duration
73% completed
99% analysed
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Study Study design Population Treatment Attrition
Selegiline
Feigin 1996132 Selegiline (deprenyl) vs. placebo
Crossover RCT (6 weeks’ washout)
Inclusion criteria:
l TS
l ADHD
l not taking fluoxetine, clomipramine, stimulant
medications, or MA0 inhibitors
24 children
Mean age 12 years, SD 2.5 years
Age range 7–16 years
88% male
100% TS
100% ADHD, % OCD NR
Current medication: haloperidol
(n= 4), clonidine (n= 6),
imipramine (n= 5), fluphenazine
(n= 4), pimozide (n= 1),
molidone (n= 1)
YGTSS global score 44.2,
SD ≈17.3
Maximum dose of 10mg/day
Starting dose of 5mg/day
8 weeks
63% completed
% analysed NR
Mecamylamine
Silver 2001146 Mecamylamine vs. placebo
Parallel
Inclusion criteria:
l TS
l behavioural and emotional symptoms associated
with TD had to be rated by the parent as more
disturbing than the tics themselves
l not on other psychotropic medications (washout
duration NR)
61 children
Mean age 11.3 years
Age range 8–17 years
88% male
100% TS
60% ADHD, 30% OCD
0% on other medications
YGTSS global score 48.8, SD NR
Maximum dose of 7.5mg/day
Start dose of 2.5mg/day
Administered 2 × day
8 weeks’ duration
62% completed
82% analysed
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
X
X
X
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
X
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
H
o
llis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
3
3
5
TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Baclofen
Singer 2001140 Baclofen vs. placebo
Crossover (tapered over 12 days’ and 5 days’ drug-free
washout)
Inclusion criteria:
l TS
l other medications stable for previous two months
and kept constant throughout the study
10 children
Mean age 11.7 years, SD 2 years
Age range 8–14 years
70% male
100% TS
50% ADHD, 30% OCD
30% on other medications
YGTSS global score 63.5, SD 5.5
Maximum dose of 60mg/day
Start dose of 15mg/day
Administered 3 × day
4 weeks’ duration
90% completed
90% analysed
Transdermal nicotine
Silver 2001147 Nicotine patch+ haloperidol vs. placebo+ haloperidol
Parallel RCT
Inclusion criteria:
l TS
l not on other medications
70 children
Mean age 11.1 years, SD 2 years
Age range 8–17 years
90% male, 100% TS
% ADHD, % OCD NR
100% on haloperidol
YGTSS global score 46.7, SD 15
Maximum dose of 7mg/day
Nicotine patch for first 19 days.
Haloperidol at optimised dose for first
5 days and then reduced by 50% for rest
of study
Outcome assessed at 19 and 33 days
80% completed
80% analysed
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Study Study design Population Treatment Attrition
Howson 2004148 Nicotine patch+ antipsychotic drug vs.
placebo+ antipsychotic drug
Crossover RCT (8 weeks’ washout)
Inclusion criteria:
l TS
l moderate to marked CGI ratings
23 children
Mean age 11.9 years, SD 2.9 years
Age range 8–17 years
82% male, 100% TS
86% ADHD, 32% OCD
96% on one or more
antipsychotic drug
YGTSS total tic score 21, SD 3
7mg one-off dose
Outcome assessed at 1 week
61% completed
61% analysed
Omega-3 fatty acids
Gabbay 2012149 Omega-3 fatty acids vs. olive oil
Parallel RCT
Inclusion criteria:
l TS
l YGTSS ≥ 20
l not on immune system affecting medications
l stable dose of tic and other psychotropic
medications for previous 3 months and during
the study
33 children
Mean age 11.3 years, SD 3 years
Age range 6–18 years
82% male
100% TS
61% ADHD, 55% OCD
76% on other medications
YGTSS global score 47.1, SD 8
Omega-3 fatty acids
Maximum dose of 6000mg
Start dose of 500mg
Olive oil placebo
Administered 1 × day
20 weeks’ duration
76% completed
100% analysed
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Head-to-head comparisons between different classes of drugs
Gafney 2002150 Risperidone vs. clonidine
Parallel RCT
Inclusion criteria:
l TS
l aged 7–17 years
No use of TS medications (washout > 5.5 × half-life of
drugs)
21 children
Mean age 11.4 years, SD 2.9 years
Range 7–17 years
90% male
100% TS
90% ADHD, 95% OCD
Mean YGTSS global score 52.1,
SD ∼15.5
Risperidone
Maximum dose of 0.06mg/kg/day
Start dose of 0.03mg/kg/day
Administered 1 × day
8 weeks’ duration
Clonidine
Maximum dose of 0.005mg/kg/day
Start dose of 0.0025mg/kg/day
Administered 1 × day
8 weeks’ duration
95% completed
100% analysed
George 1993151 Fluvoxamine vs. sulpiride
Crossover RCT (2 weeks’ washout)
Inclusion criteria:
l TS
l OCD
No use of other medications (4 weeks’ washout)
11 adults and children
Mean age 28.4 years, SD 3.0 years
Age range NR
73% male
100% TS
% ADHD NR, 100% OCD
0% current medication
Mean YGTSS global score 74.6,
SD 14.8
Fluvoxamine
Maximum dose of 300mg/day
Start dose of 50mg/day
Administered 1 × day
6 weeks’ duration
Sulpiride
Maximum dose of 1 g/day
Start dose of 200mg/day
Administered 1 × day
6 weeks’ duration
73% completed
91% analysed
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Study Study design Population Treatment Attrition
Henderick 2009152 Levetiracetam vs. clonidine
Crossover RCT (2 weeks’ washout)
Inclusion criteria:
l TS
l YGTSS total tic score ≥ 22
No use of tic suppressing medication (no patients had
used for 6 months)
10 adults and children
Mean age 14.9 years, SD 5.5 years
Age range 8–27 years
70% male
100% TS
20% ADHD, % OCD NR
0% current medication
YGTSS total tic score 24.0, SD 4.9
Levetiracetam
Maximum dose of 50mg/kg/day or
2500mg/day
Start dose of 10mg/kg/day
Administered 2 × day
6 weeks’ duration
Clonidine
Maximum dose of 0.4mg/day
Start dose of 0.05mg/day 2 × day
Administered 2 × day
6 weeks’ duration
83% completed
83% analysed
Singer 1995115 Clonidine and desipramine vs. placebo
Crossover RCT (1 week of washout)
Inclusion criteria:
l TS
l ADHD
No use of other medications (washout period NR)
37 children
Mean age 10.6 years, SD NR years
Age range 7–14 years
91% male
100% TS
100% ADHD, 0% OCD
Baseline severity NR
Clonidine
Maximum dose of 0.2mg/day
Start dose of 0.05mg/day
Administered up to 4 × day
6 weeks’ duration
Desipramine
Maximum dose of 100mg/day
Start dose of 25mg/day
Administered up to 4 × day
6 weeks’ duration
92% completed
92% analysed
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TABLE 9 Study characteristics for trials of pharmacological interventions (continued )
Study Study design Population Treatment Attrition
Kang 2009153 Clonidine patch vs. haloperidol
Controlled study
Inclusion criteria:
l TS
l aged 2–15 years
119 children
Mean age 8.5 years, SD 1.3 years
Range 2–15 years
72% male
100% TS
% ADHD NR, % OCD NR
0% on other medication
YGTSS total tic score 39.3, SD 4.2
Clonidine patch
1–2 mg/week
Administered 1 ×week
4 weeks’ duration
Haloperidol
Maximum dose of 2mg/day
Start dose of 0.5–0.7mg/day
Administered 2 × day
4 weeks’ duration
% completed NR
% analysed NR
LOI-CV, Leyton Obsessional Inventory-Child Version; NR, not recorded; SE, standard error.
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TABLE 10 Study characteristics for trials of behavioural therapy
Study Study design Population Treatment 1 Treatment 2 Attrition
HRT vs. waiting list control
Azrin 1990169 HRT vs. waiting list
Parallel RCT
Inclusion criteria:
l TS
l maintain constant
dosage of current
medications
7 childrena
Mean age 11.9 years,
SD 3.5 years
Age range 6–16 years
71% male
100% TS, 0% CTD
% ADHD NR, % OCD NR
43% on medication
Tic countb 290 per hour,
SD 218 per hour
HRT
Mean 20 sessions (range 13–30
sessions) over 8–11 months
Primary component: competing
response training
Awareness training,
self-monitoring, relaxation
training, competing response
training, contingency
management
Assessed each month for 8–11
months
Waiting list
3 months, no treatment
Assessed at 3 months
64% completedc
64% analysed
HRT/CBIT vs. SP
Deckersbach 2006168 HRT vs. SP
Parallel RCT
Inclusion criteria:
l TS
l stable medications over
3 months prior to and
during study
32 adults
Mean age 35.1 years,
SD 12.2 years
Age range NR
53% male
100% TS, 0% CTD
% ADHD NR, 30% OCD
53% on medication
YGTSS total tic scoreb
28.5, SD ≈6.1
HRT
Fourteen 50-minute sessions
over 20 weeks
Self-monitoring, competing
response training, relaxation
training, contingency
management
Assessed at 10 and 20 weeks
SP
Fourteen 50-minute sessions
over 5 months
Encouragement, reassurance,
reframing, clarification,
ventilation, modelling
appropriate behaviour,
absolution and advice giving
Assessed at 10 and 20 weeks
88% completed
94% analysed
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TABLE 10 Study characteristics for trials of behavioural therapy (continued )
Study Study design Population Treatment 1 Treatment 2 Attrition
Piaccentini 2010156 CBIT vs. SP
Parallel RCT
Inclusion criteria:
l TS or CTD
l YGTSS total tic score
of > 13 (> 9 for motor
or vocal CTD alone)
l aged 9–17 years
l stable medications over
6 weeks prior to and
during study
126 children
Mean age 11.7 years,
SD 2.3 years
Age range 9–17 years
79% male
94% TS, CTD 6%
26% ADHD, 19% OCD
37% on medication for
tics
YGTSS total tic scoreb
24.7, SD 6.1
CBIT
Eight sessions (two 90 minutes,
six 60 minutes) over 10 weeks
Primary component: HRT
Awareness training, competing
response training, relaxation
training, functional behavioural
strategies to reduce influence of
tic enhancing situations
Assessed at 5 and 10 weeks
SP
Eight sessions (two 90 minutes,
six 60 minutes) over 10 weeks
Information about tic disorders
and discussion, designed to
mimic adjunctive components
of psychopharmacological
treatment
Assessed at 5 and 10 weeks
90% completed
100% analysed
Wilhelm 2003167 HRT vs. SP
Parallel RCT
Inclusion criteria:
l TS or CTD
l stable medications over
3 months prior to and
during study
32 adults
Mean age 34.9 years,
SD ≈12.5 years
Age range NR
55% male
100% TS, 0% CTD
% ADHD NR, % OCD NR
48% on medication
YGTSS total tic scoreb
28.8, SD ≈7.5
HRT
14 sessions over 20 weeks
Awareness training,
self-monitoring, relaxation
training, competing response
training, contingency
management and inconvenience
review. Asked to practice at
home
Assessed at 20 weeks
SP
14 sessions over 20 weeks
Patients selected topic sessions
and therapists were
non-directive. Focus on
experiencing, reflecting and
expressing feelings about
current life issues and problem
solving
Assessed at 20 weeks
81% completed
91% analysed
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Study Study design Population Treatment 1 Treatment 2 Attrition
Wilhelm 2012166 CBIT vs. SP
Parallel RCT
Inclusion criteria:
l TS or CTD
l CGI score ≥ 4 and
YGTSS total tic score
of > 14 (> 10 for
motor or vocal
CTD alone)
l stable medications over
6 weeks prior to and
during study
122 adults
Mean age 31.6 years,
SD ≈13.8 years
Age range 16–NR years
64% males
84% TS, 16% CTD
28% ADHD, 18% OCD
25% on medication
YGTSS total tic scoreb
22.9, SD ≈6.6
CBIT
Eight sessions (two 90 minutes,
six 60 minutes) over 10 weeks
Extension of HRT
Psychoeducation, awareness
training, competing response
training, relaxation training,
functional behavioural strategies
to reduce influence of tic
enhancing situations
Assessed at 10 weeks
SP
Eight sessions (two 90 minutes,
six 60 minutes) over 10 weeks
Information about the course,
genetics, underlying
neurobiology and rationale for
current treatments. Discussion
of tics and related issues
Assessed at 10 weeks
86% completed
93% analysed
Video conference CBIT vs. face-to-face CBIT
Himle 2012172 Video conference CBIT vs.
face-to-face CBIT parallel
RCT
Inclusion criteria:
l TS or CTD
l aged 8–17 years
l YGTSS total tic score
of > 14 (> 10 for
motor or vocal
CTD alone)
l stable medications over
4 weeks prior to and
during study
20 children
Mean age 11.6 years,
SD 2.7 years
Age range 8–17 years
94% male
%TS NR, % CTD NR
28% ADHD, 22% OCD
28% on medication
YGTSS total tic scoreb
23.7, SD 6.0
Video conference CBIT
10 weekly sessions delivered via
video conference with therapist.
Sessions conducted according to
the CBIT manual
Parents given CBIT parent
workbook
Assessed at 10 weeks
Face-to-face CBIT
10 weekly sessions delivered
face-to-face with therapist.
Sessions conducted according
to the CBIT manual
Parents given CBIT parent
workbook
Assessed at 10 weeks
82% completed
82% analysed
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TABLE 10 Study characteristics for trials of behavioural therapy (continued )
Study Study design Population Treatment 1 Treatment 2 Attrition
Negative practice vs. HRT
Azrin 1980170 Negative practice vs. HRT
Parallel RCT
Inclusion criteria:
l TS or CTD
22 adults and children
Mean age 30.0 years,
SD NR years
Age range 11–62 years
77% male
9% TS, 91% CTD
% ADHD NR, % OCD NR
18% on medication
Tic score NR
HRT
One or two sessions of ≈2.5
hours and telephone contact
Primary component: competing
response training
Review of inconveniences caused
by tics, identification of people
or situations associated with tics,
awareness training, relaxation
training. Methods to be
practised and utilised at home
Follow-up over next 18 months
Negative practice
One session of ≈2.5 hours and
telephone contact
Written instructions and
discussion of rationale.
Purposeful performance of tic
in front of mirror saying ‘this is
what I’m supposed not to do’.
Methods to be practised and
utilised at home
Follow-up over next 18 months
100% completed
100% analysed
ERP vs. HRT
Verdellen 2004171 ERP vs. HRT
Parallel RCT
Inclusion criteria:
l TS
l stable medications over
the course of the study
25 childrend
Mean age 11.9 years,
SD 2.7 years
Age range 7–17 years
80% male
100% TS, 0% CTD
48% on medication
YGTSS total tic scoreb
19.6, SD 5.8
ERP
12 weekly 2-hour sessions
Learned to suppress tics,
practised tic suppression with
optimised exposure (patients
asked to concentrate on tics and
bring with them tic-eliciting
objects). Encouraged to practice
at home
Assessed at 12 weeks
HRT
10 weekly 1-hour treatment
sessions
Awareness training and
competing response training.
Encouraged to practice at
home
Assessed at 10 weeks
80% completed
100% analysed
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Study Study design Population Treatment 1 Treatment 2 Attrition
Relaxation therapy vs. minimal therapy
Bergin 1998173 Relaxation training vs.
minimal therapy
Parallel RCT
Inclusion criteria:
l TS
23 children
Mean age 11.3 years,
SD 3.0 years
Age range 7–18 years
83% male
100% TS, 0% CTD
57% ADHD, 0% OCD
13% on medication
YGTSS global scoreb
49.9, SD ≈12.9 (total tic
score NR)
Relaxation training
Six weekly 1-hour sessions
Awareness training,
diaphragmatic breathing,
behavioural relaxation training,
applied relaxation techniques
and electromyographic
biofeedback. Practice and
homework assignments of
≈25 minutes/day
Assessed at 6 weeks
Minimal therapy
Six weekly 1-hour sessions
Awareness training and
quiet time. Practice and
homework assignments of
≈25 minutes/day
Assessed at 6 weeks
70% completed
70% analysed
Anger control training vs. treatment as usual
Sukhodolsky 2009174 Anger control training vs.
treatment as usual
Parallel RCT
Inclusion criteria:
l TS and CTD
l 11–16 years
l ≥ 12 on the parent-
rated Disruptive
Behaviour Scale
l no changes in
medication for 6 weeks
prior to or during
the study
26 children
Mean age 12.7 years,
SD ≈0.88 years
Age range 11–16 years
92% male
% TS NR, % CTD NR
69% ADHD, 35% OCD
69% on medication
YGTSS total tic scoreb
17.5, SD ≈7.2
Anger control training
10 1-hour sessions over 10 weeks
Arousal management (education
about triggers, experience,
expression and anger
management), cognitive
restructuring of hostile
attributions and practising
problem-solving skills, and
behavioural practice for
preventing or solving
anger-provoking situations
Continued to see treating
clinician
Assessed at 10 weeks
Treatment as usual
Continued to see treating
clinician
Assessed at 10 weeks
100% completed
100% analysed
continued
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TABLE 10 Study characteristics for trials of behavioural therapy (continued )
Study Study design Population Treatment 1 Treatment 2 Attrition
Parent training vs. treatment as usual
Scahill 2006164 Parent training vs.
treatment as usual
Parallel RCT
Inclusion criteria:
l TS and CTD
l aged 6–12 years
l ≥ 3.5 on Home
Situations
Questionnaire and ≥ 4
on CGI scale
l no changes in
medication for 6 weeks
prior to or during
the study
24 children
Mean age 8.9 years,
SD 2.0 years
Age range 6–12 years
75% male
75% TS, 25% CTD
42% ADHD, 17% OCD
83% on medication
YGTSS total tic scoreb
18.2, SD 8.7
Parent training
10 sessions
Core skills: providing positive
reinforcement for appropriate
behaviour, communicating
directions effectively and being
consistent with consequences for
disruptive behaviour
Techniques learnt: positive
attending, selective ignoring,
token economies and time-out
Assignments to implement skills
at home given after each session
Treatment as usual continued
Treatment as usual
Commonly included patient
education, clinical monitoring,
medication management and
school consultations as needed
Could receive other community
clinical services, e.g. child
individual psychotherapy and
school-based mental health
services but were not to initiate
new treatments, or stop
existing treatments, during the
course of the study
96% completed
96% analysed
NR, not reported.
a Three adults were also included in this study but child data could be obtained as results were reported as individual patient data.
b Tic rating at baseline. When YGTSS total tic score not reported, another measure is presented.
c Four patients dropped out of the whole study (composed of adults and children). Attrition based on conservative assumption that all the subjects who dropped out were children.
d Forty-three adults and children were in this study but data for the 25 child participants were obtained from authors for the review.
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TABLE 11 Study characteristics for trials of physical interventions
Study Population Study design Treatment Control Attrition
DBS
Ackermans 2011194 Crossover RCT (no washout period)
(Randomised treatment order but
agreement with ethical committee
that patients could switch order.
5/6 patients had DBS first)
Inclusion criteria:
l TS
l aged ≥ 25 years
l YGTSS total tic score ≥ 25
l failed to respond to medical
and behavioural intervention
l constant medications
during study
Six adults
Mean age 40.33 years,
SD NR years
Age range 35–48 years
100% male
100% TS, 0% CTD
0% ADHD and OCD
83% on medication
YGTSS total tic score
42.3, SD 3.1
DBS
Frequency, pulse width and voltage
adapted to obtain the best clinical
effect on tic reduction. Monopolar or
bipolar electrode active contacts
chosen
Constant over 3 months
Outcome assessment after 3-month
treatment
Sham
Constant over 3 months
Outcome assessment after
3-month treatment
86% completed
86% analysed
Welter 2008195 Crossover RCT (no washout period)
Inclusion criteria:
l severe TS
l aged ≥ 18 years
l failed on best medications
Three adults
Mean age 32 years,
SD 3.5 years
Age range 30–36 years
33% male
100% TS, 0% CTD
0% ADHD and OCD
100% on medication
YGTSS total tic score
33.7, SD 3.5
DBS
Bilateral thalamic
Bilateral pallidal
Bilateral thalamic and pallidal
Applied at level bellow that inducing
adverse events during 24–48 hours,
pulse width 60 microseconds,
frequency 130Hz
Constant for 2 months
Outcome assessment after 2-month
treatment
Sham
Constant for 2 months
Outcome assessment after
2-month treatment
% completed NR
% analysed NR
continued
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TABLE 11 Study characteristics for trials of physical interventions (continued )
Study Population Study design Treatment Control Attrition
Maciunas 2007196 Crossover RCT (no washout period)
Inclusion criteria:
l ≥ one tic per minute
at screening
l aged ≥ 18 years
l failed on at least two
dopamine blockers or
catecholamine depletors and
negative effect on QoL
l constant medication use
during study
Five adults
Mean age 28.2 years,
SD NR
Age range 18–34 years
100% male
100% TS, 0% CTD
60% ADHD, 80% OCD
% on medication NR
YGTSS total tic score
37.2, range 26–49
DBS with bilateral implants on right
and left sides
off–on
on–off
on–on
Optimum set of parameters chosen
for each side depending on tics and
adverse events
Constant for 1 week
Outcome assessment after 1-week
treatment
Sham with bilateral
implants off–off
Constant for 1 week
Outcome assessment after
1-week treatment
100% completed
100% analysed
rTMS
Munchau 2002199 Crossover RCT (2 weeks’ washout)
Inclusion criteria:
l TS
l aged ≥ 18 years
l constant medications use
during study
16 adults
Mean age 38 years, SD
13.2 years
Age range 18–NR years
75% male
100% TS, 0% CTD
0% ADHD, 44% OCD
68.75% on medication
YGTSS global score
57.2, SD 20.5
rTMS
left pre-motor
motor
Two 20-minute sessions on
consecutive days. 1200 pulses, 1 Hz
at 80% of active motor threshold
Immediate outcome assessment
following treatment
Left motor sham
Two 20-minute sessions on
consecutive days
Immediate outcome
assessment following
treatment
% completed NR
% analysed NR
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Study Population Study design Treatment Control Attrition
Orth 2005197 Crossover RCT (pseudorandom
order) (4 weeks’ washout)
Inclusion criteria:
l TS
l aged ≥ 18 years
l constant medications use
during study
Five adults
Median age 29 years
Age range 19–52 years
80% male
100% TS, 0% CTD
40% ADHD, 0% OCD
80% on medication
YGTSS total tic score
23.1, SD ≈4
rTMS
left pre-motor cortex followed by
right pre-motor cortex
left pre-motor cortex followed by
sham stimulation of the right
pre-motor cortex
Two sessions on consecutive days.
1800 stimuli, 1 Hz, 80% active
motor threshold
Immediate outcome assessment
following treatment
Sham stimulation of left
pre-motor cortex followed
by sham stimulation of
right pre-motor cortex
Two sessions on
consecutive days
Immediate outcome
assessment following
treatment
100% completed
100% analysed
Chae 2004198 Crossover RCT (no washout)
Inclusion criteria:
l TS
l aged 13–60 years
l CGI moderate or more severe
l medication that might lower
the seizure threshold
Eight adults
Mean age 34.9 years,
SD 16.4 years
Age range 22–60 years
63% male
100% TS, 0% CTD
38% ADHD, 50% OCD
63% on medication
YGTSS global score
70.2, SD 22.4
rTMS
motor cortex low frequency
[10 minutes 1Hz, 600 stimuli per
session (2400 per day)]
motor cortex high frequency
[15Hz for 3 seconds and
then lower frequency (overall
2400 per day)]
pre-frontal cortex low frequency
pre-frontal cortex high frequency
For each intervention, four
sessions in 1 day with 50-minute
rest between sessions
Interventions on five consecutive
days with outcome assessment at
end of each treatment day
Sham
four sessions in 1 day
with 50-minute rest
between sessions
interventions on five
consecutive days with
outcome assessment at
end of each treatment
day
100% completed
100% analysed
continued
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TABLE 11 Study characteristics for trials of physical interventions (continued )
Study Population Study design Treatment Control Attrition
i.v. immunoglobulin vs. placebo
Hoekstra 2004187 Parallel RCT
Inclusion criteria:
l TS and CTD
l aged ≥ 14 years
l tic were primary disorder and
caused significant distress and
interference with functioning
30 adults and children
Mean age 29.8 years,
SD NR years
Age range 14–63 years
62% male
90% TS, 10% CTD
% ADHD NR, 0% OCD
55% on medication
YGTSS total tic score
25.0, SD 9.6
i.v. immunoglobulin
1 g/kg of immunoglobulin/day
over 5–6 hours on two
consecutive days
Outcome assessment at 2, 6, 8,
12 and 14 weeks
Albumin solution of same
volume over 5–6 hours on
two consecutive days
Outcome assessment at 2,
6, 8, 12 and 14 weeks
97% completed
97% analysed
Botulinum toxin
Marras 2001200 Crossover RCT (at least 8 weeks’
washout) (when botulinum given
first, outcomes measured over 12
or more weeks and, when tic levels
back down to baseline, placebo
phase started)
Inclusion criteria:
l TS or CTD
l no changes in medication use
for 1 month before the study
18 adults and children
Median age 31.5 years
Age range 15–55 years
72% male
78% TS, 22% CTD
% ADHD and OCD NR
44% on medication
YGTSS motor tic score
median 9, range ≈5–14
Botulinum toxin
Variable doses, similar to those used
for dystonia
Single injection
Outcome assessment at 2 weeks
i.v. saline
Single injection
Outcome assessment at
2 weeks
90% completed
90% analysed
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TABLE 12 Study characteristics for trials of PANDAS studies
Study Study design Population Treatment Control Attrition
i.v. immunoglobulin and plasma exchange vs. placebo
Perlmutter 1999204 Parallel RCT
Inclusion criteria:
l TS, CTD or OCD
l aged 5–14 years
l history of PANDAS-like
symptoms
l current exacerbation
29 children defined as having PANDAS
Mean age 9.6 years, SD ≈2.5 years
Age range 5–14 years
% male NR
% TS NR
% ADHD NR, 86% OCD
62% on medication
TS unified rating scale 13.2, SD ≈9.3
i.v. immunoglobulin: 1 g/kg of i.v.
immunoglobulin on two consecutive
days or
Plasma exchange: one plasma
volume (45ml/kg) exchanged per
procedure. 5–6 procedures over
10–12 days. Citrate anticoagulant.
80% of replacement fluid was
5% albumin, remaining was saline
Outcome assessment at 1 month
Follow-up of i.v. immunoglobulin
and plasma exchange groups at
1 year
i.v. saline (1 g/kg of i.v.
immunoglobulin) on two
consecutive days
Outcome assessment at
1 month
97% completed
97% analysed
Penicillin vs. placebo
Garvey 1999205 Crossover RCT (no washout
between treatments)
Inclusion criteria:
l TS, CTD or OCD
l aged 4–15 years
l history of PANDAS-like
symptoms
40 children defined as having PANDAS
Mean age 9.6 years, SD 2.6 years
Age range 52–15.9 years
73% male
97% tics, 73% OCD
51% ADHD
% on medication NR
YGTSS total tic score 15.4, SD 9.0
Penicillin prophylaxis
250mg twice a day for 4 months.
Dose adjustments if needed
Outcome assessed at 4 months
Placebo
Twice a day for 4 months.
Dose adjustments if needed
Outcome assessed at
4 months
88% completed
88% analysed
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TABLE 13 Study characteristics of qualitative studies/surveys
Study Study design Setting Subjects Study aim Outcomes/themes
Kompoliti 2006210 Structured interview
survey of consecutive
patients
Tertiary referral centre
Chicago, USA
100 TS patients or their parents
For adult and child patients
Mean age 19.4 years, SD 14 years
Mean age symptoms onset 7.3 years,
SD 5.4 years
Median YGTSS rating 4, range 0–10
42% ADHD
37% OCD
11% affective disorders
7% learning difficulties
4% pervasive developmental disorders
2% psychosis
55% previous antipsychotic drug use
To assess awareness and
concern about the side
effects of antipsychotic
drugs
Side effect awareness
Side effects experienced
Side effects concerna
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TABLE 13 Study characteristics of qualitative studies/surveys (continued )
Study Study design Setting Subjects Study aim Outcomes/themes
Rivera-Navarro 2009208 Qualitative focus
groups
Neutral settings
Madrid, Spain
29 doctors, adult and adolescent TS
patients and their relatives
Aged > 11 years
No other concomitant disease
Multiple motor tics as well as one or
more vocal tic
To explore experiences
of the communication
and impact of TS
diagnosis
Difficulties in diagnosisa
Impact of diagnosis
Communication of diagnosisa
Woods 2010211 Structured internet
survey
National internet survey
USA
465 adults with TS and 487 parents
of children with TS
Child sample
Mean age 10.6 years, SD 2.9 years
Mean parent tic questionnaire score
39.2, SD 23.2
97% formal TS diagnosis
50.9% comorbid psychiatric disorder
To describe treatment
utilisation patterns
Proportions of patients undergoing
behavioural, medical and
complementary interventions
Barriers to carea
Factors inhibiting use of behavioural
therapya
a Relevant outcomes/themes.
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Appendix 4 Grading of Recommendations
Assessment, Development and Evaluation
profile tables
G rading of Recommendations Assessment, Development and Evaluation assessment of efficacy wasconducted on child studies where available and mixed/adult studies where child studies were not
available. GRADE assessments of safety outcomes were conducted on all studies.
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TABLE 14 Haloperidol vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Haloperidol Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 6 weeks; measured with: TS global scale and Shapiro TSSS; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.50
lower (1.06
lower to 0.06
higher)
⊕⊕OO LOW Critical
Motor tic score (follow-up mean 6 weeks; measured with: TS global scale motor tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.63
lower (1.04 to
0.22 lower)
⊕⊕OO LOW Critical
Vocal tic score (follow-up mean 6 weeks; measured with: TS global scale vocal tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.24
lower (0.62
lower to 0.14
higher)
⊕⊕OO LOW Critical
Global tic score (follow-up mean 6 weeks; measured with: TS global scale global score; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.37
lower (0.75
lower to 0.02
higher)
⊕⊕OO LOW Critical
Impairment (follow-up mean 6 weeks; measured with: C-GAS; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.49
lower (0.88
lower to 0.09
higher)
⊕⊕OO LOW Important
Pharmacological interventions
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Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Haloperidol Placebo
Relative
(95% CI) Absolute
Overall clinical impression (follow-up mean 6 weeks; measured with: CGI scale; range of scores: 0–7; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 1.23
lower (1.73 to
0.74 lower)
⊕⊕OO LOW Important
EPSs (follow-up mean 6 weeks; measured with: ESRS; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 6d 5 – SMD 0.51
higher (0.06
lower to 1.07
higher)
⊕⊕OO LOW Critical
AIMS (follow-up mean 6 weeks; measured with: abnormal involuntary movements; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.11
higher (0.27
lower to 0.48
higher)
⊕⊕OO LOW Critical
a Crossover RCT with 2 weeks’ washout.
b n= 22.
c Crossover study. Participants underwent intervention and control arms.
d First-phase data used in the analysis for the EPS scale.
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TABLE 15 Pimozide vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Pimozide Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 6 weeks; measured with: TS global scale and Shapiro TSSS; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.81 lower
(1.24 to 0.38 lower)
⊕⊕OO LOW Critical
Motor tic score (follow-up mean 6 weeks; measured with: TS global scale motor tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.75 lower
(1.17 to 0.32 lower)
⊕⊕OO LOW Critical
Vocal tic score (follow-up mean 6 weeks; measured with: TS global scale vocal tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.66 lower
(1.07 to 0.25 lower)
⊕⊕OO LOW Critical
Global tic score (follow-up mean 6 weeks; measured with: TS global scale global score; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.65 lower
(1.06 to 0.23 lower)
⊕⊕OO LOW Critical
Impairment (follow-up mean 6 weeks; measured with: C-GAS; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.64 lower
(1.05 to 0.23 lower)
⊕⊕OO LOW Important
Overall clinical impression (follow-up mean 6 weeks; measured with: CGI scale; range of scores: 0–7; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 1.23 lower
(1.73 to 0.74 lower)
⊕⊕OO LOW Important
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Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Pimozide Placebo
Relative
(95% CI) Absolute
EPSs (follow-up mean 6 weeks; measured with: ESRS; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 6d 5 – SMD 0.2 higher
(0.33 lower to
0.73 higher)
⊕⊕OO LOW Critical
AIMS (follow-up mean 6 weeks; measured with: Abnormal Involuntary Movements; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.22 higher
(0.16 lower to
0.6 higher)
⊕⊕OO LOW Critical
a Crossover RCT with 2 weeks’ washout.
b N= 22.
c Crossover study. Participants underwent intervention and control arms.
d First-phase data used in the analysis for the EPS Scale.
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TABLE 16 Risperidone vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Risperidone Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 8 weeks; measured with: YGTSS total tic score; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 12 14 – SMD 1.10 lower
(1.94 to 0.26 lower)
⊕⊕OO LOW Critical
Overall clinical impression (follow-up mean 8 weeks; assessed with: CGI scale)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 9/12 (75%) 1/14
(7.1%)
RR 10.50
(1.54 to
71.38)
679 more per 1000
(from 39 more to
1000 more)
⊕⊕OO LOW Important
Fatigue (follow-up mean 8 weeks; assessed with: self-reported)
2b Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa,c None 19/39 (48.7%) 5/41
(12.2%)
RR 3.72
(1.57 to
8.85)
332 more per 1000
(from 70 more to
957 more)
⊕⊕OO LOW Important
Somnolence/sedation (follow-up mean 8 weeks; assessed with: self-reported)
2b Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousc None 11/39 (28.2%) 2/41
(4.9%)
RR 5.38
(1.24 to
23.3)
214 more per 1000
(from 12 more to
1000 more)
⊕⊕OO LOW Important
Headache (follow-up mean 8 weeks; assessed with: self-reported)
2b Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousc None 4/39 (10.3%) 12/41
(29.3%)
RR 0.40
(0.15 to
1.04)
176 fewer per 1000
(from 249 fewer to
12 more)
⊕⊕OO LOW Important
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Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Risperidone Placebo
Relative
(95% CI) Absolute
Increased appetite/weight gain (follow-up mean 8 weeks; assessed with: self-reported)
2b Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousc None 12/39 (30.8%) 1/41
(2.4%)
RR 7.68
(1.46 to
40.43)
163 more per 1000
(from 11 more to
962 more)
⊕⊕OO LOW Important
Dizziness (follow-up mean 8 weeks; assessed with: self-reported)
1b Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousd None 9/23 (39.1%) 6/23
(26.1%)
RR 1.50
(0.64 to
3.53)
130 more per 1000
(from 94 fewer to
660 more)
⊕⊕OO LOW Important
a N= 26.
b Adverse events given for outcomes with > 10 events and assessed.
c N= 80.
d N= 46.
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TABLE 17 Ziprasidone vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Ziprasidone Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 8 weeks; measured with: YGTSS total tic score; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 16 11 – SMD 1.10 lower
(1.93 to 0.27 lower)
⊕⊕OO LOW Critical
Global tic score (follow-up mean 8 weeks; measured with: YGTSS global score; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 16 11 – SMD 1.02 lower
(1.84 to 20 lower)
⊕⊕OO LOW Critical
CGI scale (follow-up mean 8 weeks; measured with: CGI-Severity; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 16 11 – SMD 0.71 lower
(1.5 lower to 0.09
higher)
⊕⊕OO LOW Important
Adverse events (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 16/16 (100%) 7/11
(63.6%)
RR 1.55
(0.99 to
2.43)
350 more per 1000
(from 6 fewer to
910 more)
⊕⊕OO LOW Critical
a Unclear whether providers or outcome assessors were blind to treatment allocation.
b N= 27.
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TABLE 18 Risperidone vs. pimozide
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Risperidone Pimozide
Relative
(95% CI) Absolute
Total tic score (follow-up mean 4 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Very seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 133 – – SMD 0.54 lower
(1.32 lower to
0.24 higher)
⊕OOO VERY
LOW
Critical
Impairment (follow-up mean 4 weeks; measured with: YGTSS impairment scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Very seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 13c – – SMD 0.77 lower
(1.57 lower to
0.02 higher)
⊕OOO VERY
LOW
Important
CGI scale (follow-up mean 4 weeks; measured with: CGI-I; range of scores: 1–7; better indicated by lower values)
1 Randomised
trials
Very seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 13c – – SMD 0.63 lower
(1.42 lower to
0.16 higher)
⊕OOO VERY
LOW
Important
Weight gain (follow-up mean 4 weeks; measured with: investigator measurement; better indicated by lower values)
1 Randomised
trials
Very seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 13c – – Mean 0.7
higher (0.18
lower to 1.73
higher)
⊕OOO VERY
LOW
Important
EPSs (follow-up mean 4 weeks; measured with: ESRS; better indicated by lower values)
1 Randomised
trials
Very seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 13c – – SMD 0.05 lower
(0.77 lower to
0.66 higher)
⊕OOO VERY
LOW
Critical
Adverse events (follow-up mean 4 weeks; measured with: Side Effects Checklist; range of scores: —; better indicated by lower values)
1 Randomised
trials
Very seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 13c – – SMD 0.12 lower
(0.84 lower to
0.59 higher)
⊕OOO VERY
LOW
Critical
a Unclear outcome assessor blinding, possible cross-intervention contamination (2-week washout in crossover study) and possible attrition bias.
b N= 13.
c Crossover study. Participants underwent intervention and control arms.
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TABLE 19 Haloperidol vs. pimozide
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Haloperidol Pimozide
Relative
(95% CI) Absolute
Total tic score (follow-up mean 6 weeks; measured with: TS global scale tic score; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.25 higher
(0.13 lower to
0.63 higher)
⊕⊕OO LOW Critical
Motor tic score (follow-up mean 6 weeks; measured with: TS global scale motor tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.04 higher
(0.33 lower to
0.42 higher)
⊕⊕OO LOW Critical
Vocal tic score (follow-up mean 6 weeks; measured with: TS global scale vocal tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.38 higher
(0.01 lower to
0.76 higher)
⊕⊕OO LOW Critical
Impairment (follow-up mean 6 weeks; measured with: C-GAS; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.14 higher
(0.24 lower to
0.52 higher)
⊕⊕OO LOW Important
Overall clinical impression (follow-up mean 6 weeks; measured with: C-GAS; range of scores: —; better indicated by higher values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.14 lower
(0.52 lower to
0.24 higher)
⊕⊕OO LOW Critical
CGI scale (follow-up mean 6 weeks; measured with: CGI-Severity; range of scores: 1–7; better indicated by higher values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0 higher
(0.37 lower to
0.37 higher)
⊕⊕OO LOW Important
EPSs (follow-up mean 6 weeks; measured with: ESRS; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 6d 5 – SMD 0.40 higher
(0.15 lower to
0.94 higher)
⊕⊕OO LOW Critical
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Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Haloperidol Pimozide
Relative
(95% CI) Absolute
Abnormal involuntary movements (follow-up mean 6 weeks; measured with: Abnormal Involuntary Movements scale; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 22c – – SMD 0.09 lower
(0.47 lower to
0.28 higher)
⊕⊕OO LOW Critical
Treatment-limiting side-effects (follow-up mean 6 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 9/22 (40.9%) 3/22
(13.6%)
RR 3.0
(0.94 to
9.62)
273 more per
1000 (from
8 fewer to 1000
more)
⊕⊕OO LOW Critical
a Crossover RCT with 2 weeks’ washout.
b N= 22.
c Crossover study. Participants underwent intervention and control arms.
d First-phase data used in the analysis for the EPS Scale.
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TABLE 20 Aripiprazole vs. other antipsychotics
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Aripiprazole Antipsychotic
Relative
(95% CI) Absolute
Global/total tic score (follow-up 8–12 weeks; better indicated by lower values)
2 Randomised
trials
Seriousa Seriousb No serious
indirectness
Seriousc None 129 114 – SMD 0.17 higher
(0.41 lower to
0.75 higher)
⊕OOO
VERY LOW
Critical
Impairment score (follow-up mean 12 weeks; better indicated by lower values)
1 Randomised
trials
Seriousd No serious
inconsistency
No serious
indirectness
Seriouse None 98 97 – SMD 0.04 lower
(0.32 lower to
0.24 higher)
⊕⊕OO LOW Critical
Clinically much or very much improved (follow-up 8–12 weeks)
2 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousc None 80/129 (62%) 67/114 (58.8%) RR 1.05
(0.85 to
1.29)
29 more per
1000 (from 88
fewer to 170
more)
⊕⊕OO LOW Critical
Adverse events – hypersomnia (follow-up 8–12 weeks)
2 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousc None 23/129 (17.8%) 19/114 (16.7%) RR 0.73
(0.51 to
1.04)
45 fewer per
1000 (from 82
fewer to 7 more)
⊕⊕OO LOW Critical
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Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Aripiprazole Antipsychotic
Relative
(95% CI) Absolute
Adverse events – EPSs (follow-up mean 8 weeks)
1 Randomised
trials
Very
seriousf
No serious
inconsistency
No serious
indirectness
Serious
g
None 6/31 (19.4%) 7/17 (41.2%) RR 0.47
(0.19 to
1.17)
218 fewer per
1000 (from 334
fewer to 70
more)
⊕OOO
VERY LOW
Critical
Adverse events – headache (follow-up 8–12 weeks)
2 Randomised
trials
Seriousa Serioush No serious
indirectness
Seriousc None 7/129 (5.4%) 12/114 (10.5%) RR 0.39
(0.13 to
1.21)
64 fewer per
1000 (from 92
fewer to 22
more)
⊕OOO
VERY LOW
Critical
a Risk of bias due to unclear blinding of patients, providers and outcome assessors in both studies and, in one study,108 lack of randomisation and differential rates of attrition.
b I2= 68%.
c N= 243.
d Unclear blinding of patients, providers and outcome assessors.
e N= 195.
f Risk of bias due to unclear blinding of patients, providers and outcome assessors, lack of randomisation and differential rates of attrition.
g N= 48.
h I2= 30% but one study showed no difference and is inconsistent.
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TABLE 21 Olanzapine vs. haloperidol
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Olanzapine Haloperidol
Relative
(95% CI) Absolute
Tics (follow-up mean 4 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 25 29 – SMD 0.37 lower
(0.91 lower to
0.17 higher)
⊕⊕OO LOW Critical
Overall clinical outcome (follow-up mean 4 weeks; measured with: CGI-Severity; range of scores: 0–7; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 25 29 – SMD 1.39 lower
(1.99 to 0.79
lower)
⊕⊕OO LOW Important
Side effects (follow-up mean 4 weeks; measured with: STESS side effects scale; range of scores: 0–7; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 25 29 – SMD 0.57 lower
(1.12 to 0.03
lower)
⊕⊕OO LOW Critical
a Possible risk of attrition bias.
b N= 54.
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TABLE 22 Antipsychotics vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Antipsychotics Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 6–8 weeks; measured with: YGTSS total tic scale and TS global scale tic score; range of scores: 0–50; better indicated by lower values)
3 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 39c 36 – SMD 0.74 lower
(1.08 to 0.41 lower)
⊕⊕OO LOW Critical
Global tic score (follow-up mean 6–8 weeks; measured with: YGTSS global and TS global scale; range of scores: 0–100; better indicated by lower values)
2 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousd None 26c 23 – SMD 0.51 lower
(0.86 to 0.15 lower)
⊕⊕OO LOW Critical
CGI scale (follow-up mean 6–8 weeks; measured with: CGI-Severity; range of scores: 1–7; better indicated by lower values)
2 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousd None 26c 23 – SMD 1.01 lower
(1.49 to 0.53 lower)
⊕⊕OO LOW Critical
a One study98 was a crossover with 2 weeks’ washout between treatments and one study103 had unclear outcome assessor blinding.
b N= 75.
c One study98 was a crossover where participants underwent intervention and control arms. N divided between intervention and control groups here.
d N= 49.
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TABLE 23 Clonidine vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Clonidine Placebo
Relative
(95% CI) Absolute
Motor tic score (follow-up mean 12–16 weeks; measured with: TSGS motor tic score, YGTSS motor tic score and motor tic severity score; better indicated by lower values)
3 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousa None 67 63 – SMD 0.55 lower
(0.9 to 0.2 lower)
⊕⊕⊕O
MODERATE
Critical
Vocal tic score (follow-up mean 12–16 weeks; measured with: TSGS vocal tic score, YGTSS vocal tic score and vocal tic severity score; better indicated by lower values)
3 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousa None 67 63 – SMD 0.30 lower
(0.62 lower to 0.01
higher)
⊕⊕⊕O
MODERATE
Critical
Impairment score (follow-up mean 12–16 weeks; measured with: TSGS school and occupational function and YGTSS impairment score; better indicated by lower values)
2 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousb None 55 51 – SMD 0.54 lower
(0.93 to 0.16 lower)
⊕⊕⊕O
MODERATE
Important
Global tic score (follow-up mean 12–16 weeks; measured with: TSGS total score YGTSS global score; range of scores: 0–100; better indicated by lower values)
2 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousb None 55 51 – SMD 0.71 lower
(1.1 to 0.31 lower)
⊕⊕⊕O
MODERATE
Important
CGI proportion improved (follow-up mean 16 weeks; assessed with: CGI-I)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousc None 23/34
(67.6%)
9/32
(28.1%)
RR 2.41
(1.32 to
4.39)
397 more per 1000
(from 90 more to
953 more)
⊕⊕⊕O
MODERATE
Important
CGI-I scale (follow-up mean 12 weeks; measured with: CGI-Severity; range of scores: 1–7; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousd None 21 19 – SMD 1.04 lower
(1.71 to 0.38 lower)
⊕⊕⊕O
MODERATE
Important
Proportion with adverse events (follow-up mean 6 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriouse None 28/34
(82.4%)
15/34
(44.1%)
RR 1.87
(1.24 to
2.81)
384 more per 1000
(from 106 more to
799 more)
⊕⊕⊕O
MODERATE
Critical
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Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Clonidine Placebo
Relative
(95% CI) Absolute
Sedation/fatigue (follow-up mean 12–16 weeks; assessed with: self-reported)
2 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousb None 19/55
(34.5%)
7/51
(13.7%)
RR 2.46
(1.34 to
4.5)
200 more per 1000
(from 47 more to
480 more)
⊕⊕⊕O
MODERATE
Critical
Dry mouth (follow-up mean 12 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousd None 12/21
(57.1%)
5/19
(26.3%)
RR 2.17
(0.94 to
5.02)
308 more per 1000
(from 16 fewer to
1000 more)
⊕⊕⊕O
MODERATE
Critical
Faintness/dizziness (follow-up mean 12 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousd None 9/21
(42.9%)
4/19
(21.1%)
RR 2.04
(0.75 to
5.54)
219 more per 1000
(from 53 fewer to
956 more)
⊕⊕⊕O
MODERATE
Critical
Irritability (follow-up mean 12 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousd None 7/21
(33.3%)
1/19
(5.3%)
RR 6.33
(0.86 to
46.86)
281 more per 1000
(from 7 fewer to
1000 more)
⊕⊕⊕O
MODERATE
Critical
a N= 130.
b N= 106.
c N= 66.
d N= 40.
e N= 34.
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TABLE 24 Guanfacine vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Guanfacine Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 4–8 weeks; measured with: YGTSS total tic score; range of scores: 0–50; better indicated by lower values)
2 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousa None 29 29 – SMD 0.73 lower
(1.26 to 0.2 lower)
⊕⊕⊕O
MODERATE
Critical
Motor tic score (follow-up mean 4 weeks; measured with: YGTSS motor tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousb None 12 12 – SMD 0.64 lower
(1.46 lower to
0.18 higher)
⊕⊕⊕O
MODERATE
Critical
Vocal tic score (follow-up mean 4 weeks; measured with: YGTSS vocal tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousb None 12 12 – SMD 0.70 lower
(1.53 lower to
0.12 higher)
⊕⊕⊕O
MODERATE
Critical
Impairment (follow-up mean 4 weeks; measured with: YGTSS impairment score; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousb None 12 12 – SMD 0.27 higher
(0.53 lower to
1.08 higher)
⊕⊕⊕O
MODERATE
Important
Global tic score (follow-up mean 4 weeks; measured with: YGTSS global score; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousb None 12 12 – SMD 0.29 lower
(1.1 lower to 0.51
higher)
⊕⊕⊕O
MODERATE
Critical
a N= 58.
b N= 24.
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TABLE 25 Clonidine patch vs. placebo patch
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Clonidine
patch Placebo
Relative
(95% CI) Absolute
Total tics (follow-up mean 4 weeks; measured with: YGTSS total tic score; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
No serious
imprecisionb
None 326 111 – SMD 0.10 lower
(0.32 lower to
0.12 higher)
⊕⊕⊕O
MODERATE
Critical
Dry mouth (follow-up mean 4 weeks; assessed with: self-reported)
1 Randomised
trials
Very
seriousc
No serious
inconsistency
No serious
indirectness
Seriousd None 5/58
(8.6%)
1/18
(5.6%)
RR 1.55
(0.19 to
12.43)
31 more per
1000 (from
45 fewer to
635 more)
⊕OOO
VERY LOW
Critical
Itchy skin (follow-up mean 4 weeks; assessed with: self-reported)
1 Randomised
trials
Very
seriousc
No serious
inconsistency
No serious
indirectness
Seriousd None 5/58
(8.6%)
2/18
(11.1%)
RR 0.78
(0.16 to
3.66)
24 fewer per
1000 (from
93 fewer to
296 more)
⊕OOO
VERY LOW
Critical
Dizziness (follow-up mean 4 weeks; assessed with: self-reported)
1 Randomised
trials
Very
seriousc
No serious
inconsistency
No serious
indirectness
Seriousd None 4/58
(6.9%)
1/18
(5.6%)
RR 1.24
(0.15 to
10.41)
13 more per
1000 (from
47 fewer to
523 more)
⊕OOO
VERY LOW
Critical
a Unclear outcome assessment blinding.
b N= 437.
c Unclear patient, provider and outcome assessor blinding and unclear risk of attrition bias.
d N= 76.
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TABLE 26 Noradrenergic agents vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Noradrenergic
agents Placebo
Relative
(95% CI) Absolute
Total tics/global tic score (follow-up mean 4–16 weeks; measured with: YGTSS global score, TS global score or YGTSS total tic score; better indicated by lower values)
4 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousa None 84 80 – SMD
0.72 lower
(1.03 to
0.4 lower)
⊕⊕⊕O
MODERATE
Critical
Impairment (follow-up mean 4–16 weeks; measured with: YGTSS impairment score; better indicated by lower values)
3 Randomised
trials
No serious
risk of bias
Seriousb No serious
indirectness
Seriousc none 67 63 – SMD
0.32 lower
(0.84 lower
to 0.2 higher)
⊕⊕OO
LOW
Important
a N= 164.
b I2= 69% for subgroup differences.
c N= 130.
A
P
P
E
N
D
IX
4
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
3
7
6
TABLE 27 Fluoxetine vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Fluoxetine Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 2–4 months; measured with: YGTSS total tic scale and Goetz simple motor tic scale; better indicated by lower values)
2 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 12c 13 – SMD 0.41 lower
(1.23 lower to
0.42 higher)
⊕⊕OO
LOW
Critical
Motor restlessnessd (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
Seriouse No serious
inconsistency
No serious
indirectness
Seriousf None 7/12
(58.3%)
2/12
(16.7%)
RR 3.50
(0.91 to 13.53)
417 more per
1000 (from
15 fewer to
1000 more)
⊕⊕OO
LOW
Critical
Insomniad (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
Seriouse No serious
inconsistency
No serious
indirectness
Seriousf None 5/12
(41.7%)
2/12
(16.7%)
RR 2.50
(0.6 to 10.46)
250 more per
1000 (from
67 fewer to
1000 more)
⊕⊕OO
LOW
Critical
Decreased appetited (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
Seriouse No serious
inconsistency
No serious
indirectness
Seriousf None 3/12 (25%) 0/12 (0%) RR 7.00
(0.4 to 122.44)
– ⊕⊕OO
LOW
Critical
Diarrhoead (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
Seriouse No serious
inconsistency
No serious
indirectness
Seriousf None 3/12 (25%) 1/12
(8.3%)
RR 3.00
(0.36 to 24.92)
167 more per
1000 (from
53 fewer to
1000 more)
⊕⊕OO
LOW
Critical
a In one trial,143 there was unclear patient, provider and outcome assessor blinding.
b N= 25
c One study144 was a crossover for which participants underwent intervention and control arms. N divided between intervention and control groups here.
d Adverse events experienced by > 3 patients have been graded.
e Safety data were for whole crossover study (4 weeks’ washout between treatments).
f N= 12.
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TABLE 28 Desipramine vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Desipramine Placebo
Relative
(95% CI) Absolute
≥ 30% reduction in total tic score (follow-up mean 6 weeks; assessed with: YGTSS total tic scale)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 11/19
(57.9%)
2/20
(10%)
RR 5.79
(1.47 to
22.77)
479 more per
1000 (from
47 more to
1000 more)
⊕⊕OO
LOW
Critical
≥ 30% reduction in motor tic score (follow-up mean 6 weeks; assessed with: YGTSS motor tic scale)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 10/19
(52.6%)
4/20
(20%)
RR 2.63
(0.99 to
6.98)
326 more per
1000 (from
2 fewer to
1000 more)
⊕⊕OO
LOW
Critical
≥ 30% reduction in vocal tic score (follow-up mean 6 weeks; assessed with: YGTSS vocal tic scale)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 11/19
(57.9%)
2/20
(10%)
RR 5.79
(1.47 to
22.77)
479 more per
1000 (from
47 more to
1000 more)
⊕⊕OO
LOW
Critical
Global tic score (follow-up mean 6 weeks; measured with: YGTSS global scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 19 20 – MD 0.96 lower
(1.63 to
0.29 lower)
⊕⊕OO
LOW
Critical
≥ 30% reduction in global tic score (follow-up mean 6 weeks; assessed with: YGTSS global scale)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 12/19
(63.2%)
1/20
(5%),
0%
RR 12.63
(1.81 to
87.98)
581 more per
1000 (from
40 more to
1000 more)
⊕⊕OO
LOW
Critical
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Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Desipramine Placebo
Relative
(95% CI) Absolute
Much or very much improved (follow-up mean 6 weeks; assessed with: CGI-I)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 11/19
(57.9%)
1/20
(5%)
RR 11.58
(1.65 to
81.26)
529 more per
1000 (from
32 more to
1000 more)
⊕⊕OO
LOW
Important
Proportion of children with adverse events (follow-up mean 6 weeks; assessed with: self-reported)
1 Randomised
trials
Very
seriousb
No serious
inconsistency
No serious
indirectness
Seriousc None 26/34
(76.5%)
15/34
(44.1%)
RR 1.73
(1.14 to
2.64)
322 more per
1000 (from
62 more to
724 more)
⊕OOO
VERY
LOW
Decreased appetite (follow-up mean 6 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 5/19
(26.3%)
0/20
(0%)
RR 11.55
(0.68 to
195.63)
– ⊕⊕OO
LOW
Critical
Difficulty sleeping (follow-up mean 6 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 4/19
(21.1%)
1/20
(5%)
RR 4.21
(0.52 to
34.36)
161 more per
1000 (from
24 fewer to
1000 more)
⊕⊕OO
LOW
Critical
a N= 39.
b Risk of bias from cross-treatment contamination.
c N= 34.
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TABLE 29 Metoclopramide vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Metoclopramide Placebo
Relative
(95% CI) Absolute
Total tics (follow-up mean 8 weeks; measured with: YGTSS total tic score; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 14 13 – SMD 1.43
lower (2.28 to
0.59 lower)
⊕⊕OO
LOW
Critical
Motor tics (follow-up mean 8 weeks; measured with: YGTSS motor tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 14 13 – SMD 1.44
lower (2.28 to
0.59 lower)
⊕⊕OO
LOW
Critical
Vocal tics (follow-up mean 8 weeks; measured with: YGTSS vocal tic score; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 14 13 – SMD 0.79
lower (1.58 to
0.01 lower)
⊕⊕OO
LOW
Critical
CGI scale (follow-up mean 8 weeks; measured with: CGI-Severity score; range of scores: 1–7; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 14 13 – SMD 1.07
lower (1.88 to
0.27 lower)
⊕⊕OO
LOW
Important
Sedation (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 3/14 (21.4%) 1/13
(7.7%)
RR 2.79
(0.33 to
23.52)
138 more per
1000 (from
52 fewer to
1000 more)
⊕⊕OO
LOW
Critical
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Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Metoclopramide Placebo
Relative
(95% CI) Absolute
Dysphoria (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 1/14 (7.1%) 1/13
(7.7%)
RR 0.93
(0.06 to
13.37)
5 fewer per
1000 (from
72 fewer to
952 more)
⊕⊕OO
LOW
Critical
Increased appetite (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 3/14 (21.4%) 1/13
(7.7%)
RR 2.79
(0.33 to
23.52)
138 more per
1000 (from
52 fewer to
1000 more)
⊕⊕OO
LOW
Critical
Weight gain (follow-up mean 8 weeks; measured with: investigator assessed; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 14 13 – MD 0.5 higher
(0.75 lower to
1.75 higher)
⊕⊕OO
LOW
Critical
a Unclear presence of patient, provider and outcome assessor blinding.
b N= 27.
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TABLE 30 Ondansetron vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Ondansetron Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 3 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 9 6 – SMD 0.38
lower (1.42
lower to 0.66
higher)
⊕OOO
VERY LOW
Critical
Motor tic score (follow-up mean 3 weeks; measured with: YGTSS motor tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 9 6 – SMD 0.14
lower (1.18
lower to 0.89
higher)
⊕OOO
VERY LOW
Critical
Vocal tic score (follow-up mean 3 weeks; measured with: YGTSS vocal tic scale; range of scores: 0–25; Better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 9 6 – SMD 0.69
lower (1.76
lower to 0.37
higher)
⊕OOO
VERY LOW
Critical
CGI scale (follow-up mean 3 weeks; measured with: CGI-Severity; range of scores: 1–7; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 9 6 – SMD 0.50
lower (1.55
lower to 0.55
higher)
⊕OOO
VERY LOW
Important
a Unclear presence of patient, provider and outcome assessor blinding.
b N= 15.
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TABLE 31 Levetiracetam vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Levetiracetam Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 4 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 11 9 – SMD 0.23
lower (0.85
lower to 0.39
higher)
⊕⊕OO
LOW
Critical
Global tic score (follow-up mean 4 weeks; measured with: YGTSS global scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 11 9 – SMD 0.09
higher (0.53
lower to 0.7
higher)
⊕⊕OO
LOW
Critical
Anxiety (follow-up mean 4 weeks; measured with: MASC; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 11 9 – SMD 0.04
lower (0.66
lower to 0.58
higher)
⊕⊕OO
LOW
Important
Depression (follow-up mean 4 weeks; measured with: CDI-S; range of scores: 1–10; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 11 9 – SMD 0.20
higher (0.43
lower to 0.82
higher)
⊕⊕OO
LOW
Important
CGI scale (follow-up mean 4 weeks; measured with: CGI-Severity; range of scores: 1–7; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 11 9 – SMD 0.14
higher (0.49
lower to 0.76
higher)
⊕⊕OO
LOW
Important
a Crossover study with possible cross-treatment contamination.
b N= 20.
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TABLE 32 Topiramate vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Topiramate Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 6 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 14 13 – SMD 0.88
lower (1.68 to
0.08 lower)
⊕⊕OO
LOW
Critical
Motor tic score (follow-up mean 6 weeks; measured with: YGTSS motor tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 14 13 – SMD 0.86
lower (1.65 to
0.06 lower)
⊕⊕OO
LOW
Critical
Vocal tic score (follow-up mean 6 weeks; measured with: YGTSS vocal tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 14 13 – SMD 0.64
lower (1.41
lower to 0.14
higher)
⊕⊕OO
LOW
Critical
Global tic score (follow-up mean 6 weeks; measured with: YGTSS global scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 14 13 – SMD 1.19
lower (2.02 to
0.36 lower)
⊕⊕OO
LOW
Critical
Adverse events (follow-up mean 6 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousb None 11/15
(73.3%)
13/14
(92.9%)
RR 0.79
(0.56 to
1.11)
195 fewer per
1000 (from
409 fewer to
102 more)
⊕⊕OO
LOW
Critical
a N= 27.
b N= 29.
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TABLE 33 Methylphenidate vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Methylphenidate Placebo
Relative
(95% CI) Absolute
Motor tic score (follow-up mean 2–16 weeks; measured with: YGTSS and global tic rating scale; better indicated by lower values)
3 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 79c 72 – SMD 0.03
lower (0.2
lower to 0.15
higher)
⊕⊕OO
LOW
Critical
Vocal tic score (follow-up mean 2–16 weeks; measured with: global tic rating and YGTSS scale; better indicated by lower values)
3 Randomised
trials
Seriousa Seriousd No serious
indirectness
Seriousb None 79c 72 – SMD 0.28
lower (0.73
lower to 0.16
higher)
⊕OOO
VERY LOW
Critical
Impairment (follow-up mean 2–16 weeks; measured with: YGTSS scale; range of scores: 0–50; better indicated by lower values)
2 Randomised
trials
Seriousa Seriouse No serious
indirectness
Seriousf None 73c 67 – SMD 0.29
lower (0.89
lower to 0.3
higher)
⊕OOO
VERY LOW
Important
Global tic score (follow-up mean 2–16 weeks; measured with: YGTSS scale; range of scores: 0–100; better indicated by lower values)
2 Randomised
trials
Seriousa Serious
g
No serious
indirectness
Seriousf None 73c 67 – SMD 0.32
lower (0.85
lower to 0.22
higher)
⊕OOO
VERY LOW
Critical
Mood (follow-up mean 2 weeks; measured with: SSEC mood index;h better indicated by lower values)
1 Randomised
trials
Very
seriousi
No serious
inconsistency
No serious
indirectness
Serious
j
None 71k – – SMD 0.27
lower (0.48 to
0.05 lower)
⊕OOO
VERY LOW
Important
continued
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TABLE 33 Methylphenidate vs. placebo (continued )
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Methylphenidate Placebo
Relative
(95% CI) Absolute
Much or very much improved: parent rated (follow-up mean 16 weeks; assessed with: CGI-I)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousl None 20/37 (54.1%) 9/32
(28.1%)
RR 1.92
(1.03 to
3.6)
259 more per
1000 (from
8 more to
731 more)
⊕⊕⊕O
MODERATE
Important
Much or very much improved: teacher rated (follow-up mean 16 weeks; assessed with: CGI-I)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousl None 24/37 (64.9%) 11/32
(34.4%)
RR 0 (0
to 3.22)
344 fewer per
1000 (from
344 fewer to
763 more)
⊕⊕⊕O
MODERATE
Important
Much or very much improved: investigator rated (follow-up mean 16 weeks; assessed with: CGI-I)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousl None 16/37 (43.2%) 9/32
(28.1%)
RR 1.54
(0.79 to
2.99)
152 more per
1000 (from
59 fewer to
560 more)
⊕⊕⊕O
MODERATE
Important
Moderate or severe sedation (follow-up mean 16 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousl None 16/37 (43.2%) 9/32
(28.1%)
RR 1.30
(0.23 to
7.28)
84 more per
1000 (from
217 fewer to
1000 more)
⊕⊕⊕O
MODERATE
Critical
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Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Methylphenidate Placebo
Relative
(95% CI) Absolute
Side effects: teacher rated (follow-up mean 2 weeks; measured with: SSEC Somatic index; better indicated by lower values)
1 Randomised
trials
Very
seriousi
No serious
inconsistency
No serious
indirectness
Serious
j
None 71k – – SMD 0.09
higher (0.12
lower to 0.3
higher)
⊕OOO
VERY LOW
Critical
Side effects: parent rated (follow-up mean 2 weeks; measured with: SSEC Somatic index; better indicated by lower values)
1 Randomised
trials
Very
seriousi
No serious
inconsistency
No serious
indirectness
Serious
j
None 71k – – SMD 0.90
higher (0.3 to
1.5 higher)
⊕OOO
VERY LOW
Critical
a Includes crossover studies with no washout period and possible cross-treatment contamination.
b N= 151.
c Two studies124,125 were crossovers in which participants underwent intervention and control arms. N divided between intervention and control groups here.
d I2= 71%.
e I2= 81%.
f N= 140.
g I2= 77%.
h Teacher rated. Outcome also reported as assessed by parents.
i Crossover with no washout period and possible cross-treatment contamination.
j N= 71.
k Crossover study. Participants underwent intervention and control arms.
l N= 69.
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TABLE 34 Dexmethylphenidate vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Dexmethylphenidate Placebo
Relative
(95% CI) Absolute
Motor tic score (follow-up mean 1 days; measured with: YGTSS motor tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 10c – – SMD 0.60
lower (1.13 to
0.07 lower)
⊕OOO
VERY
LOW
Critical
Vocal tic score (follow-up mean 1 days; measured with: YGTSS vocal tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 10c – – SMD 0.62
lower (1.15 to
0.09 lower)
⊕OOO
VERY
LOW
Critical
Impairment (follow-up mean 1 days; measured with: YGTSS impairment scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 10c – – SMD 0.41
lower (1.3
lower to 0.47
higher)
⊕OOO
VERY
LOW
Important
Global tic score (follow-up mean 1 days; measured with: YGTSS global scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 10c – – SMD 0.66
lower (1.27
lower to 0.04
higher)
⊕OOO
VERY
LOW
Critical
a Unsuitable control group, lack of washout between treatments and unclear blinding of patients, providers and outcome assessors.
b N= 10.
c Crossover study. All participants underwent intervention and control.
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TABLE 35 All stimulants vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Stimulants Placebo
Relative
(95% CI) Absolute
Motor tic score (follow-up mean 0.1–16 weeks; measured with: YGTSS and global tic rating scale; better indicated by lower values)
4 Randomised
trials
Seriousa Seriousb No serious
indirectness
Seriousc None 84d 77 – SMD 0.17 lower
(0.46 lower to
0.11 higher)
⊕OOO
VERY LOW
Critical
Vocal tic score (follow-up mean 0.1–16 weeks; measured with: YGTSS and global tic rating scale; better indicated by lower values)
4 Randomised
trials
Seriousa Seriouse No serious
indirectness
Seriousc None 84e 77 – SMD 0.36 lower
(0.76 lower to
0.03 higher)
⊕OOO
VERY LOW
Critical
Impairment (follow-up mean 0.1–16 weeks; measured with: YGTSS and global tic rating scale; better indicated by lower values)
3 Randomised
trials
Seriousa Seriousf No serious
indirectness
Serious
g
None 78d 72 – SMD 0.30 lower
(0.76 lower to
0.15 higher)
⊕OOO
VERY LOW
Important
Global tic score (follow-up mean 0.1–16 weeks; measured with: YGTSS and global tic rating scale; better indicated by lower values)
3 Randomised
trials
Seriousa Serioush No serious
indirectness
Serious
g
None 78d 72 – SMD 0.40 lower
(0.84 lower to
0.04 higher)
⊕OOO
VERY LOW
Critical
a Includes crossover studies124,125,127 with no washout period and possible cross-treatment contamination.
b I2= 49%.
c N= 161.
d Two studies124,125 were crossovers in which participants underwent intervention and control arms. N divided between intervention and control groups here.
e I2= 71%.
f I2= 64%.
g N= 150.
h I2= 69%.
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TABLE 36 Pergolide vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Pergolide Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 8 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 36 15 – SMD 0.59 lower
(1.21 lower to
0.02 higher)
⊕⊕OO
LOW
Critical
Global tic score (follow-up mean 6–8 weeks; measured with: YGTSS global tic scale; range of scores: 0–100; better indicated by lower values)
2 Randomised
trials
Seriousb No serious
inconsistency
No serious
indirectness
Seriousc None 46d 24 – SMD 0.87 lower
(1.39 to 0.34
lower)
⊕⊕OO
LOW
Critical
Impairment (follow-up mean 8 weeks; measured with: YGTSS impairment scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 36 15 – SMD 0.53 lower
(1.14 lower to
0.08 higher)
⊕⊕OO
LOW
Important
CGI scale (follow-up mean 6–8 weeks; measured with: CGI-Severity; range of scores: 1–7; better indicated by lower values)
2 Randomised
trials
Seriousb No serious
inconsistency
No serious
indirectness
Seriousc None 46d 24 – SMD 0.28 lower
(0.78 lower to
0.23 higher)
⊕⊕OO
LOW
Important
Adverse events (follow-up mean 6 weeks; assessed with: self-reported)
1 Randomised
trials
Seriouse No serious
inconsistency
No serious
indirectness
Seriousf None 7/19
(36.8%)
8/19
(42.1%)
RR 0.88
(0.4 to
1.93)
51 fewer per
1000 (from 253
fewer to 392
more)
⊕⊕OO
LOW
Critical
Side effects (follow-up mean 6–8 weeks; measured with: STESS; better indicated by lower values)
2 Randomised
trials
Seriousb No serious
inconsistency
No serious
indirectness
Seriousc None 46d 24 – SMD 0.05 lower
(0.49 lower to
0.38 higher)
⊕⊕OO
LOW
Critical
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Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Pergolide Placebo
Relative
(95% CI) Absolute
Gastrointestinal adverse events (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 26/36
(72.2%)
11/15
(73.3%)
RR 0.98
(0.68 to
1.42)
15 fewer per
1000 (from 235
fewer to 308
more)
⊕⊕OO
LOW
Critical
Headaches (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 16/36
(44.4%)
9/15
(60%)
RR 0.74
(0.43 to
1.29)
156 fewer per
1000 (from 342
fewer to 174
more)
⊕⊕OO
LOW
Critical
Mild insomnia (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 6/36
(16.7%)
0/15
(0%)
RR 5.62
(0.34 to
93.94)
– ⊕⊕OO
LOW
Critical
QRS width (follow-up mean 8 weeks; measured with: self-reported; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa none 36 15 – MD 0.70 higher
(3.35 lower to
4.75 higher)
⊕⊕OO
LOW
Critical
Rash (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 4/36
(11.1%)
1/15
(6.7%)
RR 1.67
(0.2 to
13.7)
45 more per
1000 (from 53
fewer to 847
more)
⊕⊕OO
LOW
Critical
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
X
X
X
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
X
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
H
o
llis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
3
9
1
TABLE 36 Pergolide vs. placebo (continued )
Quality assessment Number of patients Effect
Quality Importance
Number of
studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Pergolide Placebo
Relative
(95% CI) Absolute
PR interval (follow-up mean 8 weeks; measured with: self-reported; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa none 36 15 – MD 9.90 higher
(5.27 lower to
25.07 higher)
⊕⊕OO
LOW
Critical
QT interval (follow-up mean 8 weeks; measured with: self-reported; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 36 15 – MD 13.50
higher (4.29
lower to 31.29
higher)
⊕⊕OO
LOW
Critical
a N= 51.
b One study135 had associated risk of bias.
c N= 70.
d One study135 was a crossover in which participants underwent intervention and control arms. N divided between intervention and control groups here.
e Study was a crossover in which participants underwent intervention and control arms with a 2-week washout between treatments. Possibility of cross-treatment contamination.
f N= 19.
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TABLE 37 Pramipexole vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Pramipexole Placebo
Relative
(95% CI) Absolute
Total tics (follow-up mean 6 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 42 20 – SMD 0.00 lower
(0.53 lower to
0.53 higher)
⊕⊕OO
LOW
Critical
Global tic score (follow-up mean 6 weeks; measured with: YGTSS global scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 42 20 – SMD 0.01 lower
(0.54 lower to
0.52 higher)
⊕⊕OO
LOW
Critical
Depression (follow-up mean 6 weeks; measured with: CDI-S; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousc None 42 19 – SMD 0.44 lower
(0.99 lower to
0.11 higher)
⊕⊕OO
LOW
Important
Anxiety (follow-up mean 6 weeks; measured with: MASC; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousc None 42 19 – SMD 0.30 lower
(0.85 lower to
0.24 higher)
⊕⊕OO
LOW
Important
CGI improved (follow-up mean 6 weeks; assessed with: CGI scale)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 10/42
(23.8%)
4/20
(20%)
RR 1.19
(0.42 to
3.33)
38 more per
1000 (from 116
fewer to 466
more)
⊕⊕OO
LOW
Important
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TABLE 37 Pramipexole vs. placebo (continued )
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Pramipexole Placebo
Relative
(95% CI) Absolute
CGI unchanged (follow-up mean 6 weeks; assessed with: CGI scale)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 32/42
(76.2%)
16/20
(80%)
RR 0.95
(0.72 to
1.26)
40 fewer per
1000 (from 224
fewer to 208
more)
⊕⊕OO
LOW
Important
0% –
Adverse events (follow-up mean 6 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 17/42
(40.5%)
5/20
(25%)
RR 1.62
(0.7 to
3.76)
155 more per
1000 (from 75
fewer to 690
more)
⊕⊕OO
LOW
Critical
a Unclear risk of bias owing to the unclear presence of patient, provider and outcome assessor blinding.
b N= 62.
c N= 61.
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TABLE 38 Atomoxetine vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Atomoxetine Placebo
Relative
(95% CI) Absolute
Total tic score (follow-up mean 18 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousa None 74 71 – SMD 0.32
lower (0.05
lower to
0.01 higher)
⊕⊕⊕O
MODERATE
Critical
Motor tic score (follow-up mean 18 weeks; measured with: YGTSS motor tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousa None 74 71 – SMD 0.30
lower (0.62
lower to
0.03 higher)
⊕⊕⊕O
MODERATE
Critical
Vocal tic score (follow-up mean 18 weeks; measured with: YGTSS vocal tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousa None 74 71 – SMD 0.22
lower (0.54
lower to 0.11
higher)
⊕⊕⊕O
MODERATE
Critical
CGI scale (follow-up mean 18 weeks; measured with: CGI-Tic/Neuro-S; range of scores: 1–7; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousa None 74 71 – SMD 0.54
lower (0.87 to
0.21 lower)
⊕⊕⊕O
MODERATE
Important
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TABLE 38 Atomoxetine vs. placebo (continued )
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Atomoxetine Placebo
Relative
(95% CI) Absolute
Decreased appetite (follow-up mean 18 weeks; assessed with: self-reported)
1b Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousc None 12/74
(16.2%)
2/71
(2.8%)
RR 5.68
(1.32 to
24.52)
132 more
per 1000
(from
9 more to
663 more)
⊕⊕⊕O
MODERATE
Important
Nausea (follow-up mean 18 weeks; assessed with: self-reported)
1b Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Seriousc None 12/76
(15.8%)
1/72
(1.4%)
RR 11.37
(1.52 to
85.22)
144 more
per 1000
(from 7 more
to 1000
more)
⊕⊕⊕O
MODERATE
Important
a N= 145.
b Adverse events showing significant differences are graded.
c N= 148.
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TABLE 39 Selegiline vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Selegiline Placebo
Relative
(95% CI) Absolute
Motor tic score (follow-up mean 8 weeks; measured with: YGTSS motor tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 15c – – SMD 0.64 lower
(1.37 lower to
0.09 higher)
⊕⊕OO
LOW
Critical
Vocal tic score (follow-up mean 8 weeks; measured with: YGTSS vocal tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 15c – – SMD 0.30 lower
(1.02 lower to
0.41 higher)
⊕⊕OO
LOW
Critical
Impairment score (follow-up mean 8 weeks; measured with: YGTSS impairment scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 15c – – SMD 0.75 lower
(1.49 to 0.01
lower)
⊕⊕OO
LOW
Critical
Global tic score (follow-up mean 8 weeks; measured with: YGTSS global scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 15c – – SMD 0.72 lower
(1.45 lower to
0.02 higher)
⊕⊕OO
LOW
Critical
a Unclear patient, provider and outcome assessor blinding and possible attrition bias.
b N= 15.
c Crossover study. Fifteen children underwent intervention and control treatments.
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TABLE 40 Mecamylamine vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Mecamylamine Placebo
Relative
(95% CI) Absolute
BP > 90/60 (follow-up mean 8 weeks; assessed with: diastolic and systolic BP)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 4/25 (16%) 0/25
(0%)
RR 9.00
(0.51 to
158.85)
– ⊕⊕OO
LOW
Critical
Weakness (follow-up mean 8 weeks; assessed with: self-reported)
1c Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousd None 8/29 (27.6%) 3/32
(9.4%)
RR 2.94
(0.86 to
10.05)
182 more per
1000 (from
13 fewer to
848 more)
⊕⊕OO
LOW
Critical
Aggression (follow-up mean 8 weeks; assessed with: self-reported)
1c Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousd None 7/29 (24.1%) 3/32
(9.4%)
RR 2.57
(0.73 to
9.04)
147 more per
1000 (from
25 fewer to
754 more)
⊕⊕OO
LOW
Critical
Heart rate after 1 week of treatment (follow-up mean 8 weeks; measured with: monitor; better indicated by higher values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousd None 29 32 – MD 8.50 higher
(2.22 to
14.78 higher)
⊕⊕OO
LOW
Critical
a Unclear patient, provider and outcome assessor blinding and possible risk of attrition bias.
b N= 50.
c For adverse events with ≥ 10 events.
d N= 61.
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TABLE 41 Baclofen vs. placebo
Quality assessment
Number of
patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Baclofen Placebo
Relative
(95% CI) Absolute
Tic score (follow-up mean 4 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 9c – – SMD 0.54 lower
(1.50 lower to
0.42 higher)
⊕OOO
VERY LOW
Critical
Impairment (follow-up mean 4 weeks; measured with: YGTSS impairment scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 9c – – SMD 1.38 lower
(2.46 to 0.30
lower)
⊕OOO
VERY LOW
Important
Global score (follow-up mean 4 weeks; measured with: YGTSS global scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 9c – – SMD 0.95 lower
(1.93 lower to
0.02 higher)
⊕OOO
VERY LOW
Critical
Overall clinical outcome (follow-up mean 4 weeks; measured with: CGI-Severity; range of scores: 1–7; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 9c – – SMD 1.05 lower
(2.03 to 0.07
lower)
⊕OOO
VERY LOW
Important
a Unclear risk of bias from cross-treatment contamination.
b N= 9.
c Crossover study. All patients underwent intervention and placebo treatment.
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TABLE 42 Nicotine patch vs. placebo
Quality assessment
Number of
patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Nicotine
patch Placebo
Relative
(95% CI) Absolute
Motor tics (follow-up mean 1–3 weeks; measured with: YGTSS motor tic scale and TSSL simple motor tic scale; better indicated by lower values)
2 Randomised
trials
Seriousa No serious
inconsistencyb
No serious
indirectness
Seriousc None 34 36 – SMD 0.03 lower
(0.49 lower to
0.43 higher)
⊕⊕OO
LOW
Critical
Vocal tics (follow-up mean 1–3 weeks; measured with: YGTSS vocal tic scale and TSSL simple vocal tic scale; better indicated by lower values)
2 Randomised
trials
Seriousa Seriousd No serious
indirectness
Seriousc None 34 36 – SMD 0.34 higher
(0.37 lower to
1.05 higher)
⊕OOO
VERY LOW
Critical
Impairment (follow-up mean 1–3 weeks; measured with: YGTSS impairment and Conners’ Global Index social problems scale; better indicated by lower values)
2 Randomised
trials
Seriousa No serious
inconsistencye
No serious
indirectness
Seriousc None 34 36 – SMD 0.30 lower
(0.75 lower to
0.15 higher)
⊕⊕OO
LOW
Important
Global tic score (follow-up mean 3 weeks; measured with: YGTSS global scale; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousf None 27 29 – SMD 0.43 lower
(0.96 lower to
0.18 higher)
⊕⊕OO
LOW
Critical
Anxiousness/shyness (follow-up mean 1 weeks; measured with: Conners’ Parent rating scale; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Serious
g
None 14h – – SMD 0.08 lower
(0.55 lower to
0.39 higher)
⊕⊕OO
LOW
Important
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Quality assessment
Number of
patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Nicotine
patch Placebo
Relative
(95% CI) Absolute
Emotional liability (follow-up mean 1 weeks; measured with: Conners’ Parent rating scale; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Serious
g
None 14h – – SMD 0.29 lower
(0.77 lower to
0.19 higher)
⊕⊕OO
LOW
Important
Global improvement (follow-up mean 3 weeks; measured with: parent rated; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousf None 27 29 – SMD 0.79 lower
(1.34 lower to
0.25 higher)
⊕⊕OO
LOW
Important
Global improvement (follow-up mean 3 weeks; measured with: clinician rated; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousf None 27 29 – SMD 0.53 lower
(1.06 lower to
0.01 higher)
⊕⊕OO
LOW
Important
Nausea (follow-up mean 3 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousc None 25/35
(71.4%)
6/35
(17.1%)
RR 4.17
(1.95 to
8.89)
543 more per
1000 (from
163 more to
1000 more)
⊕⊕OO
LOW
Critical
Itching at patch site (follow-up mean 3 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousc None 20/35
(57.1%)
15/35
(42.9%)
RR 1.33
(0.83 to
2.15)
141 more per
1000 (from
73 fewer to
493 more)
⊕⊕OO
LOW
Critical
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
X
X
X
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
X
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
H
o
llis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
4
0
1
TABLE 42 Nicotine patch vs. placebo (continued )
Quality assessment
Number of
patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Nicotine
patch Placebo
Relative
(95% CI) Absolute
Headache (follow-up mean 3 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousc None 17/35
(48.6%)
14/35
(40%)
RR 1.21
(0.71 to
2.06)
84 more per
1000 (from
116 fewer to
424 more)
⊕⊕OO
LOW
Critical
Vomiting (follow-up mean 3 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousc None 14/35
(40%)
3/35
(8.6%)
RR 4.67
(1.47 to
14.82)
315 more per
1000 (from
40 more to
1000 more)
⊕⊕OO
LOW
Critical
a Unclear risk of bias due to unclear patient blinding and attrition from studies.
b I2= 40%.
c N= 70.
d I2= 73%.
e I2= 38%.
f N= 56.
g N= 14.
h Crossover study. All patients underwent control and intervention.
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TABLE 43 Omega-3 fatty acids vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Omega-3
fatty acids Olive oil
Relative
(95% CI) Absolute
Total tics (follow-up mean 20 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 17 16 – SMD 0.24 lower
(0.92 lower to
0.45 higher)
⊕⊕OO
LOW
Critical
Impairment (follow-up mean 20 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 17 16 – SMD 0.76 lower
(1.47 to 0.05
lower)
⊕⊕OO
LOW
Important
Global tic score (follow-up mean 20 weeks; measured with: YGTSS global tic scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 17 16 – SMD 0.67 lower
(1.38 lower to
0.03 higher)
⊕⊕OO
LOW
Critical
Proportion of children with ≥ 30% reductions in tic score (follow-up mean 20 weeks; assessed with: YGTSS total tic score)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 9/17
(52.9%)
6/16
(37.5%)
RR 1.41
(0.65 to
3.07)
154 more per
1000 (from 131
fewer to 776
more)
⊕⊕OO
LOW
Critical
Proportion of children with ≥ 30% reductions in impairment (follow-up mean 20 weeks; assessed with: YGTSS total tic score)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 10/17
(58.8%)
4/16
(25%)
RR 2.35
(0.92 to
6.01)
337 more per
1000 (from 20
fewer to 1000
more)
⊕⊕OO
LOW
Important
Proportion of children with ≥ 30% reductions in global tic score (follow-up mean 20 weeks; assessed with: YGTSS global tic score)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 9/17
(52.9%)
5/16
(31.3%)
RR 1.69
(0.72 to
3.98)
216 more per
1000 (from 87
fewer to 931
more)
⊕⊕OO
LOW
Critical
a Unclear patient blinding.
b N= 33.
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TABLE 44 Risperidone vs. clonidine
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Risperidone Clonidine
Relative
(95% CI) Absolute
Global tic score (follow-up mean 8 weeks; measured with: YGTSS global scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 9 12 – SMD 0.19 higher
(0.68 lower to
1.05 higher)
⊕⊕OO
LOW
Critical
≥ 30% reduction in global tic score (follow-up mean 8 weeks; assessed with: YGTSS global scale)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 4/9 (44.4%) 6/12
(50%)
RR 0.89
(0.35 to
2.24)
55 fewer per
1000 (from 325
fewer to 620
more)
⊕⊕OO
LOW
Critical
Depression (follow-up mean 8 weeks; measured with: HAM-D; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 9 12 – SMD 0.03 higher
(0.83 lower to
0.89 higher)
⊕⊕OO
LOW
Important
CGI scale (follow-up mean 8 weeks; measured with: CGI-Severity; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 9 12 – SMD 0.65 higher
(0.24 lower to
1.54 higher)
⊕⊕OO
LOW
Important
Clinically significant adverse events (follow-up mean 8 weeks; assessed with: self-reported)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 3/9 (33.3%) 7/12
(58.3%)
RR 0.57
(0.2 to
1.62)
251 fewer per
1000 (from 467
fewer to 362
more)
⊕⊕OO
LOW
Critical
Weight gain (kg) (follow-up mean 8 weeks; measured with: Investigator assessed; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 9 12 – MD 2.00 higher
(1.66 lower to
5.66 higher)
⊕⊕OO
LOW
Important
a Unclear outcome assessor blinding.
b N= 21.
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TABLE 45 Fluvoxamine vs. sulpiride
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Fluvoxamine Sulpiride
Relative
(95% CI) Absolute
Global tic score (follow-up mean 6 weeks; measured with: YGTSS global tic scale; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 11d – – SMD 0.23
higher (0.3
lower to 0.77
higher)
⊕OOO
VERY LOW
Critical
Mild-to-moderate depression (follow-up mean 6 weeks; assessed with: self-reported)
1e Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 0/11 (0%)d 3/11
(27.3%)
RR 0.14
(0.01 to
2.48)
235 fewer per
1000 (from 270
fewer to 404
more)
⊕OOO
VERY LOW
Critical
Akathisia (follow-up mean 6 weeks; assessed with: self-reported)
1e Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 2/11 (18.2%)d 2/11
(18.2%)
RR 1.00
(0.17 to
5.89)
0 fewer per
1000 (from 151
fewer to 889
more)
⊕OOO
VERY LOW
Critical
Mild and transient nausea (follow-up mean 6 weeks; assessed with: self-reported)
1e Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 4/11 (36.4%)d 0/11
(0%)
RR 9.00
(0.54 to
149.5)
– ⊕OOO
VERY LOW
Critical
a Small between-treatment washout period (2 weeks) and unclear risk of attrition bias.
b Mixed population of adults and children (mean age 28.4 years, SD 3.0 years).
c N= 11.
d Crossover study. All patients underwent both treatments.
e Adverse events with > 2 events.
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TABLE 46 Levetiracetam vs. clonidine
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Levetiracetam Clonidine
Relative
(95% CI) Absolute
Total tic score (follow-up mean 6 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectnessb
Seriousc None 10d – – SMD 0.22 lower
(0.78 lower to
0.34 higher)
⊕⊕OO
LOW
Critical
Global tic score (follow-up mean 6 weeks; measured with: YGTSS global tic scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectnessb
Seriousc None 10d – – SMD 0.33 lower
(0.9 lower to
0.24 higher)
⊕⊕OO
LOW
Critical
Anxiety (follow-up mean 6 weeks; measured with: MASC; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectnessb
Seriousc None 10d – – SMD 0.16 lower
(0.72 lower to
0.4 higher)
⊕⊕OO
LOW
Important
Depression (follow-up mean 6 weeks; measured with: CDI-S; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectnessb
Seriousc None 10d – – SMD 0.08
higher (0.48
lower to 0.63
higher)
⊕⊕OO
LOW
Important
CGI scale (follow-up mean 6 weeks; measured with: CGI-Severity; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectnessb
Seriousc None 10d – – SMD 0.16 lower
(0.72 lower to
0.4 higher)
⊕⊕OO
LOW
Important
a Possible cross-treatment contamination (2-week washout between treatments).
b Mixed study. Mean age 14.9 years (SD 5.5 years) and population considered to be applicable to the review of children.
c N= 10.
d Crossover study. All participants underwent clonidine and levetiracetam treatments.
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TABLE 47 Clonidine vs. desipramine
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Clonidine Desipramine
Relative
(95% CI) Absolute
Adverse events (follow-up mean 6 weeks; assessed with: self-reported)
1 Randomised
trials
Very seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 28/34
(82.4%)
26/34
(76.5%)
RR 1.08
(0.84 to
1.37)
61 more per
1000 (from
122 fewer to
283 more)
⊕OOO
VERY LOW
Critical
a Risk of selective outcome reporting bias and possible cross-treatment contamination.
b N= 34.
The adverse events outcome has been graded. For other outcomes, since only results for significant findings were presented in the publication, representative results were not available and
these outcomes could not be graded.
TABLE 48 Clonidine patch vs. haloperidol
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Clonidine
patch Haloperidol
Relative
(95% CI) Absolute
Global score (follow-up mean 4 weeks; measured with: YGTSS global scale; range of scores: 0–100; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 65 54 – SMD 0.38
lower (0.75 to
0.02 lower)
⊕OOO
VERY LOW
Critical
50% reduction in global score (follow-up mean 4 weeks; assessed with: YGTSS global scale)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 53/65
(81.5%)
36/54
(66.7%)
RR 0.55
(0.29 to
1.05)
300 fewer per
1000 (from 473
fewer to 33
more)
⊕OOO
VERY LOW
Critical
a Controlled before-and-after study with unclear methods for intervention allocation, allocation concealment, blinding of patients, providers and outcome assessors, and unclear risk of
attrition and selective outcome reporting bias.
b N= 119.
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TABLE 49 Habit reversal training/CBIT vs. SP
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Habit
reversal/CBIT Control
Relative
(95% CI) Absolute
Change in YGTSS total tic score (follow-up mean 10 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectnessb
No serious
imprecisionc
None 61 65 – SMD 0.64
lower (1 to
0.29 lower)
⊕⊕⊕O
MODERATE
Critical
Change in YGTSS total tic score at 10m follow up (follow-up mean 10 months; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower
values)
2 Randomised
trials
Seriousd No serious
inconsistency
Seriouse Seriousf None 18 21 – SMD 1.11
lower (1.8 to
0.42 lower)
⊕OOO
VERY LOW
Critical
Change in YGTSS motor tic score (follow-up mean 10 weeks; measured with: YGTSS motor tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectnessb
Seriousc None 61 65 – SMD 0.45
lower (0.81 to
0.1 lower)
⊕⊕⊕O
MODERATE
Critical
Change in YGTSS vocal tic score (follow-up mean 10 weeks; measured with: YGTSS vocal tic scale; range of scores: 0–25; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectnessb
Seriousc None 61 65 – SMD 0.54
lower (0.9 to
0.19 lower)
⊕⊕⊕O
MODERATE
Critical
Change in YGTSS impairment score (follow-up mean 10 weeks; measured with: YGTSS impairment scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectnessb
Seriousc None 61 65 – SMD 0.51
lower (0.87 to
0.16 lower)
⊕⊕⊕O
MODERATE
Critical
Behavioural interventions
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Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Habit
reversal/CBIT Control
Relative
(95% CI) Absolute
Change in YGTSS Impairment at 10m follow-up (follow-up mean 10 months; measured with: YGTSS impairment scale; range of scores: 0–50; better indicated by lower
values)
1 Randomised
trials
Seriousd No serious
inconsistency
Seriouse Seriousf None 10 11 – SMD 0.42 lower
(1.29 lower to
0.45 higher)
⊕OOO
VERY LOW
Critical
CGI much or very much improved (follow-up mean 10 weeks; assessed with: CGI-I)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectnessb
Seriousc None 32/61
(52.5%)
12/65
(18.5%)
RR 2.84
(1.62 to
4.99)
34 more per
100 (from
11 more to
74 more)
⊕⊕⊕O
MODERATE
Important
Change in anxiety: Child rated (follow-up mean 10 weeks; measured with: screen for child anxiety related emotional disorders; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectnessb
Seriousc None 61 65 – SMD 0.10 lower
(0.45 lower to
0.25 higher)
⊕⊕⊕O
MODERATE
Important
Change in anxiety: Parent rated (follow-up mean 10 weeks; measured with: screen for child anxiety related emotional disorders; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectnessb
Seriousc None 61 65 – SMD 0.15 lower
(0.5 lower to
0.2 higher)
⊕⊕⊕O
MODERATE
Important
Change in depression (follow-up mean 10 weeks; measured with: children’s depression inventory: total score; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectnessb
Seriousc None 61 65 – SMD 0.22 lower
(0.57 lower to
0.13 higher)
⊕⊕⊕O
MODERATE
Important
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TABLE 49 Habit reversal training/CBIT vs. SP (continued )
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Habit
reversal/CBIT Control
Relative
(95% CI) Absolute
Change in family functioning: parent total (follow-up mean 10 weeks; measured with: family assessment measure:-III short form; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectness
Seriousc None 61 65 – SMD 0.16
higher (0.19
lower to 0.51
higher)
⊕⊕⊕O
MODERATE
Important
Change in family functioning: child total (follow-up mean 10 weeks; measured with: family assessment measure-III short form; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectness
Seriousc None 61 65 – SMD 0.02
lower (0.37
lower to 0.33
higher)
⊕⊕⊕O
MODERATE
Important
Change in caregiver strain: total score (follow-up mean 10 weeks; measured with: Caregiver Strain Questionnaire; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectness
Seriousc None 61 65 – SMD 0.02
lower (0.37
lower to 0.33
higher)
⊕⊕⊕O
MODERATE
Important
Change in social adjustment: Family (follow-up mean 10 weeks; measured with: social adjustment scale self-report; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectness
Seriousc None 61 65 – SMD 0.15
lower (0.5
lower to 0.2
higher)
⊕⊕⊕O
MODERATE
Important
Change in social adjustment: friends (follow-up mean 10 weeks; measured with: social adjustment scale self-report; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectness
Seriousc None 61 65 – SMD 0.08
lower (0.43
lower to 0.27
higher)
⊕⊕⊕O
MODERATE
Important
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Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Habit
reversal/CBIT Control
Relative
(95% CI) Absolute
Change in social adjustment: school (follow-up mean 10 weeks; measured with: social adjustment scale self-report; better indicated by lower values)
1 Randomised
trials
No serious
risk of biasa
No serious
inconsistency
No serious
indirectness
Seriousc None 61 65 – SMD 0.10
higher (0.25
lower to 0.45
higher)
⊕⊕⊕O
MODERATE
Important
Adverse events
g
(follow-up mean 10 weeks; assessed with: self-report)
1 Randomised
trials
No serious
risk of
biash
No serious
inconsistency
No serious
indirectness
Seriousc None – – – – ⊕⊕⊕O
MODERATE
Critical
a Risk of bias considered low and not sufficient to downgrade but some minor concerns, together with minor concerns over sample size, contributed to the decision to downgrade for risk
of bias.
b Only studies in children used as basis for assessment. Studies in adults show consistency of findings but did not contribute to estimation of effect size.
c Adequate sample size to obtain clinically important effect in one big trial.
d Unclear blinded outcome assessment in both trials and ≈30% dropout during follow-up.
e Adult studies.
f Sample size below that estimated as required for detecting a clinically important effect size.
g The number of events but not the number of patients with events were reported. There were no significant differences in the rates of any adverse events except for falls and athletic
injuries, for which there were more in the control group (n= 19) than the intervention group (n= 7).
h Patients and parents were the assessors of adverse events and were not blinded to intervention allocation. However, as both the intervention and control arms consisted of active
treatments, the risk of assessor bias was considered to be minimal.
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TABLE 50 Videoconference CBIT vs. face-to-face CBIT
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Video
conference
CBIT
face-to-face
CBIT
Relative
(95% CI) Absolute
Change in YGTSS total tic score (follow-up mean 10 weeks; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 10 8 – SMD 0.18 lower
(1.11 lower to
0.75 higher)
⊕⊕OO
LOW
Critical
Change in YGTSS total tic score at 4month follow-up (follow-up mean 4 months; measured with: YGTSS total tic scale; range of scores: 0–50; better indicated by lower
values)
1 Randomised
trials
No serious
risk of biasb
No serious
inconsistency
No serious
indirectness
Very seriousa None 9 7 – SMD 0.32 lower
(1.32 lower to
0.67 higher)
⊕⊕OO
LOW
Critical
CGI much or very much improved (follow-up mean 10 weeks; assessed with: CGI-I)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousa None 8/10 (80%) 6/8 (75%) RR 1.07
(0.64 to
1.77)
5 more per
100 (from
27 fewer to
58 more)
⊕⊕OO
LOW
Important
Global Impressions much or very much improved at 4month follow-up (follow-up mean 4 months; assessed with: CGI-I)
1 Randomised
trials
No serious
risk of biasb
No serious
inconsistency
No serious
indirectness
Very seriousa None 5/9 (55.6%) 3/7 (42.9%) RR 1.30
(0.46 to
3.65)
13 more per
100 (from
23 fewer to
100 more)
⊕⊕OO
LOW
Important
a N= 18.
b Minimal additional dropout at follow-up and risk of attrition bias may be low.
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TABLE 51 Negative practice vs. HRT
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Negative
practice HRT
Relative
(95% CI) Absolute
Number of tics per day (follow-up mean 4 weeks; measured with: tic count; better indicated by lower values)
1 Randomised
trials
Very seriousa No serious
inconsistency
Seriousb Seriousc None 12 10 – SMD 1.74
higher (0.76 to
2.72 higher)
⊕OOO
VERY LOW
Critical
Proportion of patients with < 1 tic per day (follow-up mean 4 weeks; assessed with: tic count)
1 Randomised
trials
Very seriousa No serious
inconsistency
Seriousb Seriousc None 2/12
(16.7%)
8/10
(80%)
RR 4.80
(1.3 to
17.66)
1000 more per
1000 (from 240
more to 1000
more)
⊕OOO
VERY LOW
Critical
a No blinded outcome assessment.
b Mixed study of adults and children. Age range 11–62 years.
c Sample size n= 22.
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TABLE 52 Exposure and response prevention vs. HRT
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations ERP HRT
Relative
(95% CI) Absolute
YGTSS total tic score (follow-up mean 10 weeks; measured with: YGTSS total tic scale; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 11 14 – SMD 0.43 lower
(1.23 lower to
0.37 higher)
⊕⊕OO
LOW
Critical
YGTSS motor tic score (follow-up mean 10 weeks; measured with: YGTSS motor tic scale; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousb None 11 14 – SMD 0.08 higher
(0.71 lower to
0.87 higher)
⊕⊕OO
LOW
Critical
YGTSS vocal tic score (follow-up mean 10 weeks; measured with: YGTSS vocal tic scale; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousb None 11 14 – SMD 0.73 lower
(1.55 lower to
0.09 higher)
⊕⊕OO
LOW
Critical
YGTSS impairment score (follow-up mean 10 weeks; measured with: YGTSS impairment scale; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousb None 11 14 – SMD 0.04 higher
(0.75 lower to
0.83 higher)
⊕⊕OO
LOW
Important
> = 30% reduction YGTSS total tic score (follow-up mean 10 weeks; assessed with: YGTSS total tic scale)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
No serious
indirectness
Very seriousb None 7/11
(63.6%)
6/14
(42.9%)
RR 1.48
(0.7 to
3.15)
206 more per
1000 (from 129
fewer to 921
more)
⊕⊕OO
LOW
Critical
a Difference in baseline tic scores for ERP and HRT groups.
b N= 25.
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TABLE 53 Relaxation training vs. minimal therapy
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Relaxation
training
Minimal
therapy
Relative
(95% CI) Absolute
Proportion with improved YGTSS global score (follow-up mean 6 weeks; assessed with: YGTSS global scale)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 6/7 (85.7%) 6/9 (66.7%) RR 1.29
(0.74 to
2.23)
193 more per
1000 (from
173 fewer to
820 more)
⊕OOO
VERY LOW
Critical
Proportion with improved YGTSS global score at follow-up (follow-up mean 3 months; assessed with: YGTSS global scale)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 5/7 (71.4%) 5/9 (55.6%) RR 0.64
(0.16 to
2.56)
200 fewer per
1000 (from
467 fewer to
867 more)
⊕OOO
VERY LOW
Critical
a 30% attrition from the study (36% of intervention and 25% of control group).
b Sample size n= 16.
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TABLE 54 Anger control training vs. treatment as usual
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Anger
control
training
Treatment
as usual
Relative
(95% CI) Absolute
YGTSS total tic score (follow-up mean 10 weeks; measured with: YGTSS total tic scale; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Very seriousb None 13 13 – SMD 0.58 lower
(1.37 lower to
0.2 higher)
⊕OOO
VERY LOW
Critical
CBCL: Total competence score (follow-up mean 10 weeks; measured with: CBCL; better indicated by higher values)
1 Randomised
trials
Very
seriousa,c
No serious
inconsistency
Seriousd Very seriousb None 13 13 – SMD 1.18 lower
(2.01 to 0.35
lower)
⊕OOO
VERY LOW
Important
Family functioning (follow-up mean 10 weeks; measured with: family assessment device general functioning scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa,c
No serious
inconsistency
Seriousd Very seriousb None 13 13 – SMD 0.42 lower
(1.2 lower to
0.35 higher)
⊕OOO
VERY LOW
Important
CGI much or very much improved (follow-up mean 10 weeks; assessed with: CGI-I)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousd Very seriousb None 9/13
(69.2%)
2/13
(15.4%)
RR 0.36
(0.16 to
0.85)
98 fewer per
1000 (from 23
fewer to 129
fewer)
⊕OOO
VERY LOW
Important
a Control group does not account for aspects of performance bias.
b Sample size n= 26.
c Parent rated outcome and not blinded to intervention allocation.
d Outcome also related to behavioural issues and not only to TS-related issues.
A
P
P
E
N
D
IX
4
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
D
A
T
E
:
1
2
/0
9
/2
0
1
5
FILE
:
1
0
-1
4
2
-0
1
-2
P
.p
d
f
4
1
6
TABLE 55 Parent training vs. treatment as usual
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Parent
training
Treatment
as usual
Relative
(95% CI) Absolute
YGTSS total tic score (follow-up mean 10 weeks; measured with: YGTSS total tic scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa,b
No serious
inconsistency
No serious
indirectness
Very seriousc None 11 12 – SMD 0.29 higher
(0.53 lower to
1.12 higher)
⊕OOO
VERY LOW
Critical
Parenting stress (follow-up mean 10 weeks; measured with: Parenting Stress Index-Short Form; better indicated by lower values)
1 Randomised
trials
Very
seriousa,b
No serious
inconsistency
Seriousd Very seriousc None 11 12 – SMD 0.12 lower
(0.94 lower to
0.7 higher)
⊕OOO
VERY LOW
Important
CGI much or very much improved (follow-up mean 10 weeks; assessed with: CGI-I)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousd Very seriousc None 7/11
(63.6%)
2/12
(16.7%)
RR 0.44
(0.19 to
0.99)
93 fewer per
1000 (from 2
fewer to 135
fewer)
⊕OOO
VERY LOW
Important
a Control group does not avoid aspects of performance bias.
b Unclear blinded outcome assessment.
c Sample size n= 23.
d Outcome also related to behavioural issues and not only to TS-related issues.
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Physical interventions
TABLE 56 Intravenous immunoglobulin vs. i.v. saline
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
i.v.
immunoglobulin
i.v.
saline
Relative
(95% CI) Absolute
YGTSS total tic score (follow-up mean 14 weeks; measured with: YGTSS total tic scale; better indicated by lower values)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
Seriousa Seriousb None 14 15 – SMD 0.51 lower
(1.25 lower
to 0.23 higher)
⊕⊕OO
LOW
Critical
CGI much or very much improved (follow-up mean 14 weeks; assessed with: CGI-I)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
Seriousa Seriousb None 4/14 (28.6%) 1/15
(6.7%)
RR 4.29
(0.54 to
33.85)
219 more
per 1000 (from
31 fewer to
1000 more)
⊕⊕OO
LOW
Important
Adverse events (follow-up mean 14 weeks)
1 Randomised
trials
No serious
risk of bias
No serious
inconsistency
Seriousa Seriousb None 13/14 (92.9%) 4/15
(26.7%)
RR 3.48
(1.49 to
8.16)
661 more per
1000 (from
131 more to
1000 more)
⊕⊕OO
LOW
Critical
a Population was mixed (age range 14–63 years). The mean age was around 30 years and the majority of patients may have been adults.
b Overall sample size of 29 patients.
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TABLE 57 Botulinum toxin vs. i.v. saline
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
i.v.
Botulinum
toxin
i.v.
saline
Relative
(95% CI) Absolute
Shapiro TSSS (follow-up mean 2 weeks; measured with: Shapiro TSSS; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 18 – – SMD 0.02 higher
(0.63 lower to
0.67 higher)
⊕OOO
VERY LOW
Critical
Proportion of patients who felt better (follow-up mean 2 weeks)
1 Randomised
trials
Seriousa No serious
inconsistency
Very seriousb,d Seriousc None 4/18
(22.2%)
1/18
(5.6%)e
RR 4.0
(0.49 to
32.39)
167 more per
1000 (from 28
fewer to 1000
more)
⊕OOO
VERY LOW
Important
Pain score (follow-up mean 2 weeks; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 18 – – SMD 0.52 higher
(0.15 lower to
1.18 higher)
⊕OOO
VERY LOW
Critical
Weakness (follow-up mean 2 weeks)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 12/18
(66.7%)
2/18
(11.1%)e
RR 6.00
(1.56 to
23.07)
556 more per
1000 (from 62
more to 1000
more)
⊕OOO
VERY LOW
Critical
Neck discomfort (follow-up mean 2 weeks)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 3/18
(16.7%)
1/18
(5.6%)e
RR 3.00
(0.34 to
26.19)
111 more per
1000 (from 37
fewer to 1000
more)
⊕OOO
VERY LOW
Critical
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TABLE 57 Botulinum toxin vs. i.v. saline (continued )
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
i.v.
Botulinum
toxin
i.v.
saline
Relative
(95% CI) Absolute
Blurry vision (follow-up mean 2 weeks)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 1/18
(5.6%)
0/18
(0%)e
RR 3.00
(0.13 to
69.09)
– ⊕OOO
VERY LOW
Critical
Swallowing difficulty (follow-up mean 2 weeks)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 2/18
(11.1%)
0/18
(0%)e
RR 5.00
(0.26 to
97.37)
– ⊕OOO
VERY LOW
Critical
Motor restlessness (follow-up mean 2 weeks)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 2/18
(11.1%)
0/18
(0%)e
RR 5.00
(0.26 to
97.3)
– ⊕OOO
VERY LOW
Critical
Increased urge to tic (follow-up mean 2 weeks)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 1/18
(5.6%)
0/18
(0%)e
RR 3.00
(0.13 to
69.09)
– ⊕OOO
VERY LOW
Critical
New tics (follow-up mean 2 weeks)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Serious
c
None 2/18
(11.1%)
0/18
(0%)e
RR 5.00
(0.26 to
97.37)
– ⊕OOO
VERY LOW
Critical
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Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
i.v.
Botulinum
toxin
i.v.
saline
Relative
(95% CI) Absolute
YGTSS Motor tic frequency (treated tic) (follow-up mean 2 weeks; measured with: YGTSS; better indicated by higher values)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 18 – – SMD 0.14 lower
(0.8 lower to
0.51 higher)
⊕OOO
VERY LOW
Critical
YGTSS Motor tic intensity (treated tic) (follow-up mean 2 weeks; measured with: YGTSS; better indicated by higher values)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 18 – – SMD 0.91 lower
(1.59 to 0.22
lower)
⊕OOO
VERY LOW
Critical
YGTSS Motor tic interference (treated tic) (Copy) (follow-up mean 2 weeks; measured with: YGTSS; better indicated by higher values)
1 Randomised
trials
Seriousa No serious
inconsistency
Seriousb Seriousc None 18 – – SMD 0.05 lower
(0.7 lower to
0.61 higher)
⊕OOO
VERY LOW
Critical
a Unclear patient, provider and outcome assessor blinding and possible selective outcome reporting bias.
b Mixed population of children and adults.
c Total sample size n= 18.
d Outcome is very subjective and may not reflect changes in TS symptoms.
e Crossover study. Eighteen participants underwent both intervention and control conditions.
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TABLE 58 Acupuncture and Chinese herbs vs. haloperidol and artane
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Acupuncture
and Chinese
herbs
Haloperidol
and artane
Relative
(95% CI) Absolute
YGTSS global score proportion ≥ 30% reduction (assessed with: YGTSS global scale)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
Seriousb Seriousc None 28/30
(93.3%)
23/30
(76.7%)
RR 1.22
(0.98 to
1.52)
169 more per
1000 (from
15 fewer to
399 more)
⊕OOO
VERY LOW
Critical
YGTSS global score proportion ≥ 60% reduction (assessed with: YGTSS global scale)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
Seriousb Seriousc None 17/30
(56.7%)
9/30 (30%) RR 1.89
(1.01 to
3.55)
267 more per
1000 (from 3
more to 765
more)
⊕OOO
VERY LOW
Critical
a Unclear patient, provider and outcome assessor blinding.
b The control group was intended to reflect current western medicine practice and haloperidol and artane in relatively high doses were used. This may not have been a beneficial treatment
approach with which to compare the intervention.
c Sample size n= 60.
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Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infection studies
TABLE 59 Intravenous immunoglobulin vs. i.v. saline
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
i.v.
immunoglobulin
i.v.
saline
Relative
(95% CI) Absolute
TS rating score (follow-up mean 1 month; measured with: TS rating scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Very seriousb None 9 10 – SMD 0.00
higher (0.9
lower to 0.9
higher)
⊕OOO
VERY LOW
Critical
NIMH impairment (follow-up mean 1 month; measured with: NIMH global impairment scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Very seriousb None 9 10 – SMD 1.87
lower (3 to
0.75 lower)
⊕OOO
VERY LOW
Important
NIMH anxiety (follow-up mean 1 month; measured with: NIMH anxiety scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Very seriousb None 9 10 – SMD 1.03
lower (2 to
0.05 lower)
⊕OOO
VERY LOW
Important
NIMH depression (follow-up mean 1 month; measured with: NIMH global depression scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Very seriousb None 9 10 – SMD 0.64
lower (1.57
lower to 0.29
higher)
⊕OOO
VERY LOW
Important
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TABLE 59 Intravenous immunoglobulin vs. i.v. saline (continued )
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
i.v.
immunoglobulin
i.v.
saline
Relative
(95% CI) Absolute
Overall clinical outcome (follow-up mean 1 month; measured with: CGI-I; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Very seriousb None 9 10 – SMD 1.86
lower (2.98 to
0.74 lower)
⊕OOO
VERY LOW
Important
Adverse events (follow-up mean 1 month)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Very seriousb None 6/9 (66.7%) 2/10
(20%)
RR 3.33
(0.89 to
12.51)
466 more per
1000 (from 22
fewer to 1000
more)
⊕OOO
VERY LOW
Critical
a No evidence of allocation concealment and i.v. immunoglobulin and placebo group were not balanced at baseline. Unclear blinded outcome assessment.
b Sample size n= 19.
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TABLE 60 Plasma exchange vs. i.v. saline
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations
Plasma
exchange
i.v.
saline
Relative
(95% CI) Absolute
TS rating score (follow-up mean 1 month; measured with: TS rating scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 10 10 – SMD 0.88 lower
(1.81 to 0.05
lower)
⊕OOO
VERY LOW
Critical
NIMH impairment (follow-up mean 1 month; measured with: NIMH global impairment scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 10 10 – SMD 1.42 lower
(2.42 to 0.41
lower)
⊕OOO
VERY LOW
Important
NIMH anxiety (follow-up mean 1 month; measured with: NIMH anxiety scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 10 10 – SMD 1.24 lower
(2.21 to 0.26
lower)
⊕OOO
VERY LOW
Important
NIMH depression (follow-up mean 1 month; measured with: NIMH global depression scale; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 10 10 – SMD 1.06 lower
(2 to 0.11
lower)
⊕OOO
VERY LOW
Important
Overall clinical outcome (follow-up mean 1 month; measured with: CGI-I; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 10 10 – SMD 2.38 lower
(3.58 to 1.18
lower)
⊕OOO
VERY LOW
Important
Adverse events (follow-up mean 1 month)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 7/10 (70%) 2/10
(20%)
RR 3.50
(0.95 to
12.9)
500 more per
1000 (from 10
fewer to 1000
more)
⊕OOO
VERY LOW
Critical
a The use of i.v. saline as a control group resulted in the absence of patient and provider blinding and blinding of outcome assessors was unclear.
b Sample size n= 20.
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TABLE 61 Penicillin vs. placebo
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Penicillin Placebo
Relative
(95% CI) Absolute
YGTSS total tic score (follow-up mean 4 weeks; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 37 – – SMD 0.26 lower
(0.72 lower to
0.21 higher)
⊕⊕OO
LOW
Critical
YGTSS motor tic score (follow-up mean 4 months; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 37 – – SMD 0.14 lower
(0.61 lower to
0.32 higher)
⊕⊕OO
LOW
Critical
YGTSS vocal tic score (follow-up mean 4 months; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 37 – – SMD 0.23 lower
(0.69 lower to
0.24 higher)
⊕⊕OO
LOW
Critical
Rate of streptococcal infection (follow-up mean 4 months)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 14/35
(40%)
21/37
(56.8%)
RR 0.70
(0.43 to
1.15)
170 fewer per
1000 (from 324
fewer to 85
more)
⊕⊕OO
LOW
Important
Rate of neuropsychiatric exacerbations (follow-up mean 4 months)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 18/35
(51.4%)
19/37
(51.4%)
RR 1.00
(0.64 to
1.57)
0 fewer per
1000 (from 185
fewer to 293
more)
⊕⊕OO
LOW
Critical
Impairment (follow-up mean 4 months; measured with: C-GAS; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 37 – – SMD 0.20 lower
(0.66 lower to
0.27 higher)
⊕⊕OO
LOW
Important
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Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Penicillin Placebo
Relative
(95% CI) Absolute
Anxiety (follow-up mean 4 months; measured with: NIMH anxiety scale; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 37 – – SMD 0.52 lower
(0.99 to 0.05
lower)
⊕⊕OO
LOW
Important
Depression (follow-up mean 4 months; measured with: NIMH depression scale; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 37 – – SMD 0.62 lower
(1.1 to 0.15
lower)
⊕⊕OO
LOW
Important
Overall global clinical outcome (follow-up mean 4 months; measured with: CGI scale: global improvement; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 37 – – SMD 0.07 lower
(0.53 lower to
0.39 higher)
⊕⊕OO
LOW
Important
Overall TS clinical outcome (follow-up mean 4 months; measured with: CGI scale: TS improvement; better indicated by lower values)
1 Randomised
trials
Seriousa No serious
inconsistency
No serious
indirectness
Seriousb None 37 – – SMD 0.01 lower
(0.47 lower to
0.45 higher)
⊕⊕OO
LOW
Important
a Unclear blinded outcome assessment and possible cross-treatment contamination.
b Sample size n= 37.
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TABLE 62 Penicillin vs. azithromycin
Quality assessment Number of patients Effect
Quality Importance
Number
of studies Design
Risk of
bias Inconsistency Indirectness Imprecision
Other
considerations Penicillin Azithromycin
Relative
(95% CI) Absolute
Neuropsychiatric symptom exacerbations (follow-up mean 1 year; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 11 12 – SMD 0.77 lower
(1.63 lower to
0.08 higher)
⊕OOO
VERY LOW
Critical
Streptococcal infections (follow-up mean 1 year; better indicated by lower values)
1 Randomised
trials
Very
seriousa
No serious
inconsistency
No serious
indirectness
Seriousb None 11 12 – SMD 0.00
higher (0.82
lower to 0.82
higher)
⊕OOO
VERY LOW
Important
a Unclear blinded outcome assessment and potential selective outcome reporting bias.
b Sample size n= 23.
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Appendix 5 Sensitivity analyses
Sensitivity analysis was conducted on the largest meta-analyses in the review to test the effect ofassumptions made (paucity of data for other interventions made sensitivity analysis less useful).
The following shows the most conservative scenario with the following changes made:
l removal of studies with higher risk of bias (in meta-analyses with low and unclear risk of bias studies,
unclear risk of bias studies removed. In meta-analysis with unclear and high risk of bias studies, high
risk of bias studies removed)
l when SDs have been calculated for within-group changes, an assumed correlation coefficient of 0.3,
rather than 0.6, has been used
l removal of all crossover studies.
Antipsychotic studies sensitivity analysis
Crossover RCTs were removed98,100 and a correlation coefficient of 0.3 was assumed for Scahill et al.101
(in Shapiro et al.,99 there was first-phase parallel data but only post-treatment results were reported so no
SDs were assumed; in Dion et al.,102 change scores were reported so no SDs were assumed; and in Sallee
et al.,103 change scores were reported so no SDs were assumed). The overall SMD was reduced from the
original level (SMD –0.79, 95% CI –1.13 to –0.45) to SMD –0.68 (95% CI –1.10 to –0.34) but the
interpretation of findings remains the same.
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Study or subgroup SMD
SMD
IV, random, 95% ClSE Overall ROB
SMD
IV, random, 95% Cl
Test for overall effect: z = 2.60 (p = 0.009)
Test for overall effect: z = 2.63 (p = 0.008)
Test for overall effect: z = 0.35 (p = 0.73)
Test for overall effect: z = 2.23 (p = 0.03)
Test for overall effect: z = 3.94 (p <0.0001)
100.0%
16.4%
16.4%
49.6%
32.4%
17.2%
18.2%
18.2%
15.8%
15.8%
Low risk
Ziprasidone
Risperidone
Pimozide
Haloperidol
Weight
–0.83 (–1.64 to –0.02)
–0.14 (–0.93 to 0.65)
–0.14 (–0.93 to 0.65)
–0.96 (–1.80 to –0.12)
–0.96 (–1.80 to –0.12)
–0.54 (–1.13 to 0.05)
–0.64 (–1.12 to –0.16)
–1.10 (–1.93 to –0.27)
–1.10 (–1.93 to –0.27)
–0.68 (–1.01 to –0.34)
Sallee 2000103
Dion 2002102
Scahill 2003101
Shapiro 198999
Shapiro 198999
Subtotal (95% CI)
Subtotal (95% CI)
Subtotal (95% CI)
Total (95% CI)
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 3.57, df = 4 (p = 0.47); l2 = 0%
Heterogeneity: not applicable
Heterogeneity: not applicable
Heterogeneity: not applicable
Test for subgroup differences: χ2 = 3.25, df = 3 (p = 0.36); l2 = 7.6%
Heterogeneity: τ2 = 0.00; χ2 = 0.32, df = 1 (p = 0.57); l2 = 0%
Unclear risk
Unclear risk
Unclear risk
Unclear risk0.423
0.431
0.401
0.413–0.83
–0.14
–0.96
–0.54 0.301
–2 –1 0 1 2
Favours antipsychotics Favours placebo
–1.1
FIGURE 238 Sensitivity analysis for studies of antipsychotics compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of bias; SE, standard error.
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Noradrenergic agents sensitivity analysis
A correlation coefficient of 0.3 was assumed for Leckman et al.,116 Scahill et al.120 and Cummings et al.121 (Kurlan et al.113 presented net change scores so no SDs
were assumed). The overall effect size was reduced from the original level (SMD –0.65, 95% –0.96 to –0.33; n= 164) to SMD –0.55 (95% CI –0.86 to –0.24;
n= 164) but the interpretation of findings remains the same.
Study or subgroup SMD
SMD
IV, random, 95% ClSE Overall ROB
SMD
IV, random, 95% Cl
Total (95% Cl)
Test for overall effect: z = 2.48 (p = 0.01)
Test for overall effect: z = 2.44 (p = 0.01)
100.0%
34.8%
14.0%
20.8%
40.6%
24.6%
65.2%
–2 –1 2
Favours noradrenergic Favours placebo
Low risk
Low risk
Low risk
Low risk
Clonidine
Guanfacine
Weight
0 1
Test for overall effect: z = 3.44 (p = 0.0006)
–0.50 (–0.99 to –0.01)
–0.47 (–1.10 to 0.16)
–0.49 (–0.88 to –0.10)
–0.57 (–1.25 to 0.11)
–0.79 (–1.62 to 0.04)
–0.66 (–1.19 to –0.13)
–0.55 (–0.86 to –0.24)
Kurlan 2002113
Leckman 1991116 0.321
0.25
0.349
0.426
Subtotal (95% CI)
Subtotal (95% CI)
Scahill 2001120
Cummings 2002121
–0.5
–0.47
–0.57
–0.79
Heterogeneity: τ2 = 0.00; χ2 = 0.42, df = 3 (p = 0.94); l2 = 0%
Heterogeneity: τ2 = 0.00; χ2 = 0.16, df = 1 (p = 0.69); l2 = 0%
Test for subgroup differences: χ2 = 0.26, df = 1 (p = 0.61); l2 = 0%
Heterogeneity: τ2 = 0.00; χ2 = 0.01, df = 1 (p = 0.94); l2 = 0%
FIGURE 239 Sensitivity analysis for studies of noradrenergic agent compared with placebo. df, degrees of freedom; IV, independent variable; ROB, risk of bias;
SE, standard error.
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Habit reversal training/comprehensive behavioural intervention for tics sensitivity analysis
Studies with a high or unclear risk of bias were removed. There was no difference in the interpretation of findings.
Study or subgroup
Change CBIT
Mean SD
SMD
IV, random, 95% Cl
SMD
IV, random, 95% ClTotal Mean
Change SP
SD Total Weight
Piacentini 2010156
Wilhelm 2012166
Subtotal (95% Cl)
Heterogeneity: not applicable
Subtotal (95% Cl)
Heterogeneity: not applicable
Test for subgroup differences: χ2 = 0.04, df = 1 (p = 0.83); l2 = 0%
Test for overall effect: z = 3.52 (p = 0.0004)
Test for overall effect: z = 3.05 (p = 0.002)
–7.6 –3.5
–2.5–6.2
100.0%
100.0%
100.0%
100.0%
–0.64 (–1.00 to –0.29)
–0.64 (–1.00 to –0.29)
–0.59 (–0.97 to –0.21)
–0.59 (–0.97 to –0.21)
Low risk
Low risk
Overall ROB
61
61
60
60
6.21 6.3
6.22 65
65
53
53
Adults
Children
6.44
–2 –1 0 1 2
Favours SPFavours HRT/CBIT
FIGURE 240 Sensitivity analysis for studies of HRT/CBIT compared with SP. df, degrees of freedom; IV, independent variable; ROB, risk of bias.
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Appendix 6 Excluded studies
Reference Reason for exclusion
Quantitative systematic review
Ackermans L, Duits A, Temel Y, Winogrodzka A, Peeters F, Beuls EaM, et al. Long-term
outcome of thalamic deep brain stimulation in two patients with Tourette syndrome.
J Neurol Neurosurg Psychiatry 2010;81:1068–72
Inappropriate study design
Ackermans L, Temel Y, Cath D, van der Linden C, Bruggeman R, Kleijer M, et al. Deep
brain stimulation in Tourette’s syndrome: two targets? Mov Disord 2006;21:709–13
Inappropriate study design
Ackermans L, Temel Y, Bauer NJC, Visser-Vandewalle V. Vertical gaze palsy after thalamic
stimulation for Tourette syndrome: case report. Neurosurgery 2007;61:E1100
Inappropriate study design
Ahmed MA, Martinez A, Yee A, Cahill D, Besag FM, Ahmed MAS, et al. Psychogenic and
organic movement disorders in children. Dev Med Child Neurol 2008;50:300–4
Inappropriate study design
Alacqua M, Trifirò G, Arcoraci V, Germanò E, Magazù A, Calarese T, et al. Use and
tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric
setting. Pharm World Sci 2008;30:44–50
Inappropriate study design
Anca MH, Giladi N, Korczyn AD. Ropinirole in Gilles de la Tourette syndrome. Neurology
2004;62:1626–7
Inappropriate study design
Asher SWA, Aminoff MJ. Tetrabenazine and movement disorders. Neurology
1981;31:1051–4
Inappropriate population
Awaad YM, Michon AM, Minarik S. Use of levetiracetam to treat tics in children and
adolescents with Tourette syndrome. Mov Disord 2005;20:714–18
Inappropriate study design
Awaad YM, Michon AM, Minarik S. Long-term use of levetiracetam to treat tics in
children and adolescents with Tourette syndrome. J Pediatr Neurol 2007;5:209–14
Inappropriate study design
Awaad Y. Double-blind controlled randomized study of the use of levetiracetam to treat
tics in children and adolescents with Tourette syndrome. Eur J Neurol 2009;16:170
Inappropriate outcomes
Bajo S, Battaglia M, Pegna C, Bellodi L. Citalopram and fluvoxamine in Tourette’s
disorder. J Am Acad Child Adolesc Psychiatry 1999;38:230–31
Inappropriate study design
Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in
children with attention deficit hyperactivity disorder: A systemic, placebo-controlled
evaluation. Pediatrics 1990;86:184–92
Inappropriate population
Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and
adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc
Psychiatry 2005;44:73–9
Inappropriate study design
Boon-yasidhi V, Kim YS, Scahill L. An open-label, prospective study of guanfacine in
children with ADHD and tic disorders. J Med Assoc Thailand 2005;88(Suppl. 8):S156–62
Inappropriate study design
Bruun RD, Budman CL. Paroxetine treatment of episodic rages associated with Tourette’s
disorder. J Clin Psychiatry 1998;59:581–4
Inappropriate study design
Budman C, Coffey BJ, Shechter R, Schrock M, Wieland N, Spirgel A, et al. Aripiprazole in
children and adolescents with Tourette disorder with and without explosive outbursts.
J Child Adolesc Psychopharmacol 2008;18:509–15
Inappropriate study design
Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD. An open-label study of the treatment
efficacy of olanzapine for Tourette’s disorder. J Clin Psychiatry 2001;62:290–4
Inappropriate study design
Buitelaar JKC. Remoxipride in adolescents with Tourette’s syndrome: an open pilot study.
J Child Adolesc Psychopharmacol 1995;5:121–8
Inappropriate study design
Caine ED, Polinsky RJ, Ebert MH, Rapoport JL, Mikkelsen EJ. Trial of chlorimipramine and
desipramine for Gilles de la Tourette syndrome. Ann Neurol 1979;5:305–6
Inappropriate study design
Chappell PB, Leckman JF, Scahill LD, Hardin MT, Anderson G, Cohen DJ. Neuroendocrine
and behavioral effects of the selective kappa agonist spiradoline in Tourette’s syndrome:
A pilot study. Psychiatry Res 1993;47:267–80
Inappropriate study design
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Reference Reason for exclusion
Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, et al. Guanfacine
treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome:
Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995;34:1140–6
Inappropriate study design
Cheng Y, Jiang DH. [Therapeutic effect of inosine in Tourette syndrome and its possible
mechanism of action.] Zhonghua Shen Jing Jing Shen Ke Za Zhi 1990;23:90–7
Inappropriate study design
Clarke MA, Bray MA, Kehle TJ, Truscott SD. A school-based intervention designed to
reduce the frequency of tics in children with Tourette’s syndrome. [References]. Sch
Psychol Rev 2001;30:11
Inappropriate study design
Coffey BJ, Jummani R, Hirsch S, Lyon G, Spirgel A, Goldman R, et al. Aripiprazole in
tourette’s disorder: an open label safety and tolerability study in youth. J Child Adolesc
Psychopharmacol 2009;19:783–4
Inappropriate study design
Cohen DJ, Detlor J. Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen
Psychiatry 1980;37:1350–7
Inappropriate study design
Connell PH. Drug treatment of adolescent tiqueurs: a double-blind trial of diazepam and
haloperidol. Br J Psychiatry 1967;113:375–81
Inappropriate study design
Cubo E, Fernández Jaén A, Moreno C, Anaya B, González M, Kompoliti K. Donepezil use
in children and adolescents with tics and attention-deficit/hyperactivity disorder: an
18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther
2008;30:182–9
Inappropriate study design
Cui Y-H, Zheng Y, Yang Y-P, Liu J, Li J. Effectiveness and tolerability of aripiprazole in
children and adolescents with Tourette’s disorder: a pilot study in China. J Child Adolesc
Psychopharmacol 2010;20:291–8
Inappropriate study design
Dalery J, Chauvin C, Maillet J, De VR. Clinical trial of tiapride in children with TICS
disorder. J Neurol 1985;232:160
Inappropriate outcomes
Davies LS, Stern J, Agrawal NM, Robertson M. A case series of patients with Tourette’s
Syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol
2006;21:447–53
Inappropriate study design
De Bruijn SV. Risperidone versus behaviour therapy in the treatment of tic disorders –
a randomized single-blinded trial. Parkinsonism Relat Disord 2012;18(Suppl.2):S61–2
Protocol
de Jonge JL, Cath DC, van Balkom AJ. Quetiapine in patients with Tourette’s disorder: an
open-label, flexible-dose study. J Clin Psychiatry 2007;68:1148
Inappropriate study design
Drtilkova IB. Therapeutical effects of clonidine and clonazepam in children with tick
syndrome. Homeost Health Dis 1994;35:296
Inappropriate study design
Dueck A, Wolters A, Wunsch K, Bohne-Suraj S, Mueller JU, Haessler F, et al. Deep brain
stimulation of globus pallidus internus in a 16-year-old boy with severe tourette syndrome
and mental retardation. Neuropediatrics 2009;40:239–42
Inappropriate study design
Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children
suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci
1988;237:223–9
Inappropriate outcomes
Erdogan A, Karaman MG, Ozdemir E, Yurteri N, Tufan AE, Kurcer MA. Six months of
treatment with risperidone may be associated with nonsignificant abnormalities of liver
function tests in children and adolescents: a longitudinal, observational study from
Turkey. J Child Adolesc Psychopharmacol 2010;20:407–13
Inappropriate study design
Fernández-Jaén A, Fernández-Mayoralas DM, Muñoz-Jareño N, Calleja-Pérez B. An
open-label, prospective study of levetiracetam in children and adolescents with Tourette
syndrome. Eur J Paediatr Neurol 2009;13:541–5
Inappropriate study design
Findling RL, Bukstein OG, Melmed RD, Lopez FA, Sallee FR, Arnold LE, et al. A
randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate
transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin
Psychiatry 2008;69:149–59
Inappropriate population
Franklin ME, Best S, Wilson MA, Loew B, Compton SN. Habit reversal training and
acceptance and commitment therapy for Tourette syndrome: a pilot project. J Dev Phys
Disabil 2011;23:49–60
Inappropriate study design
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Reference Reason for exclusion
Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie JW. ECG changes during
haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry
1987;144:673–5
Inappropriate outcomes
Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate
therapy in children with comorbid attention-deficit hyperactivity disorder and chronic
multiple tic disorder. Arch Gen Psychiatry 1999;56:330–6
Inappropriate study design
Gilbert DL, Sallee FR, Sine L, Sethuraman G. Behavioral and hormonal effects of low-dose
pergolide in children and adolescents with Gilles de la Tourette’s syndrome. Curr Ther Res
Clin Exp 2000;61:378–87
Inappropriate study design
Gilbert DL, Zhang J, Lipps TD, Natarajan N, Brandyberry J, Wang Z, et al. Atomoxetine
treatment of ADHD in Tourette Syndrome: Reduction in motor cortex inhibition correlates
with clinical improvement. Clin Neurophysiol 2007;118:1835–41
Inappropriate study design
Himle JA, Fischer DJ, Van Etten ML, Janeck AS, Hanna GL. Group behavioral therapy for
adolescents with tic-related and non-tic-related obsessive–compulsive disorder. Depress
Anxiety 2003;17:73–7
Inappropriate study design
Himle MB, Olufs E, Himle J, Tucker BTP, Woods DW. Behavior therapy for tics via
videoconference delivery: an initial pilot test in children. Cogn Behav Pract
2010;17:329–37
Inappropriate study design
Himle MB, Woods DW, Conelea CA, Bauer CC, Rice KA. Investigating the effects of tic
suppression on premonitory urge ratings in children and adolescents with Tourette’s
syndrome. Behav Res Ther 2007;45:2964–76
Inappropriate study design
Ho C-S, Chen H-J, Chiu N-C, Shen E-Y, Lue H-C. Short-term sulpiride treatment of
children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med
Assoc 2009;108:788–93
Inappropriate study design
Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994;9:347–9 Inappropriate study design
Jankovic J, Glaze DG, Frost JD. Effect of tetrabenazine on tics and sleep of Gilles de la
Tourette’s syndrome. Neurology 1984;34:688–92
Inappropriate study design
Jimenez-Jimenez FJ. Nicardipine improves motor tics. Eur J Neurol 1997;4:498–501 Inappropriate study design
Kaido T, Otsuki T, Kaneko Y, Takahashi A, Omori M, Okamoto T. Deep brain stimulation
for Tourette syndrome: a prospective pilot study in Japan. Neuromodulation
2011;14:123–8
Inappropriate study design
Katuwawela IC. Good response to clonidine in tourette syndrome associated with
chromosomal translocation involving the IMMP2L gene. J Neuropsychiatry Clin Neurosci
2012;24:E17
Inappropriate outcomes
Kenney CJ, Hunter CB, Mejia NI, Jankovic J. Tetrabenazine in the treatment of Tourette
syndrome. J Pediatr Neurol 2007;5:9–13
Inappropriate population
Kim B-N, Lee C-B, Hwang J-W, Shin M-S, Cho S-C. Effectiveness and safety of risperidone
for children and adolescents with chronic tic or tourette disorders in Korea. J Child
Adolesc Psychopharmacol 2005;15;318–24
Inappropriate study design
Kohen DP. Coping with the stress of Tourette syndrome in children and adolescents:
use of self-hypnosis techniques. Aust J Clin Exp Hypnosis 1995;23:145–57
Inappropriate study design
Kuo SHJ-S. Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol
2010;33:32–4
Inappropriate study design
Lacruz F, Obeso JA, Martinez VE, Artieda J, Luquin R, Martinez JM. Tiapride for the
treatment of Gilles de la Tourette Syndrome. Arch Neurobiol 1985:247
Inappropriate study design
Law SFS, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children
treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry
1999;38:944–51
Inappropriate population
Leckman JF, Detlor J, Harcherik DF, Young JG, Anderson GM, Shaywitz BA, et al. Acute
and chronic clonidine treatment in Tourette’s syndrome: a preliminary report on clinical
response and effect on plasma and urinary catecholamine metabolites, growth hormone,
and blood pressure. J Am Acad Child Psychiatry 1983;22:433–40
Inappropriate outcomes
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Reference Reason for exclusion
Leckman JFD. Short- and long-term treatment of Tourette’s syndrome with clonidine:
a clinical perspective. Neurology 1985;35:343–51
Inappropriate study design
Lichter DG, Jackson LA. Predictors of clonidine response in Tourette syndrome:
implications and inferences. J Child Neurol 1996;11:93–7
Inappropriate study design
Lombroso PJ, Scahill L, King RA, Lynch KA, Chappell PB, Peterson BS, et al. Risperidone
treatment of children and adolescents with chronic tic disorders: a preliminary report.
J Am Acad Child Adolesc Psychiatry 1995;34:1147–52
Inappropriate study design
Luo J. [Observation on therapeutic effects of acupuncture on gilles de la tourette
syndrome.] Zhongguo Zhen Jiu 1997;17:429–30
Inappropriate study design
Lyon GJ, Samar S, Jummani R, Hirsch S, Spirgel A, Goldman R, et al. Aripiprazole in
children and adolescents with tourette’s disorder: an open-label safety and tolerability
study. J Child Adolesc Psychopharmacol 2009;19:623–33
Inappropriate study design
March JSF. Tics moderate treatment outcome with sertraline but not cognitive-behavior
therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2007;61:344–7
Inappropriate outcomes
McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, et al. The effects of
nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing
tic severity and frequency in Tourette’s disorder. Biol Psychiatry 1992;31:832–40
Inappropriate study design
McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J. Effectiveness and tolerability
of open label olanzapine in children and adolescents with Tourette syndrome. J Child
Adolesc Psychopharmacol 2008;18:501–8
Inappropriate study design
McDougle CJG. Haloperidol addition in fluvoxamine-refractory obsessive–compulsive
disorder: a double-blind, placebo-controlled study in patients with and without tics.
Arch Gen Psychiatry 1994;51:302–8
Inappropriate population
McKeith IG, Williams A, Nicol AR. Clonidine in Tourette syndrome. Lancet 1981;1:270–1 Inappropriate study design
Merikangas JR, Merikangas KR, Kopp U, Hanin I. Blood choline and response to
clonazepam and haloperidol in Tourette’s syndrome. Acta Psychiatr Scand 1985;72:395–9
Inappropriate outcomes
Micheli F, Gatto M, Lekhuniec E, Mangone C, Fernandez Pardal M, Pikielny R, et al.
Treatment of Tourette’s syndrome with calcium antagonists. Clin Neuropharmacol
1990;13:77–83
Inappropriate study design
Miltenberger RG, Fuqua RW. A comparison of contingent vs non-contingent competing
response practice in the treatment of nervous habits. J Behav Ther Exp Psychiatry
1985;16:195–200
Inappropriate study design
Moriarty J, Schmitz B, Trimble MR, De Koning P. A trial of eltoprazine in the treatment of
aggressive behaviours in two populations: patients with epilepsy or gilles de la tourette’s
syndrome. Hum Psychopharmacol 1994;9:253–8
Inappropriate outcomes
Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with tourette’s
disorder. J Child Adolesc Psychopharmacol 2003;13:295–9
Inappropriate study design
Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, et al. Delta
9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome:
A 6-week randomized trial. J Clin Psychiatry 2003;64:459–65
Inappropriate intervention
Muller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, et al. Treatment
of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover
trial. Pharmacopsychiatry 2002;35:57–61
Inappropriate intervention
Müller-Vahl KR, Koblenz A, Jobges M, Kolbe H, Emrich HM, Schneider U. Influence of
treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on
neuropsychological performance. Pharmacopsychiatry 2001;34:19–24
Inappropriate intervention
Murphy TK, Bengtson MA, Soto O, Edge PJ, Sajid MW, Shapira N, Yang M. Case series
on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol
2005;8:489–90
Inappropriate study design
Murphy TK, Mutch J, Reid JM, Edge PJ, Storch EA, Bengtson M, et al. Open label
aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol
2009;19:441–7
Inappropriate study design
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Reference Reason for exclusion
Niederhofer H, Staffen W, Mair A. A placebo-controlled study of lofexidine in the
treatment of children with tic disorders and attention deficit hyperactivity disorder.
J Psychopharmacol 2003;17:113–19
Paper retracted
Nolan EE, Gadow KD, Sprafkin. Stimulant medication withdrawal during long-term
therapy in children with comorbid attention-deficit hyperactivity disorder and chronic
multiple tic disorder. Pediatrics 1999;103:730–7
Inappropriate study design
O’Connor K, Gareau D, Borgeat F. A comparison of a behavioural and a
cognitive–behavioural approach to the management of chronic tic disorders. Clin Psychol
Psychother 1997;4:15–17
Inappropriate study design
O’Connor KP, Laverdure A, Taillon A, Stip E, Borgeat F, Lavoie M. Cognitive behavioral
management of Tourette’s syndrome and chronic tic disorder in medicated and
unmedicated samples. Behav Res Ther 2009;47:1090–5
Inappropriate population
O’Connor KP, Brault M, Robillard S, Loiselle J, Borgeat F, Stip E. Evaluation of a
cognitive–behavioural program for the management of chronic tic and habit disorders.
Behav Res Ther 2001;39:667–81
Inappropriate study design
Ondo WG, Jong D, Davis A. Comparison of weight gain in treatments for Tourette
syndrome: tetrabenazine versus neuroleptic drugs. J Child Neurol 2008;23:435–7
Inappropriate study design
Peterson AL, Azrin NH. An evaluation of behavioral treatments for Tourette syndrome.
Behav Res Ther 1992;30:167–74
Inappropriate study design
Porta MB. Thalamic deep brain stimulation for treatment-refractory Tourette syndrome:
two-year outcome. Neurology 2009;73:1375–80
Inappropriate study design
Pringsheim T, Pearce M. Complications of antipsychotic therapy in children with tourette
syndrome. Pediatr Neurol 2010;43:17–20
Inappropriate study design
Ramos-Rios R, Gago-Ageitos AM, Vidal-Millares M, Mazaira-Castro JA, Dominguez-Santos MD.
Clinical effects and tolerability of aripiprazole in children and adolescents with psychiatric
disorders. Eur Neuropsychopharmacol 2009;19:S691
Inappropriate study design
Rasmusson AM, Anderson GM, Lynch KA, McSwiggan HM, Scahill LD, Mazure CM, et al.
A preliminary study of tryptophan depletion on tics, obsessive–compulsive symptoms,
and mood in Tourette’s syndrome. Biol Psychiatry 1997;41:117–21
Inappropriate study design
Riddle MA, Hardin MT, King R, Scahill L, Woolston JL. Fluoxetine treatment of children
and adolescents with Tourette’s and obsessive compulsive disorders: Preliminary clinical
experience. J Am Acad Child Adolesc Psychiatry 1990;29:45–8
Inappropriate study design
Saccomani LR. Combined treatment with haloperidol and trazodone in patients with tic
disorders. J Child Adolesc Psychopharmacol 2000;10:307–10
Inappropriate study design
Sallee FR, Miceli JJ, Tensfeldt T, Robarge L, Wilner K, Patel NC, et al. Single-dose
pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child
Adolesc Psychiatry 2006;45:720–8
Inappropriate outcomes
Sallee FR, Sethuraman G, Rock CM. Effects of pimozide on cognition in children with
Tourette syndrome: Interaction with comorbid attention deficit hyperactivity disorder.
Acta Psychiatr Scand 1994;90:4–9
Inappropriate study design
Sandor P, Stephens RT. Risperidone treatment of aggressive behavior in children with
Tourette syndrome. J Clin Psychopharmacol 2000;20:710–12
Inappropriate study design
Sehgal N. Short-term versus longer term pimozide therapy in Tourette’s syndrome:
a preliminary study. Neurology 1999;52:874–7
Inappropriate intervention
Semerci BS. Case series on the use of aripiprazole for tic disorder. Eur Neuropsychopharmacol
2008;18:S432
Inappropriate study design
Seo WS, Sung H-M, Sea HS, Bai DS. Aripiprazole treatment of children and adolescents
with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol
2008;18:197–205
Inappropriate study design
Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette syndrome with
pimozide. Am J Psychiatry 1983;140:1183–6
Inappropriate study design
Song DH. Aripiprazole valuable in pediatric tic disorder or Tourette syndrome. Pharm Ther
2006;31:727–8
Inappropriate study design
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Reference Reason for exclusion
Spencer T, Biederman J, Steingard R, Wilens T. Bupropion exacerbates tics in children with
attention-deficit hyperactivity disorder and Tourette’s syndrome. J Am Acad Child Adolesc
Psychiatry 1993;32:211–14
Inappropriate study design
Stamenkovic M, Schindler SD, Aschauer HN, Kasper S. Olanzapine in Gilles de la Tourette
Syndrome patients. Paris: 11th European College of Neuropsychopharmacology Congress;
1998
Inappropriate study design
Stamenkovic M, Schindler SD, Aschauer HN, de Zwaan M, Willinger U, Resinger E, et al.
Effective open-label treatment of Tourette’s disorder with olanzapine. Int Clin
Psychopharmacol 2000;15:23–8
Inappropriate study design
Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez A. Comparison of clonidine
response in the treatment of attention-deficit hyperactivity disorder with and without
comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 1993;32:350–3
Inappropriate study design
Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in
children with Tourette’s syndrome – a pilot study. J Child Adolesc Psychopharmacol
2004;14:255–66
Inappropriate study design
Storch EA, Morgan JE, Caporino NE, Brauer L, Lewin AB, Piacentini J, et al. Psychosocial
treatment improved resilience and reduce impairment in youth with tics: an intervention
case series of eight youth. [References]. J Cogn Psychother 2012;26:56–70
Inappropriate study design
Sverd J, Cohen S, Camp JA. Brief report: Effects of propranolol in Tourette syndrome.
J Autism Dev Disord 1983;13:207–13
Inappropriate study design
Sverd J, Gadow KD, Paolicelli LM. Methylphenidate treatment of attention-deficit
hyperactivity disorder in boys with Tourette’s syndrome. J Am Acad Child Adolesc
Psychiatry 1989;28:574–9
Inappropriate study design
Toren PL. Ondansetron treatment in patients with Tourette’s syndrome. Int Clin
Psychopharmacol 1999;14:373–6
Inappropriate study design
van der Linden C, Bruggeman R, van Woerkom TC. Serotonin-dopamine antagonist and
Gilles de la Tourette’s syndrome: an open pilot dose-titration study with risperidone. Mov
Disord 1994;9:687–8
Inappropriate study design
Verdellen CW, Hoogduin CA, Keijsers GP, Verdellen CWJ, Hoogduin CAL, Keijsers GPJ.
Tic suppression in the treatment of Tourette’s syndrome with exposure therapy:
the rebound phenomenon reconsidered. Mov Disord 2007;22:1601–6
Inappropriate study design
Werry JS. Resolved: cardiac arrhythmias make desipramine an unacceptable choice in
children. J Am Acad Child Adolesc Psychiatry 1995;34:1239–48
Inappropriate population
Wetterneck CT, Woods DW. An evaluation of the effectiveness of exposure and response
prevention on repetitive behaviors associated with Tourette’s syndrome. J Appl Behav
Anal 2006;39:441–4
Inappropriate study design
Woods DW, Twohig MP. Using habit reversal to treat chronic vocal tic disorder in
children. Behav Interv 2002;17:159–68
Inappropriate study design
Woods DW, Himle MB, Miltenberger RG, Carr JE, Osmon DC, Karsten AM, et al.
Durability, negative impact, and neuropsychological predictors of tic suppression in
children with chronic tic disorder. J Abnorm Child Psychol 2008;36:237–45
Inappropriate outcomes
Woods DW, Walther MR, Bauer CC, Kemp JJ, Conelea CA. Controlled evaluation of an
educational intervention used to modify peer attitudes and behavior toward persons with
Tourette’s syndrome. Behav Mod 2005;29:900–12
Inappropriate study design
Wu M, Xiao G-H, Yao M, Zhang J-M, Zhang X, Zhou Y-B, et al. The development of
stimulus control over tics: A potential explanation for contextually-based variability in the
symptoms of Tourette syndrome. Behav Res Ther 2009;47:41–7
Inappropriate study design
Wu MX. Multicenter clinical study on the treatment of children’s tic disorder with Qufeng
Zhidong Recipe. Chin J Integr Med 2009;15:254–60
Inappropriate intervention
Wu MX. Clinical research into Qufeng Zhidong recipe used to treat 31 children with tic
disorder. J Trad Chin Med 2010;30:163–70
Inappropriate intervention
Xiang S-J, Cai Y-H, Zhang Z-D. [Observation on therapeutic effect of tic disorders treated
with local acupuncture.] Zhongguo Zhen Jiu 2010;30:469–72
Inappropriate study design
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Reference Reason for exclusion
Yoo HK, Choi S-H, Park S, Wang H-R, Hong J-P, Kim C-Y. An open-label study of the
efficacy and tolerability of aripiprazole for children and adolescents with tic disorders.
J Clin Psychiatry 2007;68:1088–93
Inappropriate study design
Young JG, Cohen DJ, Hattox SE, Kavanagh ME, Erson GM, Shaywitz BA, et al. Plasma
free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette’s
syndrome: preliminary report. Life Sci 1981;29:1467–75
Inappropriate outcomes
Zhao LL, Li AY, Lv H, Liu FY, Qi FH. Traditional Chinese medicine ningdong granule: the
beneficial effects in tourette’s disorder. J IntMed Res 2010;38:169–75
Inappropriate intervention
Qualitative systematic review
Bastiaens L. Pediatric psychopharmacology in a capitated managed care system: how do
patients fare? J Child Adolesc Psychopharmacol 1998;8:115–24
Inappropriate population
Christie D. ‘Oh no he doesn’t!’, ‘Oh yes he does!’: comparing parent and teacher
perceptions in Tourette’s syndrome. Clinical Child Psychology and Psychiatry
2002;7:553–8
Did not examine experience
of intervention, access to care
or service quality
Cutler D, Murphy T, Gilmour J, Heyman I. The quality of life of young people with
Tourette syndrome. Child Care Health Dev 2009;35:496–504
Did not examine experience
of intervention, access to care
or service quality
De Lange N, Meyer LW, Olivier MAJ. Tourette’s Syndrome: isn’t that the foul mouth
disease? Early Child Dev Care 2003;173:613–23
Did not examine experience
of intervention, access to care
or service quality
Hansen BHS. Comparison of sleep problems in children with anxiety and attention deficit/
hyperactivity disorders. Eur Child Adolesc Psychiatry 2011;20:321–30
Inappropriate population
Kompoliti K, Fan W, Leurgans S, Kompoliti K, Fan W, Leurgans S. Complementary and
alternative medicine use in Gilles de la Tourette syndrome. Mov Disord 2009;24:2015–19
Did not examine experience
of intervention, access to care
or service quality
Lewin AB, Storch EA, Storch HD. Risks from antipsychotic medications in children and
adolescents. JAMA 2010;303:729–30; author reply 30–1
Did not examine experience
of intervention, access to care
or service quality
Silva RR, Munoz DM, Barickman J, Friedhoff AJ. Environmental factors and related
fluctuation of symptoms in children and adolescents with Tourette’s disorder. J Child
Psychol Psychiatry 1995;36:305–12
Did not examine experience
of intervention, access to care
or service quality
Wigley K, Mason A, Lambert S, Collins J, Lask B, Christie D. A specialist service for
children and adolescents with Tourette’s syndrome: problems and attempted solutions.
Clin Child Psychol Psychiatry 2000;5:247–57
Did not examine experience
of intervention, access to care
or service quality
Wilkinson BJ, Marshall RM, Curtwright B. Impact of Tourette’s disorder on parent
reported stress. J Child Fam Stud 2008;17:582–98
Did not examine experience
of intervention, access to care
or service quality
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Appendix 7 Qualitative study of Experiences of
Services and Treatment interviewee identifying codes
and characteristics
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Co-occurring conditions
Participant
identification code Sex
Age
(years)
Has taken
medication
for tics
Has received some
form of behavioural
intervention for tics
Other treatment/intervention
for tics ADHD OCD ASD Anxiety Other
1 Male 14 Yes No Cognitive–behavioural therapy;
relaxation training
No Yes No No No
2 Male 11 Yes Yes No No No No No
3 Male 12 No No No Yes No Yes No
4 Male 17 No No Yes No No No No
5 Male 15 Yes Yes No No No No No
6 Female 14 Yes Yes No No No No No
7 Female 11 Yes No No Yes No No No
8 Male 17 Yes No No Yes Yes No Yes
9 Female 17 Yes No No No No No No
10 Female 17 Yes No Massage No No Yes No No
11 Male 15 Yes No Relaxation training Yes No No Yes No
12 Male 17 Yes No Yes No No Yes No
13 Male 13 No No Psychotherapy No No No No No
14 Male 11 Yes No No No No No No
15 Female 13 Yes No No No No No Yes
16 Male 13 No No No No No No No
17 Male 10 No No Auditory listening programme No No Yes No Yes
18 Male 16 Yes Yes No No No No No
19 Male 12 Yes No Relaxation training No No No No No
20 Male 12 No No No No No No No
21 Male 11 No No Yes No No No No
22 Male 16 Yes No No Yes No Yes No
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Co-occurring conditions
Participant
identification code Sex
Age
(years)
Has taken
medication
for tics
Has received some
form of behavioural
intervention for tics
Other treatment/intervention
for tics ADHD OCD ASD Anxiety Other
23 Male 13 No No No Yes No No No
24 Female 13 Yes No Yes No No No Yes
25 Male 13 No No No No No No No
26 Male 11 No No No No No No No
27 Male 15 Yes No Anger management No No No No No
28 Male 13 No No No No No No No
29 Male 16 Yes No Relaxation training No No No No No
30 Male 12 Yes No No No No No No
31 Male 12 Yes Yes No No No No No
32 Male 15 No No No No No No No
33 Male 10 No No No Yes No No No
34 Female 11 No No No No No No No
35 Female 12 No No Play therapy; cognitive–behavioural
therapy; counselling
No No No No No
36 Female 13 No No No No No No No
37 Male 13 No No Training to suppress tics
(not habit reversal)
Yes No No No No
38 Male 17 Yes Yes Yes No No No No
39 Male 14 Yes Yes No No No No No
40 Male 11 No No Yes No Yes No No
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Appendix 8 Qualitative study of Experiences of
Services and Treatment interview schedule
Introduction
This interview is about you and what you think about different treatments for Tourette syndrome. Take
your time to think about and answer the questions. Some of the questions are about personal things like
your friendships and your feelings. You don’t have to answer a question if you don’t want to. I am audio
(sound) recording this interview, but I will not put your name on the recording or the written summary
of this project. Do you have any questions before we start? Would you like to start the interview?
Background information
l How old are you?
l Do you go to school/college at the moment? (If yes, which year are you in? Have you got a favourite
subject? How are you finding school/college?)
About having TS and tics
I am just going to ask you a little bit about having TS and tics.
1. Can you tell me a bit about your tics? (prompts for vocal tics: for example, sniffing, coughing, grunting,
words, phrases. If no vocal tics at the moment, in the past? Prompts for motor tics: for example, eye
blinking, head jerk, shoulder shrugs, leg/feet or arm/hand movements)
2. Have the tics affected you in some way? (If yes, how have tics affected you? Which areas of your life
are most affected? [prompts: family life/home, school, friendships, leisure activities/hobbies])
3. What is it about tics that you find most troublesome? (prompts: urges, unwanted movements or
sounds, other people’s reactions, effort to suppress tics, physical pain or fatigue).
4. How long have you been aware that you have tics?
5. When did you first realise that you had TS? (as diagnosis)
6. What sorts of things make your tics better? (prompts: specific activities, how you are feeling, time of
day/year)?
7. What sorts of things make your tics worse? (prompts: specific classes, specific topic, teacher, other
pupils, time, why?)
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About treatment for TS and tics
1. Who do you see about your treatment for TS? (prompts: doctor, psychologist, nurse, etc.)
2. Has anyone explained to you or given you information about how best to manage/control your tics?
(If yes, who has explained or given you this information? How did you find this information? Was it
helpful? Did you do anything differently? Can you give me an example?)
3. Can you tell me what treatment you have had for your TS/tics? (prompts for medicationa; any other
treatment/intervention?; have you taken or done something else to help with your TS/tics?)
If participant has taken medication:
¢ Can you remember the names of any medication you have taken for TS? (prompts for medicationa)
¢ How many times a day did you take the medication?
¢ Do you remember the dose?
¢ For how long did you take the medication? (If stopped taking medication, why was it stopped?
Whose decision was it?)
3. For any treatment for tics reported (including medication/behavioural interventions/
other treatments):
¢ How do you feel about that treatment? (prompts: how well do you feel your treatment works/
worked for you?; Did the treatment/medicine helped? If yes, in what sense?; Did it become more
helpful/less helpful with time?; Was there something that you didn’t like of your
treatment/medication)
¢ How easy is it to follow your treatment advice (or what the doctor/psychologist/nurse ask you to do
for your tics)? (prompts: are there times you’re not able to follow advice, for example not take
tablets, not practice behavioural interventions?; if yes, how often would you say you don’t follow
your treatment [for example, miss doses]?; what makes it hard for you to follow your treatment?)
¢ Have you received information about your treatment? Has someone explained to you what it was
about, how does it work? (If yes, was the information sufficient/informative)
¢ Who helps you with your treatment for TS/tics? (prompts: role of parents, school, friends and
health professionals)
4. Have you heard of any treatments/other treatments for TS/tics? (If yes, what have you heard?)
If participant has not heard of medication for tics—describe this treatment using the guide that is
shown below; if participant has not heard of behavioural interventions for tics—describe this treatment
using the guide that is shown below.
Before providing treatment description(s):
Now I would like to give you a short description of a treatment to see what you think about it OK?; it
doesn’t mean that the treatment is better than others or that I think that you or others should try it—
I only would like to know what do you think about it.
After providing treatment description(s):
¢ How do you feel about that treatment?
¢ Is there anything that would make that treatment difficult for you?
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Guide to describe medication for tics Guide to describe behavioural interventions for tics
Sometimes medication is given to help with tics.
The medication can help:
l to reduce the strength of the tics
l to reduce the number of times tics happen
l and can also help with sleeping and attention.
Children who take medication for tics often need to:
l take it daily, sometimes about two or three times
a day
l at least take it for about 4 to 6 weeks to see if
the medicine works
l keep taking it for about a year or more if the
medicine is working
Sometimes behavioural interventions are given to help with tics.
Behavioural interventions can help to:
l be more aware of some situations that make tics more likely
to happen (for example, some places, people or thoughts);
learn ways to change or avoid those situations
l be more aware of the urges/feelings that may come before
the tics happen; learn ways to respond to these urges/feelings
with a different behaviour (for example, tightening the
tummy, holding the arms aside, breathing deeply)—which
means that the tic cannot occur until the tic-related urges/
feelings go away and reduce
Medicines may have other effects, which may make
children/young people feel drowsy, sleepy or dizzy
Family members are often involved to support the child and help
them to know that they are making progress with the therapy by
practising their strategies/exercises. Children/young people who
are in behaviour therapy often need to: meet with a doctor
(or psychologist/nurse) a number of times to practice/learn the
treatment, sometimes weekly and for a couple of months;
practice the strategies/exercises at home, often with the help of
the parent/carer
About expectations of treatment for TS and tics
Now I would like to ask you about what you would hope/like a treatment for TS/tics to do.
1. What would you most like a treatment for tics to achieve or make different? (prompts: reduce or
eliminate tics; give you better control over tics; feel less bothered/embarrassed by tics; make other
people understand tics better; have someone to talk to who understands your tics and what it’s like)
Why would you like that?
2. Is there something else you would like or hope a treatment for tics to do?
3. How well has the treatment you’ve received met these goals or things you would like from treatment?
Would you like to add something else?
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Background information (final questions)
l I am just going to finish with a couple of questions about you.
l Household members (who do you live with?).
l If siblings – where do you come in the family?
l Does anyone else in the family have TS or tics?
l Depending on family composition – Does your mum/dad/carer work? (If yes, do you know what his/her
job is?)
aPrompts for medication
Clonidine.
Risperidone.
Aripiprazole.
Sulpiride.
Haloperidol.
Olanzapine.
Quetiapine.
Pimozide.
Clonazepam.
Lorazepam.
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Appendix 9 Demographic characteristics
TABLE 63 Demographic characteristics of parents and carers completing survey
Characteristic n % Mean SD
Age (years) 256 44.0 6.3
Relationship to the child
Mother 237 92.2
Father 18 7.0
Grandparent 1 0.4
Other 1 0.4
Marital status
Married/cohabitating 201 78.2
Divorced/separated 37 14.4
Single (never married) 17 6.6
Widowed 2 0.8
Highest level of education
Did not complete secondary school/compulsory education 7 2.7
Secondary school 58 22.7
Further education (e.g. A-level) 85 33.2
Undergraduate 58 22.7
Postgraduate 48 18.8
A-level, advanced level.
Adapted from © 2015 Cuenca et al.;215 licensee BioMed Central. This is an Open Access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
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TABLE 64 Demographic and clinical characteristics of young people as reported by parents and carers
Characteristic n % Mean SD
Age (years) 295 12.4 3.0
Age of tic onset (years) 293 5.9 2.8
Age at diagnosis of TS (years) 273 9.1 2.7
YGTSS tic-related impairment score 291 2.3 1.5
Sex
Male 234 79.3
Female 61 20.7
Co-occurring conditions
OCD 106 35.9
ADHD 89 30.2
Anxiety 73 24.7
ASD 60 20.3
Depression 32 10.8
Learning disability 29 9.8
Dyspraxia 17 5.8
Dyslexia 16 5.4
Epilepsy 7 2.4
Other 14 4.7
Adapted from © 2015 Cuenca et al.;215 licensee BioMed Central. This is an Open Access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
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